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This report presents the conclusions reached and recommen-
dations made by the members of the WHO Study Group on 
Tobacco Product Regulation at its ninth meeting, where the 
group reviewed background papers specially commissioned 
for the meeting and considered  the following topics:
1. Heated tobacco products (section 2); 
2.Clinical pharmacology of nicotine in electronic nicotine 
delivery systems (section 3); 
3. A global nicotine reduction strategy: state of the science 
(section 4); 
4. A regulatory strategy for reducing exposure to toxicants in 
cigarette smoke (section 5); 
5. The science of flavour in tobacco products (section 6); 
6. Sugar content of tobacco products (section 7); 
7. Updated priority list of toxicants in combusted tobacco 
products (section 8); 
8. Approa che s to measur ing and reducing toxicant 
concentrations in smokeless tobacco products (section 9); 
9. Waterpipe tobacco smoking: prevalence, health effects and 
interventions to reduce use (section 10).
The Study Group’s recommendations in relation to each theme 
are set out  at the end of the relevant chapter, and overall 
recommendat ions are summarized in the final chapter of 
the report.
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Commentary
Scientific and regulatory approaches to reducing the harm associated with tobacco 
use have attracted much interest. This has fuelled in part the development of newer 
products, such as electronic nicotine delivery systems (ENDS) and heated tobacco 
products (HTPs), which have been promoted as less harmful or as aids to smoking 
cessation. The interest dates back several decades, well before the establishment 
of the WHO Study Group on Tobacco Product Regulation (TobReg) in 2003. 
The topic of product regulation has been addressed extensively in earlier WHO 
reports. During the past decade however, the market has developed extensively, 
with an ever-increasing range of products and industry activity and reports, as 
well as more research, country data and publications being made available.
This technical report, based largely on background papers prepared for 
a meeting of TobReg in December 2017, covers pertinent and critical issues 
in tobacco product regulation. While there was some increase in the number 
of publications relevant to sections 4–10 in the past year, there were marked 
increases in the number of scientific publications, data from national surveillance 
programmes/surveys and market developments with respect to ENDS and HTPs. 
For example, a bibliometric analysis of publications on electronic cigarettes (a 
subset of ENDS) published between 2003 and 2018 indicated an increase of 
nearly 24% between 2017 and 2018 (1). The reports in this publication were 
written according to specific terms of reference and are based on the best 
evidence available at the time they were commissioned. WHO is aware of the 
unprecedented increase in the number of publications on ENDS and on market 
developments, recent trends in the use of these products by young people in some 
countries, including Canada, some countries in Europe and the United States of 
America, and regulatory approaches to curtailing use, which are not addressed 
in this report. The section on ENDS is limited to the clinical pharmacology of 
nicotine in these products and is based on evidence available up to December 
2017, with some additions after review between March and December 2018. 
Only publications considered to be relevant to the topic were included.
WHO submitted two reports to the sixth (FCTC/COP/6/10 Rev. 1) 
and seventh (FCTC/COP/7/11) sessions of the Conference of the Parties to the 
WHO Framework Convention on Tobacco Control (WHO  FCTC), in 2014 
and 2016, respectively, on the health risks associated with ENDS, the efficacy 
of these products in helping smokers to quit smoking and reduce their nicotine 
dependence, interference with tobacco control and implementation of the 
WHO FCTC. These reports led to two decisions by the Conference of the Parties, 
in which Parties were invited to broadly pursue four regulatory objectives to 
prohibit or restrict the manufacture, importation, distribution, presentation, 
sale and use of these products, as appropriate to their national laws and public 
xii
health objectives and to consider prohibiting or regulating ENDS, including as 
tobacco products, medicinal products, consumer products, or other categories, 
as appropriate, taking into account a high level of protection for human health. 
WHO and its technical groups, including TobReg, are monitoring 
market developments, research, publications, commentaries, industry activities 
and debate on ENDS (including e-cigarettes) and other novel products and are 
reviewing global surveillance mechanisms to ensure effective monitoring and 
evaluation of these products. WHO will address the increasing numbers of 
publications and new products, variants and flavours in its next comprehensive 
review of the evidence, which will update the 2016 report. The review will also 
include the mounting evidence on the effects of these products, marketing 
trends, concern about their use by young people and the engagement of the 
major tobacco companies, especially in relation to Article 5.3 of the WHO FCTC.
This report provides the best evidence available up to December 2017, 
with some additions after review between March and December 2018. It should 
be read in relation to the earlier evidence that guided the development of policies 
and regulations by WHO Member States on tobacco products up to that time. 
Reference
1. Briganti M, Delnevo CD, Brown L, Hastings SE, Steinberg MB. Bibliometric analysis of electro-
nic cigarette publications: 2003–2018. Int J Environ Res Public Health. 2019;16(3):320. 
11. Introduction
Effective tobacco product regulation is an essential component of a comprehensive 
tobacco control programme. It includes regulation of contents and emissions 
by mandated testing, disclosure of test results, setting limits, as appropriate, 
and imposing standards for product packaging and labelling. Tobacco product 
regulation is covered under Articles 9, 10 and 11 of the WHO Framework 
Convention on Tobacco Control (WHO FCTC) (1) and in the partial guidelines 
on implementation of Articles 9 and 10 (2). Other WHO resources, including the 
basic handbook on tobacco product regulation (3) and the handbook on building 
laboratory testing capacity (4), support Member States in this area.
The WHO Study Group on Tobacco Product Regulation (TobReg) was 
formally constituted by the Director-General of WHO in 2003 to address gaps 
in the regulation of tobacco products. Its mandate is to provide evidence-based 
policy recommendations on tobacco product regulation to the Director-General. 
TobReg is composed of national and international scientific experts on product 
regulation, treatment of tobacco dependence, toxicology and laboratory analyses 
of tobacco product ingredients and emissions. The experts come from countries 
in all six WHO regions. As a formalized entity of WHO, TobReg submits technical 
reports to the WHO Executive Board through the Director-General to draw 
the attention of Member States to the Organization’s work in tobacco product 
regulation. The technical reports are based on unpublished background papers 
that have been discussed, evaluated and reviewed by TobReg.
The ninth meeting of TobReg took place in Minneapolis, United States 
of America, on 5–7 December 2017, and was generously hosted by the Masonic 
Cancer Center, University of Minnesota, USA. The participants discussed 
priorities in the regulation of nicotine and novel and tobacco products and 
addressed requests from the WHO FCTC Conference of the Parties (COP) made 
at its seventh session, as outlined in documents FCTC/COP7(4), FCTC/COP7(9) 
and FCTC/COP7(14). The requests included the following.
 ■ Continue to monitor and examine market developments and usage of 
novel and emerging tobacco products, such as heated tobacco products;
 ■ Collect scientific information on the chemicals in the contents and 
emissions of smokeless tobacco products that contribute to their tox-
icity, addictiveness and attractiveness, on analytical methods for mea-
suring them and on the levels in products on the market; and identify 
technical approaches for reducing toxicants in smokeless tobacco;
 ■ Promote research on culturally relevant interventions to prevent the 
uptake of waterpipe tobacco smoking and to promote quitting (cessa-
tion); the epidemiology of use; acute and chronic health risks; cultural 
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practices; initiation and maintenance of use; the influence of flavourings 
on initiation, maintenance of use and increasing use; risk of depend-
ence on low-nicotine tobacco products; and effective policies based 
on concepts such as information technology and communications.
In response to these requests, WHO commissioned the following background 
papers:
 ■ Heated tobacco products (section 2);
 ■ Clinical pharmacology of nicotine in electronic nicotine delivery sys-
tems (section 3);
 ■ A global nicotine reduction strategy: state of the science (section 4);
 ■ A regulatory strategy for reducing exposure to toxicants in cigarette 
smoke (section 5);
 ■ The science of flavour in tobacco products (section 6);
 ■ Sugar content of tobacco products (section 7);
 ■ Updated priority list of toxicants in combusted tobacco products 
(section 8);
 ■ Approaches to measuring and reducing toxicant concentrations in 
smokeless tobacco products (section 9);
 ■ Waterpipe tobacco smoking: prevalence, health effects and interven-
tions to reduce use (section 10).
1.1 References
1. WHO Framework Convention on Tobacco Control. Geneva: World Health Organization; 2003 
(http://www.who.int/fctc/en/, accessed 14 May 2019).
2. Partial guidelines on implementation of Articles 9 and 10. Geneva: World Health Organizati-
on; 2012 (https://www.who.int/fctc/guidelines/Guideliness_Articles_9_10_rev_240613.pdf, 
accessed 14 January 2019).
3. Tobacco product regulation: basic handbook. Geneva: World Health Organization; 2018 (htt-
ps://www.who.int/tobacco/publications/prod_regulation/basic-handbook/en/, accessed 14 
January 2019).
4. Tobacco product regulation: building laboratory testing capacity. Geneva: World Health Or-
ganization; 2018 (https://www.who.int/tobacco/publications/prod_regulation/building-la-
boratory-testing-capacity/en/, accessed 14 January 2019).
32. Heated tobacco products
Dr Richard J. O’Connor, Professor of Oncology, Department of Health Behavior, Roswell 
Park Comprehensive Cancer Center, Buffalo, New York, USA
“Nowadays, tobacco companies continue reassuring health concerned smokers by offering 
with their new products the illusion of safety.” (World No Tobacco Day 2006)
Contents
2.1 Introduction
2.2 The science of heated tobacco products
2.3 A brief history of heated tobacco products
2.4 Recent products
 2.4.1 Emissions
 2.4.2 Biomarkers of exposure
2.5 Consumer perceptions of heated tobacco products
2.6 Uptake in selected markets where products are available
2.7 Application by Philip Morris International for status as a “modified risk tobacco product”  
in the USA
2.8 Implications for regulation and tobacco control policies
2.9 Recommendations for research and policy
2.10 References
2.1 Introduction
Heated tobacco products (HTPs), also sometimes referred to as “heat-not-
burn” products, a term coined by the tobacco industry, are an emerging class 
of “potentially reduced exposure products” (PREPs) or “modified risk tobacco 
products” (MRTPs). The concept emerged in the 1980s from the tobacco 
companies Philip Morris and RJ Reynolds in the USA, which marketed Accord 
and Premier, the first generation of these products, respectively. Since then, 
these and conceptually similar products have continued to evolve and may now 
be poised to capture a significant market share. The introduction, aggressive 
marketing and growing popularity of electronic cigarettes may have facilitated the 
success of such products, partly by changing social norms and perceptions about 
conventional cigarette smoking and about the use of devices to deliver nicotine. 
There is substantial published literature on certain HTPs marketed in the 1990s 
and 2000s and emerging literature on newer products, although much of it comes 
from the tobacco industry. Further, there are few studies on prevalence and 
substitution in the marketplace, as many of these products were test-marketed 
rather than made broadly available. Still, laboratory and field research studies can 
provide information on the likelihood of such substitution.
This review is based on the literature on HTPs available through October 
2017, including their history, design, delivery of nicotine to the user and toxicants 
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and marketing (including online advertising and sales); HTP technology; 
manufacturer’s claims of reduced toxicity, harm, risk and exposure; comparison 
with conventional cigarettes; consumer perceptions of these alternative products; 
and the implications of these products for regulatory, product and market 
policy. The review focuses on HTPs marketed by tobacco companies but also 
covers handheld or portable products for use as “dry herb” vaporizers (often for 
marijuana) that could be used with tobacco. Desktop “vaporizers” usually used 
to administer marijuana were excluded, as were hookah-, waterpipe- or narghile-
type products. The review is based primarily on published literature and also on 
news reports and press releases, stockholder reports, scientific presentations and 
internet blogs, as necessary.
The PubMed search terms were: heat not burn; heat-not-burn; heated 
tobacco; tobacco heating; Accord; Eclipse; Heatbar; Premier; THS [tobacco 
heating system]; vaporizer; PREP; MRTP; THP [tobacco heating product]; iQOS; 
and glo.
2.2 The science of heated tobacco products
HTPs are based on the principle that most of the harm associated with tobacco 
smoking is due to the combustion process. In a conventional cigarette, the 
temperature of the burning cone can reach up to 900  °C, and the median 
temperature along the rod is 600  °C. This can result in combustion, pyrolysis, 
pyrosynthesis and myriad other reactions that result in the > 7000 compounds 
identified as components of tobacco smoke (1). Polycyclic aromatic hydrocarbons 
(PAHs), heterocyclic aromatic amines and some volatile organic compounds 
(VOCs) (e.g. benzene, 1,3-butadiene, acrolein, toluene) are formed primarily 
as a result of combustion. Tobacco-specific N´-nitrosamines (TSNAs) such as 
N´-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) are present in cured tobacco and are partially transferred to 
smoke in a near-linear fashion at typical cigarette temperatures. Some TSNAs 
are formed during tobacco combustion. Toxic metals such as cadmium present 
in tobacco may also be transferred to smoke at typical tobacco combustion 
temperatures. Burning of tobacco is, however, ultimately unnecessary to 
“volatilize” nicotine (although it is efficient), and alternative means of liberating 
nicotine from tobacco in an inhalable form without combustion are preferable 
from the point of view of both toxicological risk and consumer acceptability. 
One way of extracting nicotine while maintaining something visually similar to 
smoking behaviour is to heat tobacco to a temperature that volatilizes nicotine 
but does not combust the plant material. Volatilized nicotine without combustion 
would, in principle, produce a less complex aerosol with fewer toxic constituents.
Nicotine is not efficiently delivered as a gas; to deliver nicotine to the user’s 
lungs, an aerosol-forming agent must be included to suspend nicotine on aerosol 
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particles. This has been achieved by four main approaches through the decades. 
The first is in a cigarette-like device with an embedded heat source that can be 
used to aerosolize nicotine – this is the general principle underlying Premier 
and Eclipse and Philip Morris International (PMI)’s “Platform 2” product. The 
second approach is to use an external heat source to aerosolize nicotine from 
specially designed cigarettes (rolls of tobacco in paper). This is the basic design 
of Accord, Heatbar, iQOS and glo. The tobacco used in PMI’s HTP is apparently 
not typical tobacco cut-filler but rather a reinforced web of cast-leaf tobacco (a 
type of reconstituted tobacco), which includes 5–30% by weight of compounds 
that form aerosols, such as polyols, glycol esters and fatty acids. The examples 
given include glycerine, erythritol, 1,3-butylene glycol, tetraethylene glycol, 
triethylene glycol, triethyl citrate, propylene carbonate, ethyl laurate, triactin, 
meso-erythritol, a diacetin mixture, a diethyl suberate, triethyl citrate, benzyl 
benzoate, benzyl phenyl acetate, ethyl vanillate, tributyrin, lauryl acetate, lauric 
acid, myristic acid and propylene glycol (2). This composition is advantageous as 
an aerosol-forming substrate for use with a heating system. The sticks (45 mm 
long, 7 mm diameter) contain approximately 320 mg of tobacco material – much 
less than a conventional cigarette (~700 mg). In iQOS, the tobacco is heated by 
a blade in the heater device inserted into the end of the heat stick, so that the 
heat dissipates through the tobacco plug on a puff (3). The aerosol then passes 
through a hollow acetate tube and a polymer film filter on the way to the mouth. 
The product is designed not to exceed 350 °C, at which point the energy supplied 
to the blade is cut off at a maximum of 14 puffs or 6 min (3). British American 
Tobacco describes its glo product as a heating tube consisting of two separately 
controlled chambers, which are activated by a button on the device to reach the 
operating temperature (240  °C) within 30–40 s (4). The 82-mm long, 5-mm 
diameter stick inserted into the heating chamber contains approximately 260 mg 
of reconstituted sheet tobacco with 14.5% glycerol as an aerosolizing agent. The 
vent holes on the stick are described as necessary to “…provide the right amount 
of drawing effort and to encourage the…vapour to coagulate and condense….” 
(4). The stick consists of a tobacco rod, a tubular cooling section and a filter and 
mouthpiece.
A third approach is to use a heated sealed chamber to aerosolize nicotine 
from tobacco leaf directly – this is the principle underlying personal dry-herb 
vaporizers such as Pax; however, the prevalence of use of such devices for tobacco 
is unknown. A fourth approach is use of electronic nicotine delivery systems 
(ENDS) to derive flavour elements from small amounts of tobacco (see section 
3 for further information). British American Tobacco’s iFuse product appears to 
be a hybrid ENDS–tobacco product, in which the aerosol is passed over tobacco 
to pick up the flavour and is then inhaled by the user (5). The vapour appears 
to lose a small amount of heat when it passes over the tobacco chamber (from 
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35 °C to 32 °C), indicating that some tobacco is heated. As the e-liquid contains 
nicotine at 1.86 mg/mL, however, with a machine delivery of 20–40 µg per puff, 
it is difficult to estimate the contribution, if any, of the tobacco in the device to 
delivery of nicotine. The delivery of toxicants under machine smoking is reported 
to be nearly identical to that of an ENDS without a tobacco chamber, implying 
a minimal contribution of tobacco (5). The Japan Tobacco International Ploom 
TECH operates in a similar manner, except that the ENDS-like component 
appears not to contain nicotine.
2.3 A brief history of heated tobacco products
A historical perspective is important for understanding the current situation. 
Table 2.1 lists the HTPs known to have been introduced into at least a test market. 
The timeline in Fig. 2.1 places the introduction (and withdrawal) of various HTPs 
into context. Activity in this market space has been clustered, 2006–2008 and 
2015–2017 being particularly active periods.
Table 2.1. Heated tobacco products by manufacturer
Company Trade name® Brief description Current status
Philip Morris USA 
/ Altria Accord
THS consisting of small cigarettes placed in an 
external heating device. Available in tobacco 
and menthol flavours. Introduced in 1998 in test 
markets in Richmond, Virginia, USA, and Japan. 
Advertising focused on reduced second-hand 
smoke rather than reduced potential health risks. 
Withdrawn in 2006.  
No longer sold.
Philip Morris 
International Heatbar
THS, consists of small cigarettes (Heatsticks) 
placed in an external heating device with puff 
detection technology. Four blends available. 
Devices came in a range of colours. Introduced in 
Switzerland in 2006. 
Withdrawn in 2008.  
No longer sold. 
iQOS
THS, consists of small cigarettes (HEETS) placed in 
an external heating device. Available in Marlboro 
brand. Launched in Japan in 2015. 
Currently marketed in nearly 40 
countries including Canada, Italy, 
Japan and the United Kingdom. 
Expanding to other markets. 
MRTP application to FDA filed 
in May 2017 and reviewed by 
the Tobacco Products Scientific 
Advisory Committee in January 
2018.
THS 2.2
THS described in a series of published papers in 
scientific journals. Marketed as iQOS. 
Platform 2
Pressed carbon heat source (conceptually similar 
to Eclipse). 
Unclear whether available on 
the market. Branded as TEEPS in 
several PMI presentations. 
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Japan Tobacco 
International Ploom
Ploom began as independent company in 2007. 
Entered into marketing and commercialization 
agreement with Japan Tobacco International in 
2011, which purchased patents and designs for 
device and pods (Ploom name and ModelTwo 
device) outright in 2015. Pods currently have 
the Mevius cigarette brand name. Former Ploom 
company became Pax, which produces dry herb 
vaporizers. 
Currently marketed in Japan and 
Switzerland. 
RJ Reynolds 
/ Reynolds 
American Premier
Cigarette-like device designed for heating and 
aerosolizing tobacco flavour. Cigarette column 
made of aluminium capsules containing tobacco 
pellets, with a carbon element at the tip to warm 
the tobacco column. Test-marketed in St Louis, 
Phoenix and Tucson, USA, in 1988. Subject of 
complaints to the FDA as a drug delivery device. 
Withdrawn in 1989 because of 
poor sales. Not currently on the 
market. 
Eclipse
Cigarette-like device. Rod consists of reconstituted 
tobacco, with carbon element to heat and 
volatilize nicotine. Test-marketed in several 
versions between 1996 and 2000, when wider 
sales began, with accompanying advertisements 
and health claims. Subject of lawsuit over claims 
by the State of Vermont, USA. 
Withdrawn from United States 
market in 2007; remained in 
limited distribution thereafter. 
Announced “substantial 
equivalence” filing with FDA in 
October 2017 to bring improved 
version to United States market. 
Revo
Eclipse-like product test-marketed in Wisconsin, 
USA, in 2014–2015. Withdrawn in 2015.
British American 
Tobacco glo
“glo™ heats proprietary Kent Neostiks™ to 
approximately 240 °C to provide a highly satisfying 
taste, similar to that of a cigarette, with around 
90% less toxicants. glo™ also offers a number 
of added features, including: no burning or 
ash, less odour on your hands, hair, clothes and 
surroundings.” Neostiks come in three flavours. 
Available in Canada, Japan, 
Republic of Korea, Russian 
Federation and Switzerland.
iFuse
Hybrid of e-cigarette and HTP. Cartridges 
contain e-liquid with flavourings and a chamber 
containing tobacco. Heating element aerosolizes 
the liquid, which passes through the tobacco 
chamber before reaching the user. Launched in 
2015. Test-marketed in Romania.
Dry herb vaporizers
Pax Pax 2
Rectangular device. “Magnetic oven” used to 
heat plant material, “thin film Kapton heater 
flex”. Cannot be used with liquids, waxes or 
concentrates. Capacity, 1.6 mL. Comes in four 
colours. 
Available online and from 
authorized retailers. 
Pax 3
Rectangular device. “Magnetic oven” used to heat 
plant material. Can also be used with concentrates 
with special insert. Oven starts when device senses 
lips on mouthpiece. 3500-mAh battery. Capacity, 
0.17–0.35 g. Comes in four colours. 
Available online and from 
authorized retailers. 
V2 Pro Series 3
Cylindrical device. Three-in-one vaporizer, with 
different cartridges and mouthpieces for e-liquid, 
loose leaf or wax. Conduction oven. Pre-set 
temperature, 160–180 ºC. 650-mAh battery. 
Comes in three colours. Available online.
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Pro Series 7
Rectangular device. Three-in-one vaporizer, 
with different cartridges and mouthpieces for 
e-liquid, loose leaf or wax. Larger capacity, more 
customization options. Higher-temperature 
conduction oven with three levels (200, 215, 
225 ºC). 1800-mAh battery; 3.7–4.7 V. Comes in 
three colours. Available online.
Vapor Fi Orbit
Cylindrical device. 1.7-mL capacity cartridge 
for dry plant material. Temperature range, 
182–216 ºC. 2200-mAh battery. Two colours (black, 
red). Available online.
Atom
Rectangular device. Temperature range, 182, 210, 
240 ºC. Plant material packed into an external oven 
cartridge. 3000-mAh battery; 3.3–4.2 V. Motion 
sensing. Superficially similar to Pax device. Available online.
Atmos Jump
Cylindrical device. Maximum temperature, 200 ºC; 
not variable. 1300-mAh battery; 3.4 V. Available in 
four colours. Available online.
FDA: United States Food and Drug Administration; HTP: heated tobacco product; MRTP: modified risk tobacco product; PMI: Philip 
Morris International; THS: tobacco heating system.
Fig. 2.1. Timeline of introduction of heated tobacco products, 1988–2016
Eclipse
Eclipse, the successor of Premier, launched at the end of the 1980s, was available 
in various test markets in the USA between 1996 and 2007 and was extensively 
studied (6–13). The product had a carbon-heating element embedded in the tip 
of a product resembling a cigarette to heat reconstituted tobacco and glycerol 
in the rod and generate a nicotine aerosol. To use it, the smoker would light the 
heating element and puff, much like a conventional cigarette. In two separate five-
day trials, Breland and colleagues (6, 7) found that Eclipse reduced exposure to 
nicotine and NNK from that in the smoker’s own brand but increased exposure 
to carbon monoxide (CO) and required a more intensive puffing pattern. Lee et 
al. (10) found a similar pattern of results for Eclipse in the laboratory. Fagerstrom 
and colleagues (9) showed that smokers’ CO levels over two weeks of using 
Eclipse increased from 21.0 to 33.0 parts per million. In a subsequent eight-week 
study (8), in which 10 participants were selected to continue using Eclipse, no 
difference in plasma nicotine levels was seen from baseline, but the exhaled CO 
levels were higher with Eclipse than with the smokers’ own brand (32.5 versus 
22.5 parts per million). Stewart and colleagues (13) reported that a small group 
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of smokers who used Eclipse for 4 weeks showed less alveolar epithelial injury but 
increased levels of carboxyhaemoglobin and other markers of oxidative stress. 
Pauly and colleagues (14) identified a potentially unique health risk of Eclipse 
due to contamination with glass fibre. They noted that the insulation surrounding 
the carbon-heating element could fray and become loose during handling of the 
packaging or the product itself and expose smokers to inhalation of these fibres. 
Previous research had shown evidence of inhalation of cellulosic and plastic 
fibres in 87% of 114 human lung specimens (15), indicating that this was not 
simply a theoretical concern. A subsequent survey of consumers (16) showed 
that they viewed this as a health risk. RJ Reynolds vigorously objected to these 
observations and published several studies to refute them, arguing that the fibres 
were too large to be inhaled and that the number of loose fibres was not as large 
as reported (17–20).
The first health claims were made for Eclipse when it was launched 
nationally in 2003, citing potentially reduced risks for cancer, bronchitis and 
emphysema (21). The manufacturer’s advertising claimed that Eclipse reduced 
emissions of harmful smoke constituents and suggested that, next to quitting, 
Eclipse was the smoker’s “next best option”. These claims resulted in a lawsuit by 
the Attorney-General of the State of Vermont, USA, in 2005, which resulted in 
the finding in 2010 that the advertising had violated consumer protection laws 
and the Master Settlement Agreement. This was followed by a judgement against 
RJ Reynolds for US$ 8 million in 2013. A repackaged version of Eclipse, called 
Revo, was briefly test-marketed in Wisconsin, USA, in 2015. In November 2017, 
RJ Reynolds announced that they would market an improved version of Eclipse 
in 2018; this had not been launched yet as of January 2019.
Accord
Accord was first marketed in 1998 in the USA and later in Japan. This product, 
a predecessor of iQOS, had an external battery-powered heating device, into 
which specifically designed “cigarettes” were inserted for smoking. Puffing on 
the cigarette activated the heating bars in the device and generated an aerosol. 
Accord was marketed as a “cleaner” cigarette, without ash or second-hand smoke; 
no health claims were made. Review of an early study indicated that Accord use 
resulted in less CO intake and tachycardia than conventional cigarettes (22, 23). 
Accord was, however, associated with poor suppression of withdrawal (22, 23). 
In a study of concurrent use of Accord and the smokers’ own cigarettes, Accord 
suppressed cigarette smoking and exposure to CO dose-dependently after six 
weeks; i.e. the more often Accord was used, the less participants smoked their 
own cigarettes. Furthermore, the participants did not increase their puff intensity 
when they reduced the number of cigarettes per day, and smoke from Accord 
contained lower levels of CO (24). Analysis of participant exit interviews showed 
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that study participants believed Accord to be a “safer cigarette”. A study by Roethig 
et al. (25) of a second-generation electrically heated cigarette showed reductions 
in selected biomarkers of exposure (e.g. nicotine, 1-hydroxypyrene) of 43–85% 
relative to conventional cigarette smoking.
2.4 Recent products
2.4.1 Emissions
Table 2.2 summarizes the published literature on emissions of certain harmful 
and potentially harmful constituents (HPHCs) (26) under machine smoking 
conditions from the three HTPs for which there are the most published data 
– Eclipse (International Organization for Standardization (ISO) conditions), 
electrically heated cigarette smoking system (EHCSS; ISO conditions) and THS 
2.2/iQOS (Health Canada Intense (HCI) conditions) – cognizant that the data 
were published by the manufacturers. PMI experiments showed that THS 2.2 
aerosol did not contain solid carbon-derived particles, consistent with its claim 
of no combustion (27). In general, the levels of constituents were lower than in 
a comparison reference cigarette (1R6F, which has certified levels of many of 
the emissions of concern (28)). Studies conducted within (29) and outside the 
industry (30, 31) largely replicated these findings, in particular the lower levels 
of nicotine in Eclipse and EHCSS than in a reference cigarette. British American 
Tobacco presented two posters on its HTP at the 2017 meeting of the Society 
for Research on Nicotine and Tobacco (5, 32) and in late 2017 had eight studies 
published in a supplement to a journal (4, 33–40). The product, called THP1.0, 
is commercially marketed as glo. It heats tobacco (reconstituted sheet with 
14.5% glycerol contained in a superslim cigarette) to a maximum of 250 °C (32). 
Thermographic profiling suggested that the product releases moisture until 100 °C 
and then glycerol through 240  °C, followed by decomposition at 350  °C (32). 
Data from machine smoking under modified HCI conditions generally showed 
lower emissions of TobReg priority toxicants (41) than in a reference cigarette 
(Table 2.2). THP1.0 was machine-smoked under HCI conditions except for the 
blocking of vent holes on the basis of a study that showed no vent blocking under 
actual smoking conditions (according to lip imprint measurements). A second 
poster (42) gave details of effects on indoor air and claimed that THP1.0 resulted 
in lower emissions than conventional cigarettes. In a laboratory comparison 
of British American Tobacco’s iFuse with other HTPs (called cTHP in the 
paper; description fits iQOS) (43), cTHP emitted higher levels of acetaldehyde 
(125  versus 35.9 µg per 10 puffs), while iFuse emitted more formaldehyde 
(<  4.18 versus 38.7 µg per 10 puffs). Both products emitted substantially less 
acetaldehyde than the 3R4F reference cigarette (> –88%), but iFuse emitted levels 
of formaldehyde comparable to those of a conventional cigarette (–8%). Bekki et 
al. (31) showed that the transfer rate of nicotine and nitrosamines from tobacco 
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filler to aerosol in iQOS was comparable to, if not slightly higher than, that in 
conventional cigarettes.
Table 2.2. Harmful and potentially harmful constituents emitted from reference cigarette 1R6F, Eclipse, 
an electrically heated cigarette smoking system (EHCSS), a tobacco heating system (THS) and a tobacco 
heating product (THP)
Constituent
1R6F (µg/
cigarette) 
ISO (28)
1R6F
(µg/ciga-
rette) HCI 
(28)
Eclipse
(µg/ciga-
rette) ISO 
(21)
ECHSS
(µg/ciga-
rette) ISO 
(44)
THS 2.2
(µg/ciga-
rette) HCI 
(45)
THP1.0 (µg/
cigarette) 
HCI (32)
Acetaldehyde 522 1552 84.2 179 219 111
Acrolein 43 154 11.5 27.3 11.3 2.22
Acrylonitrile 7.0 24 0.44 0.258 < 0.032
4-Aminobiphenyl 1.2 2.3 0.058 < 0.051 < 0.005
2-Naphthol 8 14 0.123 0.046 < 0.012
Ammonia 9.0 30 4.37 14.2 4.01
Benzene 33 88 0.363 0.649 < 0.056
Benzo[a]pyrene 6.8 15 1.2 < 0.19 < 1.0 < 0.35
Carbon monoxide (mg) 10.1 28.0 7.5 0.465 0.531 < 0.223
Formaldehyde 27 104 12.9 5.53 3.29
Isoprene 320 881 34.3 2.35 < 0.135
Nicotine 0.721 1.90 0.18 0.313 1.32 0.462
NNK (ng) 71 187 31.8 6.18 6.7 6.61
NNN (ng) 85 212 26 19.8 17.2 24.7
Toluene 53 150 1.48 2.59 < 0.204
Tar (mg) 8.58 29.1 3.2 3.1 10.3 13.6
 
EHCSS: electrically heated cigarette smoking system; HCI: Health Canada intense smoking regimen; ISO: International Organization 
for Standardization smoking regimen; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN: N´-nitrosonornicotine; THP: 
tobacco heating product; THS: tobacco heating system.
2.4.2 Biomarkers of exposure
In 2008, Philip Morris USA and PMI published a series of papers on its EHCSS, 
including studies of toxicology, emissions (also second-hand smoke) and short- 
and long-term clinical exposure, and randomized trials (44, 46–48). A series of 
papers followed in 2012 (49–56). In 2016, PMI published another series of studies, 
this time on THS 2.2 (3, 45, 57–59), which reported the results of a broad range 
of product evaluations. The data on biomarkers after short-term exposure (~ 1 
week, generally in residence) shown in Tables 2.3 and 2.4 were extracted from 
these papers (47, 49, 51–54, 58, 59). In studies in several populations, the levels of 
key toxicants, except nicotine, were lower than with continued cigarette smoking. 
As the participants in these studies were generally confined for the duration of 
the study, however, the findings may not be generalizable to real conditions of 
use (e.g. pattern of product use, use with cigarettes or other combusted or non-
combusted products).
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Table 2.3B. Biomarker levels in short-term studies of electrically heated cigarette smoking systems, 
with end-of-study values for numbers of conventional cigarettes and heated tobacco products and for 
abstinence when available, United Kingdom and Republic of Korea
Biomarker HPHC
Republic of Korea (8 days) (51) United Kingdom (8 days) (54)
EHCSS-
K3a
Absti-
nence
Ciga-
rette
EHCSS-
K6a
EHCSS-
K3a
Absti-
nence
Nicotine equivalent Nicotine (mg/24 h) 4.2 0.1 13.1 8.6 6.5 0.0
Nicotine Nicotine 8.6 0.1 NR NR NR NR
Cotinine Nicotine (ng/mL) 85.8 0.1 234.3 158.3 125.0 0.0
NNAL NNK (ng/24 h) 80.4 45.1 293.6 100.6 104.3 59.2
COHb Carbon monoxide (%) 0.9 0.5 5.7 1.4 1.9 0.5
MHBMA 1,3-Butadiene (µg/24 h) 0.6 0.3 5.1 1.5 2.6 0.3
3-HPMA Acrolein (mg/24 h) 2.4 1.7 1.8 1.3 1.2 0.5
S-PMA Benzene (µg/24 h) 1.6 1.4 6.2 0.9 1.3 0.2
1-OHP Benzo[a]pyrene (ng/24 h) 143.6 127.0 181.6 71.9 73.1 75.1
3-OH-Benzo[a]pyrene Benzo[a]pyrene NR NR NR NR NR NR
4-Aminobiphenyl 4-Aminobiphenyl (ng/24 h) 5.5 5.5 NR NR NR NR
1-Naphthylamine 1-Naphthylamine NR NR NR NR NR NR
2-Naphthylamine 2-Naphthylamine (ng/24 h) 5.4 5.5 NR NR NR NR
o-Toluidine Toluene (ng/24 h) 29.1 30.2 135.0 58.0 49.3 47.6
HMPMA Crotonaldehyde (mg/24 h) 2.0 1.7 5.2 2.6 2.6 1.7
COHb: carboxyhaemoglobin; EHCSS: electrically heated cigarette smoking system; HMPMA: hydroxy methyl propylmercapturic 
acid; HPHC: harmful and potentially harmful constituent; 3-HPMA: 3-hydroxypropyl mercapturic acid; MHBMA: monohydroxy-
butenylmercapturic acid; NNAL: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone; NR: not reported; 1-OHP: 1-hydroxypyrene; S-PMA: S-phenylmercapturic acid. a K6 and K3 are two versions of the system 
tested.
Table 2.4. Levels of biomarkers reported in published short-term studies with tobacco heating system 2.2, 
with end-of-study values for conventional cigarettes, heated tobacco products and abstinence, when 
available
Biomarker HPHC
Japan (58, 60) Poland (59)
THS
Ciga-
rettes
Absti-
nence THS
Ciga-
rettes
Absti-
nence
Nicotine equivalent Nicotine (mg/g creatinine) 5.44 5.52 0.15 10.60 9.76 0.14
Nicotine Nicotine 19.13 21.34 0.10 20.74 19.01 0.10
Cotinine Nicotine 161.00 164.30 2.96 239.99 219.73 2.05
NNAL NNK (pg/mg creatinine) 37.77 76.55 28.63 49.65 107.04 41.51
NNN N´-nitrosonornicotine (pg/mg creatinine) 1.31 4.64 0.18 1.55 5.99 0.16
COHb Carbon monoxide (%) 2.39 5.14 2.37 1.06 4.51 0.99
MHBMA 1,3-Butadiene (pg/mg creatinine) 107.39 450.19 92.18 192.93 2399.40 163.17
3-HPMA Acrolein (ng/mg creatinine) 311.08 599.67 199.04 402.26 931.01 245.69
S-PMA Benzene (pg/mg creatinine) 143.77 850.02 126.34 164.45 2922.81 143.70
1-OHP Benzo[a]pyrene (pg/mg creatinine) 73.02 149.62 62.99 81.22 182.85 85.13
3-OH-benzo[a]pyrene Benzo[a]pyrene (fg/mg creatinine) 29.52 96.42 24.47 37.07 130.29 33.64
4-Aminobiphenyl 4-Aminobiphenyl (pg/mg creatinine) 1.53 8.57 1.49 1.90 12.58 1.60
1-Naphthylamine 1-Naphthylamine (pg/mg creatinine) 2.47 57.08 2.45 3.30 89.37 2.56
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2-Naphthylamine 2-Naphthylamine (pg/mg creatinine) 2.33 13.38 2.27 2.96 25.32 2.52
o-Toluidine Toluene (pg/mg creatinine) 50.40 98.18 48.91 51.15 121.16 41.64
CEMA Acrylonitrile (ng/mg creatinine) 10.61 54.19 9.04 13.18 99.48 12.60
HEMA Ethylene oxide (pg/mg creatinine) 997.76 2099.41 806.29 1342.40 4504.00 1248.27
HMPMA Crotonaldehyde (ng/mg creatinine) 59.51 157.83 47.84 86.65 376.78 63.25
S-BMA Toluene (ng/mg creatinine) 2098.09 2354.17 2192.86 NR NR NR
 
CEMA: 2-chloroethylmethacrylate; COHb: carboxyhaemoglobin; HEMA: hydroxyethylmethacrylate; HMPMA: hydroxy methyl 
propylmercapturic acid; 3-HPMA: 3-hydroxypropyl mercapturic acid; MHBMA: monohydroxy-butenylmercapturic acid; NNAL: 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN: N´-nitrosonornicotine; 
NR: not reported; 1-OHP: 1-hydroxypyrene; S-BMA: S-benzylmercapturic acid; S-PMA: S-phenylmercapturic acid; THS: tobacco 
heating system.
PMI also published the results of longer-term clinical studies of EHCSS (12 
weeks) and THS 2.2 (90 days). After use of EHCSS for 12 weeks by 60 participants 
in the USA, the level of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL, a biomarker of exposure to NNK) dropped by 63% (P <.0001), that of 
carboxyhaemoglobin (a biomarker of exposure to CO) by 23% (P <.0001) and 
that of S-phenylmercapturic acid (a biomarker of exposure to benzene) by 49% 
(P <.0001) (48). (The paper did not provide mean estimates at each time.) After 
90 days of use of THS 2.2 by 76 participants in Japan, the level of NNAL dropped 
by 73%, that of carboxyhaemoglobin by 42% and that of S-phenylmercapturic 
acid by 86% (61). A number of other biomarkers of exposure were measured 
(Table 2.5), and participants were followed up for 90 days for continued smoking 
and abstinence. Exposure to certain constituents was reduced with use of the 
THS rather than conventional cigarettes, although exposure to a number of 
constituents, including nitrosamines and acrolein, remained substantially higher 
than during smoking abstinence.
Table 2.5. End-of-study biomarker levels in participants in a 90-day study of random assignment to THS 2.2, 
continued cigarette smoking or abstinence, Japan
Biomarker HPHC THS
Ciga-
rettes
Absti-
nence
Differ-
ence 
from cig-
arettes 
(%)
Differ-
ence 
from ab-
stinence 
(%)
Nicotine equivalent Nicotine (mg/g creatinine) 7 6 0 8 1751
NNAL NNK (pg/mg creatinine) 23 95 14 –76 67
NNN NNN (pg/mg creatinine) 1 4 0 –67 438
COHb CO (%) 3 6 3 –48 –2
MHBMA 1,3–Butadiene (pg/mg creatinine) 142 785 137 –82 4
3-HPMA Acrolein (ng/mg creatinine) 386 696 276 –44 40
S-PMA Benzene (pg/mg creatinine) 146 1157 144 –87 1
1-OHP Benzo[a]pyrene (pg/mg creatinine) 85 167 88 –49 –3
3-OH-Benzo[a]pyrene Benzo[a]pyrene (fg/mg creatinine) 30 87 29 –65 4
4-Aminobiphenyl 4-Aminobiphenyl (pg/mg creatinine) 2 10 2 –78 –12
1-Naphthylamine 1-Naphthylamine (pg/mg creatinine) 4 55 4 –94 –16
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2- Naphthylamine 2-Naphthylamine (pg/mg creatinine) 2 149 3 –98 –11
o-Toluidine Toluene (pg/mg creatinine) 68 126 78 –46 –12
CEMA Acrylonitrile (ng/mg creatinine) 8 84 8 –91 –6
HEMA Ethylene oxide (pg/mg creatinine) 1742 3739 1633 –53 7
HMPMA Crotonaldehyde (ng/mg creatinine) 154 299 159 –48 –3
CEMA: 2-chloroethylmethacrylate; CO: carbon monoxide; COHb: carboxyhaemoglobin; HEMA: hydroxyethylmethacrylate; 
HMPMA: hydroxy methyl propylmercapturic acid; HPHC: harmful and potentially harmful constituent; 3-HPMA: 3-hydroxypropyl 
mercapturic acid; MHBMA: monohydroxy-butenylmercapturic acid; NNAL: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; 
NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN: N´-nitrosonornicotine; 1-OHP: 1-hydroxypyrene; S-PMA: 
S-phenylmercapturic acid. 
When a compensation formula
1 – ((ln(marker1)-ln(marker0)) / (ln(yield1)–ln(yield0))
is used to compare changes in machine-measured emissions (ISO yields for 
EHCSS, HCI yields for THSs, each compared with 1R6F which has certified 
values for specific HPHCs in smoke) with levels of biomarkers of exposure, 
there is clearly potentially substantial compensation, including significant, 
near-total compensation for nicotine with the THS (Table  2.6). The ability to 
obtain increased levels of nicotine may partly explain differences in adoption of 
previous-generation HTPs and of iQOS.
Table 2.6. Potential compensation for selected harmful and potentially harmful constituents (HPHCs) in 
Philip Morris International heated tobacco products relative to a reference cigarette
HPHC ECHSS (Japan), % EHCSS (USA), % THS (Japan), % THS (Poland), %
Acrolein 79 67 75 68
Acrylonitrile NR NR 64 55
4-Aminobiphenyl 79 62 55 50
2-Naphthol 99 67 69 62
Benzene 66 71 64 41
Benzo[a]pyrene 77 78 74 70
Carbon monoxide (mg) 78 73 81 63
Nicotine 58 63 96 123
NNK (ng) 80 63 79 77
Toluene 85 91 84 79
 
ECHSS: electrically heated cigarette smoking system; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NR: not reported; THS: 
tobacco heating system.
No published reports of biomarkers of exposure to the THP1.0 product were 
identified, although a trial protocol for such a study has been published (62). 
British American Tobacco has published one study of human use of the glo 
product to determine usage patterns (38). Three groups took three products 
(glo-menthol, glo-tobacco, glo + iQOS) home for up to 14 days, with up to four 
laboratory visits, while a fourth group used glo in the laboratory only. The measures 
included puffing topography, mouth-level exposure and mouth insertion depth. 
Participants who took the products home completed daily diaries of product use. 
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Overall, the puff volume was about 60 mL with the glo product, with an average 
of 10–12 puffs per session, a duration of 1.8–2.0 s and a mean interval of 8  s. 
The volume per puff and the total volume were significantly higher than with 
comparison cigarettes but comparable to those for the iQOS product. At baseline, 
participants reported using 12–15 cigarettes per day and about 8–12 units of the 
glo and iQOS per day during the 4 days at home. The mouth-level exposure per 
product used was lower with glo than with conventional cigarettes, especially for 
nicotine. The average mouth insertion depth was 7.7 mm, and the company used 
this as an argument to omit the vent-blocking procedure from the HCI machine 
smoking regimen (38).
Thus far, consumer use of personal vaporizers to heat tobacco has been 
examined in only one published study (63), in which Pax (loaded with 1  g of 
roll-your-own cigarette tobacco) was compared with the smokers’ own brand 
of cigarette and an e-GO-type e-cigarette among 15 participants in a laboratory 
paradigm with fixed puffing patterns. The vaporizer increased plasma nicotine 
to a lesser extent than the smokers’ own brand (14.3 ng/mL vs 24.4 ng/mL) and 
was equivalent to an e-cigarette, with no substantial exposure to CO. No other 
biomarkers were reported.
2.5 Consumer perceptions of heated tobacco products
Population surveys and internal industry marketing studies reveal strong 
consumer demand for products that are claimed or implied to carry reduced 
health risks (64–70). University students rated Eclipse less positively but also 
less negatively than Marlboro Lights after seeing a single advertisement for each 
product, although none had ever tried the product (71). Shiffman and colleagues 
showed in two studies (67, 69) that smokers perceived Eclipse as reducing harm 
and that interest in using Eclipse was associated with reduced intention to quit 
smoking. Hamilton and colleagues (64) showed advertisements for several PREPs 
and conventional tobacco products to smokers and found that, even though the 
advertisements contained no health claims, PREPs were still perceived as less of 
a health risk and conveyed positive messages about health and safety. Data from 
Japan (72) suggested that a significant minority of consumers were aware of and 
interested in HTPs (72). Although 48% of the 8240 respondents to the survey were 
aware of e-cigarettes and/or HTPs, actual use of any products was fairly low; 6.6% 
had used any of the products, and the vast majority had used e-cigarettes. These 
are not legally sold in Japan but may be imported by individuals for personal 
use. Only 0.51% of the respondents had ever used Ploom, and 0.55% had used 
iQOS (7.8% and 8.4%, respectively, among users of any HTP). A later study (73) 
showed a dramatic growth in use between 2016 and 2017, the prevalence of iQOS 
use rising from 0.6% in 2016 to 3.6% in 2017.
Heated tobacco products
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A common reason given for the failure of novel products is rejection 
by consumers because of their poor taste (74,75). Sensory characteristics are an 
important part of cigarette design (76, 77). A consistent finding of clinical studies 
of subjective effects of Eclipse and Accord is that the products are perceived 
negatively relative to their own brand, with generally low ratings of satisfaction 
and higher ratings of dislike (6, 7, 10, 22, 23). Established smokers who took 
part in focus groups reported significant dislike of the PREP cigarettes that they 
tried, including Eclipse and Accord, and almost all reported that they would not 
recommend the products to other smokers (78, 79). Caraballo and colleagues (78) 
found that established smokers who had tried Eclipse generally disliked the product 
and would not recommend it to other smokers. Most smokers who reported that 
they disliked Eclipse cigarettes considered them too mild and said that they did not 
deliver enough nicotine to satisfy their craving; many reported that they disliked 
the taste. Hughes and colleagues (80) reported that smokers who tried Eclipse 
generally did not like it, although they believed it to be safer than conventional 
cigarettes. A study of the Pax vaporizer (63) indicated that the vaporizer did 
partially suppress symptoms of abstinence but was considered significantly 
less satisfying and less tasty than the participants’ own brand of cigarettes.
Studies published by PMI on its THS device include data on subjective 
responses to the product, which were not provided in reports of studies of 
EHCSS and previous-generation products. These data are often important for 
understanding why smokers use a product and how effective it might be as a 
substitute (81, 82). The studies were conducted with the widely used modified 
cigarette evaluation questionnaire (83) and the brief questionnaire on smoking 
urges to measure craving (84). The cigarette evaluation questionnaire consists of 
12 items (seven-point scales) and resolves to five scales of: smoking satisfaction, 
aversion, craving reduction, enjoyment of respiratory tract sensation and 
psychological reward (83). The questionnaire on smoking urges consists of 10 
items and provides a single score on a seven-point scale (84).
In a laboratory study of a THS in Japan, the mean satisfaction scores 
decreased more for the THS than for conventional cigarettes over the course 
of the study (mean = –0.69; 95% confidence interval (CI), –0.34, –1.04) (58). 
Other scores in the cigarette evaluation questionnaire did not change or differ 
as substantially from those for cigarettes. No difference in the scores on the 
questionnaire on smoking urges was observed for the THS and conventional 
cigarettes, both of which were lower than that for smoking abstinence (as 
expected). In a similar study in Poland, the observed differences in subjective 
effects between a THS and cigarettes were substantially larger and statistically 
significant for satisfaction (mean = –1.26; 95%  CI, –0.85, –1.68), craving 
reduction (mean = –1.12; 95%  CI, –0.66, –1.58), sensation (mean = –1.00; 
95%  CI, –0.64, –1.36) and reward (mean = – 0.72; 95%  CI, –0.39, –1.06). No 
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significant difference in craving scores was seen between the THS and cigarettes, 
and both were significantly lower than those for abstinence. These studies suggest 
that Polish smokers viewed the THS less positively than Japanese smokers; this 
may have implications for the generalization of observations from one market to 
another. An earlier study of THS 2.1 (85) showed a similar pattern of results, with 
satisfaction scores on day 5 an average of 1.4 points lower for the THS than for 
conventional cigarettes (P <.001). Significant differences were also seen on the 
reward, sensation and craving subscales, the THS scoring lower than cigarettes in 
all cases. A study on longer-term use in Japan (61) suggested that the difference in 
satisfaction fades with continued use over 90 days. These data suggest that scores 
on the questionnaire on smoking urges increase for the THS over time, as do 
scores for withdrawal (as measured on the Minnesota nicotine withdrawal scale 
(86)). This may suggest some dissatisfaction with the product as a longer-term 
substitute for smoking over time.
2.6 Uptake in selected markets where products are available
Three studies have been conducted of population uptake of HTPs in Italy and 
Japan. In Italy, 1% of “never smokers”, 0.8% of former smokers and 3% of current 
cigarette smokers had tried iQOS (87). Tabuchi and colleagues (73) showed a 
rising prevalence of current use of iQOS (from 0.3% to 3.6%) and Ploom (from 
0.3% to 1.2%) after 2015, with comparable prevalence for use of glo in 2017 
(0.8%). Predictors of use of HTPs were current cigarette smoking (stronger effect 
with intention to quit), living in a more deprived area and having seen television 
promotion of iQOS. Dual use was common (72%). Unlike for conventional 
cigarette smoking, there does not appear to be an inverse relation between 
education and HTP use in Japan (88).
One reason that HTPs are gaining a market share in Japan is that nicotine-
containing ENDS are not permitted for sale. Thus, HTPs may fill a market niche in 
a country with a relatively high smoking rate and relatively weak tobacco control 
laws. iQOS has become available in several markets in the European Union 
(which permit sale of ENDS) and in Canada (which did not permit such sales 
until 2018). In a presentation to the Consumer Analyst Group of New York in 
2017 (89), PMI reported that the attained market share of iQOS had reached 4.9% 
in Japan in the fourth quarter of 2016 but was substantially lower in marketing 
focus areas in Switzerland (1.7%), Portugal (0.7%), Romania (0.6%), Italy (0.4%) 
and the Russian Federation (0.3%), where the product had been available for at 
least one year. High rates of conversion to iQOS were claimed on the basis of their 
user panels, ranging from 54% in Switzerland to 72% in Japan.
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2.7 Application by Philip Morris International for status as a 
“modified risk tobacco product” in the USA
In May 2017, PMI submitted an MRTP application for its THS/iQOS to the 
United States Food and Drug Administration (FDA) for review. The three health 
claims under consideration were:
 ■ “Switching completely from cigarettes to the iQOS system can reduce 
the risks of tobacco-related diseases.”
 ■ “Switching completely to iQOS presents less risk of harm than con-
tinuing to smoke cigarettes.”
 ■ “Switching completely from cigarettes to the iQOS system significantly 
reduces your body’s exposure to harmful and potentially harmful 
chemicals.”
In compliance with the Tobacco Control Act, redacted2 versions of the full 
application were made available for public review and comment on the website of the 
FDA (https://www.fda.gov/tobaccoproducts/labeling/marketingandadvertising/
ucm546281.htm). Much of the technical information about the device has been 
redacted. The findings cited in publicly available parts of the application that are 
not discussed above (i.e. unpublished studies) are discussed below.
The online material includes an additional human trial with THS 2.2, conducted 
in the USA in 2013–2014 (NCT01989156). Of the 160 participants who were 
randomized, 88 completed the full 90-day study. As in the studies in Japan and 
Poland, key biomarkers of exposure were significantly reduced as compared with 
those for cigarette smoking after 5 and 90 days. Compliance with abstinence 
was, however, substantially lower in this study than in that in Japan during the 
ambulatory phase, suggesting that experience in Japan cannot necessarily be 
generalized to the USA.
The MRTP documents also report on a series of studies to test the specific 
claims requested for iQOS on the United States market. A series of qualitative and 
quantitative studies is described, concluding with three “assessment phase” studies 
on comprehension of claims and risk perception in a variety of contexts (package, 
brochure, direct mail). PMI developed a multi-factor risk perception scale for use 
in this study. The studies were conducted with three samples of approximately 
2500 adult current smokers (with and without intention to quit), 2500 former 
smokers and 2500 nonsmokers. iQOS was rated as being of intermediate risk 
between cigarettes and quitting, comparable to the risk rating for e-cigarettes. 
Comprehension of claims was good, although there was evidence that about 
25% of the participants extrapolated reductions in exposure to reduced harm 
2  Applications are redacted to remove information considered to be commercially confidential 
and/or trade secrets under United States law. 
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(which is potentially erroneous). It was not evident that the claims shifted risk 
perceptions of iQOS or led to increased intention to try iQOS among smokers.
A series of observational studies were reported on product-switching in 
Germany, Italy, Japan, the Republic of Korea, Switzerland and the USA. “Whole 
offer tests” were conducted with 2089 daily smokers in the first five countries. 
iQOS was made available for free for 4 weeks, and product use was recorded in 
electronic diaries. At the end of the 4-week trial, the rate of switching to a THS 
ranged from 10% in Germany to 37% in the Republic of Korea, and the rate of 
dual use ranged from 32% in Japan to 39% in the Republic of Korea. The study in 
the USA comprised 1106 current daily smokers who, after a 1-week baseline, were 
given free access to iQOS for 4 weeks. Product use (cigarettes and Heatsticks) 
was recorded in an electronic diary. At the end of the study, approximately 15% 
of subjects had switched to the THS, as defined in the study (>  70% of total 
consumption as Heatsticks), while 22% were dual users (30–70% of consumption 
as Heatsticks).
Limited post-marketing data were presented, primarily from Japan, 
drawing on PMI’s registry of iQOS purchasers. They reported that the proportion 
of exclusive iQOS use (> 95% of total consumption) increased from 52% to 65% 
between January and July 2016. Markov modelling of transition in two cohorts 
of iQOS purchasers in Japan (September 2015 and May 2016) suggested that 
smokers who converted to exclusive iQOS use were unlikely to return to exclusive 
cigarette use (although scant details of the modelling are given in the executive 
summary).
At the meeting of the FDA Tobacco Products Scientific Advisory Committee 
in January 2018,3 PMI presented evidence in support of iQOS, including much of 
the data contained in this report. The FDA presented its preliminary evaluation 
of the submission, and the Committee expressed concern about portions of the 
evidence base, in particular the definitions of “complete switching” and limitations 
to the studies that underlie consumer understanding of the claims. The Committee 
did not support the claims of risk modification, expressed support for the claim 
of exposure modification and expressed concern that the claims as worded would 
not be effective in communicating risk.1 The Committee’s recommendations to the 
FDA are nonbinding.
2.8 Implications for regulation and tobacco control policies
Predicting the uptake of unconventional tobacco products can be difficult. 
Analyses of trial testimony by the tobacco industry on older-generation PREPs 
showed that the industry sought to shift the focus from their responsibility to 
produce “safer” products to failure of smokers to adopt the “safer” products they 
3 See https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/TobaccoPro 
ductsScientificAdvisoryCommittee/UCM599235.pdf.
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have been offered (75). Nonetheless, this market segment appears to be growing 
rather than shrinking and is capturing a significant market share in at least one 
country, Japan, where PMI claims to have sold more than 1 million iQOS devices 
(90). The human studies available (all performed by the manufacturer) indicated 
that iQOS deliver fewer toxicants than cigarettes and may serve as an effective 
short-term substitute for conventional cigarettes, as assessed by nicotine delivery 
and subjective effects measured on the cigarette evaluation questionnaire; one 
90-day study suggested similar outcomes. It must be remembered, however, that 
the participants in these research studies were compensated, and the results may 
therefore not reflect real usage patterns, including concurrent use of multiple 
products. In December 2017, committees on the Toxicity, Carcinogenicity and 
Mutagenicity of Chemicals in Food, Consumer Products and the Environment 
evaluated two HTPs on the market in the United Kingdom (iQOS and iFuse) and 
concluded (91) that:
  “While there is a likely reduction in risk for smokers switching to 
‘heat-not-burn’ tobacco products, there will be a residual risk and it 
would be more beneficial for smokers to quit smoking entirely. This 
should form part of any long-term strategy to minimize risk from 
tobacco use.”
“Product drift” may be another important consideration. In their presentation 
to the Consumer Analyst Group of New York (89), PMI described certain 
modifications made to the device from the original product pilot-tested in 
Japan in 2014–2017, including better aesthetics, blade self-cleaning, better user 
interface, faster charging, Bluetooth connectivity and an accompanying mobile 
application. Colours are being used to increase the appeal of the device. Thus, 
a product may be a “moving target” after its introduction. These practices are 
not unlike those of the tobacco industry of making minor adjustments to their 
cigarette products over time and by market (92–94), such that a Marlboro cigarette 
in 2017 is not necessarily identical to one in 2010, and a Marlboro sold in France 
is not necessarily the same as one sold in the USA. In addition, data on a product 
from research studies may not fully reflect the product currently available to 
consumers. Thus, research to support a product is not necessarily conducted 
with the final marketed product but with a prototype or even a series of different 
prototypes. While this practice is not in itself nefarious, any differences in design, 
function or presentation between the studied and marketed product should be 
established, including their impact on consumer use. The FDA requires reporting 
of changes to an existing product for marketing authorization and may monitor 
them, with greater scrutiny and requirements for changes that impinge on public 
health (e.g. changes to delivery of HPHCs; substantial design changes). European 
Union Member States have similar provisions, in line with the Tobacco Products 
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Directive. Regulators in other countries should consider a similar requirement 
for notice and justification of changes to products.
Side-stream emissions and second-hand exposure are further concerns 
with the introduction of unconventional tobacco products. Some tobacco 
manufacturers claim that certain HTPs result in minimal exposure to side-
stream smoke (42, 46, 95, 96), whereas some studies indicate substantial levels 
(97, 98). The emissions may depend in part on the design of the product. Side-
stream emissions have health and regulatory implications, and further research 
is needed to characterize environmental exposure from HTPs. Depending on the 
wording of claims, HTPs may or may not be covered by smoke-free legislation, 
for example. Nevertheless, the precautionary principle would support covering 
such emissions in regulations.
2.9 Recommendations for research and policy
Independent scientific evidence is required to verify the claims of industry 
scientists for reduced exposure and risk. The studies published in the peer-
reviewed literature up to October 2017, primarily by PMI on their THS 2.2 
product, focused on a subset of HPHCs. Biomarkers of exposure to metals, such 
as cadmium, were not reported in these studies. Metals are a concern both as 
carcinogens and potentiators (cadmium, nickel, cobalt, arsenic) and as toxicants 
in their own right (lead, copper). While most of the studies indicated reduced 
exposure to HPHCs as compared with cigarette smoking, the studies did not 
address the possibility of novel exposure from the THS, either from the heating 
system itself or from the additives used in the tobacco. In its MRTP presentation 
to the FDA Tobacco Products Scientific Advisory Committee, when pressed 
on these issues, PMI acknowledged that 50 constituents in iQOS aerosol were 
present at higher levels than in conventional cigarette smoke, three of which are 
unique to iQOS; about 750 constituents occur at equal or lower levels in iQOS 
than in conventional cigarette smoke, and > 4000 are unique to cigarette smoke. 
Of the 50 constituents, four were identified as of toxicological concern (glycidol, 
2-furanemethanol, 3-monochloro-1,2-propanediol and furfural).
Few published data are available on British American Tobacco’s HTPs, 
although a study protocol for a randomized trial has been published (62), 
suggesting ongoing work in this area by the company. No published studies 
on Japan Tobacco International’s Ploom product were identified, and data on 
exposure to tobacco HPHCs from personal vaporizers are similarly lacking. Data 
on usage and sales of personal vaporizers for tobacco use are extremely difficult 
to locate, and comparisons with this market segment cannot be made. Use of 
such devices to administer cannabis appears to be increasing (99–101).
Some suggestions for near- and long-term research priorities are:
Heated tobacco products
23
 ■ monitoring of product availability, sales and marketing with validat-
ed tools (e.g. (102));
 ■ monitoring of product use, including complete switching, dual (or 
poly) use, use as compared with ENDS and initiation by non-tobacco 
users, with a particular focus on low-risk young people who would 
not otherwise have smoked;
 ■ verification of reported product contents and emissions of the 39 pri-
ority toxicants and/or the FDA HPHC list;
 ■ evaluation of potential novel toxicants produced by heated tobacco 
products that are not covered by commonly accepted lists (e.g. Hoff-
man analytes, HPHCs);
 ■ evaluation of aerosol particle size distribution;
 ■ assessment of device function and safety (e.g. batteries);
 ■ cross-market comparisons of products, e.g. whether iQOS is the 
same in all markets and differences in the characteristics, contents 
and emissions of products and how they have changed over time;
 ■ independent clinical and biomarker analyses of users according to 
typical patterns of use, including dual or concurrent use of heat-not-
burn products and cigarettes;
 ■ public perceptions of products (awareness, intention to use, risk) 
among users and non-users of tobacco;
 ■ information on who is purchasing a product, reasons for purchasing 
and use patterns;
 ■ research on rates of conversion of smokers to HTPs and vaping 
(ENDS) products, to determine whether these products discourage 
smoking in a way that is acceptable to smokers;
 ■ modelling of potential population-level effects of the introduction 
and use of products (e.g. SimSmoke; microsimulation);
 ■ investigation of the influence of marketing strategies on user behav-
iour, including whether these products are marketed as complemen-
tary or alternative products;
 ■ effect of heat treatment on components in products other than to-
bacco (e.g. flavours); and
 ■ studies of exposure to second-hand emissions (including effects on 
children and pregnant women) and their contribution to background 
air quality.
24
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3.1 Introduction
Electronic nicotine delivery systems (ENDS) are a heterogeneous class of 
products in which an electrically powered coil is used to heat a liquid matrix, 
or e-liquid, that contains nicotine, solvents (e.g. propylene glycol, vegetable 
glycerine) and, usually, flavourings. The user inhales the resulting aerosol, which 
contains variable concentrations of nicotine (1), a dependence-producing central 
nervous system stimulant. In many countries and certainly in the two largest 
markets – the European Union and the USA – ENDS are regulated either as 
generic consumer products or as tobacco products (2).
Products such as ENDS that are marketed to the public and contain 
drugs that act on the central nervous system, such as nicotine, ideally should 
have little potential for abuse or dependence for public health reasons. This is 
true, unless some level of abuse potential is desirable to maintain compliance and 
support substitution in place of a substance of greater potential abuse and harm. 
ENDS fall into this category on the basis of claims of a potential role in smoking 
cessation and reduction.
The purpose of this background paper is to review the literature at the 
time of writing with some additions after review between March and December 
2018 on the nicotine content and nicotine delivery of ENDS and to explore factors 
that influence the emissions of nicotine and non-nicotine toxicants. In addition, 
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we review the potential role of ENDS in smoking cessation and the prospective 
population health impact. We also identify some relevant research gaps and make 
recommendations for policy.
3.2 ENDS operations
Understanding how ENDS operate is useful. Fig. 3.1 is a schematic drawing of a 
common ENDS configuration. The heating coil is attached to an electrical power 
source (usually a battery, not shown in the figure) enclosed in a fabric wick that 
is in turn surrounded by the nicotine-containing e-liquid that saturates the wick. 
When power is flowing, the coil heats and thus vaporizes some of the e-liquid 
from the wick. As the user draws air from the mouth-end of the ENDS, the vapour 
is carried away and re-condenses to form an aerosol, which is inhaled by the user.
Fig. 3.1. Schematic drawing of ENDS operation
Source: Dr Alan Shihadeh, American University of Beirut, Lebanon.
Several factors influence the amount of nicotine carried by the aerosol, including 
the electrical power flowing through the ENDS, the inhalation behaviour (or 
“puff topography”) of the user and the amount of nicotine in the e-liquid (3). 
Electrical power (W) is a function of battery voltage (V) and coil resistance 
(Ω), such that W = V2/ Ω. Early ENDS models were powered at ≤ 10 W, but the 
devices marketed currently are powered at ≥ 250 W (4, 5). Higher power is often 
achieved with coils with low resistance (e.g. < 1 Ω), application of varying voltage 
to the coil or a combination.
Puff topography variables include puff number, duration and volume and 
the interval between puffs (inter-puff interval). User puff topography is highly 
individual. Experienced ENDS users, however, typically take longer puffs than 
ENDS-naive cigarette smokers (6–9) (see Fig. 3.2 and description below).
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Fig. 3.2. Mean plasma nicotine concentrations before and after use of a combusted cigarette and of ENDS
Panel A, N=32 (8); Panel B, N=33 (8); Panel C, N=31 (8); Panel D, N=11 (4) (puff topography not available). Source: Figure adapted 
from one published previously (1) by adding puff duration data and updating Panel D.
3.3 Nicotine concentration in e-liquids
The nicotine-containing e-liquid used in ENDS comes in prefilled cartridges or 
refill bottles, depending on the type of device used. The concentration of nicotine 
in marketed e-liquid can reach 36 mg/mL or more (1), and users can choose from 
a wide range of concentrations at the point of sale; some manufacturers provide 
labelling information relevant to the e-liquid. There has been no comprehensive 
study, however, of the extent to which manufacturers accurately inform consumers 
of the nicotine concentration in a representative sample of e-liquids, globally or 
by country. Existing studies give a partial picture based on convenience samples.
The proportion of e-liquids that have clear label information on the nicotine 
content is unknown. Some studies indicate that such information is not always 
available (10, 11) or interpretable (12) from the manufacturer’s label. Nevertheless, 
the concentration of nicotine is usually reported on the label as a percentage of 
total volume or as mg/mL. Table 3.1 lists studies in which the concentration of 
nicotine was analysed in e-liquids that allegedly contained nicotine and compared 
with the concentration reported on the manufacturer’s label.
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Table 3.1. Comparison of labelled and measured concentrations of nicotine in e-liquids with declared nicotine
First author and 
reference number
Type of e-liquid 
container
Number of samples
Analysed
> ±10% of labelled 
concentration
> ±25% of labelled 
concentration
Beauval (13) Refill bottle 2 0 0
Buettner-Schmidt (14) Refill bottle 70 36 NA
Cameron (15)
Prefilled cartridge and 
refill bottle 21 13 7
Cheah (10) Cartridge 8a 8b 7b
Davis (16) Refill bottle 81 36 21
El-Hellani (17) Prefilled cartridge 4 4 4
Etter (18) Refill bottle 35 4 0
Etter (19) Refill bottle 34 10 0
Farsalinos (20) Refill bottle 21 9 0
Goniewiscz (21) Refill bottle 62 25 7
Kim (22) Refill bottle 13 7 2
Kirschner (23) Refill bottle 6 6 4
Kosmider (24) Refill bottle 9 2 0
Lisko (25) Refill bottle 29 15 7
Pagano (26) Prefilled cartridge 4 3 2
Peace (27) Refill bottle 27 16 7
Rahman (28) Refill bottle 69 65 53
Raymond (29) Refill bottle 35 22 22
Trehy (30) Prefilled cartridge 22 22 19
Trehy (30) Refill bottle 17 8 6
NA: not available. a Number of brands analysed; number of samples analysed not provided. b Number of brands in which at least 
one sample had a nicotine concentration per cartridge above the criterion.
The majority of the studies showed nicotine concentrations below those reported 
by the manufacturer, and all except one indicated that the nicotine concentrations 
in some samples were at least 10% below or above that reported on the label 
of the product, meeting a quality criterion recommended by a United States 
manufacturers’ association (31). In a median of 53% of samples, the nicotine 
concentration was misreported on the label by at least 10%, and in a median of 
26% of samples, the nicotine concentration was misreported by at least 25%.
We know of only three studies of the consistency of nicotine concentration 
in e-liquids in different batches of the same brand and model of e-liquid. The 
median variation among production batches was 0.5% in one (19) and 15% (16) 
and 16% (32) in the other two.
Other studies have shown that some products labelled as not containing 
nicotine do have measurable nicotine levels. Table 3.2 lists studies in which the 
concentration of nicotine in e-liquids was analysed and compared with a reported 
absence of nicotine on the label. Almost half the studies reported that small 
amounts of nicotine were present in some e-liquids advertised as not containing 
nicotine. Furthermore, in about 5% of samples of e-liquids allegedly without 
nicotine, the concentration of nicotine was significant.
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Table 3.2. Labelled and measured nicotine concentrations in e-liquids with declared zero nicotine
First author and 
reference number
Samples Nicotine concen-
tration in samples 
containing > 0. 1 
mg/mLAnalysed
Nicotine  
> 0.1 mg/mL Nicotine > 10 mg/mL
Beauval (13) 2 0 0 –
Cheah (10) 2 0 0 –
Davis (16) 10 0 0 –
Goniewiscz (21) 28 3 0 0.8–0.9
Kim (22) 20 0 0 –
Lisko (25) 5 0 0 –
Omaiye (33) 125 17 2 0.4–20.4
Raymond (29) 35 6 6 5.7–23.9
Trehy (30) 8 2 2 12.9–24.8/cartridge
Trehy (30) 5 2 2 12–21
Westenberger (34) 5 0 0 –
3.4 Nicotine delivery to ENDS users
The nicotine delivery profile of ENDS may be an important determinant of how 
effectively the product can substitute for a cigarette for a long-term smoker. 
Fig. 3.2 demonstrates the influence of the nicotine concentration in e-liquid, user 
behaviour and device power on the nicotine delivery profile of ENDS relative to 
a cigarette. Panel A (9) shows the nicotine delivery profile of a cigarette when 
smokers take 10 puffs with a 30-s inter-puff interval. Panel B shows the nicotine 
delivery profile of a 7.3-W ENDS loaded with 0, 8, 18 or 36 mg/mL nicotine 
e-liquid when users took 10 puffs of an average length of 3.6 s at a 30-s inter-
puff interval. Clearly, the e-liquid nicotine concentration influences delivery of 
nicotine to the users’ blood. When the 7.3-W ENDS is paired with 36 mg/mL 
nicotine e-liquid and when users take 10 ~5.6-s puffs, the pairing can match or 
exceed the nicotine delivery profile of a combusted cigarette (8).
Puff duration is also a factor in ENDS nicotine delivery: Panel  C (8) 
shows the same device and e-liquid nicotine concentration as in Panel B, but the 
study participants took shorter puffs (2.9 s on average). When the puff duration is 
shorter and all other device and e-liquid characteristics are constant, less nicotine 
is delivered. Panel D shows the nicotine delivery profile of higher-powered ENDS 
devices (mean power, 71.6 W) when users took 10 puffs at a 30-s inter-puff interval 
(4). When these higher-powered devices were paired with 4 mg/mL nicotine 
liquid, they approximated the nicotine delivery profile of a combusted cigarette.
Overall, at least in some cases, these data suggest that some ENDS can 
deliver the same dose of nicotine, at the same rate as a cigarette, to venous 
blood. Unfortunately, few studies have been conducted to compare the ability 
of ENDS and cigarettes to deliver nicotine to arterial blood, an important 
indicator of exposure of the central nervous system to the drug (35). In the only 
such comparison to date, 10 puffs (30-s inter-puff interval) from a 7.3-W ENDS 
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with 36 mg/mL liquid resulted in a lower mean arterial nicotine concentration 
(maximum, 12 ng/mL) than 10 puffs (30-s inter-puff interval) from a cigarette 
(maximum concentration, 27 ng/mL), although the time to peak concentration 
did not differ (36). The sample was, however, small (four for ENDS; three for 
cigarettes), and puff duration was not measured. Under the controlled conditions 
of this study, positron emission tomography imaging showed that this ENDS 
effectively delivered nicotine to the central nervous system.
While the ENDS used to generate the data for Fig. 3.2 can deliver nicotine 
as effectively as a cigarette under some conditions, many ENDS cannot (6, 9, 
37–41). This heterogeneity in ENDS nicotine delivery is in contrast to regulated 
nicotine replacement products that deliver nicotine more reliably, although they 
often achieve lower plasma concentrations at a slower rate. For example, as shown 
in Panel A in Fig. 3.3 (42), nicotine chewing-gum can take ≥ 30 min to achieve a 
peak plasma concentration, while Panel C shows that a nicotine patch can take 
> 2 h (43, 44); other therapeutic products (e.g. nicotine lozenges) also deliver 
nicotine within this time frame (43). Presumably, ENDS that deliver nicotine to 
the blood and brain as effectively as a cigarette are more likely to substitute for a 
cigarette, although this speculation has not been tested empirically, as the ENDS 
used in clinical trials on the question did not deliver nicotine effectively (45).
Fig. 3.3. Plasma nicotine concentrations before, during and after administration of a single dose of nicotine 
in several therapeutic forms
 
Note: the grey bar indicates duration of product use. Source: reference 42. Reprinted with permission from the Massachusetts 
Medical Society.
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3.5 Toxicant content of ENDS emissions
ENDS toxicant emissions are a function of a variety of factors, including device 
construction, device power, liquid constituents and user behaviour. We review 
below the literature on ENDS toxicant emissions, beginning with nicotine and 
then moving to non-nicotine toxicants (for reviews of older literature, see Breland 
et al. (1) and Department of Health and Human Services (46)).
3.5.1 Nicotine emissions
The “yield” of nicotine from ENDS is the amount (in mg) of nicotine in the 
aerosol produced by an ENDS under a specific puffing regimen. Knowing the 
yield of nicotine from ENDS has been considered important for understanding 
the pharmacokinetics of nicotine in ENDS users. One review of the literature 
(47) identified seven studies of nicotine yield (30, 34, 48–52); since then, several 
other studies on this issue have been published (3, 33, 53, 54).
The nicotine yields in these studies were highly variable, depending on 
the type of ENDS used, the nicotine concentration of the e-liquids and the puffing 
regime used to obtain the aerosol. Some methodological issues complicate the 
comparability of studies, including the fact that the ISO methods of machine-
smoking ENDS fail to activate some ENDS models. Although the nicotine yields 
from ENDS in these studies are not fully comparable with those from machine-
smoked cigarettes, they are usually much lower than those from cigarettes (47). 
The literature is, however, limited, for two important reasons. First, nicotine yield 
does not capture the rate of nicotine emission, which is a measure not only of 
the amount but also of the speed at which nicotine is made available to the user. 
The rate of nicotine emission is almost certainly related to the rate of nicotine 
delivery, and the rate of nicotine delivery is probably a key factor in the capacity 
of a nicotine-containing product to substitute for cigarettes by providing nicotine 
that rapidly reaches peak levels in the bloodstream and enters the brain (55). 
Secondly, ENDS and their e-liquids are so heterogeneous that the results of a 
study on a particular ENDS are probably not generalizable to another.
To address the first concern, there is growing interest in measuring 
nicotine “flux”, the rate at which nicotine is emitted from ENDS (56, 57). Nicotine 
flux can be measured (usually reported in µg/s) and can be compared among 
ENDS and with cigarettes. Those ENDS that mimic the flux of a cigarette may be 
more likely to substitute well for a cigarette than ENDS that do not. To address 
the second concern, a physics-based mathematical model has been developed 
to predict the nicotine flux of any ENDS (58) – even those that have not yet 
been constructed. The model accounts for the time it takes for the coil to heat 
up after electricity begins flowing and how much the coil cools down between 
puffs. It also accounts for the various ways in which heat can be transported 
away from the coil: by the air passing over it, by the latent heat of the e-liquid 
38
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
as it evaporates, by conduction through the metal solder to the body of the 
device and by radiation to the surroundings. The inputs to the model are the 
length, diameter, electrical resistance and thermal capacitance of the heater 
coil; the composition and thermodynamic properties of the e-liquid (including 
nicotine concentration); puff velocity and duration and inter-puff interval; 
and the ambient air temperature. In a test of the model, the authors compared 
its predictions against actual nicotine flux measurements for 100 conditions 
in which power, puff topography, ENDS type (tank or cartomizer) and liquid 
composition were varied. The mathematically predicted nicotine flux was highly 
correlated to measured values (r = 0.85, P <.0001) (58). In addition, the model 
accurately predicted the dependence of nicotine flux on device power and 
nicotine concentration (see Fig. 3.4), the ratio of propylene glycol and vegetable 
glycerine in the liquid and user puff duration. Fig. 3.4 shows that the higher the 
electrical power of the device, the lower the e-liquid nicotine concentration 
required to achieve a given flux. Cigarette flux is 100 µg/s, and the lines depict 
ENDS nicotine fluxes equivalent to twice, once and half that of a cigarette. Given 
the relation between ENDS power and liquid nicotine concentration shown in 
Fig. 3.4, a nicotine flux that is dramatically greater than that of a cigarette can be 
achieved by pairing a higher-powered ENDS with a higher concentration liquid. 
The figure does not show that some ENDS are powered well over 100 W (4, 5).
Fig. 3.4. Relation between ENDS power and e-liquid nicotine concentration and effect on nicotine flux
Source: reference 58, reproduced with permission from Dr Alan Shihadeh, American University of Beirut, Lebanon.
Another important issue with regard to ENDS nicotine emissions is the amount 
of nicotine in e-liquids and aerosols that is present in its more bioavailable, 
free-base form, as opposed to the less bioavailable protonated form (17). Some 
studies of nicotine emissions from e-cigarettes have reported nicotine yields 
without determining whether the methods used resulted in quantification of 
total nicotine or only one of its forms (38, 58), so that the reported results are 
difficult to compare or to evaluate with regard to nicotine delivery to the user. 
In an evaluation of this issue, the free-base nicotine fraction in 19 commercial 
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liquids varied widely (10–90%), and, importantly, the differences were also seen 
in the aerosol (17, 59), suggesting another factor that probably influences ENDS 
nicotine delivery to the user. Thus, in addition to measuring nicotine flux, the 
form of the nicotine in the aerosol should be determined. Overall, as for nicotine 
delivery to the user, there is considerable variation in nicotine emissions from 
ENDS, which can be explained and predicted by careful consideration of the 
many factors that influence it, especially ENDS power, liquid constituents and 
user behaviour.
3.5.2 Emissions of non-nicotine toxicants
Non-nicotine toxicants in ENDS aerosols are either present in the liquid or 
formed when the liquid is heated. Those present in the liquid before heating 
include propylene glycol and vegetable glycerine, which together make up 80–
97% of the content of most e-liquids (60), flavourings and other compounds 
added intentionally and contaminants not added intentionally. Aerosolized 
propylene glycol is a respiratory irritant (61–64) and, when administered 
intravenously at high doses, can cause potentially fatal lactic acidosis (65). 
Preclinical work also indicates that vegetable glycerine may be toxic at high doses 
(66, 67). The health effects of long-term, daily, chronic inhalation of aerosolized 
propylene glycol and/or vegetable glycerine are unknown. The flavourings used 
in e-liquids are usually compounds that are added to food, and their effects on 
the human lung after having been heated and aerosolized are unknown (68). At 
least three flavourings that have been found in e-liquids and aerosols have raised 
health concerns: diacetyl (buttery flavour), which causes bronchiolitis obliterans 
(69); benzaldehyde (fruity flavour), which is cytotoxic and genotoxic (70); and 
cinnamaldehyde (cinnamon flavour), which is also cytotoxic and genotoxic (71) 
and can cause an inflammatory response in lung cells (72). The contaminants 
include diethylene glycol, ethylene glycol and ethanol (73, 74). Even if rigorous 
quality controls are imposed to ensure contaminant-free e-liquids, the uncertain 
effects of long-term, daily, frequent inhalation of aerosolized propylene glycol and 
vegetable glycerine and the many chemical flavourings that are often combined 
in a single liquid pose a potential health threat for ENDS users.
The non-nicotine toxicants formed when the liquid is heated include 
metals, volatile aldehydes, furans and benzene. In one study of 11 “first-
generation” ENDS brands (disposable ENDSs shaped like tobacco cigarettes), 
three of each brand were puffed for 4.3 s every 5 min for two series of 60 puffs, 
and the resulting aerosol was analysed for elements, including metals (75). The 
results revealed substantial variation among brands, but many metals were found 
in the aerosol generated from most brands, “in some cases at concentrations that 
were significantly higher than in conventional cigarettes”. The authors concluded 
that most of the elements and metals in ENDS aerosols probably originate from 
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components in the atomizer, such as the filament, solder joints, wick and sheath. 
These results show how ENDS construction can contribute to the non-nicotine 
toxicant profile of the aerosol.
In a study of an advanced-generation ENDS with a 1.5-Ω heating 
element and variable voltage battery (3.3–5.0 V), the aldehyde content of aerosols 
produced from a variety of liquids (all 6 mg/mL nicotine) was compared after 
10 4-s puffs of 91 mL/puff (76). Power was manipulated systematically from 9.1 
to 16.6 W. Acetaldehyde, acetone, acrolein and formaldehyde were all present 
in ENDS aerosols, and aldehyde production increased proportionally as puff 
volume increased and dramatically when the power was > 11.7 W. The presence 
of aldehydes in ENDS aerosol is now well documented (77–79), as is the role 
of device power in forming them: increasing ENDS power from 4.1 to 8.8 W 
approximately tripled volatile aldehyde emissions (80–83). There also is some 
suggestion that flavourings contribute to non-nicotine toxicants formed during 
heating (84–87). For example, heating sweeteners in e-liquids may expose users 
to furans, a toxic class of compounds. In one study (88), a VaporFi platinum tank 
ENDS (2.3 Ω) was used to generate aerosol under various conditions, including 
power (4.2 and 10.8 W), puff duration (4 and 8 s) and sweetener (sorbitol, glucose 
and sucrose). The per-puff yield of some furans was comparable to values reported 
for combustible cigarettes, and, again, device power is a factor: increasing power 
from 4.3 to 10.8 W more than doubled furan emissions. With regard to benzene, 
increasing ENDS power from 6 to 13 W increased emissions of this carcinogen 
100 times (89), although the level remained far below those found in cigarette 
smoke. The fact that volatile aldehydes, furans and benzene are all formed by 
thermal degradation of the contents of e-liquids (e.g. propylene glycol, vegetable 
glycerine, sweeteners), coupled with the fact that increased device power 
increases the amount of these toxicants in ENDS aerosols, suggests that high-
power ENDS are a particular public health concern. To date, most studies of the 
toxicant profile of ENDS aerosols have been limited to devices powered at 25 W 
or less (e.g. references 80, 83, 88, 90), and much of the data reported here may 
not be relevant to the higher-powered devices common in some locations (4, 5).
3.6 Potential role of ENDS in smoking cessation
Six narrative reviews (91–96) and six systematic reviews (97), of which five were 
meta-analyses (98–103), addressed the role of electronic nicotine and non-
nicotine delivery systems (EN&NNDS) in smoking reduction and cessation. Two 
meta-analyses (100, 102) covered studies available up to January 2016.
All five systematic reviews of the quality of the evidence (97, 98, 100, 102, 
103) concluded that the available studies provide evidence of low to very low 
certainty, due mainly to the limitations of the cross-sectional and cohort studies 
included in the reviews and the lack of detail in many of the published articles. 
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Given these limitations, El Dib et al. (102), and Malas et al. (97) concluded that 
no credible inferences could be drawn from their reviews and that the evidence 
remains inconclusive. Similarly, a review of the systematic reviews concluded 
that “overall, there is limited evidence that e-cigarettes may be effective aids to 
promote smoking cessation” (104). The other systematic reviews, however, came 
to a different conclusion. While Kalkhoran & Glantz (101) determined that “as 
currently used, e-cigarettes were associated with significantly less quitting among 
smokers”, Hartmann-Boyce et al. (100) and Rahman et al. (98) concluded that use 
of e-cigarettes is associated with smoking cessation and reduction. Khoudigian 
et al. (103) included only randomized clinical trials. The striking disparity in the 
conclusions arises from differences in the criteria for selecting eligible studies and 
the availability of studies at the times at which the reviews were done. Table 3.3 
summarizes the studies used in each review.
Table 3.3. Comparison of studies included in reviews of the effectiveness of electronic nicotine and non-
nicotine delivery systems as quitting aids
Studies available 
for review
Review and cut-off date of literature review
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Polosa, 2011 ✓ ✓ ✓ ✓
Adkison, 2013 ✓ ✓ ✓
Caponnetto, 2013b ✓
Ely, 2013 ✓ ✓
Van Staden, 2013 ✓ ✓
Vickerman, 2013 (119) ✓ ✓ ✓
Borderud, 2014 (123) ✓ ✓ ✓
Choi, 2014 ✓ ✓ ✓
Etter, 2014 ✓ ✓ ✓
Farsalinos, 2014 (69) ✓
Grana, 2014 ✓ ✓ ✓ ✓
Nides, 2014 (39) ✓ ✓
Pearson, 2014 (122) ✓
Polosa, 2014 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Prochaska, 2014 ✓ ✓
Wagener, 2014 ✓
Al-Delaimy, 2015 (120) ✓ ✓
Biener, 2015 ✓ ✓ ✓ ✓
Brose, 2015 ✓ ✓
Harrington, 2015 ✓ ✓
Hitchman, 2015 (124) ✓
Manzoli, 2015 ✓ ✓ ✓
McRobbie, 2015 ✓ ✓
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Oncken, 2015 ✓
Pacifici, 2015 ✓
Pavlov, 2015 ✓
Polosa 2015 ✓
Shi, 2015 ✓
Sutfin, 2015 ✓
Cross-sectional studies
Siegel, 2011 ✓ ✓
Popova, 2013 ✓
Dawkins, 2013 (37) ✓ ✓
Goniewicz, 2013 (32) ✓
Pokhrel, 2013 ✓
Brown, 2014 ✓ ✓ ✓
Christensen, 2014 ✓ ✓
McQueen, 2015 ✓
Tackett, 2015 ✓
Randomized controlled trials with control group
Bullen, 2010 ✓ ✓ ✓
Bullen, 2013 (45) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Caponnetto, 2013a ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Caponnetto, 2014 ✓ ✓ ✓
Adriaens, 2014 ✓ ✓ ✓
Randomized controlled trials without control group
Hajek, 2015 ✓ ✓
Unknown
Humair, 2014 ✓ ✓
The differences in the conclusions do not arise from the evidence provided by 
the randomized clinical trials. Meta-analysis of the few existing trials showed 
that ENDS use increases the likelihood of quitting smoking by a factor of two 
when compared with placebo. Two meta-analyses (98, 99) provided an estimated 
risk ratio of 2.29 (95% CI. 1.05, 4.96) in favour of quitting, one meta-analysis 
(102) gave an estimate of 2.03 (95% CI, 0.94, 4.38) and another (103) an estimate 
of 2.02 (95% CI, 0.97, 4.22). The differences are due to slight variations in the 
weight attributed to the two randomized clinical trials analysed and treatment 
of missing data. The different conclusions arise, more specifically, from the 
conflicting evidence presented by the longitudinal and cross-sectional studies 
reviewed. Below, we concentrate on the evidence from the longitudinal studies, 
because it is difficult to interpret the direction of possible associations in cross-
sectional studies.
Since the last systematic review, seven new longitudinal studies have 
been published on the difference in quitting smoking between users and non-
users of EN&NNDS (105–110), including an update of a previous one with a 
longer follow-up (111). Table 3.4 summarizes the findings of longitudinal studies 
according to sample attributes, characteristics of EN&NNDS products used by 
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participants, measures used to typify ENDS use, criteria for nicotine dependence 
and abstinence and a summary of the results. It summarizes the seven studies 
that found a statistically significant positive or negative association between 
EN&NNDS use and smoking abstinence in systematic reviews. It also summarizes 
all seven longitudinal studies that were not included in the reviews, for a total of 
16 studies. To select the best longitudinal studies for assessing the evidence, we 
considered that the association between ENDS use and quitting smoking as the 
outcome of interest should be measured under at least three conditions to obtain 
valid results:
 ■ Criterion 1: It should be known whether the e-liquid used contains 
nicotine and the type (electrical power) of device used. Ideally, devic-
es should be classified on the basis of their tested capacity to deliver 
nicotine, but this might prove difficult in population studies without 
laboratory testing of the devices used by participants. Otherwise, it 
is difficult to assess whether the association is linked to the poten-
tial role of ENDS as a nicotine replacement aid. We know that some 
ENDS devices can deliver cigarette-like amounts of nicotine in some 
instances (4, 8); however, use of ENNDS or ENDS that cannot deliver 
nicotine because of low power and other factors is still common in 
the USA (112) and many other countries.
 ■ Criterion 2: The analysis must discriminate between people who use 
ENDS to quit smoking and those who do not. Many use ENDS for 
reasons other than to quit, including reducing their smoking (113), 
use indoors when smoking is not allowed or for recreational purpos-
es (114, 115). Conflating ENDS users who do and do not do so for 
quitting may bias the association towards the null if, as expected, the 
real effects on smoking cessation are different or even opposite.
 ■ Criterion 3: The measures of ENDS use must be accurate and refined 
in order to distinguish between established and transient, erratic use 
to assess the effects of ENDS on population health (116, 117). As 
ENDS use is a relatively new population behaviour, many people may 
experiment briefly with EN&NNDS but not adopt an established pat-
tern of use. Comparisons of “ever use” with “never use” of ENDS, for 
example, might classify as users people who have used an ENDS only 
once in their lives, while it has been standard practice to consider 
people smokers if they have smoked at least 100 cigarettes in their 
lifetime. Conflating experimenters with steadier users may result in 
the biases described in the previous paragraph.
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With these criteria in mind, we find that, of the 14 studies examined,
 ■ only two characterized the type of device used (criterion 1);
 ■ 12 studies did not restrict by or analyse the reasons for use of 
EN&NNDS, although two included adjustment for or analysis of 
some variables that could be used as proxies for using EN&NNDS 
(criterion 2); and
 ■ seven studies compared cessation only between ever and never users 
of EN&NNDS, three used a crude measure of current use, and six 
used a more elaborated measure of frequency (criterion 3).
Seven longitudinal studies met at least one of the three criteria; none met all 
three. The combined evidence from the seven studies suggests that their samples 
consisted of different subgroups that experienced different or opposing effects of 
EN&NNDS use on cigarette cessation. Consequently, it could be hypothesized 
that some smokers may successfully quit tobacco use by using some types of 
ENDS frequently or intensively, while others experience no difference or are even 
prevented from quitting. The findings of these studies are shown in Table 3.5.
Clinical pharmacology of nicotine in electronic nicotine delivery systems
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A cross-sectional study by Giovenco et al. (127) of current and former smokers 
who had quit since 2010, as reported in the 2014–2015 National Health Interview 
in the USA, lends some support to this hypothesis. The prevalence of quitting 
smoking tripled among daily ENDS users as compared with those who had never 
used ENDS, in line with the findings of Zhu et al. (128). Interestingly, Giovenco 
et al. found the opposite effect among non-daily ENDS users and former 
experimenters, with a prevalence of quitting smoking of 2.6 and 1.5 times less 
than those who had never used ENDS, respectively. Success or failure in quitting 
in different subgroups may be influenced by:
 ■ motivation to use EN&NNDS, including for quitting smoking;
 ■ patterns of quantity, frequency and duration of ENDS use;
 ■ technology used, including type of devices and e-liquids;
 ■ type of smoker, including level of nicotine dependence and history of 
previous successful and unsuccessful quit attempts; and
 ■ the regulatory environment for ENDS and tobacco use (131-133).
Further support for the possibility that some smokers may successfully quit smoking 
by using ENDS includes the fact that ENDS may be economic substitutes for 
cigarettes (134–136) and the absence of a reversal in the decreasing rate of smoking 
rate in the two major EN&NNDS markets. Current cigarette smoking among adults 
in the USA decreased from 20.9% in 2005 to 15.1% in 2015, a 27.7% decrease (P for 
trend, < 0.05) (137). The decrease includes a significant 1-year drop between 2014 
and 2015 of 1.7 percentage points, which coincided with a notable increase in the 
cessation rate in 2014–2015, attributed by the authors partly to use of EN&NNDS. 
The results were adjusted for other changes to the policy environment that might 
affect quit attempts, such as tax increases and the “Tips from former smokers” media 
campaign of the Centers for Disease Control and Prevention in the USA.
In the United Kingdom, the proportion of current adult (≥ 18 years) 
smokers in 2016 was 15.8%, the lowest prevalence recorded since the start of the 
Annual Population Survey in 2010 (138). At the same time, the increase in the 
use of EN&NNDS in England has been associated with the increasing success of 
quit attempts (139).
These data in themselves do not prove that use of EN&NNDS by 
the population is an effective quitting aid. They do show, however, that use of 
EN&NNDS is at least not changing the trend to a decreasing prevalence of 
smoking in the United Kingdom.
3.7 Potential health impact of ENDS
As some ENDS may help some smokers to quit, what is their potential health 
benefit for the population? The overall impact of using ENDS on population 
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health depends primarily on two factors. One is the capacity of ENDS to help 
prevent smoking, and the other is the relative risk associated with their use in 
comparison with a defined alternative, such as smoking (140).
3.7.1 Behavioural trajectories associated with use of ENDS
If ENDS prevent smoking, they do not entice nonsmokers into smoking but 
instead lure smokers into quitting smoking and, ideally, abstaining from nicotine. 
In other words, whatever the initial status of a person – never, current or former 
smoker – behavioural paths or trajectories associated with ENDS use must lead 
away from smoking and ultimately from nicotine dependence. Fig. 3.5 presents 
the 27 possible paths from an initial state of never, current or former smoker 
into one of four possible final states: exclusive smoker, exclusive ENDS user, 
dual user or dual abstainer. The web of trajectories in Fig. 3.5 represents only the 
behavioural paths between two nicotine products. In reality, it may be complicated 
by competition among more than two products, be they pharmaceutical, tobacco 
or consumer products.
Fig. 3.5. Web of trajectories associated with ENDS use
EN&NNDS, electronic nicotine and non-nicotine delivery systems. Source: Modified from reference 141.
The first step in understanding the effect on population health of using ENDS 
is, therefore, to estimate the probability that people in each initial state will end 
over time in one of the four final states. The probabilities are context sensitive 
EN&NNDS
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and therefore cannot be transferred among different cultural and regulatory 
environments for EN&NNDS and tobacco. Estimating the probabilities is 
complex, especially in light of the scant empirical evidence for characterizing 
them. The discussion has focused on the two most relevant combinations of 
trajectories in which EN&NNDS can play a role for or against health. One is the 
combination that leads smokers to quit smoking (blue lines in the figure), and the 
other is that which leads never smokers to smoke (red lines in the figure).
Trajectories that lead smokers to quit smoking
We discussed above the evidence for the role of EN&NNDS in quitting smoking. 
Contrary to the polarized discussion on whether ENNDS support or dissuade 
quitting, we concluded that the effects of EN&NNDS use on smoking cessation 
might depend on individual patterns of use and smoking, attitudes and behaviour, 
technology and the regulatory environment. The overall usefulness of ENDS for 
quitting might depend on the predominance of the subgroups for whom ENDS 
use might have an effect. For example, Giovenco et al. (127) showed that daily 
ENDS users quit smoking 3.2 times more often than never users; however, 
daily users represented only 5.1% of the sample. Non-daily ENDS users and 
former attempters, who represented 9.8% and 33.1% of the sample, respectively, 
however, quit smoking 2.6 and 1.5 times less often than those who had never used 
ENDS. Overall, the adjusted percentage of the total sample that quit is 26.5% with 
EN&NNDS and 28.2% without (Table  3.6). Given the predominance of non-
daily EN&NNDS users and former experimenters in the population, preventing 
quitting predominated over promoting quitting among daily users.
Table 3.6. Theoretical impact on the prevalence of population quitting among smokers who use and do 
not use electronic nicotine and non-nicotine delivery systems (EN&NNDS) by type of user
Type of EN&NNDS 
user
Prevalence of 
EN&NNDS use (%)
Rate attributable
to EN&NNDS use 
(%)
Adjusteda preva-
lence of quitting 
attributable to 
EN&NNDS use (%)
Prevalence in 
the absenceb of 
EN&NNDS use (%)
Daily 5.1 52.2 4.6 1.4
Non-daily 9.8 12.1 1.1 2.8
Former 33.1 20.2 6.3 9.3
Non-user 51.9 28.2 14.7 14.7
Total 100 -- 26.5 28.2
a Quit rate adjusted for a prevalence rate for daily and non-daily users, former experimenters and non-users of 3.18, 0.38, 0.67 and 1, 
respectively. b If the whole population were non-users at a quit rate of 28.2%.
Trajectories of never smokers to smoking
Young never smokers who experiment with ENDS are more likely to experiment 
with smoking later. A meta-analysis (142) of three longitudinal studies in the 
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USA (143–145) showed that young people who had used ENDS even once in 
their lives at baseline were twice as likely to experiment later with smoking than 
those who had never used ENDS. A more recent meta-analysis (146) that included 
the three previously mentioned studies and six additional ones (147) concluded 
that the likelihood of subsequent smoking initiation by young people who had 
ever used ENDS was about 3.5 times higher than that of never ENDS users. The 
authors also reported that using ENDS during the previous 30 days increased 
the chance of smoking at least once in the next 30 days by four. Two longitudinal 
studies in the United Kingdom (148, 149) showed a similar association between 
experimental use of ENDS and subsequent experimental smoking. The data 
available so far do not, however, prove that this evident association is causal or 
due mostly to ENDS use.
This association is difficult to understand, for several reasons (150, 151). 
In most of the longitudinal studies, use of these products was measured as at least 
once in either a lifetime or in the previous 30 days. These recall periods cover 
a mixture of behaviour in the formative years of young people, including more 
frequent experimental use of ENDS and smoking, which is tentative and volatile, 
and also less prevalent established behaviour. It can be assumed that established 
ENDS use patterns better define the likelihood of future smoking than volatile, 
tentative ENDS use, such as having a puff once in a while.
Furthermore, there are three theoretical explanations for the association. 
The first is the “common liability conjecture”. According to this theory, ENDS use 
and smoking are initiated independently of each other because they are the result 
of a common latent propensity to risky behaviour. Thus, it has been suggested that 
a large proportion of the young people who try ENDS and then smoke would have 
tried smoking regardless of the existence of ENDS. The fact that ENDS are used 
before smoking and not the other way around is due to several factors, including 
the novelty of ENDS. The second theory is the “renormalization” hypothesis, 
by which ENDS use is widespread and frequent among young people, and the 
devices and mannerisms of its use remind them of smoking. The similarity 
between ENDS use and smoking facilitates the trajectory from one product to the 
other within a social learning framework. The third theory is the “catalyst” theory, 
which comprises six hypotheses for initiation of ENDS use: flavour, health, price, 
role model, concealment and acceptance. Another three hypotheses are proposed 
to explain the transition to smoking: addiction, accessibility and experience (152). 
Proving any of these theories will face critical methodological challenges (153). 
In some longitudinal studies, adjustment has been made for variables to measure 
common susceptibility traits; however, residual confounding always muddles 
the association between ENDS use and smoking, and no one has proven beyond 
doubt which hypothesis or combination best explains the transition from never 
using nicotine to ENDS use and later to smoking.
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The fact that some “never smokers” who experiment with ENDS end up 
smoking must be reconciled with the fact that the prevalence of current smoking 
among young people in the two countries with the most prominent ENDS 
markets continues to decrease. One review (142) shows that the prevalence of 
use of ENDS at least once a month increased quickly in some countries like the 
USA (154) (probably EN&NNDS), while in others such as the United Kingdom 
the rate among nonsmokers has been stable at very low levels.
3.7.2 Harm from ENDS and electronic non-nicotine delivery systems
Although EN&NNDS may route the population through trajectories in and out 
of smoking, the overall health impact of use of ENDS depends on the health risks 
associated with their use. The long-term health effects of EN&NNDS use are still 
unknown, and determination of such effects with some degree of certainty will 
require investigations of the health outcomes of large cohorts of well-characterized 
users who are followed for many years. In the meantime, conclusions about the 
toxicity of EN&NNDS are based mainly on empirical evidence from chemical 
and toxicological studies and, to a lesser degree, clinical studies. Reviews of these 
studies have led various authors to conclude, with more or fewer caveats, that 
EN&NNDS are not harmless but are generally less dangerous than cigarettes 
(155–160), especially with regard to death from diseases associated with cigarette 
use. Efforts have been made to specify and characterize the health risks of 
EN&NNDS use by type of health condition.
Cancer risk
Ideal combinations of EN&NNDS device power settings, liquid formulation and 
use should produce an aerosol containing carcinogenic chemicals at a potency 
< 1% that of tobacco smoke and two orders of magnitude higher than that of a 
medicinal nicotine inhaler. As shown in Fig. 3.6, however, some products and 
circumstances can increase the cancer risk of EN&NNDS aerosol considerably, 
sometimes close to that of tobacco smoke (161). Aerosols with higher 
carcinogenic potency appear to be formed when the user applies excessive power 
to the atomizer coil (76). It has been argued that this occurs only under “dry 
puff ” conditions (162) – brief situations that are readily detectable by EN&NNDS 
users. There is no empirical evidence, however, that this is due only to dry puff 
conditions or, if so, how often such conditions occur.
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Fig. 3.6. Carcinogenic potency of formaldehyde and acetaldehyde in aerosol from electronic nicotine 
and non-nicotine delivery systems and in tobacco smoke, heat-not-burn devices, a nicotine inhaler and 
ambient air
Source: reproduced from reference 161 with permission from BMJ Publishing Group Ltd.
Cardiovascular risk
There is controversy about whether the risk for cardiovascular events associated 
with use of EN&NNDS is as low as its carcinogenic potential. Some consider that 
the main cardiovascular risk of ENDS aerosol is due to the toxicity of nicotine, 
which appears to pose a low short-term cardiovascular risk in healthy users (163). 
A review of clinical and cell culture studies conducted in 2015–2017 addressed 
the relation between ENDS use and indicators of risk for cardiovascular disease, 
including heart rate, blood pressure, and vagal tone; platelet aggregation and 
adhesion; aortic stiffness and endothelial function; expression of genes for 
antioxidant defence and immune system function; and indices of oxidative 
stress. Of the six studies reviewed that showed significant adverse cardiovascular 
effects, three found that ENDS had less effect on physiological cardiovascular 
risk indicators than cigarettes, and the other three found that ENDS had the 
same effect as cigarette smoking. Some studies indicated that these adverse 
cardiovascular effects are independent of nicotine, although adding nicotine may 
enhance them (164).
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Pulmonary risk
While EN&NNDS aerosol is probably less toxic than tobacco smoke and causes less 
mortality than cigarettes, the reduction in toxicity in the lung remains unknown 
for both long-term users who quit smoking and dual users. The authors of a review 
on the topic concluded that the induction of inflammation by EN&NNDS might 
differentially affect the risks for lung cancer and chronic obstructive pulmonary 
disease (165). Thus, the most recent empirical evidence suggests that EN&NNDS 
aerosol is less toxic than cigarette smoke; however, there are no empirical data to 
quantify the relative risks of exposure to EN&NNDS aerosol and tobacco smoke.
Several efforts have been made to model the potential population impact 
of EN&NNDS (166–168); however, the results are only as good as the data put 
into the model. Given the paucity of data, it is unclear which should be included 
in calculating the benefits of ENDS in worst- and best-case scenarios (169, 
170), especially for variables such as the efficacy of ENDS in helping people quit 
smoking and their safety relative to cigarettes.
Quantifying the effects of ENDS use on the health of the population is 
highly complex, as many variables must be taken into account. The available 
evidence indicates a possible positive effect of ENDS on population health, 
particularly if appropriate ENDS regulation is enacted to maximize their benefits 
and minimize their risks.
3.8 Summary of evidence, research gaps and policy issues 
derived from the evidence
ENDS are a heterogeneous class of products, with various profiles of nicotine and 
non-nicotine toxicants, which depend on factors including their construction, 
power, liquid constituents, nicotine concentration and user behaviour. The amount 
of nicotine delivered can range from none to doses that exceed those delivered by 
tobacco cigarettes in the same number of puffs. Nicotine from ENDS reaches users’ 
blood faster than from most types of nicotine replacement therapy (NRT), and, at 
least with some ENDS, at higher concentrations. ENDS could be effective in cessation 
for some smokers under some circumstances, while, for other smokers, in different 
circumstances, it might have the opposite effect. Whether an ENDS has beneficial 
or detrimental effects on smoking cessation appears to depend on the technology, 
the motivation and consumer behaviour of the ENDS user, the type of smoker who 
seeks ENDS use and the regulatory environment for ENDS and tobacco use.
Translating the evidence into a potential role of EN&NNDS in smoking 
cessation is difficult. The evidence does not allow a blanket policy recommendation 
for or against general use of ENDS and ENNDS as cessation aids. Nevertheless, it 
points to four areas for regulatory consideration by policy-makers.
The concept of nicotine flux in ENDS regulation: regulators who wish to 
maximize the potential of the ENDS technology for nicotine substitution should 
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consider the rate at which nicotine is emitted (i.e. nicotine flux) as a primary factor 
in their decision. In practical terms, factors that influence nicotine flux should not 
be regulated in isolation. ENDS nicotine flux can be modelled mathematically for 
product standards for regulatory purposes, although such standards should also be 
based on a clinical evaluation (i.e. effects in humans who are and are not ENDS users).
The relation between nicotine flux and toxicant profile: a corollary to 
the above is that the conditions under which different nicotine fluxes are obtained 
may affect the toxicant profile, because some of the same factors that increase the 
nicotine flux, such as power, also increase the concentrations of some toxicants 
in the aerosol, such as aldehydes. Therefore, regulators might consider how the 
manufacturers and the government should inform users of the balance between 
creating an adequate nicotine flux and the associated toxicant delivery.
Nicotine e-liquid concentration: despite some industry guidelines on 
labelling nicotine concentrations, the labels on many e-liquids do not indicate 
the concentration, are difficult to interpret or, most often, do not provide accurate 
information. Depriving ENDS users of accurate information on the nicotine 
concentration in e-liquids denies them important information for controlling 
their self-administration of nicotine.
Labelling and quality control for ENDS devices and e-liquids: the 
labels on all e-liquids should display the total amount of nicotine per receptacle, 
the ratio of free-base to protonated nicotine and the liquid concentration in 
mg/mL, visibly and understandably; otherwise, they should indicate that the 
e-liquids do not contain nicotine at a concentration above, for example, 0.1 mg/
mL. Quality control must be used to ensure the veracity of labelling information 
and conformity to production standards.
Although the topic is not reviewed in this paper, there is conclusive 
evidence that exposure to nicotine in e-liquids other than through aerosol 
inhalation can harm health, sometimes fatally (171). In order to avoid accidental 
exposure to nicotine, regulators should consider requiring child-resistant 
containers for all e-liquid receptacles.
The development of adequate policies and regulations on the ENDS 
issues described in this paper would benefit from disclosure requirements for 
manufacturers and effective, organized, systematic national surveillance. Key 
disclosure data to be requested from manufacturers include the voltage, resistance 
and power of marketed devices and the e-liquid constituents. In addition, 
monitoring should be conducted to determine consumer behaviour towards 
ENDS, such as who uses them, for what purpose, what and how products are 
used and the frequency of use.
Table 3.7 summarizes the evidence on the delivery of nicotine by ENDS, their 
effect on smoking cessation and their prospective impact on population health. The 
table also lists gaps in research and policy issues for each element of the evidence.
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4.1  Background
In 2015, TobReg published an advisory note in support of policy to reduce the 
nicotine content of the tobacco used in cigarettes to a level below that necessary to 
develop or maintain addiction (1). Policy to reduce nicotine could have a significant 
effect on public health by minimizing progression from experimental cigarette 
use to dependence, reducing duration of use, facilitating quitting, reducing the 
prevalence of smoking among addicted smokers and encouraging a transition to 
less harmful products for those who want or need nicotine from other sources (1, 2). 
About one billion people in the world smoke, and global consumption of cigarettes 
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and other combusted tobacco products (including cigarillos and roll-your-own 
tobacco) continues to rise (3). Article 9 of the WHO FCTC authorizes Parties to 
regulate the content and emissions of tobacco products, including nicotine (4, 5). 
There is clear evidence that reducing the nicotine content of cigarettes to a very low 
level can reduce dependence on cigarettes (1, 6, 7).
The WHO advisory note described the potential health outcomes of a 
nicotine reduction policy, while observing that many research projects, including 
clinical trials of very low nicotine content (VLNC) cigarettes, were still under 
way. The advisory note identified a number of open questions on possible health 
outcomes, including:
 ■ the use and effects of VLNC cigarettes in non-smoking adolescents 
and adults and non-dependent smokers;
 ■ the use and effects of VLNC cigarettes in vulnerable populations such 
as those with moderate or severe mental illness and pregnant women;
 ■ the use and effects of VLNC cigarettes with other forms of nicotine 
or other drugs; and
 ■ the effects of long-term use of VLNC cigarettes.
Critical discussion since publication of the advisory note focused on the open 
questions listed above (8–10), the difficulty of drawing conclusions about the 
outcomes of restricted clinical trials for the open market (8, 9, 11) and potential 
unintended effects, such as the belief that VLNC products are less toxic than 
regular cigarettes (11–13). The advisory note did not provide a detailed proposal 
of how a nicotine reduction policy would be enacted, and critical discussion has 
highlighted practical challenges to implementation of a nicotine reduction policy 
(9, 14).
This section updates the fast-growing science on nicotine reduction and 
use of VLNC products and addresses the questions about a nicotine reduction 
policy raised in both the 2015 advisory note and the critical discussion that 
followed. More than 100 relevant studies have been published since the background 
paper on nicotine reduction was presented to TobReg at its seventh meeting in 
December 2013, when discussions on nicotine reduction began. In line with 
decision FCTC/COP7(14) of the seventh session of the COP to the WHO FCTC, 
the Convention Secretariat and WHO convened a face-to-face meeting of experts 
in many disciplines on measures for reducing the addictiveness of tobacco (15–
16 May 2018, Berlin, Germany). Various clinical trials remained under way as 
of September 2017, at the time this section was written (19 September 2017; see 
Table 4.1), and the scope and relevant preliminary outcomes of these trials are 
discussed below. The plan of the FDA to pursue a nicotine reduction strategy (15) 
is also discussed.
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Table 4.1. Clinical trials of very-low-nicotine content (VLNC) cigarettes under way or still being analysed at 
19 September 2017
Principal 
investigator(s)
Clinical trial 
number Purpose Key feature
Sample 
size
Estimated 
comple-
tion date
Cassidy NCT02587312
To determine how reducing the level of 
nicotine in cigarettes affects adolescent 
smoking behaviour. Adolescents 90 May 2019
Cinciripini NCT02964182
To assess the effects of different nicotine 
levels in cigarettes and electronic cigarettes.
Combination 
with 
e-cigarettes 480
November 
2020
Colby NCT03194256
To determine how the nicotine content of 
cigarettes and the nicotine concentration 
and flavours in e-liquids influence responses 
to and use of these products by adolescent 
smokers. 
Laboratory-
based; 
adolescents; 
e-cigarettes as 
alternative 120
February 
2022
Donny NCT02301325
To evaluate the impact of low-nicotine 
cigarettes with and without transdermal 
nicotine.
Transdermal 
nicotine 240 April 2017
Donny NCT03185546
To evaluate the effects of VLNC cigarettes, 
e-cigarettes with different nicotine contents 
and e-cigarette flavourings on smoking. 
Access to 
e-cigarettes 
with varying 
nicotine 
content and 
flavours 480
September 
2021
Drobes NCT02796391
To determine the impact of gradual vs 
immediate reduction of nicotine content 
in cigarettes, in combination with targeted 
behavioural treatment, on smoking 
cessation and intermediate outcomes. Cessation 220 April 2021
Foulds, Evins NCT01928758
To evaluate the effect of progressive 
nicotine reduction in cigarettes on 
smoking behaviour, exposure to toxins 
and psychiatric symptoms in smokers with 
comorbid mood and/or anxiety disorders.
Affective 
disorders 280 October 2018
Ganz NCT01964807
To test products that provide a wide range 
of concentrations of nicotine, particles and 
other cardiovascular toxins to determine how 
the components associated with tobacco use 
adversely affect cardiovascular risk.
Laboratory- 
based; 
cardiovascular 
effects 90
September 
2018
Hatsukami NCT02139930
To compare two approaches to reducing 
levels of nicotine in cigarettes: an immediate 
vs a gradual reduction.
Gradual vs 
immediate 1250 March 2017
Hatsukami NCT03272685
To determine the effect of VLNC cigarettes in 
the complex tobacco and nicotine product 
marketplace.
Access to 
wide range 
of alternative 
products 700
December 
2022
Higgins, Heil NCT02250534
To determine the effect of extended 
exposure to cigarettes with various nicotine 
contents in disadvantaged women.
Disadvantaged 
women 282 October 2019
Higgins, Sigmon NCT02250664
To determine the effect of extended 
exposure to cigarettes with various nicotine 
contents in opioid abusers.
Opioid 
abusers 282 October 2019
Klemperer NCT03060083
To examine two strategies by randomizing 
smokers to (i) switch to VLNC cigarettes or 
(ii) reduce the number of cigarettes smoked 
per day. All smokers use a nicotine patch to 
help them reduce their nicotine intake.
Compare 
nicotine 
reduction 
to cigarette 
reduction 74
November 
2017
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Koffarnus, Bickel NCT02951143
To assess how smokers purchase and 
consume reduced-nicotine cigarettes.
Laboratory-
based; cost 232 July 2020
Kollins, 
McClernon NCT02599571
To investigate the effects of different 
nicotine levels in cigarettes in individuals 
with attention deficit hyperactivity disorder.
Attention 
deficit 
hyperactivity 
disorder 350 June 2020
McClernon NCT02989038
To evaluate reactions and choices to self-
administer cigarette smoke with various 
nicotine contents among low-frequency, 
non-dependent smokers aged 18–25 years.
Young adult 
light smokers 90 April 2019
Muscat, Horn NCT01928719
To determine whether progressively 
lowering the nicotine content of cigarettes 
reduces or eliminates nicotine dependence 
in smokers of low socioeconomic status.
Low 
socioeconomic 
status 400 October 2018
Oncken NCT02048852
To determine the effect of reducing the 
nicotine or menthol content of cigarettes or 
both in women of reproductive age.
Menthol; 
women of 
reproductive 
age 320
December 
2018
Oncken, Dornelas NCT02592772
To observe the effect of reducing the 
nicotine or menthol content of cigarettes or 
both in men. 
Menthol; 
men; gender 
differences 57
December 
2018
Peters NCT02990455
To determine whether smokers with and 
without current alcohol use disorder 
respond to reduced-nicotine cigarettes by 
increasing their alcohol consumption or 
exposure to smoke. Alcohol use 90
November 
2019
Richie NCT02415270
To determine the short-term effects of 
switching to tobacco products that deliver 
low levels of nicotine or reactive oxygen or 
nitrogen species on smoking behaviour and 
biomarkers of exposure to tobacco smoke 
and oxidative stress.
Biomarkers of 
exposure and 
harm 70 May 2017
Rohsenow NCT01989507
To determine the effect of VLNC cigarettes 
in smokers with substance use disorders 
currently or in the past year.
Substance 
abuse 250 May 2019
Rose NCT02870218
To assess use of cigarettes with 0.4, 1.4, 2.5, 
5.6 or 16.9 mg nicotine in heavy, long-time 
smokers and light smokers with a shorter 
smoking history (< 10 cigarettes/day for 
< 10 years). Participants have free access to 
nicotine-containing e-cigarettes (15 mg/
mL) throughout the 12-week study.
Dose-effect 
relation; 
heavy and 
light smokers; 
access to 
e-cigarettes 320 June 2019
Shiffman NCT02228824
To investigate the effects of cigarettes 
with different nicotine levels in non-daily 
smokers. 
Non-daily 
smokers 312 July 2017
Strasser NCT01898507
To examine the effects of smoking low-
nicotine cigarettes in groups of smokers 
with different nicotine metabolism.
Nicotine 
metabolism 210 July 2018
Tidey NCT02019459
To examine whether reducing the nicotine 
content of cigarettes to non-addictive 
levels reduces smoking in smokers with 
schizophrenia. Schizophrenia 80 August 2018
Tidey NCT02232737
To determine the effect of extended 
exposure to cigarettes with various nicotine 
contents in people with current affective 
disorders.
Affective 
disorders 282 October 2019
 
Source: Data from clinicaltrials.gov and personal communication (EC Donny). Studies found at Clinicaltrials.gov on or before 
19 September 2017 were identified with the search terms “low nicotine” and “reduced nicotine” and listed as not yet recruiting, 
recruiting, enrolling by invitation and active not recruiting. Studies with fewer than 50 participants or designs that did not address 
the impact of nicotine reduction relative to usual brand or normal nicotine content controls were omitted. A previous version of the 
table was published by Donny et al. (16). Listed by estimated date of completion.
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4.2  Individual outcomes of nicotine reduction
Most estimates of the impact of nicotine reduction on individuals are from 
randomized clinical trials in which participants are given normal or VLNC 
cigarettes for an extended time, usually under double-blind conditions (see 
Table  4.1). Laboratory assessments that allow relatively rapid assessment of 
issues such as abuse liability and compensatory smoking have provided useful 
complementary information about nicotine reduction. In both cases, the 
cigarettes used contain less nicotine in the filler, generally as a result of genetic 
engineering (e.g. Quest brands; Spectrum cigarettes made available by the United 
States National Institute on Drug Abuse). Although nicotine can be reduced by 
other methods (e.g. nicotine extraction, as in Philip Morris’ Next cigarette in 
the 1990s), relatively little clinical research has been done on cigarettes made 
by these methods because of practical issues such as cost, taste and availability. 
Furthermore, to our knowledge, no studies have been conducted to assess the 
effects of nicotine reduction in other forms of combusted tobacco (e.g. roll-your-
own products, little cigars, cigarillos). The results of research to date cannot predict 
the full effects of a policy of nicotine reduction in the real world, although this 
is important. Hence, post-marketing surveillance (see e.g. International Tobacco 
Control project: http://www.itcproject.org/) would be an important component 
of any regulatory action on nicotine reduction.
4.2.1 Behavioural compensation and exposure to toxicants
The toxicants emitted from VLNC cigarettes are generally similar to those from 
regular cigarettes (17); consequently, their effect on health depends largely on 
changes in smoking behaviour. Randomized clinical trials confirm earlier 
suggestions (1, 18, 19) that nicotine reduction reduces the number of cigarettes 
smoked per day from the number of both the usual brand and control cigarettes 
with a normal nicotine content (6, 20).4 Within 6 weeks of use, participants 
typically reported smoking 25–40% fewer cigarettes than controls (6, 19–21).1 
The common concern that smokers will compensate for the lack of nicotine 
by smoking more intensely is not supported by the evidence. Compensatory 
smoking is often observed when the nicotine content of the filler is only 
modestly reduced (20, 22)1 and when the nicotine yield of cigarettes is reduced by 
ventilation but the filler remains unchanged (often called “light” cigarettes) (23). 
Compensatory smoking does not, however, appear to be induced by cigarettes 
with ≤b2.4 mg nicotine per g of tobacco (as compared with a typical range of 10–
20 mg/g) (6, 18, 19, 22), possibly because the noxious components of smoke limit 
extreme compensatory behaviour, and more modest compensatory behaviour 
is ineffective in maintaining exposure to nicotine, given the large reduction in 
nicotine content. Instead, many studies found a reduction in exposure to the 
4  EC Donny, unpublished observation.
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toxicants that result from smoking. For example, participants who switched to 
VLNC cigarettes had similar or lower expired CO, total puff volume per cigarette, 
mouth-level exposure to smoke constituents (24) and biomarkers of exposure to 
toxicants (6, 18, 19, 21, 22, 25–27).
4.2.2  Threshold for establishing or maintaining nicotine addiction
An important question raised in the 2015 WHO TobReg advisory note is the 
threshold for establishing or maintaining nicotine addiction. It is not known 
whether there is a single threshold for different measures of addiction and 
different populations of smokers; however, data suggest that nicotine should be 
reduced to a maximum of 2.4 mg/g of tobacco and that decreasing the content 
to 0.4 mg/g of tobacco may have additional benefits. Although most smokers 
cannot discriminate between VLNC cigarettes with 2.4 and 0.4 mg/g, some can, 
suggesting that reducing the nicotine content below 2.4 mg/g might affect more 
smokers (28). Furthermore, Donny et al. (6) found that, although the number 
of cigarettes smoked per day and self-reported craving after abstinence were 
significantly reduced at ≤f2.4 mg/g, composite measures of nicotine dependence 
were significantly reduced only at 1.3 mg/g (one measure) and 0.4 mg/g (multiple 
measures), and the number of quit attempts during the follow-up period was 
significantly increased only at 0.4 mg/g. Interestingly, research on rats also 
suggested that a reduction of 85–90% or more (relative to doses that reinforce 
dependence in most rats) is required to decrease intravenous self-administration 
of nicotine reliably (29).
It is not known whether reducing nicotine to ≤t0.4 mg/g would also limit the 
development of addiction in adolescent smokers. Although some studies suggested 
greater reinforcing effects of nicotine in adolescent rats (30, 31), other research 
suggests that the threshold dose required for animals to learn to self-administer 
nicotine is similar to or higher than the dose required to maintain behaviour 
(32–34). The latter studies indicate that a product standard based on evidence for 
adult smokers would be expected also to limit smoking in tobacco-naive young 
people. Furthermore, a secondary analysis of the data of Donny et al. (6) showed 
that nicotine reduction resulted in more rapid decreases in indices of abuse liability 
(smoking satisfaction, psychological reward and enjoyment of respiratory tract 
sensations) in 18–24-year-old smokers than in adults aged ≥ 25 years (35). A study 
of adolescent smokers’ responses to use of single cigarettes with different nicotine 
contents (36) found that reduced-nicotine cigarettes had fewer positive subjective 
effects but no significant effect on withdrawal or exposure. Additional studies of 
adolescent and young adult smokers were under way as of September 2017 (see 
Table 4.1). Nevertheless, the possibility that adolescents (and other populations) 
are more sensitive to nicotine is one reason for considering product standards with 
a nicotine concentration well below 2.4 mg/g.
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4.2.3 Tobacco cessation after use of VLNC cigarettes
Whether reductions in the number of cigarettes per day, exposure to nicotine and 
nicotine dependence increase cessation is less clear. Research with participants 
who were intending to quit smoking suggest that use of VLNC cigarettes can 
increase the rate of cessation (19, 37, 38), whereas studies with participants who 
were not currently interested in quitting found persistence of smoking after 
weeks or even months of VLNC cigarette use (6, 22, 26, 39). Most of the studies, 
however, were not designed to address cessation, were not powerful enough to 
determine cessation outcomes, assessed behaviour for only a relatively short 
time, did not include giving participants alternative sources of nicotine and were 
conducted with commercially available cigarettes with a normal nicotine content. 
Two studies are important in this regard. In a 10-site clinical trial of 1250 smokers 
who were not intending to quit, participants who were randomized to receive 
VLNC cigarettes for 20 weeks self-reported more days of abstinence (10.99) than 
those assigned to cigarettes with a normal nicotine content (3.1; P <.0001) and 
were more likely to be abstinent (biochemically confirmed) at the end of the trial 
(20). In an exploratory trial, Hatsukami et al. (40) found that VLNC cigarettes 
increased the use of alternative nicotine products, including ENDS, cigars, 
cigarillos and NRT and that the more non-combusted products were used, the 
greater the number of days of abstinence from smoking. The potential interactive 
effect of nicotine reduction and alternative products has been discussed by 
several researchers (41, 42), was the topic of an announcement by the FDA (15) 
(discussed further below) and was the objective of several clinical trials that were 
under way in September 2017 (see Table 4.1).
4.2.4 Non-compliance in clinical trials
Since the 2015 WHO TobReg advisory note, it has become clear that participants 
in most studies of VLNC cigarettes continue to use non-study cigarettes, despite 
instructions to the contrary and the provision of free study cigarettes. For 
example, 75–80% of participants randomized to VLNC study cigarettes in the 
study by Donny et al. (6) were at least partially non-compliant (43). Smokers 
who were young and heavily dependent and reported that VLNC cigarettes 
were dissatisfying were more likely to be non-compliant. Most smokers had 
clearly reduced exposure to nicotine, suggesting that they had replaced many of 
their daily cigarettes with VLNC cigarettes but still used some regular-nicotine 
cigarettes. The most commonly reported context for non-compliance is the first 
cigarette of the day, underscoring the fact that non-compliance is due to nicotine 
dependence.5 To address this limitation, statistical approaches have been used 
in which data are weighted according to the probability of compliance. This 
5  EC Donny, unpublished observation.
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indicated similar effects on the number of cigarettes per day and dependence 
as non-weighted data (44).6 Other studies of incentivized compliance resulted 
in somewhat less non-compliance (40–50%) (based on urinary biomarkers) and 
replicated the reported effects of VLNC cigarettes on smoking behaviour and 
dependence, with little evidence of negative consequences beyond mild, transient 
withdrawal symptoms.1,2 Nevertheless, non-compliance may attenuate both 
positive (e.g. abstinence; see 45) and negative effects (e.g. withdrawal symptoms) 
of nicotine reduction. The extent of non-compliance despite the provision of free 
VLNC cigarettes and incentives for compliance indicates that some smokers are 
likely to seek alternative sources of nicotine, whether on the black market, by 
hoarding, by product tampering or in non-cigarette products.
4.2.5 Adverse health effects and vulnerable populations
Analyses of the potential unintended consequences of nicotine reduction have 
shown few effects on the health of participants. VLNC cigarette use is associated 
with either no change in or less expired CO (6, 18, 19, 21).7 VLNC cigarette use 
may temporarily increase the occurrence of non-serious adverse events related 
to withdrawal symptoms (19, 46)1 and attention deficit (47, 48), although few 
deficits are observed after the first week or so.8 Smoking of regular cigarettes 
suppresses body weight gain, raising the possibility that nicotine reduction could 
have unique adverse effects on obese smokers (49, 50). It is important to note 
that unintended consequences could be masked by the use of regular commercial 
cigarettes, as described above. Thus, for example, an association between VLNC 
cigarettes use and weight gain in a clinical trial was obscured by participant non-
compliance (49).
Most clinical trials of VLNC cigarettes have involved relatively healthy 
daily smokers, generally with the exclusion of individuals such as those with serious 
mental illness or those who did not smoke every day. The positive and/or negative 
effects of nicotine reduction might vary among subpopulations, and several clinical 
trials were under way or were not published as of September 2017 on subpopulations 
who might be at risk (see Table 4.1). To date, the best data on the potential effects 
on different subpopulations of smokers are from secondary analyses of previous 
trials (commonly 6) and from laboratory studies. Bandiera et al. (51) reported 
greater increases in the number of cigarettes smoked per day in a relatively small 
subgroup of 24 highly dependent smokers in the trial of gradual nicotine reduction 
by Benowitz (52); however, analysis of highly dependent smokers in the trial of 
abrupt reduction by Donny et al. (6) indicated no effect of dependence on the 
6  DK Hatsukami, personal communication.
7  DK Hatsukami, personal communication.
8  Ribisl KM, Hatsukami D, Johnson, Huang J, Williams R, Donny E. Strategies to prevent illicit trade for very 
low nicotine cigarettes (unpublished information).
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number of cigarettes smoked per day or other measures of possible compensatory 
smoking after randomization to VLNC cigarettes.2 In addition, highly dependent 
smokers showed the greatest reduction in dependence as a consequence of nicotine 
reduction.2 As noted above, studies often exclude non-daily smokers; however, a 
completed trial with non-daily smokers showed a significant (> 50%) decrease in 
the number of cigarettes per day as a consequence of nicotine reduction (53).
Participants with a history of using alcohol (54) or cannabis (55) had 
reductions in smoking similar to that of smokers without such a history when 
randomized to VLNC cigarettes, with no increase in alcohol or cannabis use, 
although nicotine deprivation might increase the motivation of some individuals to 
drink (45, 56). Tidey et al. (57) found that having depressive symptoms at baseline 
did not moderate the effects of nicotine reduction on the number of cigarettes 
smoked or measures of nicotine dependence and that randomization to VLNC 
cigarettes of smokers with severe depressive symptoms at baseline resulted in lower 
levels of depression than controls by the end of the trial. These findings are consistent 
with the results of a broader review of the potential impact of nicotine reduction 
on smokers with affective disorders (58). An intensive laboratory study of smokers 
in three vulnerable populations (with affective disorders, with opioid dependence 
and socioeconomically disadvantaged women of childbearing age) found that 
reducing nicotine levels in a dose-dependent fashion decreased the reinforcing 
effects of cigarettes similarly in these populations (59). Other trials under way as of 
September 2017 may provide further information about the potential unintended 
consequences of extended use of VLNC cigarettes in vulnerable populations; 
however, any negative effects must be weighed against the potential benefits, given 
the disproportionate harm of smoking to these populations (60–64).
4.2.6 Summary
 ■ Use of VLNC cigarettes in place of regular cigarettes reduces the 
number of cigarettes smoked per day and results in similar or less 
exposure to toxicants in clinical trials.
 ■ Compensatory smoking is observed when the nicotine content of to-
bacco filler is modestly reduced but not with VLNC cigarettes.
 ■ Less cigarette use is observed at a nicotine content of ≤ 2.4 mg/g. Less 
nicotine dependence and more quit attempts have been most reli-
ably observed at levels of 0.4 mg/g, although this observation must be 
confirmed in long-term studies. Reducing nicotine to ≤ 0.4 mg/g may 
benefit the broadest population of current and potential smokers.
 ■ Most studies were not designed to address cessation; however, most of 
the evidence suggests that use of VLNC cigarettes is likely to increase 
abstinence, even among smokers who are not intending to quit.
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 ■ Although the data are limited, reducing the nicotine content of ciga-
rettes is likely to reduce smoking among adolescents.
 ■ Use of VLNC cigarettes increases the use of alternative nicotine 
products such as ENDS, cigars, cigarillos and NRT in place of regular 
cigarettes. This conclusion warrants consideration of how nicotine 
reduction should be applied to nicotine products other than regular 
cigarettes.
 ■ Significant non-compliance in clinical trials indicates that some 
smokers experiencing nicotine reduction are likely to seek alternative 
sources of nicotine.
 ■ No significant adverse health effects have been identified with use of 
VLNC cigarettes in place of regular cigarettes.
 ■ Reduced nicotine levels decrease the reinforcing effects of regular 
cigarettes similarly in a number of potentially vulnerable popula-
tions, including smokers with affective disorders, those who use al-
cohol and other substances and women of childbearing age of low 
socioeconomic status.
4.3 Population impact of nicotine reduction
Although clinical trials provide mounting evidence on the effects of VLNC 
cigarettes on individual behaviour and health when they are used instead of regular 
cigarettes, estimation of the public health impact of a nicotine reduction policy 
requires projection of these findings to the broader population (9) under market 
conditions, which may differ significantly from clinical trial settings, and will 
be affected by industry promotional activity (9, 11). For example, observational 
studies indicate a smaller reduction in cigarette consumption with use of NRT 
than would be predicted by clinical trials, possibly because of underuse of the 
products in real situations (65). Compliance with medication is probably better 
in a clinical setting than in real situations, whereas the opposite may be true in the 
case of clinical trials with VLNC cigarettes because of the commercial availability 
of regular nicotine tobacco products outside the trial (44).
In the absence of population-based evidence on nicotine reduction, the 
WHO advisory note concluded that data from clinical studies and studies in 
experimental animals strongly suggest reduced risks at population level (1, 2). 
Questions remained, however, about the potential role of illicit sales, potential 
product manipulation by either tobacco companies or smokers, the effects of a 
nicotine reduction policy on health beliefs, experimentation and potential use of 
other highly toxic combusted tobacco products (e.g. cigarillos or roll-your-own 
tobacco), either as substitutes for or in combination with VLNC cigarettes in the 
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absence of policy measures to discourage their use (1) and the impacts of tobacco 
industry marketing that promotes use of VLNC cigarettes as part of a programme 
to counter further constraints on their other (regular) products. In this section, 
we review the current evidence on the probable population response and health 
impact of nicotine reduction.
4.3.1 VLNC cigarettes as replacements for regular cigarettes
The popularity of regular cigarettes is supported by their efficacy as a behavioural 
reinforcer (66). Nicotine is absorbed more rapidly from regular cigarettes than 
from other nicotine-containing products, even when systemic exposure to nicotine 
is similar (although the technology used in alternative products such as ENDS is 
developing rapidly) (66, 67). Cigarettes also provide a rich network of behavioural 
and sensory stimuli associated with nicotine delivery that further contributes to 
the strong conditioned rewarding effects of smoking (1, 68, 69) and to the ability 
of VLNC cigarettes to reinforce behaviour (1, 70, 71). Smokers’ consumption of 
regular cigarettes is correspondingly less sensitive to increases in price (72–75), 
indicating greater abuse liability than with other forms of tobacco or nicotine, 
including snus (76, 77), little cigars (75, 78), large cigars (75), loose smoking tobacco 
(75, 79), nicotine chewing-gum (77, 80) and e-cigarettes (80–83).
Despite the high abuse liability of regular nicotine cigarettes, extensive 
research shows that increased cost can promote quitting by current users, deter 
initiation by potential users and reduce tobacco use by continuing users (72, 74, 
84, 85). Sensitivity to cigarette price is greatest among low-income smokers (86, 87) 
and is influenced by environmental factors that include tobacco control and public 
education campaigns (88). Smokers of high-equity or “premium” cigarette brands 
are less likely to quit, indicating the importance of marketing and brand-consumer 
relations (89). Subjective characteristics, such as flavour and acceptability, also play 
a role in product use (90–92), and perceived negative characteristics (e.g. of snus or 
chewing-gum) outweigh potential reinforcing effects, resulting in limited demand 
for some tobacco substitutes regardless of price (77).
VLNC cigarettes can substitute at least partly for regular cigarettes (1, 93–
95), and laboratory studies suggest that they are a more reinforcing alternative 
than nicotine chewing-gum (96). Use of VLNC cigarettes in place of regular 
cigarettes decreases cigarette demand (6, 94). As the price breakpoint (the point 
at which purchase is no longer sustained) is higher for regular cigarettes than 
for VLNC cigarettes, smokers would quit at relatively lower prices if VLNC 
cigarettes replaced regular ones, and a subset of smokers have no demand for 
VLNC cigarettes, regardless of price (95). This is consistent with self-reports from 
as many as half of participants who use VLNC cigarettes that they would stop 
smoking within 1 year if these were the only cigarettes available for purchase 
(94). Smokers of mentholated cigarettes reported a similar intention to quit when 
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confronted with a potential ban on menthol (97). Such sensitivity to cost suggests 
that a nicotine reduction policy could increase the effectiveness of other tobacco 
control approaches such as raised price, smoke-free environments and media 
campaigns. Conversely, marketing and other social approaches could be used to 
support continued demand if the nicotine content of cigarettes were reduced.
As indicated in clinical trials (section 4.2.4), many smokers of VLNC 
cigarettes supplement their cigarette consumption outside of the study parameters. 
In a small pilot trial in New Zealand, a large price differential based on nicotine 
content prompted smokers to reduce the number of but not to eliminate their 
usual cigarettes and to replace them with VLNC cigarettes (93). This suggests 
that, in a market in which both VLNC and regular cigarettes are available, most 
smokers who continue to smoke are unlikely to use VLNC cigarettes exclusively, 
even with a significant differential in price (94, 95).
Few data are available on young and tobacco-naive users, although clinical 
trials with adolescents were under way as of September 2017. Meanwhile, the 
implications of studies of price and other abuse liability is that VLNC cigarettes 
are less likely than regular nicotine cigarettes to encourage the transition from 
experimentation to regular use. A possible, although not yet demonstrated 
outcome of nicotine reduction is that it may prevent some (possibly significant) 
proportion of children and adolescents who experiment with the most toxic (i.e. 
combusted) forms of nicotine from becoming long-term users of those products. 
In contrast, promotion may directly or indirectly encourage young people to take 
up VLNC products by convincing them that they are acceptable from a health 
perspective.
4.3.2 Substitution of VLNC cigarettes with alternative tobacco products
Tobacco products differ widely in terms of price, availability, marketing, social 
acceptability and perceived risk, as well as nicotine delivery and sensory and non-
pharmacological characteristics. The balance of these environmental and product 
factors can result in significant population changes in tobacco product use. For 
example, studies in many countries have found a shift from manufactured to roll-
your-own cigarettes, for reasons that include price and lower perceived risk (98–
100), even though roll-your-own products are inferior on subjective measures 
(79). Concurrent use of several tobacco products is increasingly common (101, 
102), including the use of tobacco with e-cigarettes and other ENDS such as 
HTPs (103, 104).
Although the prices of other combusted tobacco products are more 
sensitive than those of cigarettes, most are strong substitutes for regular 
cigarettes (75). Some cigarette smokers maintain their tobacco consumption 
when cigarette prices rise by changing from regular cigarettes to little cigars (78, 
105), and interest is increasing in other substitutes (ENDS, snus, large cigars, 
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roll-your-own) (106). Large proportions of current smokers do not accurately 
differentiate regular cigarettes, little cigars, cigarillos, roll-your-own tobacco 
and cigars when presented with images of these products and their packaging, 
indicating the possibility of substitutions among relatively similar products (107). 
The perceptions may be exaggerated by manufacturing and/or marketing by the 
tobacco industry, which may mimic or emphasize similarities in appearance or 
function among combusted or alternative products (e.g. ENDS and HTPs).
The presence of product substitutes can determine interactions among 
multiple products. For example, in a behavioural study in 2016, snus became 
a significant substitute for cigarettes once cigarillos had been removed as an 
option, and participants were less likely to break the study protocol by purchasing 
other products when cigarillos were available (108). Findings on the substitution 
patterns of users of smokeless tobacco (moist snuff, snus, chewing tobacco) and 
cigarettes are mixed (75, 92, 109–112): smokers, particularly in the USA, showed 
poor acceptance of smokeless products (90, 92, 113–115). In Sweden, although 
lower taxes on snus contributed to the switch of many male cigarette smokers to 
snus, women did not switch to the same extent, illustrating the significant role of 
social and demographic factors (114, 116).
ENDS are potential substitutes for regular cigarettes (75, 108, 117–120), 
and, although ENDS are a heterogeneous class of products (see section 3), at least 
some are more effective in decreasing regular cigarette use than NRT (119, 121–
123), partly because of similar subjective and sensorimotor characteristics (69). 
It has been reported ENDS are better accepted, provide more satisfaction and 
can better reduce craving, negative affect and stress in smokers than NRT (122, 
124), although they are rated as less satisfying than regular cigarettes (42). ENDS 
remain highly sensitive to price (81, 118) and were found to be more expensive 
than combusted products in 45 countries (125). Users of both cigarettes and 
e-cigarettes more successfully maintain reduced cigarette consumption in the 
short term than those who smoke only cigarettes (126). ENDS are generally 
perceived to pose a lower risk than regular cigarettes, although it is a misperception 
that ENDS pose an equal or greater health risk than cigarettes (127).
Use of ENDS by adults is concentrated primarily among current and 
former smokers (104, 128–137). Studies on young people have had mixed results, 
some indicating a high level of interest and/or experimentation by never smokers 
(133, 138, 139) and others reporting concurrent use of ENDS and other tobacco 
products by current smokers (130–132, 133, 140–145). Some countries have 
reported dramatic increases in ENDS use among young people; current use 
exceeded 20% among high-school-aged young people in the USA in 2018 (146). 
The association between ENDS use and cigarette smoking has led to concern that 
ENDS might act as a gateway to the use of other tobacco products, specifically 
regular cigarettes, particularly among adolescents and young adults (137, 147–
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154), although confounding factors make it difficult to interpret the study results 
(155–159). Further substantial concern has, however, been expressed recently in 
the USA about the “epidemic of youth e-cigarette use” (160) and the possible 
involvement of e-cigarettes in encouraging young people to smoke conventional 
products (161). ENDS are less likely to displace cigarette smoking among people 
who want or need to quit as long as regular nicotine cigarettes are widely available. 
A reduction of the nicotine level in combusted and other tobacco products might, 
however, increase substitution with ENDS (40).
4.3.3 The black market
If the only combusted tobacco products legally available contained very low 
nicotine levels, there would potentially be illicit trade in cigarettes with regular 
nicotine levels. As no jurisdiction has yet restricted cigarettes with regular 
nicotine, the information about illicit trade pertains to products that have been 
banned or on which taxes have been raised, and consumers have sought cheaper, 
lower-tax products.
Illicit trade can be conducted at retail locations, by street sellers and 
via the internet. Banning of some tobacco products in some jurisdictions (e.g. 
menthol and other flavoured cigarettes in Canada and clove and other flavoured 
cigarettes in the USA) has not created a major black market, and most illicit trade 
is conducted to avoid cigarette excise taxes. The National Research Council in 
the USA estimated that illicit sales accounted for 8.5–21% of the total cigarette 
market globally and for 11.6% of cigarette consumption in 84 countries in 2007 
(162). The volume of illicit trade depends on factors that include the magnitude 
of the price (or tax) differential, the ease of accessing products and the efficiency 
of tax administration.9 In jurisdictions with strong tax administration, illicit 
trade is modest. The practices of these jurisdictions include strong “track-and-
trace” systems to follow products from the manufacturer to the distributor and 
the retailer, strong customs control and rigorous tax stamping. Although thermal 
onion-skin stamps are used in many countries, encrypted tax stamps are used in 
California and Massachusetts, USA, as they are more durable and can include 
encoded information about the supply chain (163). Many countries do not have 
strong track-and-trace systems to minimize illicit trade, and these should be 
instituted to minimize illicit trade in cigarettes containing normal nicotine levels.
Another means of reducing illicit trade is to implement strong policies, 
including a penalty structure, the likelihood of detection and provisions for 
adequate staff for surveillance and enforcement. To reduce the likelihood 
of a black market, policies could address the manufacture, sales, purchase, 
use and/or possession of contraband products with a normal nicotine level. 
9  Ribisl KM, Hatsukami D, Johnson, Huang J, Williams R, Donny E. Strategies to prevent illicit trade for very 
low nicotine cigarettes (unpublished information).
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Manufacturers should be prohibited from making regular nicotine cigarettes for 
domestic distribution, and importers should be prohibited from importing such 
products. As for many other illicit products, the strongest penalties and the most 
enforcement should be imposed on the manufacturers and sellers of the products, 
such as retailers and internet vendors, rather than the smokers who possess them.
In the same way that taxation agencies check compliance by visiting 
manufacturing plants and retailers, an inspections programme should exist that 
includes testing of purchases to ensure that products with regular nicotine are not 
circulated through the retail supply chain. Policies to restrict sales from internet 
vendors are also required. In the USA, high rates of cigarette sales to minors and 
violation of tax policies led to new restrictions on payment options (e.g. Visa, 
Mastercard) and shipping options (UPS, FedEx), which drastically reduced the 
number of internet cigarette vendors and traffic to these websites (164). Similar 
policies should be enacted to restrict sales into countries that have low-nicotine 
products. Australia, for instance, has some of the highest tobacco excise taxes 
in the world, yet has successfully blocked nearly all websites selling regular 
cigarettes. In addition, enforcement agencies should make routine test purchases 
to ensure that internet vendors do not sell regular nicotine products in countries 
in which they are restricted.
Illicit trade can also be reduced by the widespread availability of substitute 
products that appeal to adult consumers. As discussed earlier, these products 
may include ENDS or snus containing nicotine. If these products are banned or 
restricted, as they are in some countries, there is likely to be greater demand for 
cigarettes on the black market.
4.3.4 Manipulation of VLNC cigarettes
Research on VLNC cigarettes has been conducted with experimental cigarettes 
that have chemical and physical properties sufficiently similar to those of 
commercial cigarettes that they are considered acceptable for use in studies of 
behaviour (17). Experimental products do not necessarily mimic the complex 
product designs and are not subject to the marketing tactics used to increase 
the appeal of commercial cigarettes and other tobacco products (89, 165). 
In an open market, branding may alter expectations or perceptions of VLNC 
cigarettes, with subsequent behavioural effects (89). Companies are likely to use 
heavy promotion both to use VLNC cigarettes to deflect attention from evidence-
based measures to reduce smoking and as a means of maintaining use of current 
products. The physical or chemical parameters of cigarette construction could 
also be manipulated to alter the formulation of VLNC cigarettes (1).
A number of studies have addressed the behavioural effects of non-
nicotine constituents present in tobacco to determine whether they add to or 
interact with the abuse liability of nicotine. Some studies of self-administration 
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by experimental animals indicated greater reinforcing effects than nicotine alone 
(166–169), while others found no additive or synergistic effects (170–172). The role 
of specific tobacco compounds and their interaction with nicotine remains poorly 
understood (1, 7, 173). Nornicotine, norharman and acetaldehyde have been 
shown to support self-administration independently of tobacco (1, 174–176) but 
only at doses substantially higher than those in cigarette smoke (7). Monoamine 
inhibitors increase self-administration of low doses of nicotine by rats, although 
reinforcement is minimal if nicotine is further reduced (177). Menthol appears 
to strengthen the reinforcing mechanism of nicotine and thus promote nicotine 
consumption and tobacco smoking, even at reduced levels of nicotine (178, 179), 
although this has not been demonstrated at the levels produced by VLNC cigarettes. 
Other research has been conducted on the development of nicotine analogues and 
their potential as substitutes (180). These and other non-nicotine constituents may 
play a greater role as determinants of behavioural reinforcement in the context of 
the low doses of nicotine available in VLNC cigarettes (171, 181).
Another possible response to a nicotine reduction policy is manipulation 
of products by cigarette smokers (2). In Malaysia, banning of the sale of nicotine-
containing e-liquid in ENDS shops resulted in not only a black-market supply 
of nicotine-containing e-liquid but also a significant increase in home-made 
nicotine-containing e-liquid (182). It is not known whether adding nicotine 
to VLNC cigarettes or other direct consumer manipulation of products would 
yield an appealing, acceptable alternative. Further types of commercial product 
manipulation that have not yet been studied include changes to the protonation 
of nicotine or the size distribution of aerosol particles, which determine the 
deposition and absorption of nicotine and other constituents (1).
4.3.5 Beliefs and attitudes regarding VLNC cigarettes and nicotine reduction
Many cigarette smokers have inaccurate beliefs about nicotine. Most participants 
in many studies misattributed nicotine as the primary cause of cancers and 
smoking-related morbidity (1, 12, 183). Beliefs about use of VLNC cigarettes reflect 
these misconceptions, as smokers perceive them as significantly less harmful than 
regular cigarettes (184, 185), potentially reinforcing interest in and use of these 
cigarettes to a greater extent than would be expected on the basis of subjective 
ratings (185, 186). Although nicotine is a precursor of carcinogenic TSNAs, and 
reduction of nicotine might decrease the levels of TSNAs in cigarette smoke, 
there is no evidence that VLNC cigarettes are less toxic. Health communication 
strategies are necessary to educate smokers about their relative toxicity and harm. 
Inaccurate beliefs about risk are not limited to VLNC cigarettes, as substantial 
proportions of smokers are unable to accurately assess the risks associated with a 
range of tobacco product categories (187, 188). A policy targeting nicotine might 
add further confusion about its relative harm, which could result in more negative 
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perceptions of NRT, ENDS or other alternative nicotine delivery systems than of 
more toxic tobacco products. Clear communication that the purpose of a nicotine 
reduction policy is to reduce dependence on the most toxic (combusted) tobacco 
products and education about the role of nicotine in addiction are therefore 
critical. The announcement by the FDA (15), which identified a continuum of 
risk across tobacco products, is an example of a health message that is sensitive to 
the role of nicotine in use versus harm.
Expectations about nicotine content influence smokers’ subjective response 
to regular and VLNC cigarettes (189, 190), including responses of the insula to 
craving and learning, as measured by functional magnetic resonance imaging (191, 
192). Sensory responses to VLNC cigarettes, specifically taste and strength ratings, 
moderate associations between beliefs and daily cigarette consumption, with higher 
subjective ratings (on scales of strength, taste, harshness and mildness), and beliefs 
about reduced harm support increased consumption (185). Expectations may also 
influence brand choice and smoking behaviour; for example, positive expectations 
of ENDS users are associated with a greater likelihood of quitting smoking but less 
likelihood of intention to quit ENDS use (193).
The WHO advisory note in 2015 reported strong public support for 
nicotine reduction (1, 194), and support has been demonstrated in population-
based surveys in New Zealand and the USA (186, 195), which may reflect beliefs 
about the disease risk associated with nicotine (186). Both surveys found about 
80% support, mainly among smokers but also among nonsmokers and various 
ethnic minority populations (186, 195). Consistently less support is shown for 
a ban on menthol than for regulation of nicotine (179, 186). Trial surveys differ 
from population surveys by providing an experiential basis for expectations. In an 
interview study in which New Zealand smokers were first given VLNC cigarettes 
to smoke, smokers were less interested in mandated nicotine reduction but 
supported their sale at a much cheaper price concurrently with regular cigarettes 
(196). In a trial in the USA, however, smokers who used VLNC cigarettes for 
6 weeks and who judged that their experimental cigarettes contained low or 
very low nicotine were approximately twice as likely to support as to oppose a 
regulated reduction in nicotine content (197).
4.3.6 Summary
 ■ VLNC cigarettes are a partial but incomplete substitute for regular 
cigarettes. A subset of current smokers would probably give up smok-
ing rather than switch to VLNC cigarettes if current high-nicotine 
cigarettes were no longer legally marketed. Most smokers who con-
tinue to smoke are unlikely to use VLNC cigarettes exclusively.
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 ■ Countries should put mechanisms in place to ensure strong tax ad-
ministration and consider other enforcement measures to limit illicit 
trade, restrict sales of regular nicotine content cigarettes into coun-
tries requiring low-nicotine content cigarettes and restrict websites 
selling regular nicotine content cigarettes.
 ■ Research was under way as of September 2017 on adolescents’ re-
sponse to low-nicotine products. It is anticipated that nicotine reduc-
tion will prevent a significant portion of children and adolescents 
who experiment with combusted tobacco products from becoming 
long-term users of those products.
 ■ Substitution among combusted tobacco products is common. A nic-
otine reduction policy might have to be applied to all combusted to-
bacco products rather than only to regular cigarettes to ensure a shift 
in population use from the most toxic and addictive products.
 ■ Reducing the nicotine content of combusted tobacco products might 
increase substitution by ENDS and possibly HTPs, which are mar-
keted and promoted by manufacturers as reduced risk products and 
safer alternatives to regular cigarettes. Independent research to sub-
stantiate industry research and claims, appropriate health communi-
cation, effective surveillance and regulatory oversight of these prod-
ucts are necessary.
 ■ Strong policies and enforcement systems can help reduce the supply 
of illicit cigarettes. Policies to reduce demand (e.g. treatment services, 
substitute non-combusted products) may also reduce illicit trade, al-
though the evidence is limited.
 ■ Smokers perceive VLNC cigarettes as less harmful than regular ciga-
rettes, which might support greater interest in and use of VLNC ciga-
rettes than would be expected from subjective ratings. Health com-
munication can address misperceptions of risk.
 ■ Physical or chemical parameters of cigarette construction could be 
manipulated by manufacturers or smokers to alter the formulation 
and reinforcing effects of VLNC cigarettes, and the effects might not 
readily be anticipated.
 ■ Support for nicotine reduction is reported from both population-
based and trial surveys.
 ■ Overall, the research suggests that a nicotine reduction policy, as part 
of a comprehensive approach and implemented with appropriate 
safeguards, could be an effective method for reducing the population 
prevalence of smoking.
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4.4 Regulatory approaches to nicotine reduction
Much of the concern about a nicotine reduction policy is based not on evidence 
of the individual effects of use of VLNC cigarettes but on the difficulties in 
successful implementation of such a policy (14) and potential unanticipated 
consequences of implementation, such as continued availability of toxic forms of 
nicotine on the black market and/or failure to adequately support less toxic forms 
of nicotine as alternatives to cigarettes (8, 10, 11, 13). These real challenges are 
difficult to model in advance of regulatory action (11, 14). One proposed solution 
is to monitor the impact of implementation in one or more communities that 
adopted reduced nicotine early on (11, 198). New Zealand has been discussed 
as a potentially ideal site for nicotine reduction, partly because of strong public 
support (194), continuing discussion of a policy of nicotine reduction (95, 
198, 199) and a geographical situation that limits the likelihood of illicit sales 
(198). In July 2017, the FDA announced that nicotine reduction was part of a 
comprehensive multi-year plan to reduce the health effects of tobacco use (15). In 
this section, we consider the feasibility of nicotine reduction, various regulatory 
approaches, potential challenges to implementation and broader philosophical 
arguments against nicotine reduction.
4.4.1 Feasibility of nicotine reduction and potential challenges
Commercial production of VLNC cigarettes that meet the product standard of 
om0.4 mg of nicotine per gram of tobacco without measurably increasing the 
toxicity of the product has been clearly demonstrated (1, 17, 198). The probable 
substitution for VLNC cigarettes of other combusted tobacco products (such as 
little cigars and roll-your-own tobacco) that approximate regular cigarettes in 
appearance and nicotine content indicates that reduced nicotine product standards 
should be extended to all combusted tobacco products. As noted in section 4.3.4, 
changes to VLNC products by manufacturers in response to a nicotine reduction 
policy could result in products with higher levels of pharmacologically relevant 
compounds that might impact behaviour. Products must be monitored to 
ensure successful policy implementation (1, 93) and to verify that non-nicotine 
compounds such as monoamine oxidase inhibitors and nicotine analogues do 
not change the reinforcement threshold of VLNC cigarettes (177).
As noted in both the WHO advisory note (1) and in subsequent discussions 
(8, 10), a nicotine reduction policy is unlikely to be successful without support 
from smokers of regular cigarettes, particularly those who are dependent on 
nicotine. While strong public acceptance has been found in population surveys 
(section 4.3.5), at least some smokers will consider the subjective trade-offs and 
policy unacceptable (200). Informing the public that nicotine reduction is part 
of a long-term strategy to phase out addiction to the most highly toxic tobacco 
products and to support the availability of less toxic alternatives, including easy 
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access to smoking cessation medication and behavioural treatment, will be 
necessary to maintain support among smokers and to provide time for smokers 
to switch from regular cigarettes before the policy is enacted (1, 198).
Political and legal challenges to nicotine reduction will be substantial, 
given that nicotine is a central feature of all successful tobacco products, as 
will tobacco industry efforts to undermine and misuse such policy (9, 14). One 
strategy that should be considered would be to prohibit the manufacture and sale 
of cigarettes with regular nicotine without criminalizing possession or use. This 
would shift the burden of compliance from individuals, and continued consumer 
demand could be moderated by education, treatment services and the availability 
of legal alternatives. Although countries that are considering nicotine reduction 
will recognize the potential threat to tax revenue, significant savings in health 
care would be expected. Ultimately, the net economic impact will be specific to 
each country and should be evaluated, as it will be an important determinant of 
the viability of a policy, even if the public health impact is clear.
4.4.2 Prerequisites for successful implementation of a nicotine  
reduction policy
The WHO advisory note (1) listed a number of preconditions that were considered 
necessary for a successful nicotine reduction policy:
 ■ comprehensive regulation of all nicotine- and tobacco-containing 
products;
 ■ other comprehensive tobacco control (increased taxes, smoking bans, 
graphic warning labels, plain packaging);
 ■ continuing communication of the health risks of smoking to both the 
general population and health professionals;
 ■ availability of affordable treatment and alternative forms of nicotine 
to reduce withdrawal symptoms in dependent smokers; and
 ■ capacity for market surveillance and product testing.
The inaccurate belief that nicotine is the main harmful constituent of cigarettes 
could decrease the sense of urgency of current smokers to quit (12, 183). Although 
this unintended consequence is unlikely to outweigh the potential benefits of 
nicotine reduction, it should be addressed by clear communication (185, 198). 
Further research and continuous evaluation will be required to ensure appropriate 
messages (e.g. accounting for differences among populations) without denying 
the harmful effects of nicotine (201). It must also be recognized that effective 
communication may not be possible in an environment where governments 
underfund evidence-based communication about the harms of smoking and 
where the bulk of communication still comes from tobacco interests and their 
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allies. Ultimately, subjective effects rather than the perceived harmfulness of 
cigarettes may best predict long-term smoking behaviour (184).
It has been speculated that regulatory environments in which principles 
of harm reduction are included with other elements of tobacco control would 
provide more favourable conditions for a nicotine reduction strategy (1, 10, 11, 
198). This might entail readily available, consumer-acceptable non-combusted 
forms of nicotine that could be used to manage withdrawal symptoms and provide 
smokers with a viable alternative to regular cigarettes, and it would demonstrate 
that reduction of the nicotine in combusted tobacco is not prohibition of nicotine 
(41). This will require further consideration in a real-world context in which there is 
already concern about the use and promotion of some alternative nicotine products.
While a nicotine reduction approach could substantially improve public 
health, it also offers considerable scope for tobacco companies to mislead 
consumers, both directly and indirectly. For example, they might use lower-
nicotine products to promote similarly branded products, to imply the safety 
of both new and established products and to present themselves as policy 
advisers. Given the industry’s long history of abusing health policy initiatives 
for promotional purposes and public relations, any enacted regulations should 
preclude inappropriate or misleading promotion by tobacco companies, directly 
or indirectly, with strong monitoring and enforcement capacity. Further, 
regulations should ensure that information and advice on the health aspects of 
VLNC cigarettes or other tobacco products come from health authorities, not 
tobacco companies or their agents. It is recommended that an international 
approach be found for regulation of communication strategies and promotion of 
VLNC, with commitments from all relevant Parties.
The WHO advisory note (1) raised the issue of the potential health risks 
introduced by alternative forms of tobacco or nicotine, which have also been 
discussed critically elsewhere (see section 4.3.2). Many of the concerns about 
the promotion of ENDS and other non-combusted tobacco product alternatives 
are related to the possibility that they would support cigarette initiation or use; 
however, these concerns should become less relevant in the context of cigarettes 
with low addiction potential (41). Likewise, concurrent use of two or more 
products, which could potentially support continued use of VLNC cigarettes, 
would be less of a problem, because these cigarettes would be less desirable and 
alternative products would be more satisfying in comparison (41). Evaluation and 
monitoring of the use and health effects of other products, including less toxic 
alternatives, and patterns of concurrent use of several products would nonetheless 
be a critical component of a nicotine reduction policy (1, 2, 9). Constraints on 
marketing and on the availability of ENDS and other alternative nicotine products 
would be appropriate to limit experimentation by nonsmokers, especially young 
people (10, 41). Health agencies should clearly and accurately communicate to 
96
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
the public the potential health risks of alternative products, including ENDS and 
HTPs, and should be careful not to encourage addiction to alternative products.
A nicotine reduction strategy should be part of a comprehensive tobacco 
control strategy that complements other evidence-based policies, such as 
increased taxes, sustained and adequately funded public education campaigns, 
restrictions on smoking in public, further product regulation as required, bans 
on tobacco industry marketing and public relations, the availability of low-
cost NRT and behavioural cessation treatment (e.g. telephone counselling 
lines) and special programmes for disadvantaged groups (95). The regulatory 
considerations reported by the FDA in its announcement of nicotine reduction 
(15) were continuing regulation of combusted cigarettes and the characteristics 
related to toxicity and the attractiveness of combusted products; the use, 
availability and health effects of ENDS and other alternatives to cigarettes, such 
as medicinal nicotine products; and regulation of health claims and other forms 
of communication of risk.
4.4.3 Strategies for implementation of a nicotine reduction policy
The WHO advisory note (1) addressed the question of a gradual versus an 
immediate reduction in nicotine content, noting that an immediate reduction is 
preferable insofar as it is less likely to introduce such unintended consequences 
as a short-term increase in compensatory smoking by dependent smokers (93). 
A 10-site, double-blind study showed that immediate, not gradual, reductions 
in nicotine content decreased the number of cigarettes smoked per day and 
biomarkers of exposure in a 20-week intervention, and measures of craving and 
dependence were significantly lower at week 20 in the group that experienced an 
immediate reduction (20). Although these data suggest potential benefits of an 
immediate reduction, it is important to note that, consistent with other reports 
(202), more participants drop out of studies when the reduction is immediate, 
suggesting that immediate reductions may make it more difficult for smokers to 
adjust, particularly in the absence of alternative sources of nicotine or smoking 
cessation treatment. As smokers will continue to have access to regular cigarettes 
until the supplies have been exhausted, more gradual introduction of VLNC 
cigarettes is the probable practical outcome, even in an immediate reduction 
policy (40). Concern about the potential discomfort of dependent smokers 
of regular cigarettes faced with immediate reduction emphasizes the need for 
readily available alternative forms of nicotine and/or medication (40, 198).
Population responses to nicotine reduction will partly reflect contextual 
differences. For example, reducing nicotine in Sweden would be likely to result 
in the adoption of snus, whereas snus is banned in most other countries in the 
European Union (11). Thus, strategies for reducing nicotine must be sensitive 
to differences in context, including other regulation and population preferences. 
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Some countries have restricted or banned the sale and importation of ENDS 
(e.g. Brazil, Singapore, Thailand, Uruguay and Venezuela). Such a ban would not 
necessarily preclude a nicotine reduction policy for combusted tobacco products; 
however, it might raise additional challenges. Care must be taken to ensure the 
availability of alternative sources of nicotine, such as medicinal nicotine, access 
to tobacco dependence treatment and the capacity or infrastructure necessary to 
address a potentially stronger illicit market.
4.4.4 Philosophical objections to nicotine reduction
Some discussions of nicotine reduction represent the policy as a de-facto prohibition 
of cigarettes (2, 10, 13, 14). In this viewpoint, nicotine reduction differs significantly 
from other tobacco control measures such as plain packaging, graphic warnings or 
flavour bans, in that it fundamentally alters the primary function of the product, 
which is to deliver nicotine (14). Nevertheless, smokers use VLNC cigarettes even 
when no other products are available, although they may be less likely to persist in 
their use over time (196). Further, unlike in a prohibition strategy, smokers would 
still have access to nicotine but in potentially less harmful delivery systems. The 
availability of other forms of nicotine would also minimize the efforts of dependent 
smokers to seek nicotine through illegal means (198).
A second objection to nicotine reduction is that it is fundamentally a 
“top–down” or paternalistic means for reducing the health risks of tobacco (9, 10). 
Limiting the sale of cigarettes to those with a VLNC intrudes on personal choice. 
Some argue, however, that support for ENDS and other alternative sources of 
nicotine could attract smokers away from cigarettes without imposing invasive 
regulations (11, 13). The advantages of avoiding a nicotine reduction policy 
include the elimination of legal or political challenges to policy, a potential black 
market and opposition from smokers (9). Questions remain about the long-term 
health consequences of alternative products, including ENDS and HTPs, the use, 
function and emissions of which continue to evolve rapidly. Ultimately, some 
combination of policies may be necessary to reduce the desirability of combusted 
products relative to alternatives; this might include increased communication 
of relative risk, increased availability of lower-risk products, an increased price 
differential between low- and high-risk products or nicotine product standards 
that reduce dependence on the most toxic products.
4.4.5 Summary
 ■ The feasibility of producing commercial VLNC cigarettes with sub-
jective characteristics similar to those of regular cigarettes but with 
reduced potential for dependence has now been reasonably estab-
lished. The toxicity of these cigarettes remains high, however, due to 
combustion and inhalation of tobacco.
98
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
 ■ The physical characteristics and construction of VLNC cigarettes 
used in clinical trials are relatively uniform; in a commercial mar-
ket of VLNC cigarettes, product characteristics other than nicotine 
might diverge significantly. Some differences, such as the levels of 
non-nicotine compounds with pharmacological effects, might have 
to be carefully monitored, or restrictions might have to be imposed 
to limit product changes.
 ■ Public education campaigns should communicate nicotine reduction 
as part of a long-term strategy, including a comprehensive tobacco 
control programme, to phase out addiction to the most highly toxic 
tobacco products. If VLNC cigarettes are sold concurrently with reg-
ular cigarettes, without substantive policy interventions or education 
campaigns, their use is likely to remain low.
 ■ The preconditions for a successful nicotine reduction strategy identi-
fied in the WHO advisory note remain valid, namely: comprehensive 
regulation of all tobacco- and nicotine-containing products, capac-
ity for surveillance and product testing, commitment to continuing 
public education and the availability of and access to tried and tested 
forms of treatment, as approved by national authorities. Inappropri-
ate or misleading promotion by tobacco product manufacturers and 
manufacturers of alternative products should be prohibited.
 ■ An immediate reduction would have clear advantages over a gradual 
reduction in nicotine content but might require a comprehensive ap-
proach in order to reduce unintended consequences.
 ■ The intent of reducing the nicotine content of regular cigarettes is 
not to prohibit their sale and use but to reduce their addictiveness, so 
that people can choose whether or not to continue using an extremely 
toxic product.
4.5 Research questions
 ■ Research to date has focused exclusively on reduced-nicotine ciga-
rettes. Future studies should address the potential effects of reduced 
nicotine in other combusted tobacco products (e.g. roll-your-own to-
bacco, little cigars, cigarillos, waterpipe tobacco) and the benefits and 
drawbacks of reducing nicotine in non-combusted tobacco products.
 ■ The positive and negative impacts of VLNC cigarettes on vulnerable 
populations, including women of reproductive age, should continue 
to be assessed. Research on the potential uptake and use of VLNC 
cigarettes by adolescents and tobacco-naive users would be particu-
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larly informative; this may have to be assessed primarily after the im-
plementation of product standards through surveillance.
 ■ Further research should be conducted on concomitant use of VLNC 
cigarettes, ENDS and other alternative tobacco and nicotine prod-
ucts, by both dependent and non-dependent smokers and tobacco-
naive users.
 ■ Studies conducted to date do not show that use of VLNC cigarettes 
increases the use of alcohol or dependence on other substances (such 
as cannabis), but continued assessment is warranted.
 ■ VLNC products with altered physical or chemical characteristics de-
signed to replace or enhance the pharmacological effects of nicotine 
have not been developed or tested to date.
 ■ Research on the impact of specific public communication strategies 
would help to maximize the benefit of a policy, minimize misunder-
standing of the impact of the change in cigarette addictiveness on its 
toxicity and inform those who are dependent on nicotine about ap-
propriate alternatives.
 ■ Research on the nature of tobacco industry abuse of nicotine reduc-
tion strategies for continued promotion of current products and for 
undermining evidence-based tobacco control policies should be con-
ducted. Research is also needed on means of regulating such activity 
nationally and internationally.
 ■ Few data are available for estimating the extent of illicit sales or of 
product tampering and related factors that could mitigate the effects 
of nicotine reduction.
4.6 Policy recommendations
 ■ A nicotine reduction policy has considerable promise as a means to 
accelerate a reduction in use of the most toxic tobacco products and 
encourage smoking cessation. Such a policy should be part of a com-
prehensive approach and might be most effective when coordinated 
with other relevant policies designed to support cessation and reduce 
smoking.
 ■ Substitution among combusted tobacco products is common, and 
the availability of high-nicotine combusted products that are simi-
lar in use and appearance to regular cigarettes is likely to mitigate 
the potential public health benefit of nicotine reduction. Therefore, a 
nicotine reduction policy might have to be applied to all combusted 
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products rather than only to regular cigarettes to support a shift in 
population use from the most toxic and addictive products.
 ■ In view of the reduced exposure to nicotine and decreased tobacco 
consumption demonstrated in many clinical and behavioural stud-
ies, there is insufficient evidence that a significant population of 
non-smoking adolescents or adults who would not otherwise have 
smoked will adopt and maintain use of VLNC cigarettes. To mini-
mize any unintended consequences in these populations, the health 
risks of both VLNC cigarettes and alternative forms of nicotine must 
be clearly communicated, including the fact that VLNC cigarettes are 
not safer than regular cigarettes.
 ■ As indicated in the 2015 WHO advisory note, a nicotine reduction 
policy should not be considered to be supplanting a comprehensive to-
bacco control policy, which should include increased taxes, sustained, 
adequately funded public education, smoking bans, graphic warning 
labels, plain packaging and other forms of product regulation. A co-
ordinated policy for all tobacco- and nicotine-containing products is 
essential, as is access to treatment for tobacco dependence.
 ■ Capacity to conduct continuous population surveillance, monitoring 
and testing of products and enforcement of product standards is criti-
cal to support a nicotine reduction policy. Monitoring should also 
include industry promotional and other activities as well as product 
availability and sales.
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5.1 Introduction
The report Scientific Basis of Tobacco Product Regulation (WHO Technical 
Report Series No. 951) (1), published in 2008, specifies an approach to lowering 
the levels of selected toxicants in mainstream cigarette smoke. We review these 
recommendations and summarize several papers published by the tobacco 
industry that discuss aspects of the proposed regulatory strategy. We also discuss 
the significant progress in evaluating biomarkers of tobacco smoke toxicants and 
carcinogens that has been made since the 2008 report and the relation of these 
biomarkers to smoke constituent levels and, in some cases, to disease incidence. 
We consider the use of mandated toxicant levels in a product regulatory strategy 
and present recommendations for an updated regulatory strategy based on 
nicotine levels in cigarettes.
5.2 Regulation of cigarette smoke constituents described in WHO 
Technical Report Series No. 951
The report Scientific Basis of Tobacco Product Regulation (WHO Technical Report 
Series No. 951) recognizes that regulatory strategies based on machine-measured 
tar, nicotine and CO yields per cigarette under the ISO smoking machine 
regimen were causing harm by misleading smokers to believe that so-called “low-
yield cigarettes” were less harmful. Thus, the report recommended establishing 
limits for certain smoke constituents expressed per mg nicotine rather than per 
cigarette, as people smoke cigarettes to obtain adequate nicotine to satisfy their 
physiological and behavioural needs, and most toxicants in smoke are delivered in 
proportion to nicotine. This shifts the emphasis towards the potential toxicity of 
smoke generated under standardized conditions. The report also recommended 
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prohibiting any communications to consumers that were based on machine 
measurements, as these can be easily misunderstood.
The report concluded that it was premature to consider biomarkers in a 
regulatory strategy, because, while biomarkers of exposure existed at the time, 
there were no validated biomarkers of harm. As discussed below, significant 
progress has been made in the application of biomarkers to evaluating the 
potential toxicity and carcinogenicity of cigarette smoke. There is presently 
no doubt that the average levels of certain biomarkers of exposure reflect the 
measured amounts of their parent compounds in cigarette smoke.
In WHO Technical Report Series No. 951, TobReg selected toxicants for 
regulation on the basis of a number of factors, including established cardiovascular 
and pulmonary toxicity and carcinogenicity, the feasibility of lowering their 
concentrations with available technology and variation in chemical classes and 
brands. Consideration was also given to the inclusion of compounds in both the 
gas and the particulate phases of cigarette smoke. Of these characteristics, the 
most important was evidence of toxicity.
Data from Health Canada and a paper on constituent levels in Philip 
Morris brands in both the USA and elsewhere (2) were available to assess 
differences in the levels of the selected toxicants in cigarettes on the market 
in Canada and the USA. These data were used to select the initial levels of the 
regulated constituents as a first step in an overall strategy to eliminate brands 
with higher levels from the market, thus lowering the overall mean values of the 
toxicants in the remaining brands. A rolling mean was envisioned, which would 
eventually drive down levels of the selected toxicants in all brands left on the 
market and prevent introduction onto the market of brands with toxicant levels 
higher than the mean.
The report recommended that the regulatory strategy be implemented 
in phases, beginning with required annual reporting of selected toxicant levels, 
followed by promulgation of the levels for toxicants above which brands could 
not be sold and, finally, enforcement of the established levels. Some progress has 
been made towards achieving these goals, but it is unclear whether there has been 
sufficient momentum.
The toxicants for which mandatory lowering is recommended and the 
initially recommended levels are summarized in columns 1–3 of Table 5.1. The 
modified intense machine smoking regimen used by Health Canada (HCI) was 
selected for measuring toxicants. This regimen is modified from the ISO method 
by increasing the puff volume from 35 mL to 55 mL and decreasing the puff interval 
from 60 s to 30 s. In addition, all ventilation holes are blocked. This method is 
referred to in the report as the “modified intense smoking” regimen. The levels 
in Table  5.1 for “international brands” (i.e. all those other than United States 
brands) are derived from a sample of brands of United-States-style cigarettes with 
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a blend of tobaccos (2). The levels in “Canadian brands” are derived from reports 
to Health Canada and are for cigarettes made mainly with Bright (flue-cured) 
tobacco. These were selected as examples because of the availability of data and 
the different types of tobacco and were expected roughly to represent the markets 
to be regulated, depending on the type of product prevalent in that market. In 
addition to the compounds listed in Table 5.1, priority toxicants recommended for 
reporting were acrylonitrile, 4-aminobiphenyl, 2-aminonapthalene, cadmium, 
catechol, crotonaldehyde, hydrogen cyanide, hydroquinone and nitrogen oxides 
(1). An additional group of 20 compounds to be considered for reporting was 
added in 2013 (see section 8).
Table 5.1. Levels of toxicants recommended for mandated lowering (µg/mg nicotine under the Canadian 
intense smoking regimen)
Toxicant
Levels recommended in 
WHO Technical Report 
Series No. 951 (1) Levels in some published surveys
Criterion for  
selecting recom-
mended levels
Interna-
tional 
brands (2)
Canadian 
brandsa (3)b (4)c (5)d
NNK 0.072 0.047 0.080 0.050–0.072 0.0273 Median value
NNN 0.114 0.027 0.134 0.077–0.142 0.0916 Median value
Acetaldehyde 860 670 676 468–626 684.1 125% of median value
Acrolein 83 97 85.4 48.8–64.3 64.5 125% of median value
Benzene 48 50 43.1 40.8–53.7 66.1 125% of median value
Benzo[a]pyrene 0.011 0.011 0.0096
0.0074–
0.0084 0.0085 125% of median value
1,3-Butadiene 67 53 50.5 38.1–52.1 71.9 125% of median value
Carbon monoxide 18 400 15 400 15 700
11 500–
14 800 16 100 125% of median value
Formaldehyde 47 97 47.3 28.2–43.7 81.4 125% of median value
Nicotine (per cigarette) – – 2.13 mg 1.56–2.33 mg 1.6 mg –
NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN: N´-nitrosonornicotine. a Data from Health Canada. b 61 United States 
brand styles, mean. c Range of means of three international brands. d 20 brands on the Chinese market, mean.
The list of compounds in Table 5.1 is still highly relevant to regulation, as all have 
well documented toxic and/or carcinogenic activity. The FDA has published a list 
of “harmful and potentially harmful constituents (HPHCs) in tobacco products 
and tobacco smoke” that includes all the compounds in Table  5.1 as well as 
those recommended for reporting (6). The FDA list of HPHCs, which focuses 
on chemicals linked to cancer, cardiovascular disease, reproductive problems, 
addiction and respiratory effects, is longer than that presented here, with 93 
constituents, because it includes every identified toxic or carcinogenic compound 
in each class rather than representatives (e.g. NNK and NNN for N-nitrosamines 
and benzo[a]pyrene for PAHs in Table 5.1).
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Table 5.1 also presents the levels of the selected toxicants per mg of nicotine 
as reported in three industry studies published subsequent to WHO Technical 
Report Series No. 951 (3–5). Generally, the means and ranges of constituent 
concentrations were similar to those in the WHO report. One industry study, not 
shown in Table 5.1, reported levels of NNN and NNK in smoke and concluded 
that they were decreasing (7).
WHO Technical Report Series No. 951 also addressed questions on 
variations in measurement of constituent levels and among brands and reported 
the coefficient of variation (standard deviation of a series of measurements 
divided by the mean of that series) for the levels of constituents in various brands. 
This was divided by the coefficient of variation of multiple measurements of a 
given constituent (e.g. variation in the analytical method) to produce a ratio. 
Constituents with high ratios, e.g. with wide variation in levels, as determined 
by analytical methods with little variation, would be the most appropriate targets 
for regulation. The report concluded that the ratios for individual toxicants in 
the Philip Morris International brands and the Canadian brands indicated that 
there was sufficient variation in the levels of most toxicants among brands that 
mandated reductions would have a substantial effect on the levels in brands 
remaining on the market.
5.3 Industry response to WHO Technical Report Series No. 951
Bodnar et al. (3) conducted a survey of selected mainstream smoke constituents 
from commercially marketed United States cigarettes, segmenting the market 
into 13 strata according to “tar” category and cigarette design parameters. The 
HCI smoking regimen was used, and the yields of mainstream smoke constituent 
per mg nicotine were estimated. Normalization per mg nicotine gave an inverse 
ranking of constituent yields from those expressed per cigarette according to the 
ISO/FTC Cambridge filter method “tar” categories, i.e. “Full flavour” > “Lights” > 
“Ultra-lights” – designations that are prohibited by the WHO FCTC.
Purkis et al. (8) reviewed measurements of smoke constituents and 
aspects of variability that can affect regulatory standards. They discussed 
method development, harmonization and standardization and reviewed such 
issues as variation among products, machine-smoking regimens and laboratory 
measurements and their potential consequences, such as misinterpretation of data. 
They called for internationally agreed testing standards and measurement tolerances.
Haussmann (9) provided a detailed discussion of the use of hazard 
indices for evaluating cigarette smoke composition, including the advantages and 
limitations of the approach described in WHO Technical Report Series No. 951. 
Haussmann concluded that application of the suggested approach would result 
in banning 39 of the 50 brands in the data set of Counts et al. (referred to as 
“International brands” in Table 5.1). He demonstrated that excluding one brand 
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because the yield of one constituent exceeded the recommended ceiling could 
mean that the yields of the other eight constituents that were present below their 
respective ceilings were not accounted for. The result would be to increase rather 
than decrease the average yield of those constituents in the remaining brands. 
Thus, the recommended levels of various constituents should be assessed carefully.
Piade et al. (10) determined the levels of the 18 priority constituents 
(expressed per mg nicotine) identified in WHO Technical Report Series No. 951 
in 262 commercial brands, including various blends from 13 countries. Principal 
component analysis was used to identify inverse correlations and other patterns. 
Three principal components explained about 75% of the data variation. The first 
was sensitive to the relative levels of gas- and particle-phase compounds, while 
the other two components grouped American and Virginia blends, revealing 
inverse correlations. For example, the levels of nitrogen oxides and amino- or 
nitroso-aromatic compounds were inversely correlated with either formaldehyde, 
acrolein, benzo[a]pyrene or dihydroxybenzenes. They concluded that regulatory 
approaches might be confounded by such inverse correlations.
Belushkin et al. (11) studied the variation in yields of smoke constituents 
for a Kentucky reference cigarette and one commercial brand analysed on several 
occasions over 7 years. They showed that statistically significant differences in the 
yields of some smoke constituents did not necessarily correspond to differences 
between products and that tolerances should be defined. They concluded that use 
of two approaches – minimal detectable differences and statistical equivalence – 
was more meaningful for comparisons than the statistical Student t test.
Eldridge et al. (4) measured toxicant levels in the tobacco and smoke 
of reference cigarettes and three commercial products, monthly for 10 months. 
The monthly variation was < 15% for most analytes but increased somewhat 
when reported as a ratio to nicotine level. They concluded that measurement 
of emissions from commercial cigarettes was subject to considerable variation, 
particularly for toxicants present at low levels.
Deng et al. (5) studied the influence of measurement uncertainty on the 
recommended regulation of the nine constituents listed in Table 5.1. Uncertainty 
was evaluated in collaborative studies conducted in 2012–2016 of the compliance 
of 20 representative cigarette samples. They concluded that measurement 
uncertainty would strongly influence implementation of the proposed regulations.
Collectively, these studies indicate some cautionary and practical notes 
for application of the proposed regulation of nine constituents per mg nicotine. 
The uncertainty in analytical chemistry measurements is well known but in most 
cases is relatively minor, particularly for constituents that occur at high levels. 
Validated methods are available for measuring all the compounds proposed 
for measurement (12–18; see also http://www.who.int/tobacco/industry/
product_regulation/toblabnet/en/). Thus, further studies on standardization of 
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methods, including time-consuming ring trials that may last years, are probably 
not required. Furthermore, the inverse correlations among constituent levels 
in certain brands may be problematic, as lowering the level of one constituent 
may increase those of others. This has been known for decades (19, 20), and it 
is industry’s responsibility to address these levels in products that they wish to 
maintain on the market. In conclusion, the main goal of these industry studies 
was to provide reasons to challenge and delay implementation of product 
standards for cigarette smoke emissions, and there are no valid scientific reasons 
that implementation cannot proceed.
5.4 Relation between smoke constituent levels and biomarkers
Biomarkers of carcinogens and toxicants in tobacco, most of which are urinary 
metabolites of tobacco smoke constituents, are robust, validated, reliable 
indicators of human exposure to tobacco product constituents (21). Several of 
these biomarkers are directly relevant to the toxicants recommended for mandated 
lowering listed in Table 5.1. For NNK, total NNAL (the sum of free NNAL and its 
glucuronides) is an accepted biomarker of exposure (22). For acrolein, the urinary 
metabolite 3-hydroxypropyl mercapturic acid has been widely used (23, 24). 
Similarly, for benzene and 1,3-butadiene, the urinary mercapturic acids, S-phenyl 
mercapturic acid and monohydroxybutyl mercapturic acid, respectively, have 
been quantified (25–27). The urinary metabolite of pyrene, 1-hydroxypyrene, has 
been used extensively as a biomarker of uptake of PAH, the class of compounds 
that includes benzo[a]pyrene (21, 28). Exhaled CO is an accepted biomarker 
of CO exposure in cigarette smokers (21). Total nicotine equivalents – the sum 
of nicotine, cotinine and 3´-hydroxycotinine and their glucuronides in urine – 
represent a high percentage of the nicotine dose received by a tobacco user and 
are an excellent biomarker of nicotine dose (29).
Most of these biomarkers have been quantified in large studies, such 
as the Health Measures Study in Canada, the National Health and Nutrition 
Examination Survey in the USA and the industry-sponsored Total Exposure 
Study, as well as in epidemiological and clinical studies (26, 30–42). The levels of 
all the biomarkers decrease significantly when people stop smoking, and all the 
urinary biomarkers correlate with total nicotine equivalents (24, 26–28, 43, 44). 
The levels of constituents in smoke and the levels of acrolein, NNK, nicotine and 
pyrene in the mouth are clearly related to the respective urinary biomarkers (33, 
34, 38, 41). Collectively, these studies demonstrate that evaluation of biomarkers 
can buttress analyses of smoke constituents in regulations by providing a definitive 
link between the levels of smoke constituents and actual human exposure. 
Furthermore, nicotine biomarkers and total NNAL have been positively related 
to lung cancer in prospective epidemiological studies (45–47) and can thus be 
considered biomarkers of potential harm.
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5.5 Use of mandated lowering of toxicant levels in a product 
regulatory strategy
The public health impact of mandated lowering of toxicant levels of cigarettes is 
virtually unknown. In order to improve public health by decreasing the disease 
and death due to tobacco product use, evaluation of a product standard must 
include population effects. According to the Family Smoking Prevention and 
Tobacco Control Act in the USA, which gives the FDA regulatory authority over 
tobacco products in the country, tobacco product standards can be adopted if 
the standard is “appropriate for the protection of the public health.” The scientific 
evidence that is considered in evaluating the public health impact of a product 
standard includes:
 ■ the risks and benefits to the population as a whole, including users 
and non-users of tobacco products, of the proposed standard;
 ■ the increased or decreased likelihood that existing users of tobacco 
products will stop using such products; and
 ■ the increased or decreased likelihood that those who do not use to-
bacco products will start using such products.
To date, a cross-sectional study has shown that urinary levels of NNAL are lower 
in countries in which cigarettes have lower levels of NNK and NNN (48), but 
it is not known whether these differences are related to the country-specific 
incidence of cancer. A dose–response relation has, however, been found between 
biomarkers of exposure to NNK and NNN and risks for cancers of the lung (46, 
47, 49) and the oesophagus (50), respectively.
To avoid replicating the negative public health impact of the low-tar 
and low-nicotine-yield cigarette experience (51) before implementation of 
mandated standards, their potential effects on smoking behaviour, exposure to 
toxicants and potential harm, consumer perceptions and misperceptions of the 
regulated product and uptake and continued use of the product (52–54) should 
be determined and appropriate action taken as necessary. One constituent that 
was not targeted in WHO Technical Report Series No. 951 but was targeted in a 
subsequent advisory note (55) is nicotine. Regulation of nicotine, as discussed in 
the previous section, might result in the greatest public health benefit (see below). 
Reducing nicotine to minimally addictive levels would prevent the development 
of dependence on cigarettes and facilitate abstinence among smokers, thereby 
reducing the prevalence of smoking.
It is notable that, since the WHO Technical Report was issued, products 
such as ENDS, with significantly lower toxicant levels and toxicity than 
conventional cigarettes (56–58), have been introduced in some markets in full 
force. If products that are demonstrated to be substantially less toxic replace 
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cigarettes among smokers and are used exclusively by smokers, the public health 
impact might be substantial provided that there are no adverse consequences 
such as inappropriate promotion or use by children and/or young people or 
continuing dual use with conventional cigarettes or other tobacco products.
5.6 Toxicants recommended for mandated lowering and 
recommended limits
Donny et al. (40) obtained highly relevant results that could change the regulatory 
landscape. They conducted a double-blind, parallel, randomized clinical trial of 
cigarettes with nicotine contents varying from 15.8 mg/g of tobacco, which is 
typical of commercial brands in the USA, to 0.4 mg/g. Regular smokers were 
assigned to smoke either low-nicotine cigarettes or their usual brand of cigarettes 
for 6 weeks. At week 6, the average number of cigarettes smoked per day was 
significantly lower for the participants randomly assigned to cigarettes containing 
2.4 mg, 1.3 mg or 0.4 mg of nicotine per gram of tobacco (16.5, 16.3 and 14.9 
cigarettes/day, respectively) than for participants who were randomly assigned 
to their usual brand or to cigarettes containing 15.8 mg/g tobacco (22.2 and 21.3 
cigarettes/day, respectively). The cigarettes with a lower nicotine content reduced 
exposure to and dependence on nicotine and also craving during abstinence from 
smoking, without increasing the expired CO level or total puff volume, which 
suggests that there was minimal compensation. These results are consistent with 
those of several smaller trials (30, 59–63) and of a trial with vulnerable adults (64).
In the trial by Donny et al. (40), participants assigned to cigarettes 
containing ≤ 2.4 mg of nicotine per gram of tobacco smoked 23–30% fewer 
cigarettes per day at week 6 than did participants assigned to cigarettes containing 
15.8 mg/g of tobacco. The results showed a clear, significant breakpoint in the 
number of cigarettes smoked per day and total nicotine equivalents in urine 
between the cigarettes containing 5.2 mg/g nicotine and those with 2.4 mg/g. 
Furthermore, and most significantly, dependence, as assessed in the Wisconsin 
inventory of smoking dependence motives, was significantly lower at week 6 
among participants who smoked cigarettes with 0.4 mg/g nicotine than among 
those who smoked cigarettes with 15.8 mg/g nicotine (P = 0.001). The cigarettes 
containing 0.4 mg/g nicotine delivered 0.04 mg nicotine in their smoke under 
HCI conditions (65).
These results suggest that a product standard could have a significant 
public health benefit for countries with the appropriate resources (see reference 
55 for more details). The amount of nicotine in cigarette tobacco filler should 
be regulated such that the level of nicotine in mainstream smoke does not 
exceed 0.04 mg per cigarette under HCI conditions (39–58 times lower than in 
typical current brands, Table 5.1). With respect to other constituents, our new 
recommended levels are the median values per mg of nicotine of the constituents 
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listed in Table  5.1, according to the latest market survey information, which 
would be obtained from major tobacco companies and Health Canada data 
on the brands with compliant nicotine levels, e.g. that deliver 0.04 mg nicotine 
per cigarette under HCI smoking conditions. This recommendation is stronger 
than the “125% of the median value” previously established by TobReg. We also 
retain the requirement for reporting levels of acrylonitrile, 4-aminobiphenyl, 
2-aminonaphthalene, cadmium, catechol, crotonaldehyde, hydrogen cyanide, 
hydroquinone and nitrogen oxides. These toxicants satisfy several criteria 
for inclusion: sufficient evidence of carcinogenicity, known respiratory or 
cardiotoxicity, differences in levels of toxicants in different brands in different 
countries, measurability and potential for decreased yields in a product (1).
We note that, when expressed per mg nicotine, the mandated toxicant 
levels would be higher than the current mandated levels for the toxicants listed 
in Table 5.2, based on data for the Spectrum cigarettes used in the clinical study 
described above (65). This is obviously a consequence of the lower recommended 
nicotine level of 0.04 mg per cigarette in mainstream smoke as compared with 
current levels, which range from 1.5 to 2 mg/cigarette. Measures of biomarkers, 
however, clearly show that smokers of these low-nicotine cigarettes excrete 
significantly lower levels of total nicotine equivalents and total NNAL in their 
urine and thus have less uptake of toxic and carcinogenic compounds (40).
Table 5.2. Levels of selected toxicants in mainstream smoke of Spectrum cigarettes (NRC 102, 0.04 mg 
nicotine per cigarette; Health Canada intense smoking regimen)
Toxicant µg/mg nicotine
Acetaldehyde 41 500
Acrolein 2070
Benzo[a]pyrene 0.220
Carbon monoxide 720 000
Formaldehyde 258
NNK 0.798
NNN 2.88
 
NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN: N´-nitrosonornicotine. Source: reference 65.
5.7  Implementation of mandated lower levels of toxicants
In order for regulators to effectively mandate lower levels of toxicants and 
nicotine in cigarettes, appropriate procedures and sufficient infrastructure and 
resources are required. These include requiring the disclosure of levels of harmful 
constituents in cigarettes and an independent laboratory to validate and monitor 
these levels routinely. In the previous WHO report (1), analysis of the constituent 
yields of cigarettes was considered to be the first step towards a mandate to reduce 
toxicants. Standardized testing procedures should be instituted that include not 
only laboratory methods (e.g. machine-determined yields that reflect a range of 
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human exposures and validated analytical chemistry methods) but also the way 
in which the cigarettes to be tested are systematically procured (e.g. different 
geographical locations, from several retail outlets within a geographical location, 
directly from manufacturers, in different months). Tracking cigarettes that are 
licit and illicit should also be considered, as well as a plan to reduce the entry of 
illicit cigarettes to the market. Furthermore, education campaigns and messages 
should be designed to minimize any misperception of the harm associated with 
smoking cigarettes. Thus, the message that combusted products are hazardous to 
health, regardless of a mandate to lower toxicant levels, must be communicated 
explicitly and clearly. Finally, a surveillance system should be in place to monitor 
any unintended consequences, and methods for correction should be considered.
5.8 Conclusions and recommendations
The regulatory strategy recommended here retains the principle of the previous 
recommendations by TobReg, revising and strengthening it such that brands 
on the market cannot exceed the median values of the constituents listed 
in Table  5.1. We also retain the requirement for reporting of several other 
constituents. Furthermore, we recommend considering a regulatory strategy in 
which the nicotine level in tobacco does not exceed 0.4 mg/g of tobacco (0.04 
mg nicotine per cigarette in mainstream smoke under HCI smoking conditions). 
The new regulation based on nicotine is the result of decades of research that has 
demonstrated that nicotine is the main chemical that drives people to smoke (66, 
67) or otherwise use tobacco and the results of clinical trials that demonstrate 
that low-nicotine cigarettes reduce exposure to and dependence on nicotine 
and the number of cigarettes smoked. Thus, we recommend that the previous 
strategy of limiting specific toxicants and the present new recommendation of 
limiting nicotine be pursued aggressively in parallel. The first, critical step in the 
toxicant reduction strategy is collection of data on current products by methods 
established by WHO Tobacco Laboratory Network (TobLabNet).
We are aware that challenges may exist in implementing product 
standards for cigarettes and that unintended consequences are possible (e.g. 
illegal markets). Therefore, it will be necessary to enforce regulations such that 
cigarettes with levels of toxicants and nicotine above the established means are 
removed from the market. A reliable system of monitoring regulated constituents 
in tobacco and smoke will have to be established. Representative analyses of 
cigarettes on the international market will have to be performed, so that the mean 
levels of the mandated toxicants in their smoke and possibly nicotine in tobacco 
are reported. Vigilant monitoring for evidence that no harm results from the new 
regulations will be necessary.
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6.1 Introduction
Most conventional, traditional and new or emerging tobacco products, including 
cigarettes, cigars, cigarillos, smokeless tobacco products (including snus), 
waterpipe tobacco and e-cigarettes with nicotine (also known as electronic 
nicotine delivery systems – ENDS) and without nicotine (also known as 
electronic non-nicotine delivery systems ENNDS) contain flavourings. Broadly 
defined, flavour is the sensory experience produced when something is ingested 
or inhaled through the mouth (1). Tobacco itself imparts a flavour (e.g. “natural 
tobacco” flavour), which depends on the type of tobacco and the curing process 
(2), and many, if not most, products include added flavours. Some flavourings 
are derived from natural products, such as cocoa, liquorice, honey and sucrose, 
while other are created synthetically, such as pyrazines for chocolate flavour and 
sucralose for sweetness. In the context of tobacco product regulation, flavours that 
are present at levels that impart a strong non-tobacco smell or taste are considered 
“characterizing”. While use of the term “characterizing” is much debated and it is 
not used worldwide, the European Union Tobacco Product Directive (3) defined 
a characterizing flavour as a:
clearly noticeable smell or taste other than one of tobacco, resulting from 
an additive or combination of additives, including, but not limited to, 
fruit, spice, herb, alcohol, candy, menthol or vanilla, which is noticeable 
before or during the consumption of the tobacco product.
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The FDA does not directly define “characterizing flavours” but used the following 
language in guidance on the flavoured cigarette ban in 2009 (4):
“… a cigarette or any of its component parts (including the tobacco, filter, 
or paper) from containing as a constituent (including a smoke constituent) 
or additive, an artificial or natural flavor (other than tobacco or menthol) 
or an herb or spice, including strawberry, grape, orange, clove, cinnamon, 
pineapple, vanilla, coconut, liquorice, cocoa, chocolate, cherry, or coffee, 
that is a characterizing flavor of the tobacco product or tobacco smoke.”
The tobacco industry has introduced flavours into tobacco products to increase 
the appeal of tobacco products. It is believed that flavours are added to these 
products to reduce their harshness, increase their appeal and improve their 
palatability. Further, the display of the names or graphic representations of 
flavours on packaging and advertising materials may enhance the attractiveness 
of a product.
We provide here a brief overview of the epidemiology of use of flavoured 
tobacco and nicotine products worldwide and perceptions of these products. 
We also discuss technological innovations that have been applied to flavoured 
products, including how they enhance appeal. We provide a general overview of the 
sensory processes underlying the perception of flavour, known pharmacological 
targets for flavour chemicals and evidence on the potential toxicity of flavours. 
Throughout, implications for research and regulation are highlighted.
6.2 Epidemiology of use of flavoured tobacco and  
nicotine products
Flavoured tobacco and nicotine products are used throughout the world. While 
there is limited systematic evidence about the availability and use of these products, 
preferences and use are often specific to countries and regions. For example, in 
Indonesia and other south Asian countries, traditional clove cigarettes (kretek), 
which contain clove pieces, oils and flavours, are highly popular. In India, spiced 
smokeless tobacco (pan masala, gutka) is used, which contains tobacco mixed 
with food spices and oils, flavourings, betel nut and other ingredients. Hookah 
smoking, which originated in India and the Middle East and is now increasingly 
popular among young people in Europe and north America, involves use of 
heavily flavoured, sweetened tobacco, known as maassel.
The tobacco industry has long used flavours in tobacco products as a 
marketing strategy (5), including towards young people (6). For example, in the 
USA in 2013, the flavoured form of non-cigarette tobacco products comprised 
52.3% “cigarette-sized cigars”, 81.3% “cigar wraps” (“blunt wraps”, “tobacco wraps” 
and “wraps”), 55.1% moist snuff, 86.1% shisha and 81.5% dissolvable tobacco 
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products (e.g. Ariva, Camel Orb/Sticks) (7). A longitudinal study of market 
trends showed that the presence of flavours accounted for 59.4% of the growth 
in smokeless tobacco sales between 2005 and 2011 (8). More recently introduced 
nicotine-containing e-cigarettes are now available in many flavours (9, 10).
Surveys indicate high rates of flavoured tobacco use, although there is 
little systematic evidence on the use of these products throughout the world. 
The National Adult Tobacco Survey in the USA in 2013–2014 revealed that 
an estimated 10.2 million e-cigarette users (68.2%), 6.1 million hookah users 
(82.3%), 4.1 million cigar smokers (36.2%) and 4.0 million smokeless tobacco 
users (50.6%) had used flavoured products in the past 30 days (11). The addition 
of multiple flavours (menthol/mint, clove/spice/herb, fruit, alcohol, candy/
chocolate/other sweet flavours) was also assessed. The most prevalent flavours 
used by type of tobacco product were: smokeless tobacco: menthol/mint (76.9%); 
hookah: fruit (74.0%); cigars, cigarillos, filtered little cigars: fruit (52.4%), candy, 
chocolate and other sweet flavours (22.0%) and alcohol (14.5%); e-cigarettes: fruit 
(44.9%), menthol/mint (43.9%) and candy, chocolate and other sweet flavours 
(25.7%); and pipes: fruit (56.6%), candy, chocolate and other sweet flavours 
(26.5%) and menthol/mint (24.8%) (11). In Poland, 26% of female smokers and 
10.5% of male smokers reported current use of flavoured cigarettes (menthol, 
vanilla or other flavour) according to an analysis of data from the Global Adult 
Tobacco Survey conducted in 2009–2010 (12).
Flavoured tobacco products are very popular among young people (13–
15). In a nationally representative sample of Canadian young people who used a 
variety of tobacco products (cigarettes, pipes, cigars, cigarillos, bidis, smokeless 
tobacco, hookah, blunts, roll-your-own cigarettes), 52% reported using flavoured 
products (16). Similarly, evidence from a national survey conducted in Poland 
showed that younger smokers were more likely to use flavoured cigarettes 
(12). Evidence from the Population Assessment of Tobacco Health study (15), 
a longitudinal national survey conducted in the USA, indicated that use of 
flavoured tobacco products was highest (80%) among children aged 12–17 years, 
73% among tobacco users aged 18–24 years and lowest in users aged ≥ 65 years 
(29%). Most of the children (81%) and young adults (86%) and only 54% of adults 
aged ≥ 25 years reported that their first product had been flavoured. Furthermore, 
first use of a flavoured tobacco product was associated with a higher prevalence 
of current tobacco use among young people and adults.
Summary: future regulations on flavoured products should consider 
the significant differences in the availability (marketing and access) and use of 
flavoured tobacco by country and by demographic group. Unfortunately, current 
surveillance tools may be inadequate for monitoring use of these products. 
For example, the Global Youth Tobacco Survey (17), an important global tool 
for monitoring tobacco use by young people, does not request information 
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specifically about flavoured tobacco use. In the Global Adult Tobacco Survey 
(18), use of flavoured and unflavoured tobacco is investigated only for waterpipe 
tobacco, and information about flavoured cigarettes can be obtained only by 
analysing text responses about the brand of cigarette smoked. To address this 
information gap, additional questions about flavoured and unflavoured products 
could be added to iterations of these surveys. Surveillance tools should also assess 
different use of flavours. Given that menthol is often regulated separately from 
other flavours, it would be advisable that questions distinguish menthol or mint 
from other flavours.
6.3 Flavoured products: perceptions, experimentation, uptake 
and regulation
There is a general perception that flavoured tobacco products are less harmful 
than other tobacco products (15, 19–21). Favourable perceptions of flavoured 
tobacco and nicotine products were recorded among both users and non-users 
of a wide range of products (e.g. cigars, e-cigarettes, hookah, kreteks, bidis and 
smokeless tobacco) (22). Flavoured non-menthol tobacco products (hookahs, 
little cigars and cigarillos, e-cigarettes) were perceived to be less harmful than 
cigarettes (20).
Perhaps not surprisingly, the presence of flavours in tobacco and nicotine 
products is associated with greater willingness to experiment with these products 
(20, 23, 24), an important consideration for young people. The availability of 
flavours has been associated with initiation of use of a variety of tobacco products, 
including hookah, e-cigarettes and cigars (25–27). The presence of flavours may 
also promote a move from experimentation to regular use; the presence of more 
flavours in e-cigarettes was associated with greater frequency of e-cigarette use 
among adolescents but not among adults (28). Further, advertising for sweet 
and fruit flavours was shown to activate brain reward areas in young adults and 
to interfere with recall of health warnings (29). For example, adolescents in the 
USA who had tried flavoured tobacco were almost three times more likely to be 
current cigarette smokers than those who had not tried these products (30), and 
more than 80% of current tobacco or nicotine users reported that they had first 
used a flavoured product (15).
In order to reduce appeal, experimentation and uptake, many countries 
have regulated flavoured tobacco products, as summarized by the Tobacco Legal 
Control Consortium (31). Some countries ban cigarettes with characterizing 
flavours, other than menthol (for example in European Union countries), while 
others have extended the ban to flavours in other tobacco products, e.g. the USA, 
Canada (little cigars, blunt wraps) and Ethiopia (all products). Several countries 
have enacted legislation also banning menthol as a flavour additive in cigarettes 
and other tobacco products. For example, Turkey has banned the addition of 
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menthol at any level and of any menthol derivatives (e.g. mint); and Canada has 
finalized a ban on the addition of any menthol in cigarettes, blunt wraps and 
most cigars sold on the Canadian market. Canada has also banned the use of any 
promotional materials, including packaging that depicts the e-liquid containing 
confectionery, desserts, cannabis, soft drinks or energy drink flavours.
Summary: both the presence of specific flavours in tobacco and nicotine 
products and the presence of flavour descriptors on packaging and in advertising 
have been linked to the appeal and uptake of tobacco and nicotine products, 
particularly among young people. Given these associations, many countries have 
regulated flavoured tobacco products. In view of differences in the timing and 
specificities of regulations in different countries and local ordinances, there is 
an opportunity for surveillance research (for example, within the International 
Tobacco Control project or other surveillance systems) to study the impact of 
regulations on the uptake of tobacco by youth, tobacco sales and use patterns and 
the subsequent response from the tobacco industry to the regulations.
6.4 A brief history of the development of flavoured tobacco by 
the tobacco and e-cigarette industry
The tobacco industry has been at the forefront in integrating flavour science and 
technology to increase product appeal and marketability. An early example is the 
addition of saccharin to chewing tobacco in the 1890s by the Reynolds Tobacco 
Company. This high-potency artificial sweetener replaced the more expensive 
sugar and increased the product’s shelf life and uniformity. The industry continued 
to improve tobacco breeding, selection, curing and manufacturing methods 
to control the harshness of tobacco smoke, added fillers, casings, humectants 
(moisteners) and designed wrapper papers and filter systems to improve appeal 
and the uniformity of flavour delivery.
For decades, tobacco companies have been the major consumers of 
cocoa and liquorice on the world market. Both are added to cigarette tobacco 
as casings, not to dominate the flavour experience but to increase taste fullness 
and reduce the harshness of smoke. In contrast, menthol in menthol cigarettes 
is a characterizing flavour, an added non-tobacco flavour listed on the product 
label, which dominates the flavour experience (32). Menthol cigarettes were first 
marketed in the USA in the 1920s, and they remain popular. Many cigarettes that 
are not labelled as mentholated may also contain low levels (33), which may be 
sufficient to enhance the appeal of the product (34).
While most early products contained natural flavours, including menthol 
extracted from mint, fruit extracts and natural terpenes and aldehydes, the 
increasing demand of the tobacco industry for standardized flavourings and the 
limited supply from natural sources prompted suppliers to develop and optimize 
chemical synthetic processes to deliver bulk amounts of key flavourings. For 
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example, most of today’s menthol supply is produced by three major chemical 
companies that developed procedures for stereo-selective synthesis or purification 
of L-menthol, the minty, cooling form of menthol (35). Similarly, chemicals in 
non-menthol products, including vanillin (vanilla flavour), pyrazines (coffee 
and chocolate flavourings), aldehydes such as benzaldehyde (a berry and candy 
flavouring) and many other tobacco flavourings are chemically synthesized, often 
from petrochemical hydrocarbon precursors (35). Modern flavoured tobacco 
products contain finely tuned mixtures of purified and recombined flavourings 
to create characterizing flavours, which are marketed after exhaustive testing by 
industry flavour panels and consumer volunteers.
Flavourings are usually added to tobacco products in the tobacco casing, 
sprayed on tobacco in humectants, in the filter and in the foil liner of tobacco 
packaging. The tobacco and flavour industries continue to introduce new flavours 
and flavour delivery systems to diversify products and increase their appeal. For 
example, the introduction of flavour capsules within the filter has resulted in a 
new category of cigarettes that release bursts of flavour when the filter is pressed. 
Cigarettes with a menthol capsule were first introduced in 2007 in Japan, then 
in 2008 in Europe and the USA and in 2011–2012 in Australia and Mexico (36). 
Most capsules in products contain menthol, but they may also contain aldehydes 
or other flavour chemicals to create flavours like spearmint, lemon mint, apple 
mint and strawberry mint (37). Some brands contain two flavour capsules, one 
containing menthol and the other a tangy, fruity flavour or more menthol. The 
capsules can be crushed individually, giving the user control over the dual flavour 
experience. The presence of flavour capsules was shown to enhance the appeal of 
cigarettes to young people (37).
After the ban on cigarettes with characterizing flavours (except for 
mentholated products) in some countries, the industry quickly developed 
alternative flavoured products, such as small cigars, some of which share the 
basic design of cigarettes and have tobacco in the wrapping paper. Flavoured 
small cigars are highly popular among young people. Patents filed by the tobacco 
industry describe innovative techniques for the application and enrichment of 
flavourings, specifically sweeteners, to cigar wrapping papers and mouthpieces to 
ensure that the product is perceived as sweet. In one study, high levels of saccharin 
and other synthetic high-intensity sweeteners were found in many popular small 
cigars or cigarillos on the United States market. Saccharin levels were especially 
high in the mouth sections and tips of the small cigars, with a sweetness intensity 
exceeding that of sugar (38). Small cigars of all flavour categories, regardless of 
whether they were labelled as sweet, contained saccharin (39, 40).
Tobacco industry patents also describe the use of recombinant, sweet taste-
stimulating proteins like thaumatin, which is 2000 times sweeter than table sugar, as 
sweeteners and of synthetic menthol derivatives as innovative cooling agents. After 
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the ban on menthol cigarettes in Canada, the tobacco industry began marketing 
cigarettes without menthol in packaging with designs almost identical to those of 
previously marketed menthol cigarettes, signalling the same cool freshness (41). 
It is unclear whether these cigarettes contain cooling additives to replace menthol.
Many of the smokeless tobacco products found in Asia (e.g. zarda, 
quiwam, gutkha, khaini) contain flavour chemicals (42, 43). Novel smokeless 
tobacco products have also been introduced in several countries, including snus 
(previously marketed only in Sweden) and new varieties of moist snuff. Snus 
and snuff are sold in many flavours, including menthol/mint, cherry, vanilla and 
strawberry, and it has been suggested that the significant rise in sales of moist 
snuff is related to the introduction of flavours (8, 44). Newly marketed snus 
products have also been found to contain very high levels of sucralose (Splenda®), 
a synthetic high-intensity sweetener that tastes more like sugar than saccharin, 
which is still used in snuff (45).
Flavoured waterpipe tobacco (maassel), is a sweetened, flavoured form 
of tobacco manufactured by fermentation of tobacco with molasses, glycerol and 
fruit essence. It is the preferred form of tobacco used in waterpipes, especially by 
adolescents and young adults (46).
E-cigarettes and ENDS, which appeared on the market in 2004, in Europe 
in 2006 and in the USA in 2007, are available in an ever-expanding range of e-liquid 
flavours, and the customized flavour and nicotine combinations are attractive to 
users. These products electrically heat and vaporize e-liquids and are available 
in a variety of devices, including cigarette-like products, vape or hookah pens, 
advanced devices known as “mods” or personal vaporizers and more discrete 
pod-devices like JUUL. In 2013–2014, 466 brands of e-cigarette were available 
online, with over 7000 unique flavour names; 242 new flavours were added each 
month (9). By 2016–2017, the number had doubled to over 15 000 flavours and 
flavour combinations (10). The counterbalancing effects of flavour options on 
promoting a switch from combustibles to e-cigarettes or ENDS against increasing 
the risk for uptake among young people is a hotly debated topic.
Summary: the tobacco and now the e-cigarette industry is constantly 
introducing innovative additives, such as flavourings and sweeteners, to increase 
the appeal of tobacco products, including waterpipes, smokeless tobacco, 
e-cigarettes and ENDS. Regulatory surveillance to detect and follow such product 
manipulations is critical to curtail the appeal of tobacco products.
6.5 Sensory systems that contribute to flavour
To understand the appeal of flavours in tobacco products, it is important to 
understand the role of the sensory components that contribute to the experience 
of flavour. The senses of taste and smell (olfaction) play the largest role in flavour 
perception; however, flavour also includes sensations of temperature, touch and 
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chemaesthesis (i.e. sensations that are produced by chemical stimulation of the 
senses of temperature, touch and pain) (47).
Taste: the sense of taste derives from taste buds located on the tongue 
and soft palate, which provide the sensations of sweetness, saltiness, sourness, 
bitterness and savoury. Because of the bitter taste of nicotine (48), bitterness is a 
dominant quality of the flavour of tobacco. The addition of flavours to tobacco 
products may serve to mask the bitter taste and improve flavour and appeal.
Olfaction: the sense of smell provides information not only about odours 
in the environment (orthonasal olfaction) but also about odours emanating from 
the mouth and airways (retronasal olfaction), which contribute significantly to 
the flavour of tobacco products. An opening at the rear of the nasal cavity that 
is connected to the back of the oral cavity (49, 50) allows odours from products 
that are taken into or inhaled through the mouth to stimulate olfactory receptors 
during exhalation.  
Temperature: temperature can contribute to the flavour of tobacco 
in at least two ways: directly, via sensations of warmth and heat produced by 
combustible or heated tobacco products, and indirectly, by modulating the rate of 
release of volatile flavour molecules that are sensed by retronasal olfaction.
Touch: in tobacco smoking, touch provides the oral “feel” of cigarettes, 
cigars, pipes and mouthpieces during smoking or vaping as well as the texture 
of smokeless tobacco products in the mouth. Touch also senses changes in oral 
mucosal surfaces such as dryness and astringency (51) that can be caused by 
inhaled or oral tobacco products.
Chemaesthesis: in addition to evoking tastes and smells, some chemicals 
can produce sensations of temperature, touch or pain by stimulating receptors in 
the mucous membranes that normally respond to either weak or strong (noxious) 
mechanical or thermal stimulation (47). Chemaesthesis plays a key role in the 
flavour of tobacco products, including the harshness of nicotine, acrolein and 
other chemical irritants in tobacco smoke and the coolness and “burning” cold 
sensations of menthol.
Interactive effects of flavour: a defining characteristic of flavour is 
integration of its multisensory components into coherent perceptions in the 
mouth. A particularly important interaction is the referral of retronasal odours 
to the mouth (52, 53), which leads to mislabelling of odours as tastes, most 
commonly for odours that have taste-like qualities, such as “sweet” odours like 
vanilla, cherry and strawberry (54). This is important, because it means that 
characterizing flavours often emerge as a seamless combination of sensations 
evoked by multiple, interacting sensory systems.
Flavour constituents of tobacco and e-cigarette products can also be 
important for their masking or inhibitory effects, such as masking a bitter taste by 
a sweet taste (55). Some studies have found evidence that sweeteners also suppress 
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pain, particularly in infants (56, 57). Sweeteners are present in smokeless tobacco 
products, for example, at levels that exceed those in confectionery products (45). 
Patents filed by the tobacco industry describe procedures for adding artificial 
sweeteners to cigar wrappings and mouthpieces to ensure that the consumer 
perceives the product as sweet. Similarly, the appeal of mentholated products 
owes much to the appeal of their cool, minty flavour, but menthol also has 
analgesic effects that can reduce the sensory irritation and harshness of nicotine 
(34, 58) and other constituents of tobacco smoke (59) and smokeless tobacco 
products (58, 60, 61).
Summary: the multimodal, integrative characteristics of flavour make 
it an important contributor to the appeal of tobacco products, ranging from 
essential tactile and thermal qualities in the mouth and throat to both taste 
and olfactory constituents in chemically derived characterizing flavours. While 
regulating individual well-known flavouring ingredients such as menthol and 
artificial sweeteners could have a straightforward effect on the appeal of tobacco 
products, interactions among flavour constituents designed to heighten appeal 
through combined sweetness or mechanisms like masking and analgesia pose 
more difficult problems for designing regulatory strategies. As flavour perception 
integrates sensory experience and is subjective, both human sensory testing and 
chemical analysis will be required to identify “the concentrations above which 
an additive will impart a characterizing flavor” (3) or increase the appeal of a 
product by masking aversive tastes or sensations. For products in which the 
flavour is perceptible but ambiguous, labelling may serve to boost the perception 
and identification of the flavour.
6.6 Flavour receptors: a new science of flavour sensing  
and coding
Molecular, genetic, pharmacological and behavioural approaches have 
revolutionized flavour research, including the discovery of flavouring receptors. 
Olfactory receptors, also called odorant receptors, were identified first in nerve 
endings in the nasal olfactory epithelium. These receptors play a dominant role 
in the retronasal sensing of volatile flavourings in tobacco and nicotine products. 
Taste receptors were identified in the taste papillae of the tongue and palate. 
Humans have a single sweet taste receptor made up of two protein subunits 
(TAS1R2 and TAS1R3) that bind sugars such as sucrose (table sugar) and, with 
much greater affinity, artificial high-potency sweeteners, such as saccharin and 
sucralose. Bitter taste receptors, the TAS2R receptors, of which humans express 
38 different versions, signal the presence of potentially poisonous chemicals and 
are probably involved in the perception of nicotine and other tobacco alkaloids 
as bitter. The presence of polymorphisms of the gene encoding a human bitter 
receptor, TAS2R38, has been linked with menthol cigarette smoking, suggesting 
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perhaps that smokers who are more sensitive to bitter tastes may use menthol to 
mask the bitter taste of nicotine or cigarette smoke (62, 63).
Receptors that mediate the chemaesthetic properties of flavours and 
other tobacco constituents, the transient receptor potential (TRP) ion channels, 
are located on nerves that transmit noxious and innocuous chemical, mechanical 
and thermal stimuli from the oral and nasal passages and airways. TRPA1 is the 
receptor for noxious aldehydes in tobacco smoke, eliciting burning and irritating 
sensations. TRPA1 also mediates the irritating effects of nicotine and flavouring 
aldehydes such as cinnamaldehyde and benzaldehyde, present in many fruity 
flavours. TRPM8 is the receptor for menthol and mediates its cooling and 
soothing effects. Experiments in mice indicated that TRPM8 is essential for the 
suppression of the irritating and aversive effects of tobacco smoke and nicotine 
by menthol (60, 64).
Summary: with more knowledge about flavour receptors and their 
pharmacology, the flavour industry can use molecular and pharmacological 
approaches to develop new, highly optimized flavour receptor modulators. 
These include novel sweet taste enhancers, bitter blockers (to reduce bitter taste), 
savoury (non-glutamate) taste enhancers and novel cooling agents. Several are 
approved as food additives, and more are in development. The tobacco industry 
has experimented with synthetic cooling agents that activate the menthol 
receptor, TRPM8, with a less minty odour, reduced irritancy and greater stability. 
The identification of flavouring receptors may provide an opportunity to regulate 
flavourings on the basis of their receptor-mediated pharmacological and 
behavioural effects in humans and animal model systems. For example, instead 
of regulating an individual flavour, such as menthol, which can be substituted 
quickly by alternative cooling agents, regulators could decide instead to control 
all TRPM8 receptor agonists in tobacco as a receptor-specific flavouring class.
6.7 Toxicological effects of flavours
While legislation and regulations vary by country, in many, inclusion of flavours 
as food additives requires scientific premarket review. In the European Union, 
flavouring additives are regulated by the European Food Safety Authority. In the 
USA, the FDA has designated the generally recognized as safe (GRAS) classification 
for food additives, in which stakeholders submit data on safety, which is reviewed 
for the intended use of a flavouring. The GRAS declaration for use of a flavour in 
confectionery products does not, however, automatically apply to its use in tobacco 
products, especially products that are inhaled, including cigarettes, cigars, hookah 
and electronic cigarettes. For example, cinnamaldehyde, the GRAS cinnamon 
flavouring widely used in baked goods and confectionaries, is added at very high 
concentrations to some electronic cigarette fluids (65). In toxicological studies, 
vapours from these liquids damaged lung epithelial cells and caused pulmonary 
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inflammation in mice (66). Other sweet flavours, including characterizing banana 
and cherry flavours, were also found to damage cells and expose e-cigarette users 
to benzaldehyde, a key component of many berry flavour mixes, with known toxic 
effects on the respiratory system (67, 68). Diacetyl, a flavour chemical commonly 
found in buttery flavours, also has a well-known toxic effect on respiration 
(69, 70). Flavour chemicals can react with solvents and other components of 
e-liquids to form irritant compounds with unknown toxicological effects (71).
Despite these concerns, some manufacturers of e-cigarette and ENDS have 
used GRAS labelling in their advertising, implying that the flavourings in their 
liquids are safe because they were previously approved for addition to food. Such 
health claims were strongly refuted by the Flavor and Extracts Manufacturing 
Association, a body of the United States flavour industry that submitted GRAS 
applications to the FDA, which stated that use of flavouring in e-cigarettes is not 
considered an intended use (72).
The lack of a regulatory process for evaluating the safety of flavouring 
agents is also a limitation for tobacco products such as snus, snuff and flavoured 
cigars, cigarettes and hookah tobacco, which may result in ingestion or inhalation 
of toxic levels of flavourings situations by consumers. For example, analytical 
studies showed that wintergreen-flavoured snuff products can expose regular 
users to levels of the wintergreen flavouring, methyl salicylate, that exceed the 
acceptable daily intake determined by the Food and Agriculture Organization 
of the United Nations and WHO for food by 12 times (73). Smokeless tobacco 
products (including zarda, quiwam, gutka and khaini varieties) have been found 
to have high levels of flavour chemicals such as eugenol, coumarin, camphor and 
diphenyl ether (43). Some snus products contain such high levels of sweeteners 
that regular use might exceed the recommended daily consumption of sugar if 
users consume other sweetened products at the same time (45).
There is little information about the fate of flavourings in combusted 
tobacco products (cigarettes, cigars, hookah) or heated nicotine solutions (as in 
e-cigarettes). The tobacco industry reported no major differences in the levels of 
toxic constituents in the smoke of menthol capsules or kretek (clove) cigarettes 
and in equivalent cigarettes without flavouring (74, 75); however, any toxic 
effects of flavours may have been masked by the overwhelming contributions 
of the other toxic constituents of cigarettes. In other studies, increased levels of 
VOCs were found in the smoke of flavoured cigarettes, and industry documents 
provide evidence that the industry knew about the carcinogenicity of some 
types of flavoured cigarettes (76, 77). In these studies, only the main smoke 
constituents (such as TSNAs and PAHs) were measured; the specific chemical 
products resulting from combusted flavourings were not examined. Analysis 
of the chemical fate of e-cigarette flavourings may provide information on 
the toxicity of flavours. When high-voltage settings are used in e-cigarettes, 
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exposure to flavourings increases, and the levels of oxidation products such as 
formaldehyde exceed toxic levels. As cigarettes, cigars and hookah tobacco burn 
at higher temperatures than vapour-producing e-cigarettes, the possibility that 
larger amounts of flavouring oxidation products and other toxic chemical species 
may be formed is a concern. Evidence obtained for e-liquid flavours suggests that 
flavour chemicals can have toxic effects (65, 78, 79).
Summary: regulations to specify acceptable levels of flavourings depend 
on the type of tobacco product, the level at which the flavouring is delivered 
to the consumer’s oral and respiratory systems and the potential for chemical 
changes during storage, heating and combustion. The chemical fate of flavourings, 
especially when heated at high temperatures, should be investigated further. This 
may result in the addition of flavourings and their chemical products to the lists 
of HPHCs curated by national regulators such as the FDA and in TobReg reports 
on toxicants in tobacco products. Future regulation of tobacco products might 
require specific reporting of the levels and toxicity of flavour chemicals.
6.8 Conclusions
Critical questions remain about the role of flavours in the appeal of and addiction 
to tobacco and nicotine products. Surveillance should be conducted worldwide 
to assess the use of flavoured tobacco products and also perceptions about the 
appeal and addictive potential of flavoured and unflavoured products. Flavours 
and sweeteners are chemicals that can be appealing independently and can also 
increase the use of tobacco products by enhancing the palatability of nicotine 
and other bitter or harsh constituents. A flavour like menthol may do this by 
pharmacologically attenuating the aversive effects of exposure to nicotine (e.g. 
cough, harshness, heat), and the presence of menthol in cigarettes is probably 
associated with increased rates of initiation of and progression to regular cigarette 
smoking, development of addiction and difficulty in quitting smoking (80). 
Much less is known about whether and how other flavour constituents influence 
preferences for and use of tobacco and nicotine products.
As flavours are complex and subjective, testing of flavoured tobacco and 
nicotine products for their appeal will require human behavioural and toxicological 
evaluations, in combination with chemical analyses. Methods for determining 
the presence and levels of flavourings should be based on what is delivered to 
the consumer (e.g. in smoke or vapour) and should also be used to determine 
potential changes in flavourings during storage, heating and combustion. Both 
the appeal and toxicity of flavourings should be evaluated. While it is important 
to determine the optimal doses of flavours that produce these effects, it is also 
important to understand the influence of the concentrations of flavours. All this 
information should be used to further refine the definition of a “characterizing 
flavour”.
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Surveillance and testing methods will have to keep up with the constant 
innovations of the tobacco industry designed to enhance the appeal of flavoured 
tobacco products, including use of new synthetic compounds and strategic place-
ment of flavouring molecules in tobacco products. Declaration of flavourings and 
their concentrations on tobacco product labels should be considered. Addition-
ally, regulatory work will have to contend with alternative marketing strategies 
introduced by the tobacco industry to deal with regulations on flavours, such as 
manipulation of packaging to continue to convey brand features associated with 
flavours (41).
Future regulations should account for the possibility that some flavours 
and flavour constituents, like sweeteners, are also positively reinforcing in 
themselves and, when combined with nicotine, might enhance the rewarding 
effects of low-dose nicotine and promote a transition to higher levels of nicotine, 
leading to addiction. Experimental evidence and monitoring of these complex 
issues will be crucial to ensure that regulations are designed to reduce the appeal 
and addictive potential of tobacco products. Better understanding of the science 
of flavours and how they enhance the appeal and addictive potential of tobacco 
products will be required to regulate these molecules.
6.8.1 Recommended priorities for research
 ■ Systematically monitor the global epidemiology of flavoured conven-
tional, traditional, new and emerging tobacco and nicotine products.
 ■ Identify flavour chemicals, their reaction products and their concen-
trations in tobacco and nicotine products and in aerosols, vapours 
and smoke.
 ■ Determine how depiction of flavours on product packaging and in 
marketing alter public perceptions and the appeal of tobacco and 
nicotine products, especially among young people.
 ■ Evaluate whether the presence of specific flavours and their con-
centrations in tobacco and nicotine products alters their appeal and 
abuse potential.
 ■ Among smokers, investigate the role of the availability of flavoured 
products as a motive for switching to less harmful tobacco products 
(relative to the degree of harm reduction).
 ■ Determine the toxicity and health effects of various concentrations of 
inhaled flavour chemicals and their metabolites and adducts.
 ■ Monitor the use of alternative chemical moieties to replace prohib-
ited flavours, and determine their appeal, toxicity and health effects.
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6.8.2 Recommended policies
 ■ Consider obtaining systematic global evidence on the use of flavoured 
tobacco and e-cigarette and ENDS products.
 ■ Consider banning the use of flavours, including menthol, in harmful 
combusted products.
 ■ Consider limiting the levels, number of and/or specific flavours al-
lowed in tobacco and nicotine products for which there is evidence 
of modified or reduced risk, to reduce initiation by young people and 
support cessation of use of combusted tobacco products.
 ■ Consider requiring that the types and concentrations of flavour chem-
icals in various products be listed among the product constituents.
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7.1 Introduction
Sugar is a component of tobacco products and is often present in large amounts. 
Sugars are naturally present in tobacco leaves and may also be added during 
manufacture (1–3). Unprocessed tobacco leaves contain many types of sugar, 
including glucose, fructose and sucrose. Drying (curing) of the leaf can affect these 
levels; while air-cured tobacco contains virtually no sugars, flue-cured tobacco 
may contain up to 25% of its weight (4, 5). In addition, during manufacture, 
various types of sugar and sugar-containing ingredients, such as honey and fruit 
syrups, may be added to the casing. The amount added depends on the tobacco 
blend and the product type. Added sugars can serve as binders, casing ingredients, 
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flavours, formulation aids or humectants (3, 4, 6). When sugars are burnt during 
combustion of tobacco products, they yield many toxic products, some of which 
have been hypothesized to affect the addictiveness of tobacco products (7). 
Sugars also contribute significantly to the flavour of tobacco products (3, 8). In 
smokeless tobacco, the sugars themselves flavour the tobacco product, whereas, in 
combusted tobacco products, sugars react with other components in the tobacco 
to produce caramel flavours and make the smoke milder to inhale (3, 9). Some 
casing materials that contain sugars have been referred to as “ameliorants” by 
the tobacco industry and are claimed to “… smooth out harshness and bitterness 
and/or eliminate pungent aromas from tobaccos” (10).
As sugar is one of the main components of tobacco products and may be 
harmful to consumers’ health by increasing the toxicity, addictiveness and/or 
attractiveness of products, it may be an appropriate candidate for regulation of 
tobacco contents. We review the evidence on the presence and effects of sugars 
in different tobacco products, including smokeless and waterpipe tobacco. 
First, we describe the variety of sugars naturally present in tobacco leaves, those 
that result from curing and those that are added to processed tobacco during 
manufacture. We also report the percentages of products with added sugars 
and the amounts of sugars added. Secondly, we summarize the evidence on 
the effect of sugars on the levels of emissions from tobacco products. Thirdly, 
we review the health effects of sugars in tobacco products, as assessed by their 
toxicity, addictiveness and attractiveness. Finally, we highlight implications for 
research and regulation.
7.2 Sugars in different types of tobacco product
Tobacco is a natural plant, and its leaves contain high levels of carbohydrates 
such as sugars (mono- and disaccharides), starch, cellulose and pectin 
(polysaccharides) (4). During drying (curing) of the green leaves into usable 
brown, dried tobacco, enzymes degrade starch into sugars. The curing conditions 
depend on the tobacco type. Virginia tobacco is flue-cured in humid conditions 
and at elevated temperatures, which allows starch to be degraded into sugar and 
stops enzymatic degradation of sugar, resulting in high levels (8–30%) in the 
cured tobacco (11). Oriental tobacco is sun-cured in a process similar to flue-
curing but less controlled, resulting in sugar levels of 10–20% in cured tobacco 
(2). In contrast, Burley tobacco is air-cured at ambient temperature in a slow 
process that results in degradation of starch into sugars and breakdown of the 
sugars by enzymes, resulting in a low sugar content (≤ 0.2%) in the cured tobacco 
(4, 11). As tobacco products contain one or a blend of tobacco varieties, the sugar 
levels of tobacco products differ widely, depending on the blend. In general, the 
sugars found most abundantly in the cured tobacco leaf are glucose, fructose and 
sucrose (4, 11).
Sugar content of tobacco products
145
Besides mono- and disaccharides, tobacco also contains considerable 
amounts of (added or naturally present) polysaccharides, such as cellulose, pectin 
and starch (9, 12). A conventional cigarette blend contains about 10% cellulose, 
10% pectin and 2% starch (4, 12). Thus, carbohydrates may comprise over 40% 
of tobacco and therefore have a substantial impact on the chemical composition 
of tobacco smoke (3).
7.2.1 Types of sugars and sugar-containing additives
Besides the sugars present in natural tobacco leaves, various types of sugar and 
sugar-containing ingredients are added to tobacco products, primarily in the 
casing. The types of sugars depend on the many natural sources and processing 
methods used. The sugars most often added to combusted and smokeless tobacco 
products are sucrose and invert sugar (a mixture of fructose and glucose) (2, 
13, 14). Other tobacco additives that contain large amounts of sugars are fruit 
juices, corn and maple syrups, molasses extracts, honey and caramel (3, 4, 6, 
15). Other substances may also have a sweet taste and characteristics similar to 
those of sugar but are not classified as such. These are acesulfame K, aspartame, 
ethyl maltol, glycerol, propylene glycol, maltitol, maltol, saccharin, sorbitol and 
thaumatin.
Sugars in tobacco products identified from manufacturers’ lists of 
ingredients in the electronic database EMTOC (16) are: brown sugar, caramel, 
(corn) syrup (solids), dextrin, dextrose, (fruit) concentrate, (fruit) juice, glucose, 
high-fructose sugar, honey, invert sugar, lactose, malt extract, maltodextrin, 
(maple) syrup, molasses, (partially) inverted sugar, sucrose (syrup), sugar cane 
(syrup), sugar syrup and unspecified sugar. Monosaccharides are simple sugars 
such as fructose, galactose and glucose, with the general formula C6H12O6. 
Disaccharides are formed by the combination of two monosaccharide molecules 
with the exclusion of a molecule of water; these include sucrose, lactose and 
maltose, with the general formula C12H22O11.
7.2.2 Amounts of sugars and sugar-containing additives
Sugars are usually added to tobacco leaves as a casing ingredient, although in 
some cases they are added in very small amounts to non-tobacco material like 
paper, filter and glue (16). The amount of sugar added to conventional cigarettes 
represents 2–18% of the weight of the tobacco (2, 12, 17, 18). The levels in 
waterpipe tobacco (maassel) are much higher, representing 50–70% of the weight 
of the product (19). Little information is available on the amounts and types of 
sugars in tobacco products. In the Netherlands, manufacturers are obliged to 
disclose the ingredients of all tobacco products on the Dutch market annually to 
an electronic database (EMTOC) (16). Analysis of these data shows that, in 2015, 
sugars were added to a substantial proportion of all types of tobacco product (20).
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Further analysis of the data for the purposes of this paper showed that 
most roll-your-own products (56%), cigarettes (77%), pipe tobacco (86%) and 
waterpipe products (100%) contained added sugars (Fig. 7.1A), whereas few cigars 
(7%) or oral tobacco products (22%) did so. The sugars used most frequently 
in all tobacco products are invert sugar and glucose, with sugar-containing 
ingredients such as caramel, honey, syrups and fruit juices (Fig.  7.1B–G). The 
weight percentage of sugar added was 2% in cigars, 3% in roll-your-own tobacco 
and in cigarettes and 12% in pipe tobacco. Remarkably, an average waterpipe 
tobacco product contained added sugars that represented 164% of the tobacco 
weight, indicating more sugar than tobacco in the final product. Although the 
amount of sugar added to oral tobacco was only 10% of the tobacco weight in 
this analysis, the final sugar levels in these smokeless tobacco products may be 
about 35% (21) because of the high levels of natural sugars present in tobacco 
leaf. These numbers depend on the types of tobacco used in products in different 
countries.
Fig. 7.1. Concentrations of sugars in tobacco products
RYO, roll-your-own. A: percentage of products with sugar added to tobacco according to the total number of products containing 
additives, for each category of tobacco product; B–G, average amount of the sugars (percentage per mg tobacco) used most often 
for each category of tobacco product; n, number of products containing added sugar; “other sugars together” shows all remaining 
sugars in the product group. Source: EMTOC database (16), in which manufacturers register all marketed tobacco products in the 
Netherlands annually and which contains information on additive composition, quantities added and function.
7.2.3 Total levels of added and endogenous sugars
Natural tobacco contains large amounts of sugar formed during growing and 
curing, as discussed above, besides the sugars added during manufacture. 
Therefore, it is more informative to measure or report the final sugar levels in 
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marketed tobacco products rather than that on the list of added sugars, which 
will provide an underestimate of the final level (22). Few reports of laboratory 
analyses of total sugar levels in tobacco products have been published. Chemical 
analysis of final tobacco products for the most commonly added carbohydrates 
(glucose, fructose and sucrose) indicated total sugar levels of ≤ 19% of the weight 
of tobacco in cigarettes (23), 0.1% in cigars, 0.03% in snuff and 27.7% in chewing 
tobacco (24).
7.2.4 Regional and cultural differences in tobacco varieties, products and use
The variety of tobacco products marketed and used depends on regional and 
cultural preferences. In a study of 2the patterns of tobacco use among adolescents 
in 32 countries (25), the national prevalence of current cigarette smoking ranged 
from 1.8% in Rwanda to 32.9% in Latvia, whereas the prevalence of current 
smokeless tobacco use ranged from 1.1% in Montenegro to 14.4% in Lesotho. 
In most European countries and the USA, the prevalence of current smoking 
was significantly higher than that of smokeless tobacco use, in contrast to the 
patterns observed in low- and middle-income countries such as in south-east 
Asia. Eurobarometer reported that, in Europe, smokeless tobacco is particularly 
popular in Sweden, whereas waterpipe use is popular in other northern European 
countries and northern Africa (26). Experience with tobacco use may vary by 
culture due to differences in availability, affordability and acceptability (25).
More information is available on the variety and blends of tobacco used in 
cigarettes, although little is known about the sugar content of specific products 
and brands. The use of sugars differs by brand and even within a brand because of 
national preferences (2). The variety of tobacco also differs by region; in general, 
however, the cigarette market appears to be dominated by two varieties: flue-
cured cigarettes and American-blend cigarettes. According to PMI, in 2008, 
Virginia-style (flue-cured, high in sugar and few additives) cigarettes dominated 
the market in Canada (99%), New Zealand (95%), Australia (92%), the United 
Kingdom (91%), Ireland (87%) and South Africa (76%). American-blend 
cigarettes (a blend of Virginia, Burley and Oriental tobacco and many additives, 
including sugars) are preferred in continental western European countries, with 
a market share of 85–100%, and in the USA, with 99% (1).
7.3 Effects of sugars on levels of emissions from tobacco products
7.3.1 Smokeless tobacco products
Users of smokeless tobacco products are exposed to emissions resulting from 
chewing or sucking. While smokeless tobacco contains high levels of sugars (see 
above), the amounts extracted during use and the resulting exposure to sugars 
are unknown.
148
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
7.3.2 Pyrolysis products of sugars and simple mixtures
Combustion in a burning cigarette has been simulated in pyrolysis studies (27, 
28) in order to understand precursor–smoke constituent relations in cigarette 
mainstream smoke (1). Studies with this method indicate that only small amounts 
of nonvolatile sugars in tobacco (approximately 0.5%) are transferred intact into 
cigarette mainstream smoke, whereas most of the sugar combusts, pyrolyses or 
is part of other pyrosynthesis processes (1, 3). Combustion processes such as 
caramelization result in many different chemical compounds, including aldehydes 
(e.g. acetaldehyde, acrolein, 2-furfural), furan derivatives, VOCs, organic acids, 
acrylamide and PAHs (usually at high temperatures). The pyrolysis conditions 
used in these studies only approximate the temperature and other conditions in 
a burning cigarette, however, and do not account for the interaction of other 
tobacco and/or smoke components with sugars during combustion. For example, 
sugars can react with amines in tobacco (ammonium compounds, amino acids, 
proteins) to form Maillard products (see also section 7.2), which can break down 
into chemical species such as aldehydes, ketones (e.g. diacetyl), acids, acrylamide, 
pyrazines and pyridines (1, 3).
7.3.3 Cigarettes and other combusted tobacco products
An independent review of the effects of the addition of sugar on smoke composition 
in 2006 concluded that adding sugars to cigarette tobacco primarily enhances the 
levels of aldehydes and ketones, especially formaldehyde, acetaldehyde, acetone, 
acrolein, 2-furfural and other furans (3). Additionally, the concentration of total 
acids in mainstream smoke was increased, resulting in a lower pH and less free-
base nicotine. Cheah et al. (29, 30) also showed that the addition of sugars to Burley 
tobacco, which contains virtually no natural sugars, increases the concentrations 
of the aldehydes acetaldehyde, acrolein, crotonaldehyde, propionaldehyde and 
butanal in mainstream tobacco smoke. The increase is specific for aldehydes, as 
much smaller increases were observed in tar, nicotine and CO levels.
While many of these conclusions have been discussed in tobacco industry 
papers and reviews published subsequently, there has been considerable debate 
about whether sugars increase the levels of acetaldehyde and, to a lesser extent, 
of acrolein. For instance, Seeman et al. (12) pointed out that cellulose rather than 
sugar is the main precursor of acetaldehyde in smoke but that this by itself does 
not imply that sugars do not also contribute. In a review of cigarette tobacco 
additives, Klus et al. (1) concluded (from the results of many studies) that adding 
sugars to tobacco increases the concentrations of phenol, furans, organic acids, 
2-furfural and formaldehyde and results in more acidic smoke. He did not report 
an association between sugars and acetaldehyde. Baker (31, 32) reported an 
increase in formaldehyde and found that sugars increase the levels of 2-furfural 
in mainstream cigarette smoke but not those of acetaldehyde or acrolein. Coggins 
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et al. (33) found that the addition of carbohydrates and sugar-containing natural 
products to tobacco resulted in only minimal changes in smoke chemistry 
but consistently resulted in a small increase in formaldehyde over that in the 
smoke of additive-free cigarettes. Roemer et al. (2) reported that, while most of 
the smoke constituents determined did not show any change in yield (per mg 
nicotine), increasing added sugar levels either increased (formaldehyde, acrolein, 
2-butanone, isoprene, benzene, toluene, benzo[k]fluoranthene) or decreased 
(4-aminobiphenyl, N-nitrosodimethylamine, NNN) the levels of constituents. 
Hahn and Schaub (34) reported an increase in the concentration of formaldehyde 
but not that of acetaldehyde after addition of 5% sucrose as compared with a 
reference tobacco blend consisting of 50% Virginia tobacco (flue-cured), 20% 
Burley tobacco (air-cured), 20% tobacco stems and 10% Oriental tobacco (sun-
cured). As Virginia tobacco contains high levels of natural sugars, relative increases 
in sugar and resulting aldehyde levels after addition of sugar are less evident.
O’Connor and Hurley (35) found that the relation between sugar and 
acetaldehyde levels is obscured by normalizing acetaldehyde yields to tar or total 
particulate matter, both of which are directly related to design features such as 
ventilation and mass of tobacco. They re-analysed a study by Zilkey et al. (36) 
and found that sugar accounted for over 50% of the variation in acetaldehyde 
levels in smoke. Re-analysis of the data of Phillpotts et al. (37) showed that sugars 
in tobacco blends accounted for an additional 11% variation in aldehyde levels, 
while total particulate matter accounted for 23% of the variation.
Waterpipe tobacco contains the highest levels of sugar of all tobacco 
products. Although this may result in higher levels of volatile aldehydes in 
smoke (38, 39), no data were available on the relation between sugar content and 
the composition of the smoke of waterpipe tobacco or of any other combusted 
tobacco products. Furthermore, correlations have been observed between sugar 
levels in e-cigarette liquids and aldehyde levels in their emissions (40).
7.4 Effects of sugars on the toxicity of tobacco products
Sugars are GRAS additives when used in food products but not when used in 
tobacco (3). When tobacco products are smoked, sugars are combusted to yield 
many toxic and carcinogenic reaction products. Furthermore, compounds are 
generally more toxic when inhaled than when ingested, because the respiratory 
system largely lacks the detoxifying metabolic pathways of the digestive system (3).
7.4.1 Smokeless tobacco
Commercially available smokeless tobacco contains 0.5–2 g of sugars per chew 
of about 10 g (41). The product is kept in the oral cavity for an average of 30 
min and used repeatedly each day (42, 43). Smokeless tobacco causes several 
types of cancer, cardiovascular disease, adverse reproductive outcomes and 
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adverse effects on oral health, including oral mucosal lesions, leukoplakia and 
periodontal disease (44), but little is known about the contribution of the sugar 
content in smokeless tobacco to these diseases. Use of smokeless tobacco has 
been associated with dental caries, and a plausible cause is the high level of 
sugars, although other causes related to tobacco use cannot be excluded. The 
sugar in smokeless tobacco forms an acid that may eat away the tooth enamel, 
cause cavities and result in mouth sores (42). Furthermore, the high levels of 
fermentable sugar can stimulate the growth of cariogenic bacteria (14, 43).
Sugars in smokeless tobacco may also influence blood glucose. A case 
study showed that blood glucose levels in a patient with diabetes who stopped 
swallowing the juice resulting from chewing tobacco dropped by 50% (from 300–
400 mg/dL to 160–200 mg/dL) (41).
7.4.2 Cigarettes with and without added sugar
Many pyrolysis products of sugar have been reported to have toxic effects (45, 
46). These include formaldehyde (irritant, carcinogenic), acrolein (irritant) and 
PAHs (carcinogenic). The extent to which they contribute to the total toxicity of 
combusted tobacco products is unknown.
In a review of tobacco additives, Klus et al. (1) concluded that “sugars and 
the kind of sugar used as additive have – if any – only small and unimpressive 
effects on cigarette mainstream smoke toxicity”. Mainstream cigarette smoke 
resulting from the combustion of cigarette tobacco with various levels of sugars 
was investigated in assays for cytotoxicity, mutagenicity and genotoxicity in 
vitro, in subchronic studies of inhalation toxicity in vivo and in studies of dermal 
tumorigenicity. None of the studies showed significant differences in markers of 
toxicity (2, 33). According to the Scientific Committee on Emerging and Newly 
Identified Health Risks of the European Union (47), however:
comparative toxicity testing strategies, …, are not considered suitable 
to address the properties outlined in the terms of reference with the currently 
available methodology. Indeed, at present, these studies lack discriminative 
power due to the high background toxicity of tobacco products and their results 
cannot be generalized to all products and brands, having a different composition 
with respect to tobacco type, blend and additives.
7.5 Effects of sugar on the addictiveness of tobacco products
No information was available on the role of sugar in the addictiveness of smokeless 
tobacco products. Sugar may, however, increase craving and reinforcement of use of 
combusted tobacco products, in addition to the well documented addictive effects 
of nicotine (7). The addictive potency of sugar in combusted tobacco products may 
be increased by several direct and indirect pathways, including the pH of smoke, 
free nicotine levels and the formation of pharmacologically active compounds.
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7.5.1 pH and free nicotine
The amount of nicotine that reaches the brain depends on the availability of 
free-base nicotine (the uncharged, volatile form), which formed at specific 
pH. High pH results in more free-base nicotine (48, 49), which readily crosses 
the cell membranes of the oral cavity and lung epithelium, resulting in higher 
levels of nicotine that reach the brain. Tobacco products and brands with 
high carbohydrate or sugar contents generate more acidic smoke, resulting in 
lower concentrations of free-base nicotine (50). To maintain a satisfying level 
of nicotine absorption from cigarettes with lower levels of free-base nicotine, 
smokers inhale more deeply and/or more frequently or increase their cigarette 
smoking frequency (51, 52). This leads to higher exposure to carcinogenic and 
toxic compounds. (For other effects of changed smoke pH see section 7.7.) Other 
studies suggest, however, that the pH-buffering capacity of the lung epithelium 
diminishes the effect of changed nicotine bioavailability when the pH of tobacco 
or smoke is changed (1).
7.5.2 Formation of pharmacologically active compounds in tobacco and smoke
Although sugars may have no addictive potential per se, combustion of sugar in 
a tobacco product results in several compounds in tobacco smoke that may have 
addictive potential. Of these, acetaldehyde is the most important (12, 53, 54), 
as it increases the firing rate of dopaminergic neurons in the ventral tegmental 
area (54). In experimental animals, intravenous acetaldehyde was addictive and 
synergistically enhanced the reinforcing effects of nicotine (53, 56–60). Although 
acetaldehyde clearly reinforces the effects in rodents, it is not known whether these 
effects also occur in humans and at the concentrations found in cigarette smoke.
Acetaldehyde exerts its addictive potential by reacting with the amino 
acids tryptamine and tryptophan, present in tobacco or in the body, resulting 
in the condensation product harman (and norharman when amino acids reacts 
with formaldehyde) (61, 62). Harman inhibits the enzyme monoamine oxidase, 
which degrades neurotransmitters involved in drug addiction, like dopamine, 
noradrenaline and serotonin (56, 61, 63). Exposure to harman therefore increases 
the amounts of dopamine and serotonin in the nucleus accumbens and potentiates 
the action of nicotine (64–66). Interestingly, an L-cysteine lozenge that reacts with 
acetaldehyde in saliva lowers the levels available for the formation of harman and 
showed potential for use as smoking cessation therapy in an initial double-blind, 
randomized, placebo-controlled trial (67).
Several studies have shown that the levels of harman and norharman 
in smokers are related to the number of cigarettes smoked (68–70), and lower 
activity of monoamine oxidase in tobacco smokers increased nicotine self-
administration (57) and maintenance of behavioural sensitization to nicotine 
(56, 71) as compared with nonsmokers.
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7.6 Dependence and quitting
Sugar in tobacco products can contribute to maintenance of tobacco use by 
enhancing dependence and making it difficult to quit. The tobacco industry 
performed several intercountry comparisons to investigate the influence of 
additives on the addictiveness of tobacco. A meta-analysis of clinical studies on 
smoking cessation rates did not show a significant difference in quit rates between 
tobacco markets dominated by Virginia flue-cured cigarettes (high in natural 
sugar but few added ingredients and no added sugars) and by American-blended 
cigarettes (many added ingredients including sugars) (72, 73). An important 
assumption in the study, however, was that the difficulty of quitting smoking is a 
valid measure of tobacco addictiveness, and no correction is needed for country-
specific factors such as product availability and cessation programmes (74). 
Also, no relevant differences were found between the two markets in smoking 
prevalence, intensity, some markers of dependence, nicotine uptake or mortality 
from smoking-related lung cancer or chronic obstructive pulmonary disease 
(73). According to Klus et al. (1), no effect of sugars was to be expected, given that 
the total sugar level (naturally present and added) in the tobacco of American-
blend and Virginia cigarettes is comparable.
Little is known about the dependence and quitting rates of smokers of 
specific types of tobacco products with different sugar contents (72). Much of the 
research on the abuse potential associated with acetaldehyde is based on studies 
of ethanol, as acetaldehyde is also a metabolite of ethanol (75), and no proper 
experiments have been conducted to evaluate withdrawal from acetaldehyde 
vapour (76). Nevertheless, the synergistic action of nicotine and acetaldehyde 
was observed only in young and not in adult rats (58), which may support the 
observation that, in humans, adolescents appear to be more prone to tobacco 
addiction than adults (58, 65, 77).
7.7 Effects of sugars on the attractiveness of tobacco products
7.7.1 Perception: sensory characteristics
The sensory characteristics of tobacco products, such as taste and smell, 
significantly influence their attractiveness (7). For instance, initial attraction may 
be established by the presence of flavourings like sugar and other sweeteners (3, 
9, 78). Manufacturers select tobacco for certain chemical criteria, such as sugar 
and nicotine content, and the annual variation in tobacco leaf composition is 
equilibrated by the use of sugars and other additives to ensure the consistent taste 
of a product over time (7). Sugar in smokeless tobacco products is perceived by 
the taste receptors in the oral cavity with olfactory stimulation. In contrast, users 
of combusted tobacco products perceive only the pyrolysis products of sugar. 
Overall, manufacturers of tobacco products adjust the taste and characteristics of 
products to the desires of consumers and to create a “pleasant experience” (79).
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7.7.2 Smoking experience and behaviour: flavour, palatability, ease of 
inhalation, frequency of use
Sugars can improve several characteristics of tobacco products, such as masking 
the harshness of the smoke and improving the taste. Volatile basic components 
like ammonia, nicotine and alkaloids give tobacco smoke a harsh taste, which 
prevents smokers from inhaling (3, 80). Combustion of sugar during smoking 
results in acids, which reduce the pH of inhaled smoke (50) and thus decrease 
its harshness and irritability (4, 9), increase the palatability of the product and 
facilitate inhalation. More frequent, deeper inhalation, which is eased by the 
addition of sugar, increases exposure to nicotine and other smoke chemicals. Sugars 
also play an important role in tobacco flavour (4, 6, 81). In smokeless tobacco, 
the sugar itself is consumed. During curing, storing, processing and smoking 
of tobacco, amino acids or ammonia react with sugars (Maillard reaction) to 
produce chemicals with highly diverse structures and flavouring potential. Many 
of these products are heterocyclic compounds, which include aromatic pyrazines, 
an important class responsible for the characteristic taste of certain cigarette 
brands. In addition, caramelization of the sugar improves the taste and smell of 
the tobacco smoke for both users and bystanders (79). This is, unlike the Maillard 
reactions, a non-enzymatic browning reaction of sugar (no amines involved).
7.7.3 Initiation
The acceptance of tobacco smoke by smokers is partly proportional to the sugar 
level in the tobacco (3, 8). The extent to which sugar in tobacco products and 
its level influence initiation of tobacco consumption has not been investigated. 
As sugar reduces pH, masking the bitter taste of cigarette smoke, new users 
experience less harshness. Furthermore, the sweet taste of the caramel flavours 
generated by the combustion of sugars is particularly attractive to adolescents (53, 
82). Thus, the presence of sugar in tobacco products may encourage adolescents 
to start smoking earlier, continue smoking for longer and increase their tobacco 
use (3). The addition of sugars to cigarettes to stimulate or enhance the sensory 
attributes of cigarette smoke and encourage smoking initiation and maintenance 
is not only scientifically plausible but has been discussed by industry as part of 
their marketing strategy (74, 83).
7.8 Regulation of sugars according to jurisdiction
Several international and national authorities regulate additives in tobacco prod-
ucts. The most important of them and the main regulations and implementations 
are listed below.
 ■ WHO FCTC: Article 9 addresses the testing and measurement of the 
contents and emissions of tobacco products and their regulation, and 
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Article 10 addresses the regulation of tobacco product disclosures, by 
allowing Parties to the WHO FCTC to adopt and implement effec-
tive legislative, executive, administrative or other measures requiring 
manufacturers and importers of tobacco products to disclose to gov-
ernment authorities information about the contents and emissions of 
tobacco products. The Framework facilitates adoption of comprehen-
sive tobacco control measures by States Parties, which may include 
reporting and disclosure, such as the requirement to submit informa-
tion on sugar levels (and the emission of sugar-related compounds) 
in tobacco products (84).
 ■ Health Canada: the use of many ingredients, including sugars, in cig-
arettes, little cigars and blunt wraps has been prohibited since 2009 in 
an amendment to Bill C-32 (85). Moreover, Canada requires manu-
facturers and importers to provide information on tobacco product 
ingredients, as set out in the Tobacco Reporting Regulations (86).
 ■ The European Tobacco Product Directive: in accordance with Di-
rective 2014/40/EU, a ban on characterizing flavours in cigarette and 
roll-your-own products (but not in other tobacco products) entered 
into force in 2014 (87). Furthermore, manufacturers in each Europe-
an Union Member State are required to disclose all marketed tobacco 
products and their composition (e.g. amount and type of added sug-
ars, tobacco variety or blend, curing method) annually to an electron-
ic database (EU-CEG). The Directive states that the sugars lost during 
curing of leaves may be replaced during manufacture; however, the 
initial sugar content of the tobacco leaf and loss during processing are 
not defined, which makes it difficult to regulate the amounts of sugar 
that can be added.
 ■ In the United Kingdom in 2003, a voluntary agreement with the to-
bacco industry set limits on the use of several sugars (sucrose, in-
vert sugar, syrups and molasses), with a maximum of 10% weight of 
the product in cigarettes, roll-your-own tobacco and cigars and 15% 
weight in pipe tobacco (88). The rationale for determining these lim-
its was not clear. The agreement has been superseded since 2014 by 
the revised European Tobacco Product Directive (89).
 ■ Brazilian Health Regulatory Agency (Anvisa): the use of some ad-
ditives in tobacco products has been restricted in a regulatory reso-
lution with legal power (RDC 14/2012) (90). The resolution prohib-
its the use of sweeteners, honey, molasses, (any product originating 
from) fruits and substances that can impart a sweet flavour, apart 
from sugars. An exception was made for sugar, allowing manufac-
Sugar content of tobacco products
155
turers to restore the quantity lost during tobacco leaf curing. In Sep-
tember 2013, this resolution was suspended by a lawsuit filed by the 
National Confederation of Industries on behalf of tobacco product 
manufacturers (90). A working group of independent experts recom-
mended that RDC 14/2012 be amended such that sugars would no 
longer be excluded from the ban on additives (91). As of June 2015, 
the Supreme Court injunction allowing the use of additives remained 
in force, with a final decision pending.
 ■ FDA: the Family Smoking Prevention and Tobacco Control Act in 
2009 included a ban on cigarettes containing certain characterizing 
flavours (92). Restrictions are considered in the use and sale of cer-
tain flavored e-liquids (93). No specific requirements or limits are set 
for the sugar content of cigarettes or other tobacco products.
7.9 Conclusions
Added sugar is one of the main ingredients in many types of tobacco product. 
The amount may be substantial, making up 2–164% of the weight of tobacco, 
depending on the type of product. As tobacco leaves themselves may contain 
high levels of natural sugar, the total amount of sugar (natural and added) in a 
tobacco product may be quite high. Limited data were available on the total sugar 
levels in different types of tobacco products.
There is little evidence that sugar contributes to the toxicity and 
addictiveness of smokeless tobacco products, apart from effects on dental health 
and possibly diabetes; however, sugars contribute to the attractiveness of the 
products by improving their taste.
Burnt and unburnt sugars contribute to the appeal of all tobacco products, 
and the combustion of sugar in tobacco products may contribute to the formation 
of toxic, carcinogenic and addictive compounds.
Some jurisdictions, such as Canada and Brazil, regulate the addition of 
sugars to tobacco products, and limits have been set in the United Kingdom. 
Stricter control measures are needed to prevent the harmful effects on health of 
the use of tobacco products containing both naturally occurring and added sugars.
7.10 Recommendations
7.10.1 Further research
There are still large gaps in understanding the health effects of sugar in tobacco 
and tobacco products, as stressed by the editor of Nicotine and Tobacco Research 
(94). In particular, more information is required on:
 ■ the relation between sugars in waterpipe tobacco and toxicants in smoke;
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 ■ biomarkers of exposure relevant to the effects of sugars on health and 
the impact of changing sugar levels on those biomarkers;
 ■ the role of sugars in the attractiveness of tobacco products to chil-
dren and young adults, e.g. by monitoring market shares according 
to sugar content and by marketing studies;
 ■ the amount of sugars that alters the overall sweetness of emissions 
and imparts a noticeable characterizing flavour;
 ■ the effect of sugars on overall rates of initiation, addictiveness, de-
pendence and quitting according to the type of tobacco product;
 ■ the role of acetaldehyde, in the amounts measured in tobacco smoke, 
on the addictive potential of (nicotine in) tobacco through monoam-
ine inhibitors such as harman and formation of acetaldehyde–bio-
genic amine condensation products in vivo; and
 ■ the effects of sugars on the overall toxicity of tobacco products, in-
cluding:
 – for smokeless tobacco products, more information on the toxic ef-
fects of the sugars themselves, e.g. whether they are associated with 
diabetes and dental caries;
 – for combusted tobacco products, more information on the role of 
sugars in inhalation toxicity; and
 – interactions of sugars with other smoke components that may in-
crease the toxicity of smoke.
7.10.2 Policy
Several policy measures may be considered for reducing the negative effects of sugar 
(and its pyrolysis products) on product toxicity, addictiveness and attractiveness.
Mandate disclosure of sugar levels
Manufacturers of tobacco products should disclose the levels of sugar (and 
other ingredients) in all types of tobacco product. This would provide valuable 
information for future regulations and regulatory decisions. Simple, fast methods 
are available for verifying reported levels, e.g. extraction of tobacco, followed by high-
performance liquid chromatography–evaporative light-scattering detection (23).
Mandate lowering of sugars in final tobacco products
Defining and regulating the maximum sugar levels in tobacco products might 
best protect consumers, as the actual source of sugars present naturally in tobacco 
or added during manufacture does not define its health effects. If desired and 
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supported by sufficient scientific evidence, the maximum sugar level could be 
lowered to virtually 0, the sugar level present in Burley tobacco leaves.
Mandate lowering of sugar in all tobacco products
Canada has banned added sugar in cigarettes, little cigars and blunt wraps but 
not in other products, such as waterpipe and smokeless tobacco. Regulation of 
sugar in only some tobacco products is likely to encourage users to shift to other 
products. Thus, the ban on flavouring additives in cigarettes in Canada and the 
USA increased the market and consumption of flavoured small cigars (86, 95).
Mandate disclosure and lowering of the most harmful components of tobacco smoke
To decrease the negative effects of smoking, upper limits could be set for the most 
harmful components resulting from the combustion of sugar in tobacco smoke 
(3). An analytical method for aldehydes, the most harmful emission compounds 
resulting from the combustion of sugar, is validated by WHO TobLabNet, and 
TobReg has included aldehydes on its list of smoke components proposed for 
mandated lowering (45). The COP identified these as priority toxicants for which 
methods should be validated. Cunningham et al., of British American Tobacco, 
supported the inclusion of aldehydes as a priority. In their paper on segregation 
of tobacco smoke toxicants for risk assessment and management purposes, 
acetaldehyde, acrolein and formaldehyde, with a margin of exposure < 10 000, 
are considered high priorities for research on reducing exposure (96).
Support research on the toxicity, addictiveness and attractiveness of sugar
Regulators could support research and reporting on compounds that result from 
the combustion of sugar in tobacco products and their toxicity, carcinogenicity, 
mutagenicity, reproductive toxicity, addictiveness and attractiveness. Scientific 
guidelines and recommendations have been issued for assessing the impact of 
tobacco additives on toxicity (97), addictiveness (98) and attractiveness (99).
Change the status and definition of “sugar”
Another important means of increasing attention to and scientific research on 
sugar would be to include it on national and international lists of target ingredients 
and constituents, e.g. the European priority list (100), in the next intended round 
of revision. The list was established in line with Article 13 of the European 
Union Tobacco Products Directive (87) and includes additives for which more 
scientific experimental reporting is required on cigarettes and roll-your-own 
tobacco, including their toxicity, addictiveness and carcinogenic, mutagenic or 
reproductive toxicity in unburnt and burnt forms. Sugar is not yet included, 
although it meets all the selection criteria (Articles 6.1 and 6.2 of the Directive).
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Require disclosure, and monitor levels of sweeteners in tobacco products, in addition 
to sugar
Besides sugar, the (high-intensity) sweetener content of tobacco products is 
used efficiently to control product palatability and to increase initiation among 
adolescents. High-intensity sweeteners are several hundred times sweeter than 
sucrose (101) and are present in many alternative tobacco products. Regulation 
of sweetener content might therefore be a means of controlling the palatability 
of a wide range of products and reducing initiation of tobacco product use. For 
instance, Canada has already banned sweeteners and several flavouring additives, 
in addition to sugar.
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8. Updated priority list of toxicants in combusted  
tobacco products
Irina Stepanov, Associate Professor, Division of Environmental Health Sciences and 
Masonic Cancer Center, University of Minnesota, Minneapolis (MN), USA
Marielle Brinkman, Senior Research Scientist, College of Public Health, Ohio State 
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8.1 Introduction
At the fifth meeting of the COP of the WHO  FCTC, WHO was requested to 
compile, make available to Parties and update a non-exhaustive list of toxic 
contents and emissions of tobacco products and provide advice about how such 
information could best be used by Parties. TobReg at its meeting in Rio de Janeiro, 
Brazil, on 4–6 December 2013 provided an updated list of priority toxicants for 
reporting and regulation.
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In this paper, we re-evaluate the list, as it has been four years since the 
updated list was issued, and new knowledge on the subject matter has become 
available. In particular, this report includes:
 ■ background information on the current TobReg priority list of toxi-
cants, including the criteria used to select specific contents and emis-
sions (8.2);
 ■ an overview of new data related to the priority list, including new 
publications on the toxicity of specific constituents, new or modified 
analytical methods and new data on variations in levels of toxicant in 
combustible tobacco brands (8.3–8.5);
 ■ a discussion of the criteria for future re-evaluation of toxicants on the 
list (8.6);
 ■ a discussion of criteria for selecting new toxicants for the list (8.7); and
 ■ research needs and regulatory recommendations for testing selected 
contents and emissions in combusted tobacco products (8.8).
Literature was searched primarily in the PubMed database and SciFinder, which 
retrieves citations from the Medline and CAplus databases. Relevant articles cited 
in publications obtained in the database search were also included. In addition, 
the websites of the United States Centers for Disease Control and Prevention, 
the United States Environmental Protection Agency, the Cooperation Centre for 
Scientific Research Relative to Tobacco (CORESTA) and other relevant websites 
that provide information on the toxicology of the constituents of interest and on 
methods were used.
8.2 Background of preparation of the priority list
Regulation of tobacco products requires establishment of a metric or set of 
metrics by which tobacco products can be assessed. The measurements that have 
been made most commonly for cigarettes have been machine-measured tar, 
nicotine and CO yields per cigarette, based on the ISO regimen and the United 
States Federal Trade Commission (FTC) method. It is well established, however, 
that such measures do not provide valid estimates of human exposure or toxicity 
and thereby cause harm by misleading smokers and most regulators (1, 2). New 
product assessment approaches for setting regulatory measures were therefore 
considered necessary.
The new approach proposed by TobReg requires quantification of the 
levels of known harmful toxicants that accompany a specified amount of nicotine, 
the principal addictive substance in smoke sought by smokers, as measured in 
a standardized machine testing regimen. Normalization of specific toxicants to 
the nicotine yield allows measurement of the toxicity of smoke generated in a 
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standardized regimen rather than the quantity of smoke generated. Standardized 
measures of toxicant yields will allow regulators to reduce the levels of identified 
priority toxicants in tobacco smoke, consistent with other regulatory approaches 
that mandate reductions of known toxicants in products used by humans. 
Selection of high-priority smoke toxicants for product assessment is a critical 
step in this strategy.
The current non-exhaustive priority list of toxic contents and emissions of 
combustible tobacco products was drawn up by TobReg from among more than 
7000 chemicals found in cigarette smoke, after an evaluation of lists of harmful 
and toxic chemicals associated with cancer, cardiovascular and pulmonary 
diseases published by several regulatory bodies. Consideration was also given to 
constituents in both the particulate and the gas phases of smoke and in different 
chemical classes. As the list represents only a small fraction of the total complex 
mixture of chemicals present in tobacco smoke, the overall toxicity of the 
emissions of tobacco products is not necessarily characterized by the toxicity of 
these chemicals. Regulation of a very large number of toxicants would, however, 
lead to significant distortions in the existing market and increase the complexity 
of regulatory oversight. Limiting the number of toxicants to a carefully selected 
priority list recognizes the practical reality of a regulatory structure.
8.2.1 Criteria for selection of toxicants for the priority list
The following criteria were used to select priority tobacco contents and emissions 
of cigarette smoke for testing, reporting and future regulation.
The presence of specific chemicals in cigarette smoke at levels that are toxic for 
smokers, as determined by well established scientific toxicity indices
Evidence of toxicity was the most important criterion. The toxicologically 
important constituents considered were those on the list reported by law 
to Health Canada for the year 2004 (3) and measured by Counts et al. (4) by 
comparing several international brands manufactured by Philip Morris. The list 
was selected by Health Canada to represent those constituents of tobacco smoke 
that contribute most to its toxicity.
Quantitative data for characterizing the hazards of the reviewed toxicants 
were generated by calculating “toxicant animal carcinogenicity indices” and non-
cancer response indices with a modification of a simplified system presented 
by Fowles and Dybing (5). For these calculations, published toxicant yields 
(obtained with the modified intense smoking regimen) were normalized per 
milligram of nicotine and multiplied by cancer and non-cancer potency factors. 
“Cancer potency factors” were defined as T25 per milligram (1/T25), where T25 is 
the long-term daily dose that will produce tumours at a specific tissue site above 
the background rate in 25% of animals (6). For non-cancer potency factors, 
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the long-term reference exposure levels published by the California Office of 
Environmental Health Hazard Assessment (USA) in February 2005 (http://
www.oehha.ca.gov/air/chronic_rels/AllChrels.html) were used. Toxicant yields 
measured in a consistent manner with the modified intense smoking regimen are 
available from three sources: Counts et al. (4), a set of Canadian brands (3) and a 
set of Australian brands (7).
Variations in concentrations among cigarette brands that are substantially greater 
than the variation in repeated measurements of the toxicant in a single brand
Mandated reductions are likely to have the greatest impact on lowering the mean 
levels per milligram of nicotine for those toxicants with the broadest variation 
in levels around the midpoint. The variation in levels of different toxicants can 
be expressed as the coefficient of variation, which is the standard deviation of 
the measurement across brands divided by the mean value for all the brands. As 
the reproducibility of testing can vary substantially for different toxicants and 
with different testing methods, repeated measurements are used to estimate the 
mean value for a brand, and the variation of the repeated measurements defines 
the CI around that mean value. A second approach is direct determination of 
the range of toxicants in brands by determining the maximum and minimum 
values for each toxicant in the brand data set, expressed as the ratio of the median 
value for that toxicant. This does not include adjustment for variation in replicate 
measurements of the toxicant. Another useful approach to assessing variations 
in toxicant levels is to compare the mean levels of toxicants in different data sets. 
This analysis can identify levels of toxicants that differ within the same brand 
sold in different markets or by different manufacturers, which indicates that it is 
clearly possible to manufacture cigarettes that yield lower levels of that particular 
toxicant.
The availability of technology to reduce the concentration of a given toxicant in 
smoke, should an upper limit be mandated
The ability of the tobacco industry to modify their products to comply with lower 
toxicant levels is another factor to be considered in selecting toxicants for tobacco 
product regulation. For instance, the levels of the carcinogenic TSNAs NNK 
and NNN in smoke can be reduced by changing agricultural practices, curing 
and tobacco blending (8). The levels of volatile toxicants, such as acetaldehyde, 
acrolein and formaldehyde, can be reduced by reducing the concentration of 
sugars added to tobacco or using charcoal filters or other filter modifications (9). 
Reductions in benzo[a]pyrene yields can be achieved by treating, extracting or 
modifying the tobacco blend (10).
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8.2.2 Key decisions of the Conference of the Parties on priority contents and 
emissions of combustible tobacco
Table 8.1 summarizes the key COP decisions and TobReg’s progress in regulating 
the contents and emissions of combustible tobacco products under WHO FCTC 
Articles 9 and 10. The initial list of nine priority emissions identified by TobReg 
at the third COP and for which validation of testing methods in cigarette smoke 
was recommended are listed in Table 8.2. These toxicants were selected among 43 
toxicologically relevant compounds for which the hazard indices were calculated 
and other criteria were reviewed as described above. Nicotine was not included in 
the list of emissions but was recommended for testing in tobacco filler (contents). 
Following the COP mandate, analytical methods for these selected priority 
emissions were developed and validated by the WHO Tobacco Laboratory 
Network (TobLabNet).
Table 8.1. History of COP decisions and TobReg progress relevant to the testing and reporting of emissions
COP session COP decisions
TobReg progress and reports on contents 
and emissions
COP 1
(Geneva, 2006)
COP/1/INF.DOC./3: set up a working group to 
prepare guidelines pursuant to Articles 9 and 10 of 
the WHO FCTC. First phase to comprise testing and 
measuring tobacco product contents and emissions.
COP 2
(Bangkok, 2007)
COP/2/DIV/9: continue the work of TobReg, including 
on product characteristics, such as design features, 
to the extent that they affect the objectives of the 
WHO FCTC.
COP/2/8: TobReg presented a progress report that 
included the proposal that the provisional list of 
cigarette emissions consist of 44 “Hoffmann analytes”. 
COP 3
(Durban, 2008)
COP/3/DIV/3: decisions relevant to the priority list 
included:
•	 validate, within 5 years, analytical chemical 
methods for testing and measuring cigarette 
contents and emissions identified as priorities in 
the progress report of the working group, with 
two smoking regimens (ISO and modified intense 
method with blocked ventilation holes).
•	 when appropriate, design and validate methods 
for testing and measuring product characteristics 
identified in the progress report of the working 
group.
COP/3/6: the new progress report presented by 
TobReg identified:
•	 three contents for which methods for testing 
and measuring should be validated as a priority 
(nicotine, ammonia, humectants);
•	 nine emissions for which methods for testing and 
measuring should be validated as a priority (NNK, 
NNN, acetaldehyde, acrolein, benzene, benzo[a]
pyrene, 1,3-butadiene, CO, formaldehyde);
•	 the smoking regimens for validation of the test 
methods: (i) ISO 3308:2000 and (ii) a modified 
intense method with blocked ventilation holes; 
and
•	 a provisional list of product characteristics for 
testing and disclosure.
COP 4
(Punta del Este, 
2010)
COP/4/DIV/6: continue validation of analytical 
chemical methods for testing and measuring 
cigarette contents and emissions.
COP/4/INF.DOC./2: three analytical methods have 
been validated:
•	 CO in emissions;
•	 NNN and NNK in emissions; and
•	 nicotine content of tobacco.
COP 5
(Seoul, 2012)
COP/5/DIV/5:
continue validation of the analytical chemical 
methods for testing and measuring cigarette 
contents and emissions;
compile a non-exhaustive list of toxic contents and 
emissions of tobacco products. 
COP/5/INF.DOC./1: work in progress:
•	 validation of methods for humectants and 
ammonia in cigarette tobacco filler;
•	 validation of the method for benzo[a]pyrene in 
mainstream cigarette smoke.
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COP 6
(Moscow, 2014)
COP6(12): finalize validation of the analytical 
chemical methods for testing and measuring 
cigarette contents and emissions.
COP/6/14: TobReg proposed:
•	 a non-exhaustive list of 39 toxicants in tobacco 
products for monitoring and eventual regulation;
•	 a shorter list of nine toxicants for mandated 
lowering;
•	 development of the following standardized 
methods by TobLabNet: cadmium and lead 
content; nicotine in the smoke of waterpipes 
(shisha); and nicotine, NNN, NNK and benzo[a]
pyrene in smokeless tobacco products.
COP 7
(Delhi, 2016)
COP7(14):
finalize validation of the analytical chemical methods 
for aldehydes and VOCs in cigarette emissions;
assess the availability of validated analytical methods 
for the extended list of toxicants in contents and 
emissions of tobacco products, as reported in FCTC/
COP/6/14. 
COP/7/INF.DOC./1: method validation is completed 
for all mandated contents and emissions, except for 
aldehydes and VOCs.
COP 8
(Geneva, 2018)
COP8(21):
encourage Parties to acknowledge and implement 
TobLabNet methods.
COP/8/8: Method validation is completed for 
aldehydes and VOCs. All mandated contents and 
emissions are now validated.
TobReg identified the following opportunities 
for extending the list of toxicants in contents and 
emissions:
•	 extend SOPs to include the remaining aldehydes 
and VOCs;
•	 prepare a SOP for the metal content of cigarette 
tobacco filler;
•	 devise methods for the analysis of waterpipe 
tobacco and charcoal. 
 
CO: carbon monoxide; COP: Conference of the Parties; ISO: International Organization for Standardization; NNK: 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN: N´-nitrosonornicotine; SOP: standard operating procedure; VOC: volatile 
organic compound.
Table 8.2. Emissions of combusted tobacco products considered and evaluated for inclusion in the lists of 
priorities for testing, reporting and regulation
Toxicants 
evaluated by 
TobReg
Carcinogenicity or toxicity data Inclusion on priority lists
TACI TNCRI
COP/3/6 COP/6/14
Toxicants 
selected for 
testing and 
measuring
Expanded 
priority list for 
monitoring 
and regulation
Proposed for 
mandatory  
reduction
Alkaloids
Nicotinea – – X x –
Aldehydes
Acetaldehyde 6.1 67.1 X x x
Acrolein – 1099 X x x
Formaldehyde – 19.8 X x x
Crotonaldehydea – – – x –
Propionaldehyde – – – x –
Butyraldehyde – – – x –
Aromatic amines
3-Aminobiphenyl – – – x –
4-Aminobiphenyla – – – x –
1-Aminonaphthalene 0.00036 – – x –
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2-Aminonaphthalene 0.00068 – – x –
Hydrocarbons
Benzene 2.6 0.64 X x x
1,3-Butadiene 9.9 2.4 X x x
Isoprene 3.7 – – x –
Styreneb – 0.01 – – –
Toluene – 0.22 – x –
PAHs
Benzo[a]pyrenea 0.0086 – X x x
TSNAsa
NNK 3.4 – X x x
NNN 0.29 – X x x
NAB – – – x –
NAT – – – x –
Phenols
Catechol 0.58 – – x –
m- and p-Cresol – 0.01 – x –
o-Cresol – 0.01 – x –
Phenol – 0.07 – x –
Hydroquinone 1.2 – – x –
Resorcinol – – – x –
Other organic compounds
Acetone – – x
Acrylonitrile 1.4 2.1 x
Quinoline – – x
Pyridine – – x
Metals and metalloids
Arsenicc – 0.16
Cadmium 1.7 2.6 x
Chromiumb – –
Lead 0.00 – x
Mercury – 0.02 x
Nickelb – –
Seleniumb – –
Other constituents
Ammonia – 0.07 x
COa – 1.3 X x x
Hydrogen cyanide – 17.2 x
Nitrogen oxides – 3.1 x
 
CO: carbon monoxide; NAB: N′-nitrosoanabasine; NAT: N′-nitrosoanatabine; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; 
NNN: N′-nitrosonornicotine; PAH: polycyclic aromatic hydrocarbon; TACI: toxicant animal carcinogenicity index; TNCRI: toxicant non-
cancer response index; TSNA: tobacco-specific N-nitrosamine.  
aJustification for inclusion on the priority lists (initial and/or expanded) of some toxicants: nicotine was not on the initial priority list of 
emissions but was recommended for testing in tobacco (contents) and was subsequently listed with other toxicants in the extended 
list. Benzo[a]pyrene was included despite its low TACI because it is a proxy for the family of PAHs found in smoke and because there is 
a wealth of evidence for the carcinogenicity of many of these PAHs. The toxicant 4-aminobiphenyl was added because it is a human 
carcinogen, although experimental data did not allow proper calculation of T25. NNK and NNN were included as they had already been 
identified in the first report on mandating reductions in toxicant yields (12). Crotonaldehyde was included because of its reactive α,β-
unsaturated aldehyde structure, although a tolerable level value was lacking. CO was also included even though it has a relatively low 
toxicant non-cancer response index, as it is thought to be mechanistically related to cardiovascular disease.  
b Originally considered (11) but not included in the final recommended list because it occurs at low levels and is not considered to 
contribute appreciably to hazard indices.  
c Added after the expanded list was reported in document COP/6/14.
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In response to the subsequent COP request to compile a non-exhaustive list of 
toxic contents and emissions of tobacco products, TobReg at its meeting in Rio 
de Janeiro, Brazil, on 4–6 December 2013 re-evaluated the priority toxicant list by 
examining the lists of harmful and toxic chemicals published by several regulatory 
bodies, including Health Canada, the National Institute for Public Health and 
the Environment in the Netherlands (RIVM) and the FDA, and reviewing the 
list of toxicants assessed in an earlier WHO technical report on the scientific 
basis of tobacco product regulation (11). TobReg subsequently drew up a non-
exhaustive list by adding toxicants that satisfied the criteria for sufficient evidence 
of carcinogenicity or with known respiratory or cardiac toxicity, variations in 
levels in different brands in different countries that were readily measurable and 
possibilities for lowering yields in a product (Table 8.2). The list, composed of 37 
such toxicants plus nicotine, was presented to the COP for discussion at its sixth 
session. Only a few toxicants on the originally assessed list of 43 constituents were 
not included in the updated list. For instance, chromium, nickel and selenium 
occur either at low levels or could not be quantified in the three analysed data 
sets; therefore, although these elements are quite toxic, they were not considered 
to contribute appreciably to hazard indices and were not included.
In the same report (COP/6/14), TobReg proposed that the nine 
compounds originally selected for method validation (emissions) should be 
considered for mandatory reduction. TobReg concluded that these compounds 
are the most hazardous toxicants in cigarette smoke that could be reduced in 
emissions; they represent different chemical families of toxicants and different 
phases of smoke, are toxic to the pulmonary and cardiovascular systems and are 
carcinogenic. The nine toxicants are: acetaldehyde, acrolein, benzene, benzo[a]
pyrene, 1,3-butadiene, CO, formaldehyde, NNK and NNN (Table  8.2). The 
remaining toxicants on the priority list of 39 should be measured and reported.
8.3 Overview of new scientific knowledge on toxicity
8.3.1 Aldehydes (acetaldehyde, acrolein, formaldehyde, crotonaldehyde, 
propionaldehyde, butyraldehyde)
Aldehydes are toxic to the respiratory system (13). Acetaldehyde and formaldehyde 
are also toxic to the cardiovascular system and are respiratory tumorigens (14, 
15). Acrolein is an intense irritant, is toxic to lung cilia and has been proposed 
as a lung carcinogen (16, 17). Crotonaldehyde is a potent irritant and a weak 
hepatocarcinogen and forms DNA adducts in the human lung (18).
New studies on mechanisms of toxicity and carcinogenicity
The genotoxicity of acetaldehyde, acrolein and formaldehyde in human lung 
cells was demonstrated in the γH2AX assay, which detects early cellular response 
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to DNA double-strand breaks and is used as a biomarker of DNA damage in 
human epidemiology (19). All three aldehydes were genotoxic in a dose- or 
time-dependent manner, acrolein having the strongest potential to induce DNA 
damage, followed by formaldehyde and acetaldehyde. A computational fluid 
dynamics modelling study of simulated human oral breathing, representative 
aldehyde yields from cigarette smoke and lifetime average daily doses indicated 
that the order of concern for human exposure is acrolein > formaldehyde > 
acetaldehyde (20). An analysis of the mode of action of the toxicity of acrolein 
in the lower respiratory system, reflecting the exposure of smokers who inhale 
tobacco smoke, suggested that the mechanisms of acrolein toxicity include 
oxidative stress, chronic inflammation, necrotic cell death, necrosis-induced 
inflammation, tissue remodelling and destruction and subsequent loss of lung 
elasticity and enlarged lung airspaces (21). These processes are consistent with 
the inflammation and necrosis in the middle and lower regions of the respiratory 
tract that occur in chronic obstructive pulmonary disease. The findings of another 
study suggested that acrolein contributes to the dysfunctional innate immune 
responses observed in the lung during cigarette smoking (22). In addition, acrolein 
may contribute to bladder carcinogenesis in smokers. Lee et al. (23) analysed 
acrolein–deoxyguanosine adducts in normal human urothelial mucosa and in 
bladder tumour tissues and measured their mutagenicity in human urothelial 
cells. The adduct levels in both types of tissue were higher than the levels of 
those due to the known bladder carcinogen 4-aminobiphenyl, and they induced 
mutation signatures and spectra that appeared to be much more mutagenic than 
those due to 4-aminobiphenyl. The levels of acrolein–deoxyguanosine were two 
times higher in bladder tumour tissues than in normal cells.
A study of transcription responses to aldehyde exposure in human lung 
carcinoma lines showed a different ranking from that in the studies described 
above (24). Formaldehyde gave the strongest response, with differential expression 
of 66 genes (mostly involved in apoptosis and DNA damage) by more than 1.5 
times. Acetaldehyde dysregulated 57 genes, while acrolein caused upregulation of 
only one gene involved in oxidative stress.
While formation of DNA adducts is a critical factor in the mutagenicity 
and carcinogenesis of aldehydes, protein modifications may also play a role. 
For instance, in addition to N2-ethylidene-2´-deoxyguanosine, its major DNA 
adduct, acetaldehyde also formed hybrid protein adducts with malondialdehyde, 
a product of lipid peroxidation induced by toxic constituents and reactive species 
in cigarette smoke. Formation of hybrid malondialdehyde–acetaldehyde protein 
adducts in the lung has been shown to initiate several pathological conditions, 
including inflammation and inhibition of wound healing (25). Antibodies 
(immunoglobulins) involved in the immune response to these adducts (i.e. 
IgM, IgG and IgA) are predictive of progression of atherosclerotic disease and 
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of cardiovascular events such as acute myocardial infarction or coronary artery 
bypass grafting (26).
It is also important to consider the effect of gene polymorphisms on the 
response of humans to toxicants. For instance, risk assessments of acetaldehyde 
have so far been based on thresholds determined in animal toxicology studies, 
which do not account for the genetic-epidemiological and biochemical evidence 
that ALDH2-deficient humans are highly vulnerable to the carcinogenic effects 
of this chemical. In a study on exposure to acetaldehyde through alcohol 
consumption, ALDH2 inactivity was associated with odds ratios of up to 7 for 
head-and-neck and oesophageal cancers (27). A study of a Japanese cohort of 
patients with myocardial infarction and stable angina and matching controls 
suggested that the inactive ALDH2 genotype may increase the risk for myocardial 
infarction in smokers (28).
Additional potential mechanisms of the toxicity and carcinogenicity 
of aldehydes have been investigated. Acrolein has been shown to affect the 
metabolism and fate of aromatic amines by interacting with enzymes responsible 
for their acetylation (29). A study of potential interactions between acrolein and 
the antiretroviral drug zidovudine, which is used widely in limited-resource 
countries but is associated with hepatotoxicity, strongly suggest that exposure 
to acrolein through smoking and/or alcohol consumption can contribute to the 
major mechanisms by which zidovudine induces hepatotoxicity (30). Another 
study suggested that exposure to acetaldehyde and formaldehyde may induce 
carcinogenesis in carriers of the BRCA2 mutation (31). Mutations in BRCA2, 
which is a tumour suppressor gene, increase the risk for breast cancer and are 
also associated with susceptibility to ovarian, pancreatic and other cancers. Both 
aldehydes selectively deplete BRCA2 by proteasomal degradation, which may 
trigger spontaneous mutagenesis during DNA replication (31).
New studies on health effects other than respiratory toxicity and carcinogenicity
Addictiveness: there is accumulating evidence that acetaldehyde also contributes 
to the addictiveness of tobacco (32). Studies of self-administration in laboratory 
animals add to understanding of the behavioural correlates of acetaldehyde 
administration and possible interactions with the neurotransmitters for 
motivation, reward and stress-related responses, such as dopamine and 
endocannabinoids (33). Another possible mechanism is via the formation of 
harman, a condensation product of acetaldehyde and amines in saliva. Harman is 
a monoamine oxidase inhibitor and can help to maintain behavioural sensitization 
to nicotine. In support of this hypothesis, it was shown that smokers given a 
lozenge containing L-cysteine (an amino acid that reacts with acetaldehyde) had 
higher rates of smoking cessation than those treated with placebo (34). It should 
be noted, however, that harman is also present in tobacco and cigarette smoke.
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Cardiovascular effects: the cardiovascular effects of acrolein have been reviewed 
(35). In vitro and in vivo, cardiovascular tissues appear to be particularly sensitive 
to the toxic effects of acrolein, which can generate oxidative stress in the heart, 
form protein adducts with myocyte and vascular endothelial cell proteins and 
cause vasospasm. Therefore, chronic exposure to acrolein could contribute to 
cardiomyopathy and cardiac failure in humans. This conclusion is supported by 
the results of a study of mice exposed chronically to acrolein, which suggested that 
even relatively low exposure to acrolein, such as that from second-hand smoke or 
e-cigarettes, could increase cardiovascular risk by reducing endothelium repair, 
suppressing immune cells or both (36). Exposure to acrolein was also assessed 
in 211 participants in the Louisville Healthy Heart Study who were at moderate-
to-high risk for cardiovascular disease (37). Exposure to acrolein was associated 
with platelet activation, suppression of circulating angiogenic cell levels and 
increased cardiovascular disease risk.
Glucose and lipid metabolism: in rats, exposure to acrolein caused metabolic 
impairment by inducing hyperglycaemia and glucose intolerance, accompanied 
by a significant increase in the level of corticosterone and modest but insignificant 
increases in the level of adrenaline (38). The association between urinary levels 
of acrolein metabolites and diabetes and biomarkers of insulin resistance was 
investigated in 2027 adults who participated in the 2005–2006 National Health 
and Nutrition Examination Survey in the USA (39). A positive association was 
found between the biomarkers analysed, suggesting a potential role of acrolein in 
the etiology of type-2 diabetes and insulin resistance in humans.
Other effects: acrolein may affect intestinal epithelial integrity. After oral exposure 
of mice to acrolein, damage was found to the intestinal epithelial barrier, resulting 
in increased permeability and subsequent bacterial translocation (40). Song et al. 
(41) provided additional evidence that acrolein is a risk factor for otitis media.
The developmental and reproductive toxicity of aldehydes has also been 
studied. Amiri & Turner-Henson (42) reported the results of a cross-sectional 
study of a convenience sample of 140 healthy pregnant women, in which 
the relation between exposure to formaldehyde and fetal growth during the 
second trimester was examined. A linear regression model showed that the 
dichotomized level of formaldehyde exposure (<  0.03 and >  0.03 parts per 
million) was a significant predictor of biparietal diameter percentile after 
control for maternal race (P <.006). In a study in an animal model, exposure 
to 5 mg/kg acrolein in utero resulted in significantly decreased testosterone 
synthesis in male offspring (43).
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New epidemiological evidence
A study of more than 2200 smokers in the Multiethnic Cohort study in the USA 
showed that urinary biomarkers of acrolein and crotonaldehyde exposure were 
significantly different among five ethnic groups (44). Native Hawaiians had the 
highest and Latinos the lowest geometric mean levels of urinary biomarkers of 
both aldehydes after adjustment for confounders. These results are consistent 
with the findings of an epidemiological study in this cohort, in which native 
Hawaiians had a higher risk for lung cancer and Latinos a lower risk as compared 
with Whites, for the same number of cigarettes smoked (45). These results suggest 
that acrolein and crotonaldehyde may be involved in the etiology of lung cancer 
in smokers.
8.3.2 Aromatic amines (3-aminobiphenyl, 4-aminobiphenyl, 
1-aminonaphthalene, 2-aminonaphthalene)
Exposure to aromatic amines is associated with bladder cancer (46), and 2-ami-
nonaphthalene and 4-aminobiphenyl are known human bladder carcinogens 
(15). In one study, the mean level of 4-aminobiphenyl was 4.8 times higher in 
smokers (> 20 cigarettes/day) than nonsmokers, reaffirming that tobacco smoke 
is a major source of exposure to this carcinogen (47).
Aromatic amines may present a risk for non-urological cancer. A cohort 
of 224 male workers at a single factory who were followed from 1953 to 2011 had 
high risks for both lung cancer and bladder cancer associated with exposure to 
2-aminonaphthalene (48). A systematic review and meta-analysis of studies on 
the risk for lung cancer among workers exposed to 2-aminonaphthalene showed 
a significantly increased lung cancer risk, the effect estimates being similar in 
studies with and without concomitant occupational exposure to other lung 
toxicants and carcinogens (49). Exposure to benzidine and 2-aminonaphthalene 
was monitored in both studies.
8.3.3 Hydrocarbons (benzene, 1,3-butadiene, isoprene, toluene)
Benzene and butadiene cause cancers of the haematolymphatic organs and are 
classified as known human carcinogens (15). Isoprene causes tumours at various 
sites in laboratory animals (50). 1,3-Butadiene and toluene are respiratory 
toxicants, and toluene is also toxic to the central nervous system and is a 
reproductive toxicant. These compounds are present in high amounts in cigarette 
smoke and probably play a role in lung cancer in smokers (14, 15, 51).
The tobacco smoke-related health effects of 1,3-butadiene and the possible 
impacts of risk reduction strategies were evaluated from the ratio (margin of 
exposure) between the most sensitive toxicity end-point and appropriate 
estimates of exposure to 1,3-butadiene in mainstream and second-hand tobacco 
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smoke (52). The authors concluded that the risks for cancer (leukaemia) and non-
cancer (ovarian atrophy) could be significantly reduced by lowering the levels of 
1,3-butadiene in smoke. They proposed that analysis of the margin of exposure is 
a practical means for assessing the impact of risk reduction strategies on human 
health. In a review of non-cancer health effects of benzene, it was concluded that 
exposure to benzene can have numerous outcomes in the reproductive, immune, 
nervous, endocrine, cardiovascular and respiratory systems (53).
Cardiovascular effects
A potential association between exposure to benzene and an increased risk for 
cardiovascular disease has been investigated in mice and humans (54). The effects 
of benzene in mice were assessed by direct inhalation, while the effects in humans 
were assessed in 210 people with mild-to-high risks for cardiovascular disease 
risk by measuring urinary biomarkers. Mice had significantly reduced levels of 
circulating angiogenic cells and higher plasma levels of low-density lipoprotein 
than control mice that breathed filtered air. In humans, smokers and people with 
dyslipidaemia had higher exposure to benzene, which was negatively correlated 
with populations of circulating angiogenic cells and associated with the risk for 
cardiovascular disease assessed on the Framingham risk score.
New epidemiological evidence
The results of a study with a sample of adult participants in the Gulf Long-term 
Follow-up Study in the USA during 2012 and 2013 suggested that ambient expo-
sure to benzene and toluene is associated with haematological effects, including 
decreased haemoglobin and mean corpuscular haemoglobin concentration and 
increased red cell distribution width (55). The evidence was particularly strong 
for benzene.
In the Multiethnic Cohort study, benzene uptake was compared in smokers 
in five different ethnic groups by analysing urinary S-phenylmercapturic acid, a 
specific biomarker of exposure to benzene (56). African Americans had significantly 
higher and Japanese Americans significantly lower levels of S-phenylmercapturic 
acid than Whites. While benzene is not generally considered to cause lung cancer, 
these differences are consistent with those for lung cancer risk in this cohort.
8.3.4 Polycyclic aromatic hydrocarbons (benzo[a]pyrene)
PAHs are formed during incomplete combustion of organic matter and always 
occur as mixtures. Many PAHs are potent carcinogens or toxicants in laboratory 
animals (57), and many are present in cigarette smoke, including the prototypic 
PAH benzo[a]pyrene, classified as a human carcinogen by a working group 
convened by the International Agency for Research on Cancer (IARC) (57, 58). 
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PAHs are widely accepted to be major contributors to lung cancer in smokers 
(57, 59–61). A study of benzo[a]pyrene and the TSNA NNK in A/J mice showed 
dose-dependent tumorigenesis at lower doses than previously reported (62).
Zaccaria and McClure (63) analysed published studies on benzo[a]
pyrene and other PAHs and found a correlation between the derived relative 
potency factors for immune suppression for nine PAHs and their potency factors 
for cancer, confirming previous observations of an association between the 
carcinogenicity of PAHs and immunosuppression.
Environmental exposure to benzo[a]pyrene is correlated with impaired 
learning and memory in adults and poor neurodevelopment in children. A 
comprehensive literature review was conducted to determine the potential 
mechanism of neurotoxicity by benzo[a]pyrene (64). The results suggest that 
neurotoxic effects are observed at lower exposure than those associated with 
cancer. It was proposed that benzo[a]pyrene binding to the aryl hydrocarbon 
receptor results in loss of neuronal activity and decreased long-term potentiation, 
compromising learning and memory.
8.3.5 Tobacco-specific N-nitrosamines
TSNAs are important constituents of tobacco products, and two, NNK and 
NNN, are probably responsible for cancers of the lung, pancreas, oral cavity 
and oesophagus in tobacco users (65, 66). Both have been classified as human 
carcinogens by working groups at IARC (66, 67). These nitrosamines are formed 
from tobacco alkaloids during tobacco processing. The amounts that are formed 
depend on tobacco type, nitrate content and tobacco processing techniques, 
resulting in wide variation in the amounts in various cigarette brands (65, 68–70). 
In smokers, increases in smoke TSNA yields due to changes in cigarette design, 
including filter ventilation, were accompanied by an increase in the incidence 
of lung adenocarcinoma, the type of lung cancer that is induced by NNK in 
laboratory animals (71, 72).
New evidence in laboratory animals
The carcinogenicity of NNK and its metabolite NNAL was studied in male F-344 
rats treated for 70 weeks. Both compounds induced a high incidence of lung 
tumours, and metastases were observed from primary pulmonary carcinomas to 
the pancreas. The results clearly demonstrate the potent pulmonary carcinogenicity 
and DNA damaging activity of NNK and NNAL in rats (73). In another study by 
the same group (74), NNN induced 96 oral cavity tumours and 153 oesophageal 
tumours in 20 male F-344 rats treated chronically with this carcinogen in their 
drinking water. This study showed for the first time the carcinogenic potency of 
NNN in the oesophagus and identified NNN as a strong oral cavity carcinogen 
present in tobacco.
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New evidence in humans
Consistent with the data on carcinogenicity in animals, a positive association 
was found between prospectively measured exposure to NNN and NNK and 
risks for oesophageal and lung cancer, respectively, in smokers in the Shanghai 
Cohort Study. Additional analyses of the same cohort indicated that exposure to 
NNK was not associated with oesophageal cancer, and exposure to NNN was not 
associated with the risk of smokers for lung cancer (75). Together, these results 
reaffirm the organ specificity of NNN and NNK towards the oesophagus and 
the lung, respectively, in smokers, consistent with the findings in F-344 rats. The 
uptake of NNK was also measured in 2252 smokers in the Multiethnic Cohort 
study (76). After adjustment for age at urine collection, sex, creatinine and total 
nicotine equivalents, a marker of total nicotine uptake, the highest exposure to 
NNK was found for African Americans and the lowest for Japanese Americans. 
These findings are consistent with the findings on lung cancer risk of smokers in 
these groups.
Mechanistic studies and studies in laboratory animals indicate that DNA 
adduct formation is a critical step in NNN- and NNK-induced carcinogenesis. 
Higher levels of these adducts were found in the oral cells of smokers with head-
and-neck squamous cell carcinoma than in cancer-free smokers (77).
8.3.6 Alkaloids (nicotine)
Nicotine is the major known addictive agent in tobacco and cigarette smoke (78) 
and is a key driver of tobacco use. Nicotine content can greatly influence the 
extent and pattern of product use and can also define the category of users to 
whom a product will appeal. Further, it affects exposure to other toxicants and 
carcinogens in the product.
New evidence on the effects of nicotine reduction in cigarette smoke
Reduction of the nicotine content of cigarettes to a minimal or non-addictive 
levels has been recommended for consideration by TobReg and proposed by the 
FDA as an approach for reducing or eliminating the use of combusted tobacco 
products (79, 80). The feasibility of this approach is confirmed by the results of a 
number of studies. In a double-blind, parallel, randomized clinical trial conducted 
between June 2013 and July 2014 at 10 sites in the USA, 840 participants were 
randomly assigned to smoke either their usual brand of cigarettes or one of six 
types of investigational cigarettes with a nicotine content ranging from 0.4 mg/g 
to 15.8 mg/g of tobacco (comparable to the nicotine content of commercial 
brands) for 6 weeks (81). At the end of the study, participants assigned to cigarettes 
containing 2.4, 1.3 or 0.4 mg of nicotine per gram of tobacco had smoked a 
smaller average number of cigarettes per day than those assigned to their usual 
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brand or to cigarettes containing 15.8 mg/g (P <.001). Cigarettes with a lower 
nicotine content than control cigarettes reduced exposure to and dependence 
on nicotine and also reduced craving during abstinence from smoking, without 
significantly increasing the expired CO level or total puff volume, suggesting 
minimal compensation.
In a follow-up randomized, parallel-arm 8-week study by Hatsukami et 
al. (82), smokers who were unwilling to quit were randomly assigned to normal 
or VLNC cigarettes, and use of alternative nicotine products, smoking behaviour 
and biomarkers of tobacco exposure were assessed. The offer of and instructions 
for use of reduced-nicotine cigarettes led to reduced smoking rates, reduced 
biomarkers of exposure to smoke toxicants and greater use of alternative tobacco 
or nicotine products than continued use of cigarettes with normal nicotine.
Health effects other than addiction
Nicotine can contribute to acute cardiovascular events and accelerated 
atherogenesis in tobacco users, probably due to stimulation of the sympathetic 
nervous system, decreasing coronary blood flow, impairment of endothelial 
function and other pharmacological effects (83). A systematic review of studies 
in humans and animals on the health effects of exposure to nicotine during 
pregnancy and adolescence indicated that nicotine contributes critically to 
adverse effects, including reduced pulmonary function, auditory processing 
defects and impaired infant cardiorespiratory function, and it may contribute 
to cognitive and behavioural deficits in later life (84). The study also found that 
exposure to nicotine during adolescence is associated with deficits in working 
memory, attention and auditory processing, as well as increased impulsivity and 
anxiety, and studies in animals suggest that nicotine increases the liability for 
addiction to other drugs.
8.3.7 Phenols (catechol, m-, p- and o-cresols, phenol, hydroquinone, 
resorcinol)
Catechol is a co-carcinogen (85) that is present in high amounts in cigarette 
smoke (66). The United States Environmental Protection Agency has classified 
m-, o- and p-cresols as possible human carcinogens on the basis of genetic toxicity 
and increased incidences of skin and nasal tumours in rodents. Cresols are also 
respiratory toxicants. Hydroquinone is mutagenic in vitro and in vivo, including 
in a study in which it had significant genotoxicity in vitro in the γH2AX assay 
(19). It has been shown reproducibly to induce benign neoplasms in the kidneys 
of male F-344 rats dosed orally, but the data on humans are inadequate. Phenol 
is a respiratory toxicant, elicits cardiovascular effects and is a tumour promoter. 
Resorcinol was reported to have a range of toxic effects in various studies and is 
considered to be a respiratory toxicant.
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8.3.8 Other organic compounds (acetone, acrylonitrile, pyridine, quinolone)
Acetone is a respiratory toxicant and can irritate the respiratory tract. Acrylonitrile 
is a respiratory toxicant and is classified by the IARC as possibly carcinogenic to 
humans (Group 2B) (14). It readily forms adducts with proteins, and the levels 
of such adducts are higher in smokers than in nonsmokers (14, 86). Acrylonitrile 
is also mutagenic in some assays (14). Few studies have been conducted on the 
toxicity of pyridine; some suggest effects on the respiratory tract, the central 
nervous system and the liver. Quinoline is an irritant after acute exposure 
and showed liver toxicity and carcinogenicity in animals. No significant new 
toxicological findings on these organic compounds have been identified since 2013.
8.3.9 Metals and metalloids (arsenic, cadmium, lead, mercury)
Arsenic and cadmium are human carcinogens (87). These metals are lung 
carcinogens and could also play a role in bladder (arsenic) and kidney (cadmium) 
cancers. Arsenic also has cardiovascular and reproductive effects, and cadmium 
is a neurological and respiratory toxicant. Lead is a neurological, reproductive 
and cardiovascular toxicant and a probable human carcinogen (88). Mercury is 
classified by IARC in Group 2B and is also a reproductive toxicant (89). These 
elements are present in varying amounts in cigarette smoke (66) and smokeless 
tobacco (90); the levels are probably affected by their concentrations in the soils 
in which the tobacco is grown. Pinto et al. (91) detected significantly higher levels 
of arsenic, lead and cadmium in the lung tissue of smokers than nonsmokers. The 
exposure of young children to second-hand tobacco smoke can result in blood 
lead levels that are associated with decreased IQ and cognition (92).
Carcinogenicity
The association between long-term exposure to cadmium, measured in urine, 
and mortality from cancer was investigated in 3792 American Indians in Arizona, 
Oklahoma and North and South Dakota (USA) who participated in the Strong 
Heart Study during 1989–1991. Exposure to cadmium was associated with 
mortality from all cancers and with that from cancers of the lung and pancreas 
(93). In a review of the literature, Feki-Tounsi & Hamza-Chaffai (94) concluded 
from the available in vitro and epidemiological studies that exposure to cadmium 
is associated with an increased risk of bladder cancer and may be involved in 
urothelial toxicity and carcinogenesis.
Neurotoxicity
Cadmium and lead are neurotoxicant components of tobacco smoke and could 
contribute to depression associated with smoking. The association between blood 
cadmium and lead levels and current depressive symptoms was investigated in a 
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cross-sectional study of adult participants in the National Health and Nutrition 
Examination Survey 2011–2012 in the USA (N = 3905). Blood cadmium was 
associated with higher odds for depressive symptoms in male participants aged 
20–47 years, and blood lead, cigarette smoking and obesity were associated with 
depressive symptoms in female participants in this age range (95). The finding of 
effects on spatial and nonspatial working memory, anxiety-related behaviour and 
motor activities in female adolescent mice exposed to cadmium and/or nicotine 
supports these conclusions (96, 97). Nicotine and cadmium increased the 
metabolism, food intake and weight of treated mice as compared with controls. 
Nicotine administration increased motor function, while cadmium decreased 
motor activity. Both compounds induced a reduction in the memory index. 
Combined treatment with nicotine and cadmium induced decreases in weight 
and motor activity, increased anxiety and a significant decrease in nonspatial 
working memory.
Cardiovascular disease
It has been hypothesized that cadmium contributes to the cardiovascular 
risk associated with smoking by injuring vascular endothelial cells (98). In a 
systematic review of epidemiological studies of the association between exposure 
to cadmium and cardiovascular disease, the pooled relative risks (95% CIs) for 
cardiovascular disease, coronary heart disease, stroke and peripheral arterial 
disease were: 1.36 (1.11, 1.66), 1.30 (1.12, 1.52), 1.18 (0.86, 1.59) and 1.49 (1.15, 
1.92), respectively (99). With the experimental evidence, the review supports an 
association between exposure to cadmium and cardiovascular disease, especially 
coronary heart disease.
Other health effects
Mice exposed to sodium arsenite for 90 days showed increased micronucleated 
polychromatic erythrocytes and an increase in genotoxic and germ-cell toxic 
effects in liver, kidney and intestinal tissues as compared with a control group. 
Combined treatment with smokeless tobacco extract induced a significant 
increase in sperm head abnormality as compared with either material alone (100).
The effect of exposure to lead in cigarette smoke on fetal growth was 
studied by measuring blood lead concentrations in 150 healthy pregnant women 
(101). The birth weight of the infants of mothers who smoked was significantly 
lower than that of infants born to non-smoking mothers (P <.001) and was 
negatively correlated with lead levels in plasma (r = –0.38; P <.001) and in whole 
blood (r = –0.27; P <.001).
Exposure to mercury has been hypothesized to lead to metabolic 
syndrome and diabetes mellitus. Reviews of the literature indicated that, while 
epidemiological data suggest a possible association between total mercury 
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concentrations in biological matrices and the incidence of these health outcomes, 
the relation is not consistent (102, 103). A more comprehensive review of the 
health effects associated with exposure to mercury suggests that chronic exposure, 
even to low concentrations of mercury, can cause cardiovascular, reproductive 
and developmental toxicity, neurotoxicity, nephrotoxicity, immunotoxicity and 
carcinogenicity (104).
8.3.10 Other constituents (ammonia, carbon monoxide, hydrogen cyanide, 
nitrogen oxides)
Ammonia is a respiratory irritant and toxicant, which increases the prevalence 
of respiratory symptoms, asthma and impaired pulmonary function in various 
industrial and agricultural settings (105–108). Limited studies suggest that people 
with asthma are more sensitive to the respiratory effects of ammonia (108, 109).
CO is a well established cardiovascular toxicant, which competes with oxygen for 
binding to haemoglobin. In smokers, it is considered to reduce oxygen delivery, 
cause endothelial dysfunction and promote the progression of atherosclerosis 
and other cardiovascular diseases (110–112).
Hydrogen cyanide is a well-known toxic agent, its primary targets being 
the cardiovascular, respiratory and central nervous systems. It acts by inhibiting 
cytochrome oxidase in the respiratory chain. Cigarette smoke can reduce 
detoxification of hydrogen cyanide, leading to chronic exposure of smokers to 
this toxin and consequent amblyopia, retrobulbar neuritis, sterility and a potential 
contribution to impaired wound healing (112, 113).
Nitrogen oxides are respiratory and cardiovascular toxicants. Nitric 
oxide, the primary form in fresh cigarette smoke, induces vasodilation and 
causes DNA strand breaks and lipid peroxidation, possibly contributing to 
carcinogenesis (114). It may also contribute to nicotine addiction by increasing 
nicotine absorption, reducing symptoms of stress and increasing post-synaptic 
dopamine levels (115). Nitrogen dioxide is a pulmonary irritant.
8.4 Availability of analytical methods
8.4.1 Standardized WHO TobLabNet methods for the analysis of priority toxicants
To ensure implementation of Articles 9 and 10 of the WHO FCTC, laboratory 
capacity must be available that meets the highest standards of excellence, 
transparency, reliability and credibility (116). Standardized, reliable, accurate 
analytical methods are required by laboratories to conduct the scientifically 
rigorous testing required for tobacco products globally (117). Consensus on a 
set of methods may partly depend on successful transfer of such methods to 
other laboratories. Established, validated WHO TobLabNet standard operating 
procedures (SOPs) as of October 2018 are summarized in Table 8.3.
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Table 8.3. Standardized WHO TobLabNet standard operating procedures for the analysis of priority toxicants
SOP Title Priority toxicants
Year of 
publica-
tion
SOP 01 Intense smoking of cigarettes
Necessary for mainstream cigarette 
smoke generation 2012
SOP 02
Validation of analytical methods of tobacco product contents 
and emissions Describes method validation 2017
SOP 03
Determination of tobacco-specific nitrosamines in mainstream 
cigarette smoke under ISO and intense smoking conditions Mainstream NNK, NNN (emissions) 2014
SOP 04 Determination of nicotine in cigarette tobacco filler Nicotine (content) 2014
SOP 05
Determination of benzo[a]pyrene in mainstream cigarette 
smoke
Mainstream benzo[a]pyrene 
(emissions) 2015
SOP 06 Determination of humectants in cigarette tobacco filler
Propylene glycol, glycerol, triethylene 
glycol (content) 2016
SOP 07
SOP 08
SOP 09
Determination of ammonia in cigarette tobacco filler
Determination of aldehydes in mainstream cigarette smoke 
under ISO and intense smoking conditions
Determination of volatile organics in mainstream cigarette 
smoke under ISO and intense smoking conditions
Ammonia (content)
Acetaldehyde, acrolein, formaldehyde 
(emissions)
1,3-Butadiene, benzene (emissions)
2016
2018
2018
SOP 10
Determination of nicotine and carbon monoxide in 
mainstream cigarette smoke under intense smoking 
conditions
Mainstream nicotine and CO 
(emissions) 2016
 
CO: carbon monoxide; ISO: International Organization for Standardization; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; 
NNN: N´-nitrosonornicotine; SOP: standard operating procedure.
8.4.2 Overview of methods for the remaining priority toxicants
The priority toxicants for which standardized WHO TobLabNet SOPs are not 
available are described below, with published methods for their quantification in 
tobacco products and mainstream smoke.
Aldehydes (butyraldehyde, crotonaldehyde, propionaldehyde).
Ding et al. (118) reported a significant improvement in terms of ease of use, 
efficiency and environmental friendliness to previous methods for the analysis of 
acetaldehyde, acrolein, acetone, crotonaldehyde, formaldehyde, propionaldehyde 
and methyl ethyl ketone. The method involves use of a double filter (Cambridge 
pads, one pre-treated with dinitrophenylhydrazine and one dry) to trap and 
derivatize carbonyls in mainstream smoke simultaneously. The hydrazones are 
then quantified by ultra-high-pressure liquid chromatography (LC) coupled 
with tandem mass spectrometry (MS/MS) with a 4-min run time. The accuracy 
of the method, determined from spiking at low, medium and high levels, was 
83–106%, and its precision, determined from 30 replicate measurements of 
reference cigarette smoke (3R4F), was < 20% relative standard deviation for all 
target analytes. The limits of detection of the WHO priority toxicants were 2.7 
µg for acetaldehyde, 0.1 µg for acrolein, 0.2 µg for crotonaldehyde, 2.4 µg for 
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formaldehyde and 0.6 µg for propionaldehyde. This method is ideal for regulatory 
analyses, as it can be used with linear smoking machines, which greatly increases 
sample throughput.
Researchers at the China National Tobacco Corporation established a 
simple method for rapid determination of acrolein, acetone, propionaldehyde, 
crotonaldehyde, butanone and butyraldehyde in mainstream smoke (119). 
Although the analysis time is short (4 min), data mining of the full and daughter 
scans must be conducted to overcome difficulties in separating and quantifying 
isomers of acetone–propionaldehyde and butanone–butyraldehyde with this 
atmospheric pressure chemical ionization MS/MS technique. The results obtained 
with a reference cigarette (3R4F, 35-mL puff volume, eight puffs) are consistent 
with those reported in the literature. The limits of detection of the WHO priority 
toxicants were 0.007 µg/L for acrolein, 0.021 µg/L for acetone, 0.008 µg/L for 
propionaldehyde, 0.004 µg/L for crotonaldehyde, 0.012 µg/L for butanone and 
0.006 µg/L for butyraldehyde. Modifications were made to the chemical ionization 
source in order to introduce the gas sample directly into the ionization region.
In another reported method, mainstream smoke from cigarettes was 
collected in sulfuric acid (20%) and ascorbic acid (25 mmol/L) impingers 
(120), and a dispersive liquid–liquid microextraction method was used to 
simultaneously extract the solution and convert benzaldehyde, butyraldehyde 
and furfural into their hydrazone derivatives, which were then quantified by 
high-performance LC. The matrix spike recovery was 88.0–109%, and the relative 
standard deviation for inter- and intra-day assays were <  8.50%. The limits of 
detection of the WHO priority toxicants were 14.2 µg/L for benzaldehyde, 21.3 
µg/L for butyraldehyde and 7.92 for furfural. This method is quicker, simpler and 
less expensive than previously published liquid phase microextraction methods 
for the analytes tested.
Aromatic amines (1-aminonaphthalene, 2-aminonaphthalene, 3-aminobiphenyl, 
4-aminobiphenyl)
In another method, the gas (0.6 M hydrochloric acid impinger) and particulate 
(glass-fibre filter) phases of mainstream smoke were collected, and the resulting 
acid solution was used to extract the filter in an ultrasonic bath (121). The extract 
was cleaned by passage through two solid-phase extraction cartridges of different 
polarity and separated on a phenyl-hexyl column. Nine aromatic amines were 
quantified by LC–MS/MS. The method was validated by spiking the target analytes 
into the extract from a reference cigarette (3R4F) at three levels (low, medium, 
high). Recovery of the WHO priority toxicants was 84.8–97.8%, and intra- and 
inter-day precision was < 9% and < 14%, respectively. The limits of detection for 
the WHO priority toxicants were 0.08 ng/cigarette for 1-aminonaphthalene, 0.09 
ng/cigarette for 2-aminonaphthalene, 0.05 ng/cigarette for 3-aminobiphenyl and 
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0.03 ng/cigarette for 4-aminobiphenyl. This method is similar to that reported by 
Xie et al. (122), but gave better separation and baseline resolution of the target 
aromatic amines.
Deng et al. (123) used a novel dispersive liquid–liquid microextraction 
clean-up method and faster ultraperformance convergence chromatography 
MS/MS to quantify nine aromatic amines in mainstream smoke. This approach 
resulted in an instrument run time of 5 min, a substantial improvement over the 
30 min required for the high-performance LC method of Zhang et al. (121). In 
this method, supercritical CO2 is used as the primary mobile phase to ensure 
higher flow rates with a lower pressure drop across the column and faster run 
times. The method was validated with a reference cigarette (3R4F). The recovery 
from spiked (low, medium, high) mainstream smoke extracts of the 3R4F was 
69.4–120% for the WHO priority toxicants. The limits of detection of the WHO 
priority toxicants were 0.29 ng/cigarette for 1-aminonaphthalene, 0.21 ng/
cigarette for 2-aminonaphthalene, 0.02 ng/cigarette for 3-aminobiphenyl and 
0.03 ng/cigarette for 4-aminobiphenyl.
Hydrocarbons (isoprene, toluene)
Sampson et al. (124) reported an automated, high-throughput method for accurate 
quantification of a broad range of hazardous VOCs, including acrylonitrile, 
benzene, butyraldehyde, 1,3-butadiene and toluene, in mainstream smoke. The 
gas phase was collected into a polyvinyl fluoride gas sampling bag, and isotopically 
labelled analogues were added as internal standards to account for any losses due 
to handling and ageing. The particle phase was collected onto a glass-fibre filter 
and spiked with internal standards. After heating, the bags and filter headspace 
were sampled by automated solid-phase microextraction and quantified by gas 
chromatography (GC) with mass selective detection. The method was validated 
with reference cigarettes (1R5F and 3R4F) smoked under ISO and HCI puffing 
regimens. The results were comparable to those in other reports, except for 
toluene, which was found at a level ~30% lower than in previous reports. The 
inter- and intra-run precision was ≤a20%. There was a high correlation (0.97) 
between toluene and m- and p-xylene levels in mainstream smoke. This method 
was later used by the same group to quantify the target analytes in 50 US 
commercial brands (125). The limits of detection of the WHO priority toxicants 
were not reported in either article; however, the lowest calibration standards 
used were 0.14 parts per billion by volume for all WHO priority toxicants except 
benzene, which was 0.1 parts per billion by volume.
Phenols (catechol, m-, p-, o-cresols, phenol, hydroquinone, resorcinol)
A simple, precise method for quantifying WHO priority phenols in mainstream 
smoke was reported by Saha et al. (126). The method involves single-drop 
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microextraction and LC–MS/MS to reduce organic solvent consumption, 
shorten sample preparation time and eliminate the derivatization steps required 
in previously published GC–MS methods. The limits of detection of the WHO 
priority toxicants were 0.30 ng/mL for catechol, 0.05 ng/mL for o- and p-cresol, 
0.15 ng/mL for phenol, 0.30 ng/mL for hydroquinone and 0.20 ng/mL for 
resorcinol. The method reported by Wu et al. at Labstat International (127) with 
LC–MS/MS improved on the Health Canada methods (T-114, T-211) by use of 
a shorter analytical column with smaller particle size to resolve the three cresol 
positional isomers fully.
Other organic compounds (acetone, acrylonitrile, pyridine, quinoline)
A multi-analyte method that includes acrylonitrile is discussed above in the section 
on hydrocarbons, and a multi-analyte method that includes acetone is discussed 
in the section on aldehydes. Qualitative two-dimensional chromatography time-
of-flight MS methods for the analysis of organic compounds in the vapour (128) 
and particle phases (129) of mainstream tobacco smoke were reported by tobacco 
industry researchers. These methods are not suitable for testing emissions but 
could be useful for regulatory purposes to differentiate mainstream tobacco smoke 
emissions resulting from different product designs or to identify adulteration.
Metals and metalloids (arsenic, cadmium, lead, mercury)
Traditional sample collection methods for quantifying cadmium in mainstream 
smoke were critically evaluated (130). A platinum trap was used to determine 
breakthrough in two different sample collection methods: electrostatic 
precipitation and Cambridge filter pad. The detection limit of cadmium that had 
passed through the primary traps to the platinum traps was 0.30 ng/cigarette. 
Cadmium breakthrough from the Cambridge filter was significant (4–23% 
of the sample) but was negligible with electrostatic precipitation (<  1%). This 
technique was used by Fresquez et al. (131) in a high-throughput method for the 
analysis of mercury in the gas phase of cigarette and little cigar smoke emitted 
by ISO and HCI puffing regimens. The method is much quicker, simpler and 
more environmentally friendly than previously reported methods, because it 
eliminates the need for impingers, strong oxidizing agents (e.g. permanganate) 
and strong acids (e.g. sulfuric acid). The limit of detection was 0.27 ng cadmium/g 
in tobacco and 0.097 ng mercury/cigarette. The same team used high-throughput 
methods to establish the amounts of all WHO priority toxicant metals in the 
tobacco filler (content) of 50 brands of cigarettes on the United States market 
(132). Microwave digestion was used for sample preparation, except for mercury, 
which was introduced directly into the analyser. The analytical instrumentation 
included a direct combustion analyser for mercury and an inductively coupled 
plasma MS for all other elements except arsenic and selenium, which were run 
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separately with a different inductively coupled plasma MS method. The accuracy 
of the method was determined with standard tobacco reference materials, and the 
results were within the target ranges and the results for WHO priority toxicant 
metals, except for lead, which was slightly lower (4%) than the lower range of the 
target value for the Oriental tobacco reference material. The limits of detection 
of the WHO priority toxicants in tobacco were 0.082 µg/g (magnetic sector) and 
0.25 µg/g (quadrupole) for arsenic, 0.23 µg/g for cadmium, 0.16 µg/g for lead and 
0.00063 µg/g for mercury.
Other constituents (hydrogen cyanide, nitric oxides)
Hydrogen cyanide was quantified in mainstream smoke by collecting smoke 
samples on a sodium hydroxide-treated Cambridge filter pad and quantified by 
ion chromatography with pulsed amperometric detection (133). In comparison 
with the traditional continuous flow analyser method, the filter-based method 
offers convenience, greater accuracy and a wider linear quantification range. 
The method performance was evaluated by spiking hydrogen cyanide onto 
filters containing particulate from commercial cigarettes made of blended and 
flue-cured tobaccos. The mean recovery was 97%, and the intra- and inter-day 
relative standard deviation was < 6%. The limit of detection of hydrogen cyanide 
was 3 µg/L for a 25-µL injection loop. Mahernia et al. (134) used polarography 
to measure hydrogen cyanide concentrations in 50 large cigars and cigarettes 
purchased in the Islamic Republic of Iran. Mainstream smoke was drawn from 
each tobacco product with a pump and passed through a glass tube containing 
sodium hydroxide (0.1 M). The concentration of the cyanide was determined by 
fortifying the solution with known quantities of cyanide and using the standard 
addition method. The hydrogen cyanide level in the tobacco products was 17.6–
1550 µg per rod. Limits of detection for hydrogen cyanide were not provided. No 
recent methods for the analysis of nitric oxides were found.
8.5 Update on variations in toxicants among brands
The variations in toxicants reported in mainstream tobacco smoke generated by 
standardized machine smoking methods, the HCI puffing regimen for cigarettes 
and little cigars and the Beirut puffing regimen for waterpipe tobacco are 
summarized in Table 8.4. Variations in toxicants in the tobacco filler (content) of 
cigarettes, little cigars, waterpipe tobacco and waterpipe charcoal are summarized 
in Table 8.5. More research is needed on emissions of WHO priority toxicants 
from the increasingly popular, newer tobacco products (in comparison with 
cigarettes) in order to determine the 10th, 25th, 75th and 90th percentiles, so 
that global comparisons can be made as a first step towards establishing limits for 
the WHO priority toxicants.
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Table 8.4. Variations in WHO priority toxicants, expressed as mass per rod or session (waterpipe), in 
mainstream smoke from combustible products
Toxicant Cigarettesa Little cigarsa Waterpipes
Aldehydes
Acetaldehyde (µg) 1198–1947 (118) (USA) NR 120–2520 (135) 
Acetone (µg) 385–724 (118) (USA) NR 20.2–118 (135)
Acrolein (µg) 107 –169 (118) (USA) 105–185 (136) (USA) 10.1–892 (135)
Crotonaldehyde (µg) 25–72 (118) (USA) NR NR
Formaldehyde (µg) 55–108 (118) (USA) NR 36–630 (135)
Propionaldehyde (µg) 116–232 (118) (USA) NR 5.71–403 (135)
Aromatic amines
1-Aminonaphthalene (ng) 4.31–33.37 (121) (China) NR 6.20 (135) 
2-Aminonaphthalene (ng) 0.89–4.60 (121) (China) NR 2.84 (135) 
3-Aminobiphenyl (ng) 1.46–4.68 (121) (China) NR < 3.30 (137) (Germany)
4-Aminobiphenyl (ng) 0.38–5.95 (121) (China) NR
Hydrocarbons
Benzene 58.7–128.5 (125) (USA) NR 271 (135)
1,3-Butadiene 67.8–118.3 (125) (USA) NR Present (138)a
Isoprene NR NR 4.00 (135)
Toluene 81–178 (125) (USA) NR 9.92 (135)
Polycyclic aromatic hydrocarbons
Benzo[a]pyrene (ng) NR 17–32 (139) (USA) LOD–307 (135)
Pyreneb (ng) NR NR 30–12 950 (135)
Tobacco-specific 
N-nitrosamines
NAB (ng) NR NR 8.45 (135)
NAT (ng) NR NR 103 (135)
NNK (ng) NR 438–995 (139) (USA) LOD–46.4 (135)
NNN (ng) NR 434–1550 (139) (USA) 34.3 (135)
Alkaloids
Nicotine, mg NR 1.85–6.15 (140) (USA) > 0.01–9.29 (135)
Phenols
Catechol (µg) 49.6–118 (127) (Canada) NR 166–316 (135)
m-Cresol (µg) 1.93–6.92 (127) (Canada) NR NR
p-Cresol (µg) 5.28–17.7 (127) (Canada) NR NR
m+p-Cresol (µg) 7.24–24.6 (127) (Canada) NR 2.37–4.66 (135)
o-Cresol (µg) 2.21–7.93 (127) (Canada) NR 2.93–4.41 (135)
Phenol (µg) 8.34–32.7 (127) (Canada) NR 3.21–58.0 (135)
Hydroquinone (µg) 60.1–140 (127) (Canada) NR 21.7–110.7 (135)
Resorcinol (µg) 1.25–2.46 (127) (Canada) NR 1.69–1.87 (135)
Other organic compounds
Acetone NR NR 20.2–118 (135)
Acrylonitrile (µg) 19.7–37.7 (125) (USA) NR Present (138)a
Pyridine NR NR 4.76 (135)
Quinoline NR NR BLQ
Metals and metalloids
Arsenic (ng) NR NR 165 (135)
Cadmium (ng) NR NR < 100 (141) (UK)
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Chromiumc (ng) 0.60–1.03 (142) (USA) NR 250–1340 (135)
Lead (ng) NR NR 200–6870 (135)
Mercury (ng) NR 5.2–9.6 (131) (USA) < 100 (141) (UK)
Other priority toxicants
Carbon monoxide, mg NR  NR 5.7 - 367 (135)
Hydrogen cyanide NR NR NR
Nitric oxide, mg
140.9–266.8 (143) (Russian 
Federation) NR 0.325–0.440 (135)
BLQ: below limit of quantification; LOD: below the limit of detection; NAB: N´-nitrosoanabasine; NAT: N´-nitrosoanatabine; NNK: 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN: N´-nitrosonornicotine; NR: not reported; UK: United Kingdom.  
a Health Canada intense puffing regimen: 55 mL puff volume, 2-s puff duration every 30 s, 100% vent blocking).  
b Present, presence in mainstream smoke extrapolated from urinary biomarker.  
c Currently not a TobReg priority toxicant.
Table 8.5. Variations in WHO priority toxicant content in tobacco filler or charcoal (waterpipe) of 
combustible tobacco products, expressed as mass of chemical per mass of tobacco (g)
Toxicant Cigarettes Little cigars Waterpipe tobacco Waterpipe charcoal
Nicotine (mg)
16.2–26.3 (144)
 (USA)
10.5–17.8 (145) 
(Pakistan) 10.3–19.1 (144) (USA)
0.48–2.28 (146)
(USA)
1.8–41.3 (147)
(Jordan) NA
Benzo[a]pyrene (ng) NR NR NR
1–26 (148, 149)
(Lebanon, USA)
Pyrene (ng) NR NR NR
6–170 (148, 149)
(Lebanon, USA)
Arsenic (µg)
0.22–0.36 (132)
(USA) NA
0.062 (0.023)b (150)
(Egypt)
0.018 (0.013) (150)
(Egypt)
Cadmium (µg)
1.0–1.7 (132)
(USA) NA
0.34 (0.007) (150)
(Egypt)
0.005 (0.017)b (150)
(Egypt)
Chromiuma (µg)
1.3–3.1 (132)
(USA) NR
0.15–0.37 (151)
(USA, Middle East)
0.161–8.32 (152)
(Worldwide)
Lead (µg)
0.60–1.16 (132)
(USA) NR
0.15 (0.008)b (150)
(Egypt)
0.97 (0.01)b (150)
(Egypt)
Mercury (µg)
0.013–0.020 (132)
(USA)
0.017–0.024 (132)
(USA) NR NR
 
NR: not reported. a Currently not a TobReg priority toxicant. b Mean (relative standard deviation).
8.6 Criteria for future re-evaluation of toxicants on the list
The criteria for selecting priority toxicants and the overall recommendations 
of TobReg indicate four areas that should guide periodic re-evaluation of the 
priority list.
Toxicological profile of specific contents and emissions: the priority list 
of toxicants was identified to help WHO  FCTC Parties and Member States to 
fulfil the requirements of Articles 9 and 10 of the WHO FCTC. Monitoring of 
the priority list is viewed as an initial step towards regulating the contents and 
emissions of combustible tobacco products. Up-to-date scientific knowledge on 
the toxicity of the selected emissions is critical to ensure the continuous relevance 
of the priority list and to inform future regulatory measures.
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Validated methods: the contents and emissions of priority toxicants 
must be measured according to WHO TobLabNet SOPs to ensure accurate, 
reproducible results that can serve as a basis for regulatory measures. Development 
of standardized methods by TobLabNet is guided by robust, well-characterized, 
published protocols, which are reviewed, tested and further validated by 
TobLabNet. Advances in analytical chemistry and toxicological data are reviewed 
periodically by TobLabNet to identify priorities for testing methods.
Brand variations: according to the partial guidelines on Articles 9 and 10 
to the WHO FCTC, the tobacco industry is ultimately responsible for generating 
and reporting data on priority contents and emissions for each brand. Such data 
can be generated according to the WHO TobLabNet SOPs, as noted in the decision 
of the eighth COP of the WHO  FCTC in October 2018 (FCTC/COP8(21)). 
Emissions of many priority chemicals have not been measured systematically in 
all commercially available products. Thus, periodic review of new reports on the 
chemical composition of combustible tobacco products establishes a frame of 
reference for understanding variations in emissions among product types and the 
lowest practicably achievable levels of priority toxicants.
Correlations among constituents within a brand: a positive correlation 
among several toxicants would suggest that the levels of one could serve as a 
proxy for several other toxicants in a regulatory strategy. A negative correlation 
would suggest that mandatory lowering of one toxicant could result in increases 
in the levels of negatively correlated toxicants. While caution should be exercised 
in relying on these assumptions, close monitoring of the relations among 
constituents could provide insight for future selection of toxicants for mandatory 
reduction.
8.7 Criteria for selection of new toxicants
Addition of new constituents to the non-exhaustive priority list should be con-
sidered in the future. Several criteria for the selection of new toxicants are listed 
below.
Substantial evidence of risk to human health: for instance, Talhout et al. 
(153) listed 98 hazardous smoke constituents on the basis of the risk for human 
inhalation. In addition, the FDA identified 93 HPHCs for potential reporting and 
regulation (154). The HPHC list comprises chemicals and chemical compounds 
in tobacco or tobacco smoke that are taken into the body (inhaled, ingested or 
absorbed) and cause or have the potential to cause direct or indirect harm to 
users and non-users of tobacco products. The FDA selected constituents that had 
been identified as known, probable or possible human carcinogens by either the 
IARC, the United States Environmental Protection Agency or the United States 
National Toxicology Program, as well as those identified by the United States 
National Institute for Occupational Safety and Health as potential occupational 
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carcinogens. Constituents identified by the United States Environmental 
Protection Agency or the Agency for Toxic Substances and Disease Registry 
as having adverse respiratory or cardiac effects, constituents identified by the 
California Environmental Protection Agency as reproductive or developmental 
toxicants and constituents reported in the literature as contributing to abuse 
liability were also included. Forty toxic and carcinogenic constituents are listed 
on both the FDA HPHC list and by Talhout et al. (153) but are not currently 
on the TobReg list (Table 8.6). These constituents could be prioritized for future 
consideration by TobReg, for instance by applying hazard indices and generating 
data on variations in their levels among brands.
Table 8.6. Constituents to be considered for future inclusion on the TobReg priority toxicant list
Constituent
Health effect 
(154)
Risk associated with inhalation (mg/
m3) (153)
Acetamide CA 5.0 × 10–4 (cancer)
Acrylamide CA 8.0 × 10–3 (cancer)
3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole CA 1.4 × 10–6 (cancer)
2-Amino-3-methyl)-9H-pyrido[2,3-b]indole CA 2.9 × 10–5 (cancer)
2-Amino-6-methyldipyrido[1,2-a:3’,2’-d]imidazole CA 7.1 × 10–6 (cancer)
2-Amino-3-methylimidazo[4,5-f]quinoline CA 2.5 × 10–5 (cancer)
2-Amino-9H-pyrido[2,3-b]indole CA 8.8 × 10–5 (cancer)
2-Aminodipyrido[1,2-a:3´,2´-d]imidazole CA 2.5 × 10–5 (cancer)
Benz[a]anthracene CA, CT 9.1 × 10–5 (cancer)
Beryllium CA 4.2 × 10–6 (cancer)
Chromium CA, RT, RTD 8.3 × 10–7 (cancer)
Chrysene CA, CT 9.1 × 10–4 (cancer)
Cobalt CA, CT 5.0 × 10-4 (respiratory)
Dibenz[a,h]anthracene CA 8.3 × 10–6 (cancer)
Dibenzo[a,e]pyrene CA 9.1 × 10–6 (cancer)
Dibenzo[a,h]pyrene CA 9.1 × 10–7 (cancer)
Dibenzo[a,i]pyrene CA 9.1 × 10–7 (cancer)
Dibenzo[a,l]pyrene CA 9.1 × 10–7 (cancer)
Ethyl benzene CA 7.7 × 10–1 (liver and kidney)
Ethyl carbamate CA, RDT 3.5 × 10–5 (cancer)
Ethylene oxide CA, RT, RDT 1.1 × 10–4 (cancer)
Hydrazine CA, RT 2.0 × 10–6 (cancer)
Indeno[1,2,3-cd]pyrene CA 9.1 × 10–5 (cancer)
Methyl ethyl ketone RT 5.0 (developmental)
1-Methyl-3-amino-5H-pyrido[4,3-b]indole CA 1.1 × 10–5 (cancer)
5-Methylchrysene CA 9.1 × 10–6 (cancer)
Naphthalene CA, RT 3.0 × 10–3 (nasal)
Nickel CA, RT 9.0 × 10–5 (lung fibrosis)
N-Nitrosodiethanolamine CA 1.3 × 10–5 (cancer)
N-Nitrosodiethylamine CA 2.3 × 10–7 (cancer)
N-Nitrosodimethylamine CA 7.1 × 10–7 (cancer)
N-Nitrosomethylethylamine CA 1.6 × 10–6 (cancer)
N-Nitrosopiperidine CA 3.7 × 10–6 (cancer)
193
Updated priority list of toxicants in combusted tobacco products
N-Nitrosopyrrolidine CA 1.6 × 10–5 (cancer)
Polonium-210 CA 925.9 (cancer)
Propylene oxide CA, RT 2.7 × 10–3 (cancer)
Selenium RT 8.0 × 10–4 (respiratory)
Styrene CA 9.2 × 10–2 (neurotoxicity)
Vinyl acetate CA, RT 2.0 × 10–1 (nasal)
Vinyl chloride CA 1.1 × 10–3 (cancer)
 
CA: carcinogen; CT: cardiovascular toxicant; RDT: reproductive or developmental toxicant; RT: respiratory toxicant.
Constituents in the same chemical class as current priority toxicants: the 
rationale for including such constituents is that several compounds can be 
analysed simultaneously with the same analytical technique. Examples include 
metals and other trace elements, as well as PAHs. The elements beryllium, 
chromium, cobalt, nickel, polonium-210 and selenium, listed in Table  8.6, 
can be analysed by a multi-element method with cadmium and other metals 
already on the TobReg priority list. At least 23 different PAHs could be analysed 
with the same analytical technique (155). Eight PAHs listed in Table  8.4 – 
benz[a]anthracene, dibenz[a,h]anthracene, dibenzo[a,e]pyrene, dibenzo[a,h]
pyrene, dibenzo[a,i]pyrene, dibenzo[a,l]pyrene, indeno[1,2,3-cd]pyrene and 
naphthalene – could be analysed with benzo[a]pyrene. It has been demonstrated 
that the levels of these PAHs correlate negatively with those of nitrate and TSNAs; 
however, the relations depend on tobacco type (156). In addition, in many studies 
of human exposure, urinary levels of 1-hydroxypyrene or phenanthrene tetraols, 
which are biomarkers of exposure to the non-carcinogenic PAHs pyrene and 
phenanthrene, respectively, are analysed to assess exposure to PAHs (157, 158). 
As these two compounds are present in tobacco smoke at much higher levels 
than benzo[a]pyrene and other carcinogenic PAHs, simultaneous analysis of 
pyrene and phenanthrene with benzo[a]pyrene could provide information for 
future monitoring of changes in human exposure due to reductions in the levels 
of these constituents in smoke.
Chemicals or chemical compounds that are precursors to toxic 
emissions in tobacco smoke: for instance, nitrite and nitrate in tobacco leaf 
are precursors to the carcinogenic nitrosamines NNK and NNN in tobacco 
and smoke and to nitrogen oxides in smoke. Well established data from both 
academic and industry researchers show that nitrate and nitrite in tobacco 
significantly affect the composition of tobacco smoke (159, 160). In addition, 
nitrate levels in tobacco affect the levels of ammonia in cigarette smoke, which 
in turn influences smoke pH and the bioavailability of nicotine. Therefore, nitrite 
and nitrate levels in tobacco filler of cigarettes are important predictors of the 
toxicological properties of tobacco smoke. The current TobReg priority list 
includes nitric oxides in the gas phase of tobacco smoke; however, analysis of 
such constituents of tobacco smoke may be complicated, with inconsistent results 
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among laboratories. Therefore, analysis of nitrites and nitrates in tobacco filler 
would be a robust, informative alternative.
Constituents that contribute to the palatability and/or addictiveness of 
tobacco products: the impact of additives on the attractiveness and abuse liability 
of tobacco products has been reviewed (161). For instance, sugars in tobacco filler 
of combustible products are a group of additives that could be considered for 
future monitoring and regulation. Sugars in tobacco contribute to the formation 
of acetaldehyde in tobacco smoke (162, 163), potentially contributing to the 
addictive potential of tobacco smoke, either directly or through the formation of 
harman (32–34).
8.8 Research needs and regulatory recommendations
8.8.1 Research needs, data gaps and future work
This review of the toxicity, analytical methods and reports on the levels of the 
priority toxicants in combustible tobacco products indicates that the following 
areas require research.
Despite toxicological evidence of the importance of the 39 priority 
toxicants and the availability of analytical methods, brand- and product-specific 
information on the levels of emissions of toxicants in diverse combustible 
tobacco products is lacking. Information on variations in the levels of toxicants 
in different brands and types of combustible tobacco products (e.g. cigarettes, 
cigarillos, waterpipes) could justify regulation of specific emissions. In view of the 
widespread global use of combustible products manufactured locally (e.g. bidis) 
or made by consumers (e.g. roll-you-own cigarettes), better characterization of 
these products is essential.
Evaluation of standardized methods for the analysis of certain 
constituents in tobacco filler (contents) is a more robust alternative to 
measurements in cigarette smoke in some cases. For instance, nitrate and nitrite 
levels in tobacco strongly influence the levels of nitric oxides in tobacco smoke. 
Analysis of these constituents in tobacco filler will require less time and resources 
and could provide more consistent data from laboratories than analysis of nitric 
oxide emissions. Furthermore, the validated methods can be used directly for 
the analysis of smokeless tobacco products. Carcinogenic TSNAs are formed in 
tobacco during processing, and the contribution of pyrolysis to their levels in 
smoke, if any, is minimal. Therefore, the levels in tobacco are strong predictors of 
the levels in cigarette smoke (68, 86, 164, 165).
While TobReg previously recommended that upper limits for emissions of 
toxicants in tobacco products should be set on the basis of established toxicological 
principles (166), the extent to which toxicant levels must be reduced, as a 
complex mixture or singly, in order to minimize the harm caused by tobacco 
products remains unknown. Laboratory in vitro and in vivo studies are required 
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to better understand the effect of the complex chemistry of tobacco products 
on the carcinogenic and toxic potency and the toxicity thresholds of individual 
constituents. Studies of human exposure and molecular epidemiology, including 
studies of prospective cohorts, would indicate the optimal reductions in tobacco 
toxicant levels necessary to achieve the maximum public health benefit.
Research is needed to better understand which ingredients or 
constituents contribute to the addictiveness and palatability of tobacco 
products, either independently or by increasing the bioavailability of nicotine. 
This information will have an impact on future regulatory approaches. For 
instance, it has been suggested that measures to reduce the attractiveness and 
palatability of tobacco products might have a greater impact on public health 
than reducing toxic emissions (167).
Current work to prioritize toxic emissions and the development of 
methods for product testing should be extended to human exposure and 
health outcomes. The smoker–cigarette interaction is more complex than any 
single machine-based regimen (1), and it is not clear whether reductions in per-
milligram nicotine emissions will lead to corresponding reductions in human 
exposure. Laboratory capacity should be built for analysing biomarkers of the 
priority toxicants in human biological samples. Analyses of spent cigarette 
filters might be considered as a less expensive measure of human toxicant intake 
(69, 168–170). In addition, research should be conducted to identify suitable 
biomarkers of potential harm that could be used to evaluate the long-term health 
impact of future product standards.
8.8.2 Regulatory recommendations and support to Parties
TobLabNet has completed validation of methods for measuring selected emissions 
in cigarette tobacco filler and in mainstream cigarette smoke, and the SOPs for 
these methods are available on the WHO Tobacco Product Regulation website. 
It is recommended that Parties consider requiring cigarette manufacturers to 
conduct emission testing in accordance with the TobLabNet SOPs and to report 
the results to national authorities. This recommendation is part of a decision by 
the eighth COP (FCTC/COP8(21)), which encourages Parties to acknowledge 
and implement the WHO TobLabNet methods as appropriate and emphasizes 
the need for further support of TobLabNet’s capacity-building activities by WHO.
Assessment of studies on the toxicity of the extended list of priority 
toxicants has demonstrated their continued role in the toxic and addictive potential 
of combustible tobacco products. The methods validated by TobLabNet can be 
used for other toxicants on the extended priority list, as reviewed in this report. 
Therefore, it is recommended that Parties consider requesting, as applicable and 
appropriate, manufacturers to report on the emissions of the additional priority 
toxicants with methods based on the TobLabNet SOPs.
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SOPs for the analysis of priority contents and emissions for which 
methods validated by TobLabNet are not yet available should be developed next, 
as recommended by TobReg (166): cadmium and lead in tobacco; nicotine in 
waterpipe smoke; and nicotine, TSNAs and benzo[a]pyrene in smokeless tobacco.
Of the constituents not currently on the priority list, it is recommended 
that Parties consider requiring that manufacturers report on the levels of nitrate 
and nitrite in tobacco filler (content), as a potential proxy for nitric oxide emissions. 
An easy, cost–effective method for the analysis of nitric oxide in tobacco smoke is 
not yet available. Nitrate and nitrite in aqueous tobacco extracts can be analysed 
by adapting the TobLabNet method for ammonia in tobacco filler (SOP 07). In 
addition, given their importance to human biomonitoring research, pyrene and 
phenanthrene (and potentially other carcinogenic PAHs listed in Table 8.6) could 
be monitored simultaneously with benzo[a]pyrene by the TobLabNet method.
It is recommended that reference tobacco product materials be made 
available to TobLabNet laboratories participating in WHO method validation 
to aid in determining the success of method transfer, in terms of the accuracy, 
repeatability and reproducibility of each method. Suitable sample matrix-matched 
certified and standard reference materials can be analysed at the same time as 
test materials as a form of quality control for the evaluation of data generated in 
interlaboratory testing. Commercially available certified and standard reference 
materials are listed in Table 8.7.
Table 8.7. Certified and standard reference materials suitable for quality control of samples
Name Description Issuer Certified values
SRM 3222 Cigarette tobacco filler NIST Nicotine, NNN, NNK, VOCs
1R6F Reference cigarette KTRDC
Mainstream smoke emissions, puff count for 
ISO and HCI puffing, filler content, physical 
properties
RT5 High-TSNA ground tobacco KTRDC
Nicotine, nornicotine, anabasine, anatabine, 
NNN, NAT, NAB, NNK, moisture
RT4 Burley tobacco
RTDAC Dark, air-cured, ground tobacco
RT3 Turkish Oriental ground tobacco
RT2 Flue-cured ground tobacco
RTDFC Dark fire-cured ground tobacco
1R6F (RT1) Ground filler
1R5F (RT7) Ground filler
STRP 1S1 Loose leaf chewing tobacco NCSU
Content values are not certified, but may be 
reported in the scientific literature
STRP 2S1 Loose leaf chewing tobacco
STRP 1S2 Dry snuff
STRP 1S3 Moist snuff
STRP 2S3 Moist snuff
197
Updated priority list of toxicants in combusted tobacco products
CRP1 Snus
CRP2 Moist snuff
CRP3 Dry snuff
CRP4 Loose leaf chewing tobacco
 
HCI: Health Canada intense; ISO: International Organization for Standardization; KTRDC: University of Kentucky Center for Tobacco 
Reference Products; NAB: N′-nitrosoanabasine; NAT: N′-nitrosoanatabine; NCSU: North Carolina State University Smokeless Tobacco 
Reference Products; NIST: National Institute of Standards and Technology; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; 
NNN: N′-nitrosonornicotine; VOCs: volatile organic compounds.
It is recommended that a research agenda be prepared on which constituents 
contribute to the addictiveness and palatability of tobacco products, with identi-
fication or development of methods for their quantification in tobacco and smoke 
and establishment of ranges of emissions in various cigarette brands.
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9.1 Introduction
This section presents possible means of measuring and decreasing the levels of 
certain harmful agents in smokeless tobacco products, in conformity with the 
decision at the seventh session of the Conference of the Parties to the WHO FCTC 
in 2016 (COP7) (1). Global estimates suggest that 367 million people in all six 
WHO regions use smokeless tobacco (2), comprising almost 90% of adult tobacco 
consumption in south-east Asia (mainly Bangladesh and India), where its use 
exceeds that of combustible tobacco products (3). This section builds on several 
reports on smokeless tobacco that provide more detail on product chemistry (4, 5).
Smokeless tobacco products are complex and contain both inorganic and 
organic chemicals that contribute to their addictive, toxic or carcinogenic effects 
(6). Of the harmful chemicals in smokeless tobacco, TSNAs are the most abundant 
and include potent compounds, such as NNN and NNK, which are known human 
carcinogens; NNN is known to cause oral cancer (6). During cultivation and 
production, the levels of these agents or their precursors can be increased by soil 
uptake, biosynthesis of alkaloids and microbial activity, including the formation 
of mycotoxins, nitrite and TSNAs (4, 7). In certain product types, fire-curing can 
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increase the levels of harmful agents, such as VOCs and PAHs, while the inclusion 
of certain additives (areca nut, tonka bean, khat, diphenyl ether, caffeine, pH-
boosting agents) and chemicals, can increase addiction and carcinogenicity (4, 
5). Microorganisms play an important role throughout production, resulting 
in chemical changes during the production of tobacco products. Harmful and 
carcinogenic agents are generated throughout production (8, 9, 10).
The wide variety of smokeless tobacco products ranges from simple to 
elaborate hand-made and industrial preparations consisting of tobacco mixed 
with a wide spectrum of non-tobacco plant materials and chemical additives. 
Manufactured and cottage-industry products include tobacco leaves, loose flaked 
tobacco, finely minced tobacco, pulverized tobacco, pressed cakes, tars, gel-like 
pastes, tobacco-containing toothpaste and pressed pellets. Smokeless tobacco 
products can be generally subdivided into four main categories on the basis of 
key ingredients (a similar scheme was presented previously) (4, 6, 11):
 ■ category 1, which contains tobacco with few or no alkaline modifiers;
 ■ category 2, which contains tobacco and substantial amounts of alka-
line agents;
 ■ category 3, which contains tobacco, one or more alkaline agents and 
areca nut; and
 ■ category 4, which contains tobacco mixed with other chemical or 
plant ingredients with
 ■ additional bioactivity, such as stimulants.
Because of the constituents it contains, each product category harms health. The 
tobacco contained in these products contributes to their toxicity, carcinogenicity 
and addictiveness. Approximately 70 Nicotiana species are known; however, only 
a few are used to make smokeless tobacco products. In general, Nicotiana species 
have different levels of alkaloids (12, 13); the most commonly used species, N. 
tabacum (cultivated tobacco), has a moderate amount of nicotine, whereas N. 
rustica has extremely high levels (14). Some smokeless tobacco products contain 
N. glauca (tree tobacco), which has high concentrations of the tobacco alkaloid 
anabasine; accidental poisoning and fatalities have been associated with use of 
this species in a few cases (15, 16). The presence of different species of tobacco 
can result in exposure to different proportions of tobacco alkaloids, which can 
contribute to addictiveness, toxicity and carcinogenicity, as tobacco alkaloids are 
necessary precursors of TSNAs (10, 12, 14, 17, 18). The presence of nicotine, 
common to all smokeless tobacco products, promotes continued use and can 
result in repeated, often daily, exposure to carcinogens and toxicants (4).
Although tobacco contains thousands of chemicals (19), many of the 
carcinogenic agents in smokeless tobacco products are not present or are present 
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at very low concentrations in newly transplanted tobacco (17) but form and 
accumulate between cultivation and the finished product. Certain chemical 
constituents of tobacco are synthesized from metals and nitrate, which are 
absorbed by tobacco during growth (18). According to the soil characteristics 
and the environment in which tobacco is grown, certain microorganisms may 
occur naturally inside the plant (endophytes) or on its surface (epiphytes) (20, 
21). During cultivation, harvesting and processing, other microorganisms may 
be deposited on tobacco from air, water, soil or manure (if used) or introduced 
by human handling or as additives. The microbial communities present during 
production and in the final product can affect the product constituents. Smokeless 
tobacco production also includes steps such as fire-curing of green leaves, which 
can introduce additional chemical agents, such as VOCs, phenolic compounds 
and PAHs (22–24). During processes such as fermentation, ageing and storage, 
microorganisms are viable and metabolically active in tobacco (8–10, 25), and 
their presence can result in the generation of reactive agents such as nitrite and 
other harmful by-products (aflatoxins, endotoxins, TSNAs, other nitrosamines, 
ethyl carbamate) (9, 26, 27) (Table 9.1). Studies published by tobacco industry 
scientists have shown that toxicant levels can be lowered by changes in growing 
practices, manufacturing processes and continuous monitoring (19, 28).
Table 9.1. Potential sources of carcinogens, toxicants and biologically active compounds in smokeless 
tobacco products, originating mainly from soil, microbial action, fire-curing and additives
Agent class
IARC-classified carcinogens (groups 1, 
2A, 2B), toxicants or biologically active 
compounds Potential source or cause
Metals and metalloids
Group 1: arsenic, beryllium, cadmium, nickel 
compounds, polonium-210
Group 2A: inorganic lead compounds
Group 2B: cobalt sensitization: aluminium, 
chromium, cobalt, nickel
Dermal irritants: barium, mercury
Copper in areca nut may contribute to oral 
submucosal fibrosis 
Absorption from the soil or by deposition of soil 
particles on tobacco leaf surfaces; potentially 
present in other ingredients (betel leaf, slaked 
lime) used with tobacco
Nitrosation agents Group 2B: nitrite Generated by microorganisms
Mycotoxins
Group 1: aflatoxins (mixtures of )
Group 2B: aflatoxin M1, ochratoxin A,
sterigmatocystin Formed by fungi (Aspergillus)
Nitrosamines
Tobacco-specific N´-
nitrosoamines 
Group 1: N´-nitrosonornicotine,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol (NNAL)
Formed by microbial-generated nitrite followed 
by nitrosation during curing, fermentation and 
ageing (nitrite reacts with alkaloids)
Volatile N´-
nitrosoamines 
Group 2A: N-nitrosodimethylamine
Group 2B: N-nitrosopyrrolidine,
N-nitrosopiperidine, N-nitrosomorpholine, 
N-nitrosodiethanolamine
Formed by microbial-generated nitrite followed 
by nitrosation during curing, fermentation and 
ageing (nitrite reacts with certain secondary and 
tertiary amines)
 Nitrosoacids Group 2B: N-nitrososarcosine
Carbamates Group 2A: ethyl carbamate
Formed during fermentation (reaction of urea and 
ethanol) 
210
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
Polycyclic aromatic 
hydrocarbons
 
Group 1: benzo[a]pyrene
Group 2A: dibenz[a,h]anthracene
Group 2B: benz[a]anthracene, benzo[b]
fluoranthene, benzo[j]fluoranthene, 
benzo[k]fluoranthene, dibenzo[a,i]pyrene, 
dibenzo[a,i]pyrene, indeno[1,2,3-cd]pyrene, 
5-methylchrysene, naphthalene Deposited on tobacco during fire-curing
Volatile aldehydes
Group 1: formaldehyde
Group 2B: acetaldehyde Deposited on tobacco during fire-curing
Non-tobacco plant 
materials
Group 1: areca nut
Liver toxicant: tonka bean
Stimulant: khat, caffeine Additives
 
Source: reference 29.
Smokeless tobacco users are exposed to inorganic, organic and biological agents 
and their interactions. The areas of concern depend on product types and 
the region of the world because of different soil constituents (metals, nitrate, 
microbial communities), tobacco species grown, agricultural practices, product 
processing steps and permissible inclusion of certain additives.
9.2 Product composition
Tobacco products are highly complex mixtures that contain nicotine, Group 1 
carcinogens (as evaluated by IARC working groups) (6)) and toxic metals, such as 
arsenic, cadmium and lead (30). These products also contain nitrate, which can 
be metabolized by microbes to nitrite; nitrite initiates the formation of TSNAs 
and other nitrosamines (9, 31). Certain NOx gases present during fire-curing can 
also cause nitrosation (32). In particular, nitrosation of nornicotine yields N´-
nitrosonornicotine, a known human carcinogen (IARC Group 1) which is known 
to cause oral cancer (6). The concentrations of these agents in various smokeless 
tobacco products have been surveyed extensively (4–6, 33).
The concentrations of total and free nicotine vary widely among product 
types. Detectable concentrations of total nicotine in smokeless tobacco products 
range from < 0.2  mg/g to 95  mg/g (11, 14). High nicotine concentrations are 
found in products such as dry snuff and Sudanese toombak (14, 34). The high 
concentrations in certain products, such as toombak, gul, tobacco leaf and zarda, 
are attributed to use of the N. rustica variety of tobacco, a nicotine-enriched to-
bacco species (11, 14). For a given product, the percentage of nicotine that is 
unprotonated is calculated from the pH of the product and the appropriate pKa 
of nicotine (8.02) with the Henderson–Hasselbach equation (35). The pH of 
smokeless tobacco products has been reported to range from pH 4.6 to pH 11.8; 
in this range, < 0.1–99.9% of the nicotine present would be free nicotine (3). 
The highest pH values were observed for nass (36) and also iqmik which is used 
in Alaska (23). As nicotine is converted to free nicotine, it is more readily re-
leased from tobacco during use and passes across biological membranes (37–39). 
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Limiting both total nicotine concentrations and the permissible pH could main-
tain lower free nicotine concentrations in smokeless tobacco products.
Metals and metalloids are naturally present in soil (40), and a number 
of these and other inorganic compounds are absorbed into tobacco plant tissue 
(41) and are also present in smokeless tobacco products (4, 42–45). In a study by 
Golia et al. (41), certain metals, including cadmium, lead, zinc and copper, were 
in higher concentrations on tobacco leaf surfaces near the ground (primers) than 
on leaves higher up the tobacco stalk. This was the case for Oriental, flue and 
Burley tobaccos. It is possible that soils containing metals may be splashed on to 
tobacco leaves during rain or may be deposited on tobacco leaves that are spread 
out on the ground.
The levels of metals in smokeless tobacco products vary among countries. 
The amounts in products may be influenced by the soil content, pH (46) and 
industrial contamination (43, 47–48). The concentration of metals varies by 
product type and country of origin. High concentrations have been reported 
in products from Ghana, India and Pakistan, with higher levels of lead, nickel 
and chromium in products from Pakistan than in those from Ghana and India. 
Products from India had high iron and copper levels, while those from Ghana had 
higher levels of copper, iron and aluminium than those from the other countries 
(43). Swedish snus has a very low metal content (49) due to deliberate selection of 
tobacco (28) or other processes, such as washing tobacco leaves (28, 50).
The concentrations of total TSNAs range from < 0.5 to 12 630 µg/g, with 
the highest concentration in Sudanese toombak products. The highest values are 
consistently seen in products that undergo fermentation (e.g. toombak, khaini, dry 
snuff, moist snuff) (11, 14, 27, 51–53). Fermentation is used in tobacco processing 
to enhance taste but is characterized by microbial proliferation and active 
metabolism to nitrite, which reacts with natural tobacco alkaloids to form TSNAs 
(8, 9). The lowest TSNA concentrations are found in products such as snus and 
dissolvable oral tobacco that do not contain fermented tobacco. (“Dissolvables” 
are products that essentially include tobacco and other ingredients compressed 
into chewable tablets, wafer-like strips or elongated sticks.) Snus products that are 
not fermented but are pasteurized eliminate microorganisms and result in low 
TSNA concentrations such as that in moist snuff. Some products in India that are 
labelled “snus” have high TSNA levels (53).
A wide variety of microbes, including bacteria (Staphylococcus, Coryne-
bacterium, Lactobacillus, Enterobacter, Clostridium, Bacillus, Serratia and Escheri-
chia) and fungi (Aspergillus, Fusarium, Cladosporium, Candida, Alternaria and 
Acremonium), can generate nitrite. Some of these organisms are potentially 
harmful or pathogenic (26, 54, 55). Microbial production of nitrite is a major 
determinant of the concentrations of TSNAs and other nitrosamines in tobacco 
(9, 36, 56). A number of species, including Staphylococcus, Corynebacterium, 
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Lactobacillus and genera in the Enterobacteriaceae family, present in smokeless 
tobacco products contain a respiratory nitrate reductase and associated 
transporters that export nitrite (encoded in the nar gene operon) (57). Dry snuff 
also contains a periplasmic nitrate reductase (nap gene), mainly in species in the 
Enterobacteriaceae family, which may also result in the release of nitrite (58). In 
some species, nar genes are activated when oxygen levels decrease (59).
As tobacco is cured, tobacco cells rupture and release nitrate (31). 
Nitrate-reducing microbes can convert nitrate to nitrite under low-oxygen 
conditions. Certain bacteria can convert nitroalkanes (if present) to nitrite in 
the presence of oxygen (60). Nitrite that is not further metabolized is generally 
expelled due to its toxicity. Fermentation, ageing, storage and tightly sealed 
packaging, with low oxygen, provide conditions in which respiration by nitrate-
reducing bacteria involves generating and exporting nitrite (8–10). Regardless 
of how nitrite is formed, once formed, it can combine with alkaloids and other 
secondary and tertiary amines to form nitrosamines (31). Certain secondary or 
tertiary amines can also react with nitrite to form volatile nitrosamines, such as 
N-nitrosodimethylamine, and nitrosoacids (31).
9.3 Agricultural practices and manufacturing processes  
that result in the formation and accumulation of harmful 
compounds
Many of the harmful agents in tobacco products are at lower levels or almost 
entirely absent from freshly transplanted tobacco (61) but begin accumulating 
in the early stages of cultivation and curing. Growing tobacco involves a number 
of agronomic decisions – type or species of tobacco to be grown, harvest timing 
and procedures, types of fertilizers and agrichemicals and application rates – 
and environmental factors such as soil composition, climate and rainfall, which 
collectively determine the chemistry of a product (4).
The constituents of a finished smokeless tobacco product, including 
nicotine (in its various ionic forms), toxicants and carcinogens, result from the 
presence of inorganic, organic and biological agents and their interactions (4, 
19, 31, 40, 42, 43). Naturally occurring organic constituents of tobacco used 
in smokeless tobacco products include lignins, fatty acids, sugars, alkaloids, 
terpenoids, polyphenols, cembranoids and carotenoid pigments. The breakdown 
products of some of these constituents contribute to volatile flavour chemicals 
and the colouration of cured tobacco (18, 19, 61).
Methods of tobacco growing, harvesting and curing vary geographically, 
which may affect product chemistry (19). During the growing season, tobacco 
can absorb metals (41, 43), as noted above. Addition of nitrate fertilizer boosts 
plant mass and also increases the concentrations of nitrate, nicotine and other 
alkaloids in leaves − all precursors of TSNAs (18, 31, 61, 62, 63). Agricultural 
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plant protection chemicals applied to tobacco may also persist on the tobacco 
at harvest (64). Exposure to the soil and atmosphere during cultivation and 
harvesting can result in the introduction of microbes and also fungi that 
generate mycotoxins. At harvesting, tobacco may be laid on the ground (18) or 
piled in a field for extended periods (≤ 45 days) (65). Contact with the soil offers 
an opportunity for the introduction of microorganisms and other organisms 
(insects) into the tobacco.
After harvest, tobacco leaves are cured by sun, air, flue or fire, the four 
primary means for traditional products (except products such as dissolvables). 
Sun-curing involves drying tobacco in the sun, whereas air-curing involves 
hanging tobacco in a well-ventilated barn. Flue-curing is done by exposing the 
leaves to elevated temperatures fuelled by wood, coal, oil or liquid petroleum gas 
in a tightly constructed building equipped with ventilators and flues (18). During 
fire-curing, leaves are dried in smoke from the burning of wood or sawdust, 
when smoke-derived chemicals such as PAHs and VOCs can accumulate on the 
tobacco leaves (22, 23, 24). The levels of PAHs in fire-cured tobacco exceed those 
in air-cured tobacco (23) (see Fig. 9.1).
Fig. 9.1. Effects of type of curing on levels of polycyclic aromatic hydrocarbons in tobacco used to make 
smokeless products
5MC: 5-methylchrysene; ACL: acenaphthylene; ACT: acenaphthene; ANT: anthracene; BAA: benz[a]anthracene; BAP: benzo[a]
pyrene; BBF: benzo[b]fluoranthrene; BEP: benzo[e]pyrene; BJF: Benzo[j]fluoranthene; BKF: benzo[k]fluoranthrene; CHR: chrysene; 
DBA: Dibenz[ah]anthracene; DEP: Dibenzo[ae]pyrene; DIP: Dibenzo[ai]pyrene; FLR: fluoranthene; FLU: fluorene; INP: Indeno[1,2,3-
cd]pyrene; NAP: naphthalene; PHE: phenanthrene; PYR: pyrene. BAA, BAP, BBF and BKF are on the FDA list of HPHCs (60). Source: 
reference 23.
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After curing, tobacco may undergo further ageing, fermentation or long-term 
storage, and these production stages may increase microbial proliferation in 
anaerobic conditions. During these phases, dramatic chemical changes occur that 
include rapid catalysis of sugars, increases in pH and temperature and increases in 
the concentrations of nitrite and TSNAs (8). Microbes may be deliberately added 
during fermentation (9). Also, viable microorganisms are present in purchased 
products (25, 55). Aflatoxins, carcinogens produced by certain Aspergillus mould 
species, may accumulate during cultivation or subsequent production steps and 
have been found in certain smokeless tobacco products (7, 66). Microbial action 
is clearly a driver of the evolving product chemistry.
9.4 Product additives
During manufacture, almost all products are augmented with some level of 
additives, including flavouring compounds that are not necessarily toxic but 
may add to the attractiveness of products, thus promoting initiation or fostering 
use. Flavourings used in these products are drawn from extracts, oleoresins, 
spice powders, individual compounds (e.g. menthol, vanillin) and more than 60 
essential oils (67). Some substances used as additives that have known adverse 
health effects include khat (an addictive plant), tonka bean (a liver toxin) and 
areca nut (an addictive psychoactive substance); areca nut is known to cause 
cancer and oral malformations, such as oral submucosal fibrosis (68, 69). In some 
cases, areca nut and other ingredients are added at substantial levels to tobacco-
containing products (zarda, rapé) or hand-made preparations (e.g. betel quid, 
tombol, dohra, moawa and mainpuri) (3, 7, 70, 71).
9.5 Harmful agents in smokeless tobacco products and methods 
to reduce their effects
Damaging agents in smokeless tobacco products can be reduced in several 
ways, including by changes to smokeless tobacco production (19). Some of these 
measures may help decrease TSNA levels (9, 28, 72). Means of altering the levels 
of harmful agents may include the following.
 ■ Fertilizers: decreasing the use of nitrate-containing fertilizers or us-
ing other fertilizers (e.g. urea or other non-nitrate fertilizers late in 
the growing season) could limit the formation of nitrosamines by de-
creasing the accumulation of nitrate at harvest (18, 61).
 ■ Surface disinfection of harvested tobacco: washing harvested leaf 
material with a dilute bleach solution (hyprochlorite:water solution) 
can disinfect leaf surfaces. This procedure removes not only microor-
ganisms but also soil (50,56). Protocols effective in disinfecting food 
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products, such as leafy greens, may be useful for eliminating surface 
contamination. Disinfection of tobacco leaves have been shown re-
duce the levels of surface microbes (28, 50, 56).
 ■ Practices used effectively in the food industry can reduce contami-
nation of tobacco by microorganisms and soil. In Sweden, snus 
must meet food regulatory standards, which has led to a product with 
reproducibly lower toxicant levels (28).
 ■ Electron beam technology: high-energy electron beam irradiation 
is a non-thermal, chemical-free technology, in which compact linear 
accelerators generate highly energetic (10 MeV) electrons, that has 
been used to pasteurize foods and sterilize medical devices. The tech-
nology is often called “cold pasteurization”, because it irradiates prod-
ucts without generating excess heat, which might cause undesirable 
product changes (73). Although the appropriate dose of irradiation 
may depend on the product, electron beam technology could elimi-
nate viable organisms present in tobacco that generate mycotoxins 
or nitrite and remove viable and potentially harmful organisms in 
smokeless tobacco. Because electron beam technology does not gen-
erate heat, it may be possible to use it to sterilize tobacco, ingredients, 
packaging material and the final product. Irradiation of tobacco early 
in production, especially before fermentation and ageing, may elimi-
nate some microorganisms that generate nitrite resulting in lower 
TSNA as compared to non-irradiated tobacco.
 ■ Changes related to fire-curing and air-curing: the levels of PAHs 
and volatile aldehydes are higher in fire-cured tobacco (22, 23, 30, 
74); the process of fire-curing should be omitted, if possible. Dur-
ing air-curing, microbial treatment with Bacillus amyloliquefaciens 
DA9, an organism that efficiently accumulates nitrite, may decrease 
nitrite and TSNA concentrations (75). During curing, conditions of 
high humidity (70%) and temperatures ranging from 10°C to 32°C 
that may be found in poorly ventilated curing facilities are conducive 
to mould growth and the potential formation of mycotoxins, such as 
aflatoxins and ochratoxins (11, 76). Efforts should be made to prevent 
these conditions and monitor to ensure mould growth is prevented.
 ■ Pasteurization: the Swedish Match Company uses pasteurization in 
the preparation of Swedish snus, a smokeless tobacco product with 
a low TSNA concentration (28, 77). Ground, blended leaf tobacco is 
mixed with water and sodium chloride in closed process blenders, 
then heat-treated with hot water and steam injection to achieve tem-
peratures up to 80–100 ºC for several hours. The mixture is cooled, 
216
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
and other ingredients, such as flavours and humectants, are added 
before the product is packaged. This process changes taste, reduces 
microbial activity and yields a product with a shelf life of 14–30 weeks 
when refrigerated, according to a manufacturer (28, 76). Snus prod-
ucts continue to have low TSNA levels (28), which have been reduced 
and maintained over several decades. In 2017, the average level of 
NNN plus NNK in the products of the Swedish Match Company was 
0.47 µg/g product, dry weight (28, 77).
 ■ Modified fermentation: fermentation is the main process in the 
production of tobacco products that increases levels of nitrite and 
TSNAs (8), and it should be modified (9) or avoided entirely. Dur-
ing fermentation, microbial populations can rapidly proliferate or 
decrease and can increase pH, oxalate, nitrite and TSNA levels (8, 9). 
The steps in the formation of TSNAs are shown in Fig. 9.2. Cleaning 
of fermentation equipment before use and addition of non-nitrite-
producing microbes at that stage can reduce TSNA levels (9). Use 
of oxygen-rich endothermic fermentation (78) may also decrease the 
anaerobic respiratory nitrate reduction that occurs during tobacco 
fermentation (8, 9). Addition of suitable fermentation organisms that 
do not produce nitrite (9) may be required after irradiation. A prod-
uct free of microbes (as is the case for snus) would generally be seen 
as beneficial (8, 9, 28) as compared with products harbouring un-
known microorganisms, including those that generate nitrite or are 
otherwise harmful to the user.
 ■ Microwave technology: this technology has been used safely over 
the past 50 years for cooking, drying, pasteurizing, sterilizing, bac-
terial destruction and enzyme deactivation in food products, but 
has only recently been used in continuous in-line processing in the 
United States. The principle of microwave technology is simple: when 
a substance is subjected to microwave radiation, water molecules in 
the material absorb the energy and internal heat is generated volu-
metrically by their molecular vibration. Continuous microwave heat-
ing equipment and technology was first used for aseptic processing 
of food products in a North Carolina processing facility in 2008. Mi-
crowave technology has been used in producing pharmaceutical and 
nutraceutical products. In India, commercial ready-to-eat meals were 
processed in-pack using proprietary microwave technology. Micro-
wave energy likely increases temperature inside of the microbial cell, 
denaturing critical biomolecules and resulting in reduced cell efficacy 
and often death (79–83). Although not used for tobacco presently, 
microwave technology that has been used successfully with food 
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products may be assessed for its applicability in reducing or eliminat-
ing microorganisms in tobacco or tobacco products.
 ■ Nitrite scavengers: although the most efficient approach to minimiz-
ing nitrite in smokeless tobacco products is complete elimination of 
nitrite-generating organisms, the use of agents that act as nitrite scav-
engers has been investigated (28). Certain polyphenols, vitamin  C, 
tocopherol, green tea extract, a green tea component (epigallocat-
echin gallate) and morpholine could be investigated as potential ni-
trite scavengers to neutralize nitrite generated during smokeless to-
bacco processing (28, 84, 85).
 ■ Product refrigeration: continuing growth of microbial populations 
and potential formation of nitrosamine compounds in products can 
be controlled by refrigeration. One manufacturer encourages refrig-
eration of its products, including at points of sale (28).
Fig. 9.2. Processes that can increase the concentrations of nitrosamines in smokeless tobacco products
NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN: N´-nitrosonornicotine. 
Source: references 9, 10, 18, 31, 61
Smokeless tobacco production can result in the presence of nitrosamines and 
microbes, including bacteria and fungi. Tobacco contains nitrate, tobacco 
alkaloids and certain secondary and tertiary amines, which play a role in the 
formation of nitrosamines. The most abundant carcinogens in tobacco products 
are TSNAs, but they also include other nitrosamines such as N-nitrosamino acids 
and volatile N-nitrosamines. Nitrosamines can be formed at various stages in 
smokeless tobacco production. One TSNA, NNN, is a human carcinogen known 
to cause oral cancer (6, 54).
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9.6 Detection of microorganisms
Culture counts in standard culture media: microbial contamination can 
be assessed on culture media plates, but this method is time-consuming, as it 
involves pouring media plates, streaking and interpreting growth; it may be 
difficult to find the appropriate media for testing specific organisms in tobacco 
(87). Many different microorganisms grow in tobacco, and they can be cultured 
on various media, including tryptic soy agar (55), sheep blood agar, mannitol salt 
agar and MacConkey agar plates (25). According to the “great plate anomaly” 
(87), certain taxa may be overrepresented, such that less abundant yet important 
taxa remain unidentified, and no single medium will capture the microbial 
diversity of tobacco products. The expertise, volume of supplies and requirement 
for sterile facilities to set up, inoculate, incubate and correctly interpret media 
plates may be too costly in certain localities, and less expensive, less complicated 
methods may have practical advantages.
Culture counts on disposable microbiological films: an alternative 
to culture media is a small two-layer film. The upper film is lifted open so that 
the inoculum can be spread on the lower film surface, which is then incubated 
and read for the extent of microbial growth. Although other products may exist, 
media for testing a wide variety of bacteria are made by 3M Corp. 
9.6.1 Rapid detection of live microorganisms by cell viability
Plate reader format: it would be helpful to know the extent of microbial 
contamination on tobacco at various points during cultivation and production 
and in final tobacco products. An assay of microbial viability based on 
luciferase (e.g. BacTiter-Glo) indicates the number of viable microorganisms by 
quantification of ATP, a molecule present in all living cells (88). A single reagent 
causes cell lysis and generation of a luminescent signal, which is proportional 
to the ATP concentration and is directly proportional to the number of viable 
cells. This assay detects a variety of bacteria and fungi. Data can be recorded 
5 min after addition and mixing of the reagent. The assay can detect as few as 10 
bacterial cells on a luminometer or a CCD camera. The application can be used 
with a 96-well plate reader (88).
Handheld luminometer: ATP measurement has been miniaturized in 
handheld readers made by at least six manufacturers. Handheld luminometers to 
test for ATP allow determination of the extent of microbial contamination in 5–20 
seconds. Several manufacturers make ATP luminometers, and their capability has 
been compared. One manufacturer makes devices to enumerate specific bacterial 
groups, total viable count, Enterobacteriaceae, coliform, E. coli and Listeria spp. 
These devices are used in various industries (e.g. health care, pharmaceuticals, 
water treatment, dairy, meat, produce). A portable unit could be used to test tobacco 
products, preparations or related ingredients on site within minutes (90, 91).
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Detection of organisms by qPCR: organisms could also be detected by 
quantitative polymerase chain reaction (qPCR), a technique in which probes 
against specific gene regions bind, replicate and can be quantified. These and other 
organisms can be detected with the use of properly designed molecular probes. 
Molecular probes can be designed for qPCR that are specific for nitrate-reducing 
organisms and genes (e.g. narG, napA, etc.) and used quantification by qPCR (89).
Detection of nitrate-reducing organisms: in addition to enumeration 
of microorganisms to assess the extent of contamination, actual nitrate-reducing 
organisms in tobacco products should be identified. One means may involve 
growing microbes on nitrate agar with an added nitrite indicator. Another 
approach is use of Greise reagent (produced from sulfanilamide with NO2, 
followed by addition of naphthylethylenediamine) (92).
9.7 Overview of analytical methods used to measure toxicants in 
smokeless tobacco
Analytical methods for measuring tobacco constituents (Table 9.2) depend mainly 
on GC and LC linked to various types of mass spectrometers (single and triple quad; 
MS, MS/MS) and other detectors, such as inductively coupled plasma and flame 
ionization detectors. This is not an exhaustive list, but it shows some recent papers 
describing approaches utilized by various laboratories for analysing tobacco products.
Table 9.2. Methods for measuring tobacco constituents
Analyte Measurement method
Nicotine (35, 93) GC-MS, GC/FID
Minor alkaloids (13) GC-MS/MS
Flavours and non-tobacco plant constituents, including 
coumarin and camphor (94) GC-MS
PAHs (22, 23, 24) GC-MS
VOCs (22) GC-MS
Toxic metals (42) ICP-MS
TSNA (11, 52, 53) LC–MS/MS 
Aflatoxins (7) UHPLC-MS/MS
Areca-nut-related compounds (95) LC/MS /MS
pH (34, 35) Ion probe 
Nitrate and nitrite (96) Ion chromatography
Fungi (76) Culture media specific to fungi
Bacteria (25) Culture media specific to bacteria
Identification of metals and alkaline agents (97) X-ray fluorescence (XRF)
Identification of tobacco species (Nicotiana tabacum, N. 
rustica, N. glauca), non-tobacco plant materials (e.g. areca nut, 
tonka bean) and alkaline agents (magnesium carbonate, slake 
lime) (11, 52, 71) Fourier transform/infrared spectroscopy (FT/IR)
 
GC: gas chromatography; LC: liquid chromatography; MS: mass spectrometry; PAHs: polycyclic aromatic hydrocarbons; TSNAs: 
tobacco-specific nitrosamines; VOCs: volatile organic compounds.
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Other techniques that have been used to measure these analytes could be 
substituted, with appropriate validation, if necessary. For regulatory agencies 
with limited funding or space, compact or portable instrumentation is available, 
including GC-MS systems that could allow the detection and quantification of 
nicotine, minor alkaloids, arecoline (areca nut), flavours and non-tobacco plant 
constituents (coumarin, diphenyl ether, camphor). Some GC-MS systems are 
miniaturized, mobile and cost less than conventional bench systems.
9.8 Regulatory approaches and responses
Various regulatory and other responses have been used. While the European 
Union regulates smokeless tobacco under directive 2001/37/EC (98), Sweden 
is exempted from the prohibition on marketing of certain types of tobacco for 
oral use. In the United States, smokeless tobacco has been regulated by the FDA 
since the passage of the Family Smoking Prevention and Tobacco Control Act 
in 2009 (99). Elsewhere, there is limited regulation of smokeless tobacco use, 
such as prohibiting products or regulating the contents. Despite attempts by the 
states of Andhra Pradesh, Bihar, Goa, Maharashtra and Tamil Nadu in India to 
prohibit sales of gutkha and pan masala as food products (3), manufacturers 
have circumvented the ban (100), in the case of gutkha by dividing the product 
into attached packages with tobacco flakes in one and the other constituents in 
the other. However, Goa has reportedly sustained a ban on smokeless tobacco 
products through the Goa Public Health (Amendment) Act, 2005 (101).
An example of a targeted approach to reducing toxicants in smokeless 
tobacco is the rule proposed by the FDA in January 2017 for NNN in finished 
smokeless tobacco products (72), which was based on the carcinogenicity of 
NNN, a major contributor to elevated oral cancer risks associated with smokeless 
tobacco use. Elements of the standard include:
 ■ required expiration date and, if applicable, storage conditions (e.g. re-
frigeration at point of sale) for finished smokeless tobacco products;
 ■ a mean level of NNN in any batch of finished smokeless tobacco 
products of ≤ 1 µg/g of tobacco (dry weight) at any time up to the 
expiration date;
 ■ testing to assess the stability of NNN levels in finished smokeless to-
bacco products and to establish and verify the product’s expiration 
date and storage conditions; and
 ■ batch-testing to determine whether the products conform to the pro-
posed NNN level.
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The FDA also proposed various evidence-based, broadly stated considerations 
with regard to this regulation (72), which might be helpful for other regulatory 
bodies pursuing toxicant reduction in smokeless tobacco products.
 ■ Regulation of smokeless tobacco toxicants may affect consumer per-
ceptions of the harm of smokeless tobacco use.
 ■ Users of smokeless tobacco products might interpret a reduction in 
one or more toxicants as resulting in less harm, which could reduce 
their motivation to quit. FDA, however, does not expect the proposed 
product standard to appreciably discourage cessation of smokeless to-
bacco products in such a way as to offset the beneficial public health 
impact from reduced cancer risk.
 ■ Health messages must continue to educate consumers with evidence-
based advice about all products.
Another approach is the GothiaTek standard instituted by Swedish Match, a 
snus manufacturer, in the late 1990s. It set maximum allowable concentrations 
of nitrite, TSNAs (NNN and NNK), N-nitrosodimethylamine, benzo[a]pyrene, 
aflatoxins, agrochemicals and various metals, and these have been met (28, 
102). Snus is made with air-cured tobacco that is pasteurized, fire-curing and 
fermentation are omitted, and products are refrigerated at points of sale and have 
very low TSNA concentrations (22).
In contrast to the FDA product standard for NNN, GothiaTek limits are 
set on an “as is” (wet weight) basis (22). Other components include:
 ■ standards for raw materials, including guidance levels for agricultural 
residues
 ■ quality control and quality assurance measures during manufacture
 ■ heat treatment of tobacco
 ■ reduced water content
 ■ flavourings consistent with the Swedish Food Act for additives and 
flavourings.
The GothiaTek standard does not regulate product pH or nicotine content (102), 
but, for certain harmful and carcinogenic agents, it serves as a reference for what is 
possible if tobacco product makers or regulators wish to decrease toxicant levels. 
The levels of most GothiaTek toxicants decreased or remained stable between 
2009 and 2017. The agents included are related to soil content, curing, microbial 
activity, and agrochemical use and are shown in Table 9.3.
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Table 9.3. Systematic decreases in toxicant levels regulated under GothiaTek in 2009, 2015 and 2017
Potential source and chemical 
component 2009 levela 2015 levelb 2017 levelb Limit (2009)
Limit (2015, 
2017)
Soil metal content  
Arsenic (μg/g) 0.1 < 0.06 M 0.06   0.5  0.25
Cadmium (μg/g) 0.6 100.28 M 0.27 1 0.5
Chromium (μg/g) 0.8 100.46 M 0.46 3 1.5
Lead (μg/g) 0.3 100.15 M 0.15 2 1X
Mercury (μg/g) NA < 0.02 < 0.02 NA  0.02
Nickel (μg/g) 1.3 100.87 M 0.82   4.5  2.25
Curingc  
Acetaldehyded (μg/g) NA 106.5   6.3 NA 25XX
Crotonaldehyded (μg/g) NA 1< 0.10   < 0.10 NA  0.75
Formaldehyded (μg/g) NA 1  2.3   2.3 NA 7.5
Benzo[a]pyrenee (ng/g) 1.1 < 0.6 < 0.6 20  1.25
Microorganisms (fungi)      
Aflatoxin (ng/g) NA < 2.1 < 2.1 NA  2.5
Ochratoxin A (ng/g) NA 102.3 2 NA 10X
Microorganisms (bacteria)  
Nitrite (μg/g) 2.0 1.7 1.5 7 3.5
NNN+NNK (μg/g) 1.6 0.39 0.47 10  0.95
NDMA (ng/g) 0.7 < 0.6 < 0.6 10 2.5
Agrochemicals (μg/g) NA b b NA   a
 
NA: not available; NDMA: N-nitrosodimethylamine; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN: N´-
nitrosonornicotine. These analytes are derived primarily from soil uptake (toxic metals), curing and the presence and activity of 
fungi and bacteria. Units are converted from per kilogram to per gram. 
a In accordance with the Swedish Match Agrochemical Management Programme (28).  
b Below Swedish Match internal limits (102). 
c Snus is not fire-cured; these analytes are often formed during fire-curing in the manufacture of other products (dry and moist snuff). 
d These aldehydes are volatile organic compounds.
e This compound is a polycyclic aromatic hydrocarbon.
9.9 Policy recommendations and summary
In this section, we have described research to identify the major characteristics of 
concern and approaches to measuring and decreasing the levels of certain harmful 
agents in smokeless tobacco products. We concur with the recommendations of 
TobReg in 2015 (29) for the establishment of regulatory limits for carcinogens in 
smokeless tobacco products, which are still valid and are reiterated below.
 ■ Reduce toxicity: decrease or eliminate use of N. rustica; limit bacte-
rial contamination, which can promote nitrosation and carcinogen 
formation; require that tobacco be flue- or sun-cured rather than fire- 
or air-cured to avoid bacterial growth; kill bacteria by pasteurization; 
improve storage conditions, such as by refrigerating products before 
sale; affix the date of manufacture; eliminate ingredients such as areca 
nut and tonka bean that are known to be carcinogenic.
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 ■ Impose product standards: set an upper limit of 2 μg/g (dry weight) 
for NNN plus NNK and an upper limit of 5 ng/g (dry weight) for 
benzo[a]pyrene; and monitor the levels of arsenic, cadmium and lead 
in tobacco.
 ■ Reduce appeal and addictiveness: take steps to reduce the appeal of 
and addiction to tobacco products, including by prohibiting addition 
of sweeteners and flavourings (including herbs, spices and flowers) 
and setting limits on free nicotine and pH.
 ■ Apply uniform standards for transnational products: hold export-
ed smokeless tobacco products to the same (or higher) standards as 
in the country of manufacture.
WHO TobReg also recommended that communications about smokeless tobac-
co products be regulated to prevent unsubstantiated claims about exposure or 
disease reduction (103).
We have summarized below some concerns associated with the carcino-
genic, toxic and addictive agents in smokeless tobacco products and propose ways 
of lowering the concentrations of these agents. Decreasing the levels of nicotine, 
free nicotine, arsenic, cadmium, lead, benzo[a]pyrene and NNN plus NNK will 
not make smokeless tobacco products safe; however, it is prudent to decrease the 
levels of known addictive, toxic or carcinogenic agents.
The concerns associated with smokeless tobacco products include:
 ■ use of high-nicotine tobacco, including N. rustica;
 ■ inclusion of alkaline agents that substantially raise the pH, increase 
free nicotine concentrations and contribute to higher blood nicotine 
levels, cardiovascular risk and addiction;
 ■ presence of toxic metals in tobacco due to soil uptake or deposited 
from contaminated soil or the environment;
 ■ use of fire-curing, which can introduce chemicals from smoke, such 
as PAHs (including benzo[a]pyrene), phenols and volatile aldehydes;
 ■ presence of microbial contamination (bacteria and fungi) on tobacco 
leaves, especially those organisms that promote the formation of af-
latoxins, ochratoxin A, nitrite or nitrosamines (particularly TSNAs), 
and the conditions most conducive to their formation;
 ■ presence of microbes (bacteria and fungi) that can cause infectious 
disease, become resistant to antibiotics, alter oral biofilms or displace 
the healthy microflora of the gastrointestinal tract;
 ■ soil fertilization practices that result in elevated levels of nitrate, lead-
ing to increased levels of nitrite and nitrosamines in tobacco at harvest;
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 ■ presence of harmful agricultural chemical residues on tobacco at harvest;
 ■ presence of viable microorganisms (including pathogens) in pur-
chased products that can be transferred to users and may become 
established in the oral cavity or the gastrointestinal tract;
 ■ use of fermentation, ageing, product storage or other processes that 
provide anaerobic conditions that can contribute to rapid formation 
of nitrite and TSNA;
 ■ presence of high residual levels of nitrate in finished tobacco products;
 ■ presence of areca nut (IARC Group 1 human carcinogen) and other 
additives of recognized toxicity or carcinogenicity;
 ■ presence of flavouring additives that have toxic effects; and
 ■ presence of flavouring additives that enhance initiation of tobacco 
use by adding appeal, impeding cessation or masking the recognition 
or severity of disease symptoms.
Attention should also be paid to the contribution of non-tobacco ingredients and 
plant materials in smokeless tobacco products. Steps that might decrease the level 
of TSNAs, the most abundant carcinogens in smokeless tobacco products, are 
shown in Fig. 9.3.
Fig. 9.3. Countermeasures that might contribute to reducing concentrations of TSNAs and other harmful 
agents in tobacco products
N2: nitrogen; NOx: nitrogen oxide; TSNA: tobacco-specific N´-nitrosamines.
To address the concerns listed above, in addition to the steps recommended by TobReg and specific product standards, product 
manufacturers could take a number of steps to decrease the concentrations of harmful agents in tobacco products.
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 ■ Because nornicotine is the precursor of NNN, genetically screen to-
bacco cultivars for lower nornicotine content as a means of reducing 
the formation of NNN.
 ■ Screen soils for metal contamination and nitrate levels.
 ■ Investigate agronomic means for minimizing the concentrations of 
nitrate and agricultural chemicals in or on plants at harvest.
 ■ Use gloves when harvesting or handling tobacco to prevent the trans-
fer of organisms on the skin (e.g. Staphylococcus) to the tobacco and 
also to protect workers from “green tobacco sickness”.
 ■ Wash harvested tobacco with dilute bleach solution (1:250 
hyprochlorite:water) to remove soil, soil metals, manure, agricultural 
chemicals, insects and microorganisms.
 ■ Ensure that curing facilities are clean so that other organisms (espe-
cially nitrate-reducing organisms) are not introduced.
 ■ Identify harmless chemical or biological agents that could be added 
to prevent microbial growth.
 ■ Screen cured tobacco for elevated nitrite or the presence of nitrite-
generating organisms (e.g. Staphylococcus, Corynebacterium) before 
further processing.
 ■ Pasteurize or heat-treat products.
 ■ Clean fermentation vats before use.
 ■ Add non-nitrate-reducing fermentation organisms before fermentation.
 ■ Investigate means for lowering nitrate levels during fermentation 
(selective filtration, denitrification, cycle liquid from fermentation 
through a cell that reacts nitrite with chemicals scavengers or denitri-
fying organisms).
 ■ Add nitrite scavengers (vitamin C, tocopherol, green tea extract, 
Kunlun tea extract, cysteine) before fermentation.
 ■ Assay final products for microbial growth.
 ■ Keep products in refrigerated storage before sale.
These observations provide additional support for the feasibility of monitoring 
and controlling the levels of some carcinogenic and other harmful agents in 
smokeless tobacco products.
9.9.1 Disclaimer
The findings and conclusions in this chapter are those of the author(s) and do not 
necessarily represent the views of the Centers for Disease Control and Prevention. 
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Use of trade names is for identification only and does not imply endorsement by 
the Centers for Disease Control and Prevention, the Public Health Service, or the 
United States Department of Health and Human Services.
9.10 References
1. Decision FCTC/COP7(14). Further development of the partial guidelines for implementation 
of Articles 9 and 10 of the WHO FCTC (Regulation of the contents of tobacco products and 
Regulation of tobacco product disclosures). In: Report of the seventh session of the Conference 
of the Parties to the WHO Framework Convention on Tobacco Control. Geneva: World Health 
Organization; 2016) (http://www.who.int/fctc/cop/cop7/FINAL_COP7_REPORT_EN.pdf, 
accessed 15 May 2019).
2. WHO global report on trends in prevalence of tobacco smoking 2000–2025, 2nd edition. Ge-
neva: World Health Organization; 2018.
3. Eriksen M, Mackay J, Schluger N, Gomeshtapeh FI, Drope J, editors. Tobacco atlas. Fifth edition. 
Atlanta (GA): American Cancer Society and World Lung Foundation; 2015 (https://tobaccoat-
las.org/, accessed 16 July 2019).
4. Smokeless tobacco and public health: a global perspective. Chapter 3. Global view of smo-
keless tobacco products: constituents and toxicity (NIH/CDC Monograph). Bethesda (MD): 
Department of Health and Human Services; 2014:75–114 (NIH Pub. 14-7983) (https://cancer-
control.cancer.gov/brp/tcrb/global-perspective/SmokelessTobaccoAndPublicHealth.pdf, 
accessed 16 July 2019).
5. Stanfill SB. Chapter 7: Toxic contents and emissions in smokeless tobacco products. In: WHO 
Study Group on Tobacco Product Regulation. Report on the scientific basis of tobacco pro-
duct regulation. Sixth report of a WHO study group (WHO Technical Report Series, No. 1001). 
Geneva: World Health Organization; 2017:23–39. (http://www.who.int/tobacco/publications /
prod_regulation/trs1001/en/, accessed 16 July 2019).
6. Smokeless tobacco and some tobacco-specific N-nitrosamines. Lyon: International Agency 
for Research on Cancer; 2007 (IARC Monographs on the Evaluation of Carcinogenic Risks to 
Humans, Vol. 89) (http://monographs.iarc.fr/ENG/Monographs/vol89/index.php, accessed 
20 September 2018).
7. Zitomer N, Rybak ME, Li Z, Walters MJ, Holman MR. Determination of aflatoxin B1 in smokeless 
tobacco products by use of UHPLC-MS/MS. J Agric Food Chem. 2015;63(41):9131–8.
8. Di Giacomo M, Paolino M, Silvestro D, Vigliotta G, Imperi F, Visca P et al. Microbial commu-
nity structure and dynamics of dark fire-cured tobacco fermentation. Appl Environ Microbiol. 
2007;73:825–37.
9. Fisher MT, Bennett CB, Hayes A, Kargalioglu Y, Knox BL, Xu D et al. Sources of and technical 
approaches for the abatement of tobacco specific nitrosamine formation in moist smokeless 
tobacco products. Food Chem Toxicol. 2012;50:942–8.
10. Andersen RA, Burton HR, Fleming PD, Hamilton-Kemp TR. Effect of storage conditions on ni-
trosated, acylated, and oxidized pyridine alkaloid derivatives in smokeless tobacco products. 
Cancer Res. 1989;49:5895–900.
11. Stanfill SB, Connolly GN, Zhang L, Jia TL, Henningfield J, Richter P et al. Surveillance of interna-
tional oral tobacco products: total nicotine, unionized nicotine and tobacco-specific nitrosa-
mines. Tob Control. 2011;20:e2.
12. Sisson VA, Severson RF. Alkaloid composition of Nicotiana species. Beitr Tabakforsch Int. 
1990;14:327–39.
13. Lisko JG, Stanfill SB, Duncan BW, Watson CH. Application of GC-MS/MS for the analysis of to-
Approaches to measuring and reducing toxicant concentrations in smokeless tobacco products
227
bacco alkaloids in cigarette filler and various tobacco species. Anal Chem. 2013;85:3380−4.
14. Idris AM, Nair J, Ohshima H, Friesen M, Brouet I, Faustman EM et al. Unusually high levels 
of carcinogenic tobacco-specific nitrosamines in Sudan snuff (toombak). Carcinogenesis. 
1991;12:1115–8.
15. Steenkamp PA, van Heerden FR, van Wyk B. Accidental fatal poisoning by Nicotiana glauca: 
identification of anabasine by high performance liquid chromatography/photodiode array/
mass spectrometry. Forensic Sci Int. 2002;128:208–17.
16. Furer V, Hersch M, Silvetzki N, Breuer GS, Zevin S. Nicotiana glauca (tree tobacco) intoxication 
– two cases in one family. J Med Toxicol. 2011;7(1):47–51.
17. Bhide SV, Nair J, Maru GB, Nair UJ, Kameshwar Rao BV, Chakraborty MK et al. Tobacco-specific 
N-nitrosamines [TSNA] in green mature and processed tobacco leaves from India. Beitr Tabak-
forsch Int. 1987;14:29–32.
18. Burton HR, Dye NK, Bush LP. Distribution of tobacco constituents in tobacco leaf tissue. 1. To-
bacco-specific nitrosamines, nitrate, nitrite, and alkaloids. J Agric Food Chem. 1992;40(6):1050–5.
19. Rodgman A, Perfetti TA, editors. The chemical components of tobacco and tobacco smoke, 
2nd edition. Boca Raton (FL): CRC Press; 2013.
20. Chen Z, Xia Z, Lei L, Xu S, Wang M, Cun L et al. Characteristic analysis of endophytic bacteria 
population in tobacco. Acta Tabacaria Sinica. 2014;20:102–7.
21. List of tobacco pests and diseases. In: Ephytia [website]. Paris: French National Institute for 
Agricultural Research; 2019 (http://ephytia.inra.fr/en/C/10749/Tobacco-List-of-tobacco-pests-
and-diseases, accessed 16 July 2019).
22. Stepanov I, Jensen J, Hatsukami D, Hecht SS. New and traditional smokeless tobacco: compa-
rison of toxicant and carcinogen levels. Nicotine Tob. Res. 2008; 10:1773–82.
23. Hearn BA, Ding YS, England L, Kim S, Vaughan C, Stanfill SB et al. Chemical analysis of Alaskan 
iq’mik smokeless tobacco. Nicotine Tob Res. 2013;15(7):1283–8.
24. Stepanov I, Villalta PW, Knezevich A, Jensen J, Hatsukami D, Hecht SS. Analysis of 23 polycyclic 
aromatic hydrocarbons in smokeless tobacco by gas chromatography–mass spectrometry. 
Chem Res Toxicol. 2010;23:66–73.
25. Han J, Sanad YM, Deck J, Sutherland JB, Li Z, Walters MJ et al. Bacterial populations associated 
with smokeless tobacco products. Appl Environ Microbiol. 2016;82:6273–83.
26. Larsson L, Szponar B, Ridha B, Pehrson C, Dutkiewicz J, Krysińska-Traczyk E et al. Identification 
of bacterial and fungal components in tobacco and tobacco smoke. Tob Induced Dis. 2008;4:4.
27. Pauly JL, Paszkiewicz G. Cigarette smoke, bacteria, mold, microbial toxins, and chronic lung 
inflammation. J Oncol. 2011:819129.
28. Rutqvist LE, Curvall M, Hassler T, Ringberger T, Wahlberg I. Swedish snus and the GothiaTek 
standard. Harm Reduct J. 2011;8:11.
29. WHO Study Group on Tobacco Product Regulation. Report on the scientific basis of tobacco 
product regulation: sixth report of a WHO study group (WHO Technical Report Series No. 
1001). Geneva: World Health Organization; 2018 (https://www.who.int/tobacco/publications/
prod_regulation/trs1001/en/, accessed 16 July 2019).
30. Fact sheet, smokeless tobacco health effects. Atlanta (GA): Centers for Disease Control and 
Prevention; 2018 (https://www.cdc.gov/tobacco/data_statistics/fact_sheets/smokeless/, 
accessed 16 July 2019).
31. Spiegelhalder B, Fischer S. Formation of tobacco-specific nitrosamines. Crit Rev Toxicol. 
1991;21:241.
32. Wang J, Yang H, Shi H, Zhou J, Bai R, Zhang M et al. Nitrate and nitrite promote formation 
of tobacco-specific nitrosamines via nitrogen oxides intermediates during postcured storage 
under warm temperature. J Chemistry. 2017;6135215 (https://doi.org/10.1155/2017/6135215, 
accessed 20 July 2019).
228
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
33. Bhisey RA, Stanfill SB. Chapter 13. Chemistry and toxicology of smokeless tobacco. In: Smoke-
less tobacco and public health in India. New Delhi: Ministry of Health and Family Welfare; 2017 
(https://www.researchgate.net/, accessed 23 September 2018).
34. Lawler TS, Stanfill SB, Zhang L, Ashley DL, Watson CH. Chemical characterization of domestic 
oral tobacco products: total nicotine, pH, unprotonated nicotine and tobacco-specific N-nitro-
samines. Food Chem Toxicol. 2013;57:380–6.
35. Notice regarding requirement for annual submission of the quantity of nicotine contained in 
smokeless tobacco products manufactured, imported, or packaged in the United States. Was-
hington (DC): Centers for Disease Control and Prevention; Department of Health and Human 
Services; 1999 (https://www.gpo.gov/fdsys/pkg/FR-1999-03-23/pdf/99-7022.pdf, accessed 16 
July 2019).
36. Brunnemann KD, Genoble L, Hoffmann D. N-Nitrosamines in chewing tobacco: an internatio-
nal comparison. J Agric Food Chem. 1985;33:1178–81.
37. Tomar SL, Henningfield JE. Review of the evidence that pH is a determinant of nicotine dosage 
from oral use of smokeless tobacco. Tob Control. 1997;6(3):219–25.
38. Fant RV, Henningfield JE, Nelson RA, Pickworth WB. Pharmacokinetics and pharmacodynamics 
of moist snuff in humans. Tob Control. 1999;8:387–92.
39. Alpert HR, Koh H, Connolly GN. Free nicotine content and strategic marketing of moist snuff 
tobacco products in the United States: 2000–2006. Tob Control. 2008;17:332–8.
40. Alloway BJ, editor. Heavy metals in soils: trace metals and metalloids in soils and their bioavai-
lability. Dordrecht: Springer Netherlands; 2013.
41. Golia EE, Dimirkou A, Mitsios IK. Accumulation of metals on tobacco leaves (primings) grown in 
an agricultural area in relation to soil. Bull Environ Contam Toxicol. 2007;79:158–62.
42. Pappas RS, Stanfill SB, Watson C, Ashley DL. Analysis of toxic metals in commercial moist snuff 
and Alaskan iqmik. J Anal Toxicol. 2008;32(4):281–91.
43. Pappas RS. Toxic elements in tobacco and in cigarette smoke: inflammation and sensitization. 
Metallomics. 2011; 3(11):1181–98.
44. Zakiullah SM, Muhammad N, Khan SA, Gul F, Khuda F, Khan H. Assessment of potential toxi-
city of a smokeless tobacco product (naswar) available on the Pakistani market. Tob Control. 
2012;(4):396–401.
45. Gupta P, Sreevidya S. Laboratory testing of smokeless tobacco products. Final report to the 
India Office of the WHO (allotment No: SE IND TOB 001.RB.02). New Delhi; 2004.
46. Zaprjanova P, Ivanov K, Angelova V, Dospatliev L. Relation between soil characteristics and 
heavy metal content in Virginia tobacco. In: World Congress of Soil Science. Brisbane, Aust-
ralia. 2010:205–8 (https://www.iuss.org/19th%20WCSS/Symposium/pdf/2027.pdf, accessed 
16 July 2019).
47. Mulchi CL, Adamu CA, Bell PF, Chaney RL. Residual heavy metal concentrations in sludge 
amended coastal plain soils – II. Predicting metal concentrations in tobacco from soil test 
information. Commun Soil Sci Plant Anal.1992;23(9–10):1053–69.
48. Adamu CA, Bell PF, Mulchi CL, Chaney RL. Residual metal levels in soils and leaf accumulati-
ons in tobacco a decade following farmland application of municipal sludge. Environ Pollut. 
1989;56:113–26.
49. New limit values for GothiaTek. In: Swedish Match [website]. Stockholm: Swedish Match; 
2016 (https://www.swedishmatch.com/Media/Pressreleases-and-news/News/New-limit-va-
lues-for-GOTHIATEK/, accessed 16 July 2019).
50. Wahlberg I, Wiernik A, Christakopoulos A, Johansson L. Tobacco-specific nitrosamines: a mul-
tidisciplinary research area. Agro Food Industry Hi Tech. 1999;10(4);23–8.
51. Richter P, Hodge K, Stanfill S, Zhang L, Watson C. Surveillance of moist snuff: total nicotine, 
moisture, pH, un-ionized nicotine, and tobacco-specific nitrosamines. Nicotine Tob Res. 2008; 
Approaches to measuring and reducing toxicant concentrations in smokeless tobacco products
229
10(11):1645–52.
52. Stanfill SB, Croucher R, Gupta P, Lisko J, Lawler TS, Kuklenyik P. Chemical characterization of 
smokeless tobacco products from South Asia: nicotine, unprotonated nicotine, tobacco-speci-
fic N-nitrosamines and flavor compounds. Food Chem Toxicol. 2018;118:626–34.
53. Stepanov I, Gupta PC, Dhumal G, Yershova K, Toscano W, Hatsukami D et al. High levels of
54. tobacco-specific N-nitrosamines and nicotine in Chaini Khaini, a product marketed as snus.
55. Tob Control. 2015;24,e271–4.
56. Balbo S, James-Yi S, Johnson CS, O’Sullivan MG, Stepanov I, Wang M et al. (S)-N′-nitrosonor-
nicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats. Car-
cinogenesis. 2013;34:2178.
57. Smyth EM, Kulkarni P, Claye E, Stanfill SB, Tyx RE, Maddox C et al. Smokeless tobacco products 
harbor diverse bacterial microbiota that differ across products and brands. Appl Microbiol 
Biotechnol. 2017;101:5391.
58. Wiernik A, Christakopoulos A, Johansson L, Wahlberg I. Effect of air-curing on the chemical 
composition of tobacco. Recent Adv Tob Sci. 1995;21:39–80.
59. González PJ, Correia C, Moura I, Brondino CD, Moura JJG. Bacterial nitrate reductases: mole-
cular and biological aspects of nitrate reduction. J Inorg Biochem. 2006;100:1015–23.
60. Tyx RE, Stanfill SB, Keong LM, Rivera AJ, Satten GA, Watson CH. Characterization of bacteri-
al communities in selected smokeless tobacco products using 16 S rDNA analysis. PLoS One 
2016;11:e0146939.
61. Nishimura T, Vertes AA, Shinoda Y, Inui M, Yukawa H. Anaerobic growth of Corynebacteri-
um glutamicum using nitrate as a terminal electron acceptor. Appl Microbiol Biotechnol. 
2007;75:889–97.
62. Gadda G, Francis K. Nitronate monooxygenase, a model for anionic flavin semiquinone inter-
mediates in oxidative catalysis. Arch Biochem Biophysics. 2010;493:53–61.
63. Burton HR, Dye NK, Bush LP. Distribution of tobacco constituents in tobacco leaf tissue. 1. To-
bacco-specific nitrosamines, nitrate, nitrite, and alkaloids. J Agric Food Chem. 1992;40(6):1050–5.
64. Burton HR, Dye NK, Bush LP. Relationship between tobacco-specific nitrosamines and nitrite 
from different air-cured tobacco varieties. J Agric Food Chem. 1994;42:2007–11.
65. Bush LP. Alklaloid biosynthesis. In: Davis DL, Nielsen MT, editors. Tobacco: production, chemis-
try and technology. Oxford: Blackwell; 1999;285–91.
66. Ghosh RK, Khan Z, Rao CVN, Banerjee K, Reddy DD, Murthy TGK et al. Assessment of or-
ganochlorine pesticide residues in Indian flue-cured tobacco with gas chromatography-single 
quadrupole mass spectrometer. Environ Monit Assess. 2014;186:5069–75.
67. Idris AM, Ibrahim SO, Vasstrand EN, Johannessen AC, Lillehaug JR, Magnusson B et al. The 
Swedish snus and the Sudanese toombak: are they different? Oral Oncol. 1998;34(6):558–66.
68. Harmful and potentially harmful constituents (HPHCs) [website].Washington (DC): Food and 
Drug Administration; 2018 (https://www.fda.gov/TobaccoProducts/Labeling/ProductsIngre-
dientsComponents/ucm20035927.htm, accessed 17 January 2019).
69. Smokeless tobacco ingredient list as of April 4, 1994. Report to the Subcommittee on Health 
and the Environment, Committee on Energy and Commerce. Washington (DC): House of Re-
presentatives; 1994 (http://legacy.library.ucsf.edu/tid/pac33f00/pdf, accessed 16 July 2019).
70. Garg A, Chaturvedi P, Gupta PC. A review of the systemic adverse effects of areca nut or betel 
nut. Indian J Med Paediatr Oncol. 2014;35(1):3–9.
71. Prabhu RV, Prabhu V, Chatra L, Shenai P, Suvarna N, Dandekeri S. Areca nut and its role in oral 
submucous fibrosis. J Clin Exp Dent. 2014;6(5):e569–75.
72. Bao P, Huang H, Hu ZY, Haggblom MM, Zhu YG. Impact of temperature, CO2 fixation and ni-
trate reduction on selenium reduction, by a paddy soil clostridium strain. J Appl Microbiol. 
2013;114:703–12.
230
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
73. Stanfill SB, Oliveira-Silva AL, Lisko J, Lawler TS, Kuklenyik P, Tyx R et al. Comprehensive chemi-
cal characterization of rapé tobacco products: flavor constituents, nicotine, tobacco-specific 
nitrosamines and polycyclic aromatic hydrocarbons. Food Chem Toxicol. 2015;82:50–8.
74. Tobacco product standard for N-nitrosonornicotine level in finished smokeless tobacco pro-
ducts. Washington (DC): Department of Health and Human Services, Food and Drug Admi-
nistration; 2017 (https://www.fda.gov/downloads/aboutfda/reportsmanualsforms/reports/
economicanalyses/ucm537872.pdf, accessed 16 July 2019).
75. Pillai SD, Shayanfar S. Electron beam technology and other irradiation technology applications 
in the food industry. Top Curr Chem. 2017;375:6. doi: 10.1007/s41061-016-0093-4.
76. Idris AM, Ibrahim SO, Vasstrand EN, Johannessen AC, Lillehaug JR, Magnusson B et al. The 
Swedish snus and the Sudanese toombak: are they different? Oral Oncol. 1998;34(6):558–66.
77. Wei W, Deng X, Cai D, Ji Z, Wang C, Li J et al. Decreased tobacco-specific nitrosamines by mi-
crobial treatment with Bacillus amyloliquefaciens DA9 during the air-curing process of Burley 
tobacco. Agric Food Chem. 2014;62:12701−6.
78. Saleem S, Naz A, Safique M, Jabeen N, Ahsan SW. Fungal contamination in smokeless tobacco 
products traditionally consumed in Pakistan. J Pak Med Assoc. 2018;68(10):1471–77.
79. How long is the shelf life of snus. Stockholm: Swedish Match; 2018 (https://www.swedish-
match.ch/en/what-is-snus/qa/shelf-life-of-snus/, accessed 16 July 2019).
80. Brenik W, Rudhard H. Method of endothermic fermentation of tobacco. US Patent 04343318. 
Washington (DC): Patent Office; 1982 (https://pubchem.ncbi.nlm.nih.gov/patent/US4343318 
#section=Patent-Submission-Date, accessed 16 July 2019).
81. Chandrasekaran S, Ramanathan S, Basak T. Microwave food processing—a review. Food Res 
Intl. 2013;52:243–61 (https://doi.org/10.1016/j.foodres.2013.02.033, accessed 16 July 2019).
82. Industrial Microwave Systems LLC [website]. New Orleans (LA): Industrial Microwave Systems 
LLC; 2019 (http://www.industrialmicrowave.com, accessed 16 July 2019).
83. Brinley TA, Dock CN, Truong VD, Coronel P, Kumar P, Simunovic J et al. Feasibility of utiliz-
ing bioindicators for testing microbial inactivation in sweet potato purees processed with a 
continuous-flow microwave system. J Food Sci. 2007;72(5):235–42.
84. David JRD, Graves RH, Szemplenski T. Handbook of aseptic processing and packaging, 2nd 
edition. Boca Raton (FL): CRC Press; 2013.
85. Parrott DL. Microwave technology sterilizes sweet potato puree. Food Technol. 2010:66–70 
(https://ucanr.edu/datastoreFiles/608-672.pdf, accessed 20 July 2019).
86. Lee S, Kim S, Jeong S, Park J. Effect of far-infrared irradiation on catechins and nitrite scaveng-
ing activity of green tea. J Agric Food Chem. 2006;54(2):399–403.
87. Rundlöf T, Olsson E, Wiernik A, Back S, Aune M, Johansson L et al. Potential nitrite scavengers 
as inhibitors of the formation of N-nitrosamines in solution and tobacco matrix systems. J Agric 
Food Chem. 2000;48(9):4381–8.
88. Cockrell WT, Roberts JS, Kane BE, Fulghum S. Microbiology of oral smokeless tobacco prod-
ucts. Tob Int. 1989;191:55–7.
89. Harwani D. The great plate count anomaly and the unculturable bacteria. Int J Sci Res. 
2012;2(9):350–1.
90. Technical bulletin: BacTiter-Glo™ microbial cell viability assay (document TB337). Madison (WI): 
Promega Corporation; 2019 (https://www.promega.com/, accessed 20 July 2019).
91. Law AD, Fisher C, Jack A, Moe LA. Tobacco, microbes, and carcinogens: correlation between 
tobacco cure conditions, tobacco-specific nitrosamine content, and cured leaf microbial com-
munity. Microb Ecol. 2016;72:1–10.
92. Omidbakhsh N, Ahmadpour F, Kenny N. How reliable are ATP bioluminescence meters in 
assessing decontamination of environmental surfaces in healthcare settings? PLoS One. 
2014;9(6):e99951.
Approaches to measuring and reducing toxicant concentrations in smokeless tobacco products
231
93. Performance evaluation of various ATP detecting units (Food Science Center report RPN 
13922). Chicago (IL): Silliker Inc; 2010.
94. Sigma-Aldrich [website] (https://www.sigmaaldrich.com, accessed 16 July 2019).
95. Stanfill SB, Jia LT, Watson CH, Ashley DL. Rapid and chemically-selective quantification of nico-
tine in smokeless tobacco products using gas chromatography/mass spectrometry, J Chrom 
Sci. 2009;47(10):902–9.
96. Lisko JG, Stanfill SB, Watson CH. Quantitation of ten flavor compounds in unburned tobacco 
products. Anal Methods. 2014;6(13):4698–704. doi: 10.1039/C4AY00271G.
97. Jain V, Garg A, Parascandola M, Chaturvedi P, Khariwala SS, Stepanov I. Analysis of alkaloids 
in areca nut-containing products by liquid chromatography-tandem mass spectrometry. J 
Agric Food Chem. 2017;65, 1977–1983 (https://doi.org/10.1021/acs.jafc.6b05140, accessed 
20 July 2019).
98. Stepanov I, Hecht SS, Ramakrishnan S, Gupta PC. Tobacco‐specific nitrosamines in smokeless 
tobacco products marketed in India. Carcinogenesis. 2015;116:16–9 (https://doi.org/10.1002/
ijc.20966, accessed 16 July 2019).
99. Dalipi R, Margui E, Borgese L, Depero E. Multi-element analysis of vegetal foodstuff by means 
of low power total reflection X-ray fluorescence (TXRF) spectrometry. Food Chem. 2017; 
218:348–55.
100. Directive 2001/37/EC of the European Parliament and of the Council (L194/26–L194/34). 
Brussels: European Commission; 2001 (https://ec.europa.eu/health/sites/health/files/to-
bacco/docs/dir200137ec_tobaccoproducts_en.pdf, accessed 22 July 2019).
101. Family Smoking Prevention and Tobacco Control Act 2009. Washington (DC): United States Con-
gress (Public Law 111-31 111th Congress) (https://www.gpo.gov/fdsys/pkg/PLAW-111publ31 
/pdf/PLAW-111publ31.pdf, accessed 16 July 2019).
102. Vidhubala E, Pisinger C, Basumallik B, Prabhakar DS. The ban on smokeless tobacco products 
is systematically violated in Chennai, India. Indian J Cancer. 2016;53:325–30.
103. Arora M, Madhu R. Banning smokeless tobacco in India: policy analysis. Indian J. Cancer. 
2012;49(4):336–41.
104. GothiaTek limits for undesired components. Stockholm: Swedish Match; 2017 (https://www.swe-
dishmatch.com/Snus-and-health/GOTHIATEK/GOTHIATEK-standard/, accessed 16 July 2019).
105. Gray N, Hecht S. Smokeless tobacco – proposals for regulation. Lancet. 2010;375:1589–91
232
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
233
10. Waterpipe tobacco smoking: prevalence, health 
effects and interventions to reduce use
Mohammed Jawad and Christopher Millett, Public Health Policy Evaluation Unit, Imperial 
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10.1 Introduction
At the seventh session of the COP to the WHO  FCTC, document FCTC/
COP/7/10 presented policy options and best practice for the control of waterpipe 
tobacco product use in relation to the WHO FCTC (1). This section builds on 
the evidence presented in document FCTC/COP/7/10 in preparation for the 
eighth session of the COP. The purpose is to provide a comprehensive analysis 
of waterpipe tobacco control and to outline challenges and recommendations to 
improve the prevention and control of waterpipe tobacco use. The objectives are 
to analyse studies on waterpipe tobacco in order to:
 ■ summarize regional and global patterns of waterpipe tobacco use, in-
cluding changes in prevalence;
 ■ evaluate the acute and chronic health effects of waterpipe tobacco use;
 ■ describe cultural practices in relation to initiation and maintenance of use;
 ■ explain the influence of flavourings on initiation, maintenance of use 
and increasing use;
 ■ explore dependence liability with low-nicotine products;
 ■ evaluate the evidence base for culturally relevant, waterpipe-specific 
interventions to prevent uptake and promote cessation;
 ■ outline effective policies based on conceptual frameworks; and
 ■ make recommendations for research and regulation.
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This section is limited to waterpipe tobacco and its accessories. Electronic nicotine 
devices with synonyms of “waterpipe” (e.g. shisha or hookah pens, electronic 
shisha or hookah) are not addressed. We focus on the most recent literature to 
minimize overlap with document FCTC/COP/7/10 and the WHO advisory note 
on waterpipe tobacco smoking (2).
10.2 Prevalence, health effects and effective interventions to 
reduce use
The literature on waterpipe tobacco is relatively limited but is growing 
exponentially. In 2016, the number of citations in five clinical databases (Medline, 
Embase, Web of Science, PsychInfo, Global Health) that contained synonyms of 
“waterpipe” in the title or abstract was more than 10 times the number in 2006 
(285  versus 25) (Fig.  10.1). Academia is continuously providing strengthened 
evidence for the prevention and control of waterpipe tobacco use.
Fig. 10.1. Numbers of citations in five clinical databases with synonyms of “waterpipe” in the titles or 
abstracts, 1990–2017
Source: databases – Embase, Medline, Global Health, PsychInfo, Web of Science; duplicate entries removed; 1 January–27 August 
only, in 2017.
10.2.1 Regional and global patterns of waterpipe tobacco use
Document FCTC/COP/7/10 noted that estimates of prevalence were available 
for some countries in all WHO regions (1). Generally, studies reported high 
prevalence among children aged 13–15 years and university students, although 
these population groups were surveyed in only a few countries, and many of the 
studies were not nationally representative.
To the best of our knowledge, 131 studies have reported jurisdictionally 
representative estimates of the prevalence of waterpipe tobacco use in 84 countries 
(3). About one third of the estimates derive from three international surveys: the 
Global Adult Tobacco Survey, the Global Youth Tobacco Survey and the Special 
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Eurobarometer Survey. Fig. 10.2 shows combined data from the latest wave of 
the Global Adult Tobacco Survey and Special Eurobarometer Survey (wave 87.1, 
2017) (4, 5), both among adults, and also the results of other studies in which 
similar methods were used (6–9). The figure reveals two important findings: an 
increasing prevalence in the WHO European Region and an absence of studies 
with comparable survey tools in the WHO Eastern Mediterranean Region, where 
waterpipe tobacco use is the highest globally.
Fig. 10.2. Regular or occasional waterpipe tobacco use among adults
Source: references 4–9.
The lack of data on the prevalence among adults in the WHO Eastern Mediterranean 
Region is in contrast to its involvement in the Global Youth Tobacco Survey. 
Fig.  10.3 shows data from the latest waves of the Global Youth Tobacco Survey 
(5) and other methodologically similar national school-based surveys (10–13). The 
figure shows an estimated prevalence of 5.0–14.9% in many countries in all WHO 
regions, which is a concern and warrants further investigation and intervention. 
The highest estimated prevalence is in the Eastern Mediterranean Region (Lebanon, 
37.0%; West Bank, 35.2%) and in Cyprus (33.2%) (Fig. 10.4).
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Fig. 10.3. Use of waterpipe tobacco in the past 30 days by children aged 13–15 years
Fig. 10.4. Use of waterpipe tobacco in the past 30 days by young people, Middle East
Source: references 5–10.
Few studies have reported trends in waterpipe use. In 28 European Union Member 
States that were surveyed in 2009 and again in 2017, the mean prevalence of 
regular waterpipe tobacco use among adults increased by 11.2% (4).
Waterpipe tobacco use appears to be increasingly popular among 
children aged 13–15 years, especially in the WHO Eastern Mediterranean Region 
(Fig. 10.4). In the USA, one national survey reported no or very little change in 
the prevalence of use in the past 30 days among young adults aged 18–24 years, 
which remained at 2–3% between 2011 and 2016 (14). In contrast, a number of 
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other surveys conducted between 2008 and 2015 among young people in the 
USA, including the National Youth Tobacco Survey, showed absolute increases 
in waterpipe use in the past 30 days of 0.3–1.0% each year (15–22). Similar 
increases were seen in repeated national school surveys in Canada and Lebanon 
(23–26), while in Jordan much larger absolute increases were seen, of about 2.9% 
per year between 2008 and 2011 (27). In the study in Jordan, increased use over 
time was associated with higher maternal education, frequent physical activity, 
ever cigarette use and waterpipe use by peers (28). In Turkey, the Global Adult 
Tobacco Survey indicated a decrease in waterpipe use, from 2.3% in 2008 to 0.8% 
in 2010 (29).
While waterpipe tobacco use is best characterized as intermittent, its 
interactions with other tobacco products are a potential cause for concern. In a 
longitudinal study of schoolchildren in Jordan, the risk of cigarette initiation was 
significantly higher among waterpipe tobacco smokers than those who had never 
smoked (30). A similar conclusion was made in a study of adolescents in the 
USA, which was of the same methodological design but additionally controlled 
for baseline propensity to smoke (31). In a study of university students in North 
Carolina (USA), those whose first tobacco product was waterpipe tobacco were 
more likely to be dual or multiple tobacco users at the time of the survey (32).
In contrast to cigarette use, there is no clear pattern of increased waterpipe 
use with lower socioeconomic status. Nevertheless, inequalities by socioeconomic 
status may develop as both the public perception of waterpipe tobacco and the 
regulatory environment shift.
10.2.2 Acute and chronic health effects
Waterpipe users are exposed to toxicants from both the tobacco and the charcoal 
used to heat it. Toxicant yield studies have consistently found substantial levels 
of tar, nicotine, CO and cancer-causing chemicals in waterpipe tobacco smoke 
(33). A population-level modelling study of exposure to cigarettes and waterpipe 
toxicants among 13–15-year-olds in the WHO Eastern Mediterranean Region 
(34) included estimates of the population intake of tobacco toxicants while 
factoring in frequencies of use and waterpipe sharing. It showed that waterpipe 
tobacco users were exposed to about 70% of all tobacco-derived CO and benzene, 
while cigarette users were exposed to only 30% (34). The high levels of CO and 
benzene probably come from the charcoal used to heat the tobacco.
In the acute phase, the absorbed components of waterpipe tobacco and 
charcoal combustion cause adverse cardiovascular and respiratory changes. 
Increased blood pressure and heart rate (35, 36) are expected, given the 
considerable but variable nicotine content of waterpipe tobacco (37). Reduced 
lung function is also commonly reported (38). Particularly with waterpipe 
tobacco, CO levels rise sharply secondary to charcoal combustion, and reported 
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cases of CO poisoning among waterpipe tobacco users are widespread. It should 
be noted that non-tobacco, “herbal” waterpipe products are also heated with 
charcoal, resulting in a toxicological profile similar to that tobacco waterpipe 
products except for the absence of nicotine (39, 40).
Growing evidence shows the risk of second-hand waterpipe tobacco 
smoke, particularly in waterpipe cafes. One pre–post study of 15 people 
passively exposed to waterpipe tobacco smoke showed an average increase in 
carboxyhaemoglobin from 0.8% (± 0.2) to 1.2% (± 0.8) after they had sat next 
to four to five active smokers for 30 min (41). Another showed that the level of 
acrolein, a harmful respiratory toxicant, increased in nonsmokers in waterpipe 
cafes or at waterpipe smoking events in homes (42). The effects of second-hand 
waterpipe tobacco smoke on other cardiorespiratory and toxicant parameters 
are less certain (41, 43, 44). In an analysis of air quality, non-smoking rooms in 
waterpipe cafes had > 10 times the concentration of fine particulate matter as 
smoke-free rooms in other venues (45). Assessments of poor air quality inside 
waterpipe cafes have been replicated in studies in the United Kingdom (46).
Emerging evidence suggests that waterpipe tobacco has harmful long-
term effects on health, similar to those of other forms of smoked tobacco. 
Table  10.1 summarizes the findings of several published systematic reviews 
(36, 47–50) and a further nine studies published after the reviews (51–59), thus 
providing the latest evidence of long-term harm. The table shows that waterpipe 
tobacco use is associated with respiratory and cardiovascular disease, five types 
of cancer, adverse complications in pregnancy (low birth weight and intrauterine 
growth restriction) and a number of other diseases. Second-hand smoke from 
waterpipe tobacco use has been shown to induce wheezing in children (60, 61). 
A further two cohort studies showed that waterpipe tobacco use was associated 
with increased overall mortality (56, 62); one of these also showed an increase in 
mortality from cancer (56). It is nevertheless difficult to draw clear conclusions 
from these studies because of the common practice of dual use of waterpipes and 
cigarettes. Many systematic reviews on this topic therefore rate the risk of bias 
as high. Consequently, the quality of the epidemiological studies on health and 
waterpipe tobacco use remains low, and further high-quality research, especially 
with enough statistical power to determine the relation between waterpipe 
tobacco smoking and health outcomes among never-cigarette-users, should be 
conducted to help to confirm these associations.
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Table 10.1. Mortality and diseases associated with waterpipe tobacco use
Outcome No. of studies Odds ratio (95% CI)
Mortality -- --
Overall 2 1.25 (1.03, 1.51)a
Cardiovascular disease 1 0.94 (0.43, 2.07)
Cancer 1 2.82 (1.30, 6.11)a
Cardiovascular disease -- --
Coronary artery disease 3 1.47 (1.06, 2.04)a
Hypertension 1 1.95 (1.54, 2.48)a
Respiratory disease -- --
Chronic obstructive pulmonary disease 5 2.33 (1.96, 2.77)a
Bronchitis 2 3.85 (1.92, 7.72)a
Asthma in children (active exposure) 2 1.32 (1.20, 1.46)a
Wheeze in children (passive exposure) 2 1.61 (1.25, 2.07)a
Cancer
Bladder 6 1.28 (1.10, 1.48)a
Colorectal 3 1.20 (0.79, 1.82)
Gastric 4 2.35 (1.47, 3.76)a
Head and neck 7 3.00 (2.39, 3.76)a
Liver 1 1.13 (0.62, 2.78)
Lung 6 3.96 (2.96, 5.30)a
Oesophageal 5 2.61 (2.12, 3.26)a
Pancreatic 1 1.60 (0.91, 2.82)
Prostate 1 7.00 (0.88, 55.66)
Pregnancy-related diseases
Low birthweight 4 1.54 (1.16, 2.04)a
Intrauterine growth restriction 1 3.50 (1.10, 12.60)a
Other diseases
Diabetes 1 0.52 (0.27, 1.00)
Gastroesophageal reflux disease 2 1.31 (1.13, 1.53)a
Hepatitis C 3 0.98 (0.76, 1.25)
Infertility 1 2.50 (1.00, 6.30)a
Mental health 2 1.33 (1.25, 1.42)a
Multiple sclerosis 1 1.77 (1.36, 2.31)a
Periodontal disease 3 3.65 (2.22, 6.01)a
a Statistically significant positive association between waterpipe tobacco use and this disease in a random effects meta-analysis.
10.2.3  Cultural practices and initiation and maintenance of use
Cultural practices of waterpipe smoking are broadly embedded within a strong 
network of social acceptance, at the levels of family, peers and communities. 
Users and non-users alike have a positive attitude towards waterpipe tobacco use, 
which stems from the social environment in which it is consumed, the attraction 
towards the array of flavours and elaborately designed apparatuses and the 
portrayal of waterpipes in marketing media (63–65).
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One of several recommendations for research in the second WHO 
advisory note on waterpipe tobacco use (2) was on cultural practices and how 
they affect initiation and maintenance of use. For policy, the MPOWER package 
(66) is intended to assist countries in implementing effective interventions to 
reduce the demand for tobacco products. The six components of MPOWER are: 
Monitor tobacco use and prevention policies, Protect people from tobacco smoke, 
Offer help to quit tobacco use, Warn about the dangers of tobacco, Enforce bans 
on tobacco advertising, promotion and sponsorship, and Raise taxes on tobacco. 
Several Parties to the WHO FCTC, such as India, the Islamic Republic of Iran, 
Kenya, Malaysia, Pakistan, the United Arab Emirates and the United Republic of 
Tanzania, have gone beyond MPOWER and enforced (although, in some cases, 
then reversed), a total prohibition on public consumption of waterpipe tobacco, 
at either state or national levels. This policy may be based on social norms, as 
waterpipe tobacco use is embedded within the cultures of these Parties. The 
extent to which prohibitions on waterpipe tobacco use have been enforced and 
their impact on smoking prevalence remain uncertain, and this should be a key 
area of evaluation for these Parties. Evaluation within the International Tobacco 
Control Policy Evaluation Project is recommended (67).
In Europe and north America, acculturation may determine waterpipe 
tobacco use. A study in the USA showed that immigrants from Arab countries 
who felt less acculturated into north American identity were more likely to 
use waterpipes (68). Furthermore, qualitative research in Canada showed that 
immigrants from Arab countries saw themselves as expressing their cultural 
heritage by smoking waterpipes, and, in the United Kingdom, non-Arab users 
saw themselves as experiencing an alternative culture (69).
Individual patterns of waterpipe use vary widely; the extent of within- and 
between-culture variation is, however, unclear. For example, in a study of waterpipe 
tobacco smoking behaviour in Lebanon, users on average drew an inhalation every 
17 s (70), whereas in a methodologically identical study in neighbouring Jordan, 
the frequency was 8 s and resulted in far greater exposure to toxicants. Gender 
differences in waterpipe smoking patterns were also noted in these studies, males 
tending to take larger puffs and spending more time smoking than females (71).
Cultural differences are also apparent commercially. In commercial 
waterpipe premises, where about half of all waterpipe tobacco is consumed (72, 
73), café cultures range from a quiet coffee shop-like atmosphere to a busy, loud 
bar-like environment (74). The café culture is likely to be associated with the 
patterns of use; for example, covert observation of commercial waterpipe premises 
in the USA indicated that some café owners insist that all clients entering the 
premises smoke a waterpipe (74). In boisterous cafes that attract many customers, 
they are likely to associate waterpipe tobacco with socializing, whereas those that 
frequent quieter cafes may be more likely to indulge in solo, nicotine-driven use.
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10.2.4  Influence of flavourings
Most of the waterpipe tobacco that is consumed is flavoured (75, 76). Flavours 
are aggressively marketed by the waterpipe tobacco industry; in a review of 52 
marketing material items from a waterpipe trade exhibition, flavours were among 
the most commonly elicited themes (77). Alarmingly, the most common theme 
was that waterpipe tobacco was safe or safer than cigarettes (77). Marketing 
practices of the waterpipe tobacco industry have indicated that tobacco and 
flavouring components may be sold separately to either evade flavouring bans or 
reduce the tobacco weight in order to lessen the excise tax (77).
Waterpipe tobacco flavourings play a dominant role in perceptions of their 
safety and their attraction, in particular to young people. A review conducted in 
April 2016 of 10 qualitative studies on the role of flavours in waterpipe tobacco 
found that flavours were appealing or tasty (78). In four studies (in Canada, 
the United Kingdom and the USA), young adults reported using waterpipes 
specifically for their flavour and because they did not wish to use other tobacco 
products (78). There was also a perception that flavoured waterpipe tobacco was 
less harmful than cigarettes. In the same review, adults in Canada and Lebanon 
explained that young people used waterpipe tobacco because of their flavours, 
and another explained that flavours were responsible for initiation of waterpipe 
tobacco use by young adults (78). In a large survey of adolescents in the USA, 
nearly 80% of users of waterpipes in the past 30 days reported that the flavours 
were a reason for use (79).
These qualitative studies are supported by other research. In an experiment 
in the USA, 367 adult waterpipe smokers were asked to choose from menus with 
hypothetical combinations of different session types (80). Flavoured waterpipe 
tobacco products were preferred significantly more than non-flavoured ones, 
and flavour more strongly influenced the decision to smoke waterpipes than 
price or nicotine content (80). The association was stronger for females and for 
non-cigarette smokers. In another experiment in the USA, 36 adult waterpipe 
smokers completed two waterpipe sessions, one with their preferred flavour of 
waterpipe tobacco and another with a non-preferred flavour, in a randomized 
cross-over design (81). Those who smoked their preferred flavour reported a 
better subjective smoking experience on a visual analogue scale, such as more 
interest in continued use, greater pleasure derived from smoking, increased 
liking and enjoyment and willingness to continue use (81). The fact that the 
study was conducted on the premise that waterpipe tobacco users have preferred 
flavours is an important finding in itself. Together, these studies suggest that 
flavour restrictions or flavour bans might be effective in discouraging waterpipe 
tobacco use.
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10.2.5  Dependence liability of low-nicotine products
The second WHO advisory note on waterpipe tobacco smoking clearly demarcated 
the role of nicotine dependence in waterpipe tobacco use (2). Regular waterpipe 
users absorb enough nicotine to reach a dependence threshold and exhibit 
typical symptoms of dependence, such as craving, withdrawal symptoms and 
difficulty in quitting. Regular waterpipe use is, however, relatively uncommon 
outside the Eastern Mediterranean Region. In one study, it was estimated that 
users would have to smoke a waterpipe at least three times per week to become 
dependent (82), whereas in the USA only 11.7% of young adults who had smoked 
a waterpipe in the past 30 days smoked at this level of frequency or more (83).
There are two issues with regard to the dependence liability of low-nicotine 
waterpipe tobacco products. The first is that there is almost no regulation of 
waterpipe tobacco manufacture, which results in widely different nicotine levels 
among products. In an experiment in which 110 waterpipe smokers engaged in 
a 45-min session of smoking, brands labelled “0.05% nicotine” resulted in higher 
mean peak plasma levels of nicotine than brands labelled “0.5% nicotine” (37). 
Given the lack of attention to policy on waterpipe tobacco, discussions about 
manufacture should prioritize flavour bans, as flavours have been shown to play 
a larger role in waterpipe purchase than low nicotine (80).
The second issue is that waterpipe tobacco already contains less nicotine 
than cigarettes, and, while dependence on waterpipe tobacco is well documented, 
it remains relatively uncommon at a population level. When standardized to 
the nicotine yield per minute of smoking, waterpipe tobacco contains 2–13 
ng less nicotine than cigarettes for every minute smoked (Table 10.2). Because 
the nicotine level is already low and dependence relatively uncommon on a 
population level, the justification for low-nicotine waterpipe tobacco is unclear.
Table 10.2. Nicotine yield per minute in waterpipe tobacco and cigarettes
Reference Nicotine yield (ng/min)
No. of times less concentrated 
than in cigarettesa
34 0.11 1.9–5.6
70 0.08 2.7–8.0
84 0.05 4.4–13.2
a Based on data from Hoffman & Hoffman (85), who estimated a nicotine yield of 1–3 ng/cigarette and an average time to consume 
a cigarette of 5 min.
10.2.6 Interventions
A review of interventions to reduce waterpipe tobacco use found only four 
individual-level and five group-level interventions (86). A further search for 
this section found no further interventional studies, indicating lack of research 
in this area. Of five randomized controlled trials, only two showed statistically 
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significant higher quit rates in the intervention group (87, 88); in one trial, a 
cigarette-specific intervention was tested in waterpipe tobacco users (87). The 
details of these interventions are shown in Table 10.3. Non-randomized studies 
had mixed results for cessation and behavioural and knowledge outcomes and 
were generally of much lower methodological quality.
The behavioural interventions used in these randomized studies varied 
widely but were broadly based on the same principles as cigarette behavioural 
interventions. In the study by Asfar et al. (89), the intervention consisted of three 
45-min, individual and in-person counselling sessions by a trained physician and 
five 10-min phone calls before and after the proposed quit date. Dogar et al. (87) 
provided two structured behavioural sessions, the first lasting 30 min and the 
second 10 min, based on the WHO “5 As” approach, and used behavioural change 
techniques considered to be effective for cigarette smoking cessation. Lipkus et 
al. (90) showed participants 20 slides giving factual information about waterpipe 
tobacco use, including its effects on health. Mohlman et al. (88) delivered health 
promotion in villages over 12 months, including deglamourizing tobacco use in 
primary schools and describing its health hazards in primary schools, mosques 
and homes; education was also given in handling peer pressure to smoke in 
preparatory and secondary schools. Nakkash et al. (91) delivered 10 sessions to 
students, four of which were on knowledge and six on skill-building (e.g. media 
literacy, decision-making and refusal skills).
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10.3 Future research
Four areas of research on waterpipe tobacco should be addressed, according to 
the findings in this section.
1. Surveillance of waterpipe tobacco use should continue: nonethe-
less, researchers should consider using improved, standardized tools 
to measure prevalence, so that estimates can be compared between 
countries. Simple estimates of prevalence among adults in the East-
ern Mediterranean Region and young people in central Europe and 
in the South-East Asia Region are a priority. For researchers, a tool-
box of survey items is available that covers use patterns, dependence, 
exposure and policy (92). An often overlooked but important detail 
is the type of waterpipe tobacco consumed. This report summarizes 
studies that mainly focused on mo’assel tobacco, a flavoured tobacco 
type commonly marketed in commercial venues. Other waterpipe 
tobacco types, often consumed in the WHO Eastern Mediterranean 
and South-East Asia regions, are associated with distinct patterns of 
use and sociodemographic correlates (93).
2. High-quality epidemiological studies on the long-term health ef-
fects of waterpipe tobacco should be conducted: in particular, not 
much is known about the long-term health effects of intermittent or 
infrequent use or the cumulative harm of dual use of waterpipe to-
bacco and cigarettes (34). Furthermore, understanding of the harm 
due to the potential of waterpipe tobacco to act as a gateway to other 
tobacco use will strongly inform the policy debate and action. Model-
ling studies could complement traditional epidemiological approach-
es in filling this research gap. While evidence for the long-term health 
effects of waterpipe tobacco use is being collected, better characteri-
zation of the product, by charcoal and tobacco type, will be an impor-
tant step to better understanding its potential harm.
3. As Parties to the WHO FCTC continue to develop and implement 
policies on waterpipe tobacco, the policies should be formally eval-
uated: it is important to evaluate the impact of policies on the use of 
and attitudes towards waterpipe tobacco and any unintended conse-
quences and to monitor industry compliance. Sharing of experience 
will guide efforts to reduce the health effects of waterpipe tobacco 
use. Key considerations are whether enforcement in waterpipe cafes 
will be offset by increased use at home and whether policies to reduce 
waterpipe tobacco use will increase use of other tobacco products.
4. Evidence for the effectiveness of individual and group interventions 
is needed to support waterpipe tobacco cessation: while research is 
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lacking on effective individual and group interventions, this should 
not delay implementation and evaluation of population-level inter-
ventions that have been shown to work. The main gaps in individual 
and group interventions include the effectiveness of pharmacological 
cessation aids (94) and the extent to which interventions for cigarette 
users can be transposed directly for waterpipe tobacco users. Re-
searchers who are considering conducting individual or group inter-
ventions should consult an inventory of behaviour change techniques 
for waterpipe tobacco use (95). Population-level approaches described 
in the MPOWER framework should be implemented immediately.
10.4 Policy recommendations
An extensive list of policy recommendations aligned with the WHO  FCTC 
is given in documents FCTC/COP/7/10 (1) and FCTC/COP7(4) (96). We 
support these recommendations as important measures for the prevention and 
control of waterpipe tobacco use. Below, we provide an abridged list of policy 
options that build on the success of the MPOWER framework and could be 
considered the most pertinent. This is prudent, given that countries that have not 
implemented MPOWER fully have a higher prevalence of waterpipe tobacco use 
(97). While MPOWER is applicable to all tobacco products, we call for renewed 
implementation explicitly incorporating the particularities of waterpipe tobacco 
smoking, such as the predominant use of flavours, lengthy, stationary tobacco use 
and regular use at commercial venues. We call this revision MPOWER-W.
In implementing the policies listed below, it should be remembered that 
waterpipe tobacco substitutes (e.g. “herbal” substances and steam stones) still 
require charcoal as the heating source (76) and should be classified as tobacco 
products because of the known chemical composition of the smoke they produce, 
the fact that they are marketed with waterpipe tobacco products and the fact 
that products claimed to be tobacco-free may nevertheless contain tobacco (39, 
98). Similar calls have been made for products that are used as substitutes for or 
mimic smokeless tobacco (99).
1. Monitor tobacco use and prevention policies (Article 20 of the 
WHO FCTC).
 Surveillance of waterpipe tobacco use has improved substantially 
during the past decade, but many countries still do not have mecha-
nisms to estimate the prevalence of waterpipe tobacco use, exposure 
to second-hand smoke and waterpipe tobacco industry activities. This 
section shows that comparable prevalence estimates for adults are not 
available for the Eastern Mediterranean Region, and prevalence esti-
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mates for young people are not available for central Europe and the 
South-East Asia Region. High-quality surveillance is essential for the 
prevention and control of waterpipe tobacco use. Prevalence should 
be measured with standardized tools (92), perhaps supplemented by 
routine administrative data or directories of waterpipe cafes (100).
2. Protect people from exposure to second-hand tobacco smoke (Ar-
ticle 8 of the WHO FCTC).
 Commercial establishments that allow customers to smoke water-
pipe tobacco on their premises should be included in comprehensive 
smoke-free laws. There is evidence of the harm of second-hand smoke 
from waterpipe smoking (41, 43, 44). Studies of cigarette smoking 
in commercial premises have shown that comprehensive smoke-free 
laws reduce the harm of second-hand smoke, help smokers to quit 
and reduce smoking among young people (101). Waterpipe tobacco 
sessions can be lengthy (e.g. up to several hours), and movement of 
smokers outdoors increases their public visibility and may be noisy 
and create a nuisance for nearby residents (98). Turkey and sever-
al countries in the Eastern Mediterranean Region have instituted 
zoning laws to prohibit waterpipe cafes within a certain distance of 
residential areas and educational establishments (102). Zoning laws 
should be co-implemented with smoke-free laws to maximize protec-
tion of the public.
3. Offer help to quit tobacco use (Article 14 of the WHO FCTC).
 Regular waterpipe tobacco smokers are nicotine dependent. There-
fore, Parties to the WHO FCTC should integrate waterpipe tobacco 
cessation into traditional smoking cessation services. Although the 
literature on effective individual interventions is sparse, they show 
promising results and should be scaled up and evaluated for exchange 
among countries. It is also important to address the strong social 
components of waterpipe tobacco use.
4. Warn about the dangers of tobacco (Articles 11 and 12 of the 
WHO FCTC).
 Health warnings on waterpipe tobacco packs should, as for cigarettes, 
cover at least 50% of the principal display areas and include graphic 
imagery, which is more effective in reaching people with low literacy. 
Health warnings should also be applied to waterpipe accessories, such 
as the device and charcoal. Evidence strongly suggests that waterpipe 
tobacco use is harmful to health (36, 47–50), but the industry com-
plies poorly with WHO FCTC recommendations for health warnings 
(103, 104). As waterpipe devices are elaborate, well decorated and a 
248
W
H
O
 T
ec
hn
ic
al
 R
ep
or
t S
er
ie
s N
o.
 1
01
5,
 2
01
9
WHO Study Group on Tobacco Product Regulation   Seventh report
component of the positive affect of waterpipe tobacco smoking, the 
device should be regulated to a standardized size and pattern to re-
duce its attractiveness.
5. Enforce bans on tobacco advertising, promotion and sponsorship 
(Article 13 of the WHO FCTC).
 Complete bans on waterpipe tobacco advertising, promotion and 
sponsorship, which are commonly seen in and around waterpipe ca-
fes and on social media, should be enforced. In contrast to the prod-
ucts of transnational tobacco companies, most waterpipe tobacco is 
advertised and promoted by retailers or at waterpipe cafes (77, 105, 
106). Student offers, discounts and the display of waterpipe devices 
in shop windows are common approaches to encouraging waterpipe 
tobacco use.
6. Raise taxes on tobacco (Article 6 of the WHO FCTC).
 Taxes on waterpipe tobacco should be raised, at least to be in line with 
the tax rate on cigarettes. Tobacco taxation is one of the most effective 
policies in tobacco control, but waterpipe tobacco is taxed at a much 
lower rate than cigarettes. A national survey in Lebanon indicated 
that a 10% increase in waterpipe tobacco taxes would result in a 14% 
decrease in consumption in homes (107). While the impact of such 
a tax on use in waterpipe cafes is unknown, policy-makers should be 
mindful that, when waterpipe tobacco is used by a group, the effect of 
taxation is weakened, as the cost per user is lower. Therefore, larger 
increases in taxes on waterpipe tobacco will be required to achieve a 
similar effect to cigarette taxation.
10.4.1 Policies relevant to waterpipe tobacco use
The six policies listed above are the backbone of tobacco control policy globally as 
part of the comprehensive policy recommendations in the WHO FCTC; however, 
two further recommendations do not fall within the MPOWER framework. 
Introduction of MPOWER-W will guide policies to address waterpipe-specific 
priorities.
First, as most waterpipe tobacco is flavoured, a ban on flavours is likely to 
have a profound effect on the waterpipe tobacco industry (108). It would reduce 
the attractiveness of waterpipe tobacco, promote cessation and prevent uptake, 
especially by young people. Policy-makers should be wary, however, that a flavour 
ban could be circumvented by separate sale of flavours in bottles, to be added by 
the user to an unflavoured tobacco mix. Such bottles are likely to be specific to 
waterpipe tobacco use, and any shift to this approach by the industry could be 
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prevented by tightly regulated, enforced policy. Flavours can also be added to 
charcoal and water rather than to the tobacco, and parts of the apparatus can be 
replaced with fruit-based accessories (such as cored fruit in place of the head, 
where the tobacco is held). Manipulations of tobacco flavouring in retail settings 
should be prohibited by policy-makers to ensure that any flavour ban is upheld 
throughout the supply chain.
Secondly, as many of these policies target customers of waterpipe 
cafes, licensing might be the most effective method for reducing the burden 
of enforcement on local governments and ensuring that waterpipe retailers 
understand their legislative responsibilities (98). In addition to the above policies, 
a licensing framework could incorporate wider protection not directly related 
to tobacco, such as health and safety requirements, quality control measures 
to promote good sanitation (e.g. disposable hoses and mouthpieces and device 
cleaning procedures) and age restrictions on entry. By including tobacco control 
policies within this licensing framework, enforcement can be cost-effective. 
Furthermore, depending on the country, the terms of waterpipe tobacco licenses 
may be under the jurisdiction of local governments, which would facilitate 
implementation of local policies such as flavour bans and the categorization 
of non-tobacco (“herbal”) products as tobacco products, without the need for 
changes to national licensing frameworks.
10.5 Conclusions
Research on waterpipe tobacco use is increasing exponentially, providing 
evidence that use of this harmful tobacco product is prevalent in many countries 
on all continents, particularly among children aged 13–15 years. While waterpipe 
tobacco users may become dependent on nicotine, most are not dependent and 
may therefore be more susceptible to population-level policies than individual or 
group interventions. The prevalence of waterpipe tobacco smoking continues to 
rise in many countries, mainly because of lack of regulation of the industry. Public 
health concern about waterpipe tobacco centres on the fact that it is predominantly 
a flavoured product and that flavour encourages its use and may be more important 
than price in the decision to smoke it. A ban on flavoured waterpipe tobacco could 
reduce the appeal of these products, thereby reducing demand and ultimately 
improving public health. The ban should, however, be complementary to tobacco 
control policies such as higher taxation, comprehensive smoke-free laws and 
public education to remove misperceptions of harm. Renewed implementation 
of MPOWER with incorporation of the particularities of waterpipe tobacco 
smoking could facilitate prevention and control of waterpipe tobacco use. In the 
meantime, the research priorities include continued, standardized surveillance, 
better-quality epidemiological studies of harm, evaluation of policies and the 
design of prevention and cessation interventions.
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11.  Overall recommendations
The WHO Study Group on Tobacco Product Regulation publishes reports to 
provide a scientific basis for tobacco product regulation. In line with Articles 9 
and 10 of the WHO FCTC, the reports identify evidence-based approaches to the 
regulation of tobacco products.
At its ninth meeting, the Study Group discussed: the prevalence and 
health effects of waterpipe tobacco smoking and interventions to reduce use; 
approaches to reducing toxicant concentrations in tobacco products, including 
cigarettes and smokeless tobacco; the state of the science on a global nicotine 
reduction strategy; the clinical pharmacology of nicotine in ENDS; the sugar 
content of tobacco products; a regulatory strategy for reducing exposure to 
toxicants in cigarette smoke; an updated list of priority toxicants in tobacco 
products for regulatory purposes; heated tobacco products; and the science of 
flavours in tobacco products. The aim of the discussions was to update knowledge 
in these areas in order to inform policy at global level and to advance tobacco 
product regulation.
The report provides guidance through the Executive Board to Member 
States. It focuses primarily on requests of the COP to the WHO FCTC to WHO 
through the Convention Secretariat at its seventh session, in 2016, as articulated 
in decisions FCTC/COP7(4), FCTC/COP7(9) and FCTC/COP7(14). These 
decisions informed the content of the background papers in the above areas, for 
which Member States have requested technical assistance as a basis for national 
policies. The 10-member Study Group invited subject matter experts, who 
drafted background papers, contributed to discussions and provided the most 
up-to-date empirical data on the topics considered. Sections 2–10 of the report 
provide scientific information and policy recommendations to guide Member 
States in navigating difficult issues in tobacco product regulation. Further, the 
report provides guidance to Member States on the most effective evidence-
based means for bridging regulatory gaps in tobacco control and for developing 
coordinated regulatory frameworks for tobacco products to guide international 
policy. Additionally, it identifies areas for further work and future research, 
focusing on the regulatory needs of Member States; it takes into consideration 
regional differences, thus providing a strategy for continued, targeted technical 
support to Member States.
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11.1 Main recommendations
The main recommendations of this report to policy-makers and all other inter-
ested parties include the following.
 ■ Monitor and collect reliable, independent data on heated tobacco 
products and alternative products in order to understand behaviour 
and potential risks to users and bystanders and to verify claims of 
reduced exposure and risk.
 ■ Consider and examine the design features that determine nicotine 
flux in ENDS and the extent to which these products could promote 
or impede cessation of smoking, and invest in research on appropri-
ate policies and regulations on ENDS.
 ■ Consider a regulatory strategy for reducing exposure to toxicants in 
combusted tobacco product smoke that includes a nicotine level in 
tobacco that does not exceed 0.4 mg/g of tobacco (0.04 mg nicotine 
per combusted product in mainstream smoke under HCI smoking 
conditions). This should be accompanied by a reliable system for 
monitoring regulated constituents in tobacco and smoke, compre-
hensive tobacco control and concerted national and international ef-
forts to prevent black markets.
 ■ Consider a nicotine reduction policy coordinated with policies that 
allow adequate access to nicotine replacement therapies and other 
products, if and as approved by relevant authorities and with appropri-
ate safeguards. This should be supported by population surveillance, 
monitoring and testing of products, enforcement of product stan-
dards, and a strong focus on protecting children and young people.
 ■ Consider banning or restricting the use of flavours in nicotine de-
livery systems and tobacco products in order to reduce initiation by 
young people, and consider banning or restricting flavours in com-
busted tobacco products to promote cessation.
 ■ Require manufacturers to disclose relevant information on sugar con-
tent, and consider lowering the level of sugars in tobacco products to re-
duce their effects on product toxicity, addictiveness and attractiveness.
 ■ Require manufacturers, as applicable and appropriate, to report 
priority toxicants analysed with methods based on the SOPs of the 
WHO TobLabNet.
 ■ Lower the levels of addictive, toxic and carcinogenic agents in tobacco 
products, including cigarettes and smokeless tobacco, recognizing that 
decreasing the levels of these agents will not make these products safe.
 ■ Consider applying WHO FCTC provisions to waterpipe tobacco for 
the prevention and control of waterpipe tobacco use.
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Continuing research is required to monitor product development and use, 
promotional strategies and other activities of the tobacco and related industry to 
build intelligence to protect public health. Specific recommendations on each of 
the topics considered in this report can be found in sections 2.9, 3.8, 4.5–4.6, 5.8, 
6.8, 7.10, 8.8, 9.9 and 10.3–10.5.
11.2 Significance for public health policies
The Study Group’s report provides helpful guidance for understanding the 
content, emissions and design features of selected products, such as smokeless 
tobacco, waterpipes, heated tobacco products and ENDS and describes the public 
health impact of these products and features. In recent years, unconventional 
nicotine and tobacco products have permeated several markets, for which there 
is no precedent, and these present unique regulatory challenges to Member 
States. Further, there is better understanding of the science, adverse effects, 
characteristics, contents and emissions of conventional products owing to 
advances in knowledge; therefore, the report provides updated information for 
Member States on novel and emerging tobacco products and nicotine delivery 
systems to support them in formulating effective strategies for regulating tobacco 
and nicotine products.
Because of the unique composition of the Study Group, with regulatory, 
technical and scientific experts, it can navigate and distil complex data and 
research and synthesize them into recommendations for policy development at 
country, regional and global levels. The recommendations promote international 
coordination of regulatory efforts and the adoption of best practices in tobacco 
product regulation, strengthen capacity for tobacco product regulation in all 
WHO regions and provide a ready, science-based resource for Member States.
11.3 Implications for the Organization’s programmes
The report fulfils the mandate of the WHO Study Group on Tobacco Product 
Regulation to provide the Director-General with scientifically sound, evidence-
based recommendations for Member States about tobacco product regulation. 
Tobacco product regulation is a highly technical area of tobacco control, in which 
Member States face complex regulatory challenges. The outcomes of the Study 
Group’s deliberations and its main recommendations will improve Member 
States’ understanding of tobacco and nicotine products. The report’s contribution 
to the body of knowledge on tobacco product regulation will play a pivotal role 
in informing the work of the tobacco programme in the WHO Department for 
Prevention of Noncommunicable Diseases, especially in providing technical 
support to Member States. It will also contribute to further development of 
partial guidelines for implementation of Articles 9 and 10 of the WHO FCTC.
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This report presents the conclusions reached and recommen-
dations made by the members of the WHO Study Group on 
Tobacco Product Regulation at its ninth meeting, where the 
group reviewed background papers specially commissioned 
for the meeting and considered  the following topics:
1. Heated tobacco products (section 2); 
2.Clinical pharmacology of nicotine in electronic nicotine 
delivery systems (section 3); 
3. A global nicotine reduction strategy: state of the science 
(section 4); 
4. A regulatory strategy for reducing exposure to toxicants in 
cigarette smoke (section 5); 
5. The science of flavour in tobacco products (section 6); 
6. Sugar content of tobacco products (section 7); 
7. Updated priority list of toxicants in combusted tobacco 
products (section 8); 
8. Approa che s to measur ing and reducing toxicant 
concentrations in smokeless tobacco products (section 9); 
9. Waterpipe tobacco smoking: prevalence, health effects and 
interventions to reduce use (section 10).
The Study Group’s recommendations in relation to each theme 
are set out  at the end of the relevant chapter, and overall 
recommendat ions are summarized in the final chapter of 
the report.
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